AU2014216054B2 - Cultures with improved phage resistance - Google Patents

Abstract

The present invention provides methods and compositions related to modulating the resistance of a cell against a target nucleic acid or a transcription product thereof. In some preferred embodiments, the present invention provides compositions and methods for the use of one or more cas genes or proteins for modulating the resistance of a cell against a target nucleic acid or a transcription product thereof. In [0 some embodiments, the present invention provides methods and compositions that find use in the development and use of strain combinations and starter culture rotations. In additional embodiments, the present invention provides methods for labelling and/or identifying bacteria. In some preferred embodiments, the present invention provides methods for the use of CRISPR loci to determine the potential virulence of a phage against a cell and the use of CRISPR-cas to modulate the genetic sequence [5 of a phage for increased virulence level. In still further embodiments, the present invention provides means and compositions for the development and use of phages as biocontrol agents. A DGCC7710> )RT R S1 R S2 R R S30 R S31 R S32 RT Challenge the strain with phage 858 and select a phage resistant mutant DGCC7710RH1 R) R Sn R S1 R S2 R R S30 R S31 R S32 RT The CRISPR I locus of the mutant has an additional spacer which shares 100% identity with region 31 921-31 950bp of the phage R R S1 R S2 R R S30 R S31 R S32 RT Space TCAACAATTGCAACATCTTATAACCCACTT 858 TCAACAATTGCAACATCTTATAACCCACTT

Description

P/00/011 Regulation 3.2 AUSTRALIA Patents Act 1990 COMPLETE SPECIFICATION FOR A DIVISIONAL PATENT ORIGINAL Name of Applicant: DUPONT NUTRITION BIOSCIENCES APS Actual Inventor(s): Christophe FREMAUX Dennis ROMERO Rodolphe BARRANGOU Philippe HORVATH Patrick BOYAVAL Address for Service: Houlihan 2 , Level 1, 70 Doncaster Road, Balwyn North, Victoria 3104, Australia Invention Title: CULTURES WITH IMPROVED PHAGE RESISTANCE The following statement is a full description of this invention, including the best method of performing it known to the Applicant:- 2 5 CULTURES WITH IMPROVED PHAGE RESISTANCE The present application is a divisional application from Australian patent application number 2008223544. The entire disclosures of Australian patent application number 2008223544 and its [0 corresponding International application, PCT/US2008/002714, are incorporated herein by reference. FIELD OF THE INVENTION The present invention provides methods and compositions related to modulating the resistance of a cell against a target nucleic acid or a transcription product thereof. In some preferred embodiments, [5 the present invention provides compositions and methods for the use of one or more cas genes or proteins for modulating the resistance of a cell against a target nucleic acid or a transcription product thereof. In some embodiments, the present invention provides methods and compositions that find use in the development and use of strain combinations and starter culture rotations. In additional embodiments, the present invention provides methods for labelling and/or identifying bacteria. In some preferred !0 embodiments, the present invention provides methods for the use of CRISPR loci to determine the potential virulence of a phage against a cell and the use of CRISPR-cas to modulate the genetic sequence of a phage for increased virulence level. In still further embodiments, the present invention provides means and compositions for the development and use of phages as biocontrol agents. !5 BACKGROUND OF THE INVENTION Cultures, and starter cultures, in particular are used extensively in the food industry in the manufacture of fermented products including milk products (e.g., yogurt, buttermilk, and cheese), meat products, bakery products, wine, and vegetable products. The preparation of cultures is labor intensive, occupying much space and equipment, and there is a considerable risk of contamination with spoilage 30 bacteria and/or phages during the propagation steps. The failure of bacterial cultures due to bacteriophage (phage) infection and multiplication is a major problem with the industrial use of bacterial cultures. There are many different types of phages and new strains continue to emerge. In addition, there is a need for methods and compositions for tracking bacteria used in such cultures. Indeed, despite advances in culture development, there is a continuing need to improve cultures for use in industry. 35 SUMMARY OF THE INVENTION The present invention provides methods and compositions related to modulating the resistance of a cell against a target nucleic acid or a transcription product thereof. In some preferred embodiments, the present invention provides compositions and methods for the use of one or more cas genes or proteins for 40 modulating the resistance of a cell against a target nucleic acid or a transcription product thereof. In some embodiments, the present invention provides methods and compositions that find use in the development and use of strain combinations and starter culture rotations. In additional embodiments, the 3 5 present invention provides methods for labelling and/or identifying bacteria. In some preferred embodiments, the present invention provides methods for the use of CRISPR loci to determine the potential virulence of a phage against a cell and the use of CRISPR-cas to modulate the genetic sequence of a phage for increased virulence level. In still further embodiments, the present invention provides means and compositions for the development and use of phages as biocontrol agents. [0 The present invention provides methods for generating at least one bacteriophage resistant variant strain, comprising the steps of: (a) exposing a parent bacterial strain comprising at least a portion of a CRISPR locus to at least one nucleic acid sequence to produce a mixture of bacteria comprising at least one bacteriophage resistant variant strain comprising a modified CRISPR locus; (b) selecting a bacteriophage resistant variant strain from the mixture of bacteria; (c) selecting the bacteriophage [5 resistant variant strains comprising an additional nucleic acid fragment in the modified CRISPR locus from the bacteriophage resistant strains selected in step (b); and (d) isolating at least one bacteriophage resistant variant strain, wherein the strain comprises an additional nucleic acid fragment in the modified CRISPR locus. In some preferred embodiments, the methods further comprise the step of comparing the CRISPR locus or a portion thereof of the parent bacterial strain and the modified CRISPR locus of the !0 bacteriophage resistant variant strain to identify bacteriophage resistant variant strains comprising at least one additional nucleic acid fragment in the modified CRISPR locus that is absent from the CRISPR locus of the parent bacterial strain. In some particularly preferred embodiments, the methods further comprise the step of selecting bacteriophage resistant variant strains comprising an additional nucleic acid fragment in the modified CRISPR locus. In some embodiments, the parent bacterial strain is exposed to !5 two or more nucleic acid sequences. In some preferred embodiments, the parent bacterial strain is simultaneously exposed to two or more nucleic acid sequences, while in some alternative embodiments, the parent bacterial strain is sequentially exposed to two or more nucleic acid sequences. In some particularly preferred embodiments, the parent bacterial strain is exposed to the nucleic acid sequence through infection by at least one bacteriophage comprising the nucleic acid sequence In some further 30 preferred embodiments, the at least one bacteriophage is selected from the group of virus families consisting of: Corticoviridae, Cystoviridae, Inoviridae, Leviviridae, Microviridae, Myoviridae, Podoviridae, Siphoviridae, and Tectiviridae. In some additional preferred embodiments, the at least one bacteriophage is a naturally occurring bacteriophage, while in other preferred embodiments, the at least one bacteriophage is a mutated bacteriophage obtained through selective pressure using a bacteriophage 35 resistant bacterial strain. In yet further preferred embodiments, the parent bacterial strain is exposed to the nucleic acid through a natural mechanism of nucleic acid uptake. In some embodiments, the natural mechanism of nucleic acid uptake comprises natural competence. In some additional embodiments, the natural mechanism of nucleic acid uptake parent bacterial strain by conjugation or transformation. In still other embodiments, the bacteriophage resistant strain is a bacteriophage insensitive mutant. In yet 40 additional embodiments, the parent bacterial strain is a bacteriophage insensitive mutant. In some further embodiments, the 5' end and/or the 3' end of the CRISPR locus of the parent bacterial strain is compared 4 5 with the modified CRISPR locus of the bacteriophage resistant variant strain. It some still further embodiments, the 5' and/or the 3' end of the at least the first CRISPR repeat or at least the first CRISPR spacer of the CRISPR locus of the parent bacterial strain is compared with the modified CRISPR locus of the bacteriophage resistant variant strain. In still further embodiments, the bacteriophage resistant variant strain comprises at least one additional nucleic acid fragment in the modified CRISPR locus. In some [0 additional embodiments, at least a portion of the CRISPR locus of the parent bacterial strain and at least a portion of the modified CRISPR locus of the bacteriophage resistant variant strain are compared by amplifying at least a portion of the CRISPR locus and at least a portion of the modified CRISPR locus, to produce an amplified CRISPR locus sequence and an amplified modified CRISPR locus sequence. In still further embodiments, amplifying is conducted using the polymerase chain reaction. In some [5 preferred embodiments, at least a portion of the CRISPR locus of the parent bacterial strain and at least a portion of the modified CRISPR locus of the bacteriophage resistant variant strain are compared by sequencing at least a portion of the CRISPR locus and at least a portion of the modified CRISPR locus. In some particularly preferred embodiments, the methods further comprise the step of sequencing the amplified CRISPR locus sequence and the amplified modified CRISPR sequence locus. In some !0 additional embodiments, the additional nucleic acid fragment in the modified CRISPR locus is an additional repeat-spacer unit. In some preferred embodiments, the additional repeat-spacer unit comprises at least about 44 nucleotides. In some alternative preferred embodiments, additional repeat-spacer unit is comprises between about 44 and about 119 nucleotides. However, it is not intended that the present invention be limited to these specific size ranges, as other sizes find use in the present invention, as !5 described herein. In some embodiments, the additional repeat-spacer unit comprises at least one nucleotide sequence that has at least about 95% identity to a CRISPR repeat in the CRISPR locus of the parent bacterial strain. In some further embodiments, the additional repeat-spacer unit comprises at least one nucleotide sequence that has at least about 95% identity to a nucleotide sequence in the genome of at least one bacteriophage. In some particularly preferred embodiments, the parent bacterial strain is an 30 industrially useful strain. In some additional embodiments, the parent bacterial strain is susceptible to infection by at least one bacteriophage. In some further preferred embodiments, the parent bacterial strain comprises a culture selected from starter cultures, probiotic cultures, and dietary supplement cultures. In some preferred embodiments, the parent bacterial strain comprises a strain obtained from a culture. In some particularly preferred embodiments, the culture is a starter culture, a probiotic culture, 35 and/or a dietary supplement culture. In yet additional embodiments, the parent bacterial strain is selected from Escherichia, Shigella, Salmonella, Erwinia, Yersinia, Bacillus, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Agrobacterium, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Francisella, Brucella, Campylobacter, Klebsiella, Frankia, Bartonella, Rickettsia, Shewanella, Serratia, 40 Enterobacter, Proteus, Providencia, Brochothrix, Bifidobacterium, Brevibacterium, Propionibacterium, Lactococcus, Lactobacillus, Pediococcus, Leuconostoc, and Oenococcus.

5 5 The present invention also provides at least one bacteriophage resistant variant strain obtained using the methods set forth herein. In some preferred embodiments, the present invention provides bacteriophage resistant variant strains, wherein the bacteriophage resistant variant strain is an industrially useful strain. In some preferred embodiments, the bacteriophage resistant variant strain comprises an industrially useful strain that is at least one component of a starter culture, probiotic culture, dietary [0 supplement culture, and/or other useful cultures. The present invention also provides compositions comprising a bacteriophage resistant variant strain produced using the methods set forth herein. In some embodiments, the present invention provides compositions comprising at least two bacteriophage resistant variant strains produced using the methods set forth herein. The present invention also provides foods and/or feeds comprising at least one of these [5 compositions. The present invention also provides methods for preparing food and/or feed comprising adding at least one of these compositions to the food or feed. The present invention also provides starter cultures, probiotic cultures, dietary supplement cultures, and other useful cultures that comprise at least one of these compositions. The present invention also provides fermentation methods comprising adding at least one of these compositions to a starter culture. In some embodiments, the present invention !0 provides fermentation methods comprising adding at least one of these compositions to a fermentation medium, under conditions such that fermentation of the components of the fermentation medium occur. In some embodiments, the fermentation is unaffected by the presence of bacteriophages. In some embodiments, the fermentation medium is a food product. In some preferred embodiments, the food product is a dairy product. In some particularly preferred embodiments, the dairy product is milk. In !5 some further embodiments, at least two different compositions comprising two or more bacteriophage resistant variant strains are sequentially exposed to the fermentation medium. The present invention also provides methods for reducing the detrimental bacteriophage population in a fermentation medium comprising exposing a fermentation medium to at least one bacteriophage resistant variant strain produced using the methods set forth herein, under conditions such 30 that the bacteriophage population is reduced. The present invention also provides methods for generating at least one bacteriophage resistant variant strain, comprising the steps of: (a) exposing a parent bacterial strain comprising at least a portion of a CRISPR locus to at least one nucleic acid sequence to produce a mixture of bacteria comprising at least one bacteriophage resistant variant strain comprising a modified CRISPR locus; (b) selecting a 35 bacteriophage resistant variant strain from the mixture of bacteria; (c) comparing the CRISPR locus or a portion thereof of the parent bacterial strain and the modified CRISPR locus of the bacteriophage resistant variant strain to identify bacteriophage resistant variant strains comprising at least one additional nucleic acid fragment in the modified CRISPR locus that is absent from the CRISPR locus of the parent bacterial strain; (d) selecting the bacteriophage resistant variant strains comprising an additional nucleic 40 acid fragment in the modified CRISPR locus; (e) analyzing the at least one additional nucleic acid 6 5 fragment in the modified CRISPR locus to identify the at least one bacteriophage resistant variant strain; and (f) isolating the at least one bacteriophage resistant variant strain. The present invention also provides methods for generating CRISPR-escape phage mutants comprising: (a) obtaining: at least one parent phage and a phage-resistant bacterial strain comprising at least one CRISPR locus, wherein the CRISPR locus comprises a nucleic acid sequence that is at least t0 about 95% identical to at least one protospacer sequence in the genome of the at least one parent phage; (b) exposing the at least one parent phage to the phage-resistant bacterial strain, under conditions such that at least one phage variant is produced; and (c) selecting the at least one phage variant, wherein the at least one phage variant exhibits the ability to infect the phage-resistant bacterial strain and is a CRISPR escape phage mutant. In some embodiments, the phage-resistant bacterial strain is a bacteriophage [5 resistant variant strain obtained using the methods set forth herein. In some embodiments, the methods further comprise the step of comparing at least a portion of the at least one protospacer sequence and a CRISPR motif positioned near the at least one protospacer sequence in the phage variant with the at least one protospacer sequence and CRISPR motif of the parent phage. In yet additional embodiments, the methods further comprise the step of selecting the variant phages that infect the phage resistant bacterial !0 strain, wherein the variant phages comprise the CRISPR-escape phage mutants, and wherein the CRISPR-escape phages comprise at least one mutation in the at least one protospacer sequence and/or in the CRISPR motif of the CRISPR-escape phage mutants. In yet additional embodiments, the methods are iteratively repeated one or more times using the CRISPR-escape phage mutants and different CRISPR phage-resistant bacterial strain comprising at least one CRISPR locus, wherein the CRISPR !5 locus comprises a nucleic acid sequence that is at least about 95% identical to at least one protospacer sequence in the genome of the CRISPR-escape phage mutants. In yet additional embodiments, at least one bacteriophage is selected from the group of virus families consisting of: Corticoviridae, Cystoviridae, Inoviridae, Leviviridae, Microviridae, Myoviridae, Podoviridae, Siphoviridae, and Tectiviridae. In some preferred embodiments, the phage-resistant bacterial strain is selected from Escherichia, Shigella, 30 Salmonella, Erwinia, Yersinia, Bacillus, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Agrobacterium, Staphylococcus, Enterococcus, Clostridium, Camplyobacter, Corynebacterium, Mycobacterium, Treponema, Borrelia, Francisella, Brucella, Klebsiella, Frankia, Bartonella, Rickettsia, Shewanella, Serratia, Enterobacter, Proteus, Providencia, Brochothrix, Bifidobacterium, Brevibacterium, Propionibacterium, Lactococcus, Lactobacillus, Pediococcus, 35 Leuconostoc, Streptococcus, and Oenococcus. The present invention also provides CRISPR-escape phage mutants obtained using the methods set forth herein. In some embodiments, the CRISPR-escape phage mutants comprise two or more mutations present in at least two protospacer sequences and/or in the CRISPR motif. The present invention also provides CRISPR-escape phage mutants, wherein the genome of the 40 CRISPR-escape phage mutants is genetically engineered to comprise mutations in at least one protospacer and/or the CRISPR motif. In some embodiments, at least one CRISPR motif is mutated in 7 5 the CRISPR-escape phage mutants, while in some alternative embodiments, at least one CRISPR motif is deleted in the CRISPR-escape phage mutants. The present invention also provides compositions comprising at least one CRISPR-escape phage mutants. The present invention also provides methods for controlling bacterial populations in a product comprising exposing compositions comprising at least one CRISPR-escape phage mutant to a [0 fermentation medium, wherein the fermentation medium contains at least one population of undesirable bacteria, under conditions such that the population of the undesirable bacteria is reduced, and the fermentation medium is used to generate the product. In some embodiments, the product is selected from foods, feeds, cosmetics, personal care products, health care products, veterinary products, and dietary supplements. In some further embodiments, the methods are repeated at least once and the different [5 compositions and/or compositions comprising different CRISPR-escape phage mutants are used in rotation. In some embodiments, the present invention provides methods and compositions for the use of one or more cas genes or proteins for modulating resistance in a cell against a target nucleic acid or a transcription product thereof. In some additional embodiments, the present invention provides !0 compositions and methods for the use of a recombinant nucleic acid sequence comprising at least one cas gene and at least two CRISPR repeats together with at least one CRISPR spacer, wherein at least one CRISPR spacer is heterologous to at least one cas gene and/or at least two CRISPR repeats to modulate resistance against a target nucleic acid or transcription product thereof. In yet additional embodiments, the present invention provides at least one nucleic acid sequence comprising at least one cas gene. !5 In still further embodiments, the present invention provides at least one nucleic acid sequence comprising at least one cas gene and at least two CRISPR repeats. In some embodiments, the present invention provides a nucleic acid sequence comprising at least one cas gene and at least one CRISPR spacer. In yet further embodiments, the present invention provides a nucleic acid sequence comprising at least one cas gene, at least one CRISPR spacer and at least two CRISPR repeats. In further 30 embodiments, the present invention provides a recombinant nucleic acid sequence comprising at least one cas gene and at least two CRISPR repeats together with at least one CRISPR spacer, wherein the CRISPR spacer is heterologous to the at least one cas gene and/or the at least two CRISPR repeats. The present invention also provides constructs comprising one or more of the nucleic acid sequences described herein. In yet additional embodiments, the present invention provides vectors 35 comprising one or more of the nucleic acid sequences or one or more of the constructs described herein. In still further embodiments, the present invention provides cells comprising the nucleic acid sequence or the construct or the vector described herein. The present invention also provides methods for modulating (e.g., conferring or increasing) the resistance of a cell against a target nucleic acid or a transcription product thereof comprising the steps of: 40 (i) identifying a sequence (e.g., a conserved sequence) in an organism (in some embodiments, this is a sequence that is essential to the function or survival of the organism); (ii) preparing a CRISPR spacer 8 5 which is homologous to the identified sequence; (iii) preparing a nucleic acid (e.g., a recombinant nucleic acid) comprising at least one cas gene and at least two CRISPR repeats together with the CRISPR spacer; and (iv) introducing the nucleic acid into a cell thus to render the cell resistant to the target nucleic acid or transcription product thereof. The present invention also provides methods for modulating (e.g., conferring or increasing) the [0 resistance of a cell against a target nucleic acid or a transcription product thereof comprising the steps of: (i) identifying one or more CRISPR spacers or pseudo CRISPR spacers in an organism resistant to the target nucleic acid or transcription product thereof; (ii) preparing a recombinant nucleic acid comprising at least one cas gene or protein and at least two CRISPR repeats together with the identified one or more spacers; and (iii) introducing the recombinant nucleic acid into a cell thus to render the cell resistant to [5 the target nucleic acid or transcription product thereof. The present invention also provides methods for modulating (e.g., conferring or increasing) the resistance of a cell comprising at least one or more cas genes or proteins and two or more CRISPR repeats against a target nucleic acid or a transcription product thereof comprising the steps of: (i) identifying one or more CRISPR spacers in an organism resistant to the target nucleic acid or !0 transcription product thereof; and (ii) modifying the sequence of one or more CRISPR spacer(s) in the cell such that the CRISPR spacer(s) has homology to the CRISPR spacer(s) in the organism. The present invention also provides methods for modulating (e.g., reducing or decreasing) the resistance of a cell comprising at least one or more cas genes or proteins and two or more CRISPR repeats against a target nucleic acid or a transcription product thereof comprising the steps of: (i) !5 identifying one or more CRISPR spacers in an organism that is substantially resistant to the target nucleic acid or transcription product thereof; and (ii) modifying the sequence of at least one or more CRISPR spacer(s) in the cell such that the CRISPR spacer(s) has a reduced degree of homology to the spacer(s) in the organism. The present invention also provides methods for modulating (e.g., reducing or decreasing) the 30 resistance of a cell comprising at least one or more cas genes or proteins and two or more CRISPR repeats against a target nucleic acid or a transcription product thereof comprising modifying the one or more cas genes or proteins and/or two or more CRISPR repeats in the cell. The present invention also provides methods for identifying a CRISPR spacer or pseudo CRISPR spacer for use in modulating the resistance of a cell against a target nucleic acid or a transcription product 35 thereof comprising the steps of: (i) preparing a cell comprising at least two CRISPR repeats and at least one cas gene or protein; (ii) identifying at least one CRISPR spacer or pseudo CRISPR spacers in an organism that is substantially resistant to the target nucleic acid or transcription product thereof; (iii) modifying the sequence of the CRISPR spacer in the cell such that the CRISPR spacer has homology to the spacer of the organism; and (iv) determining if the cell modulates resistance against the target nucleic 40 acid or transcription product thereof, wherein modulation of the resistance of the cell against the target 9 5 nucleic acid or transcription product thereof is indicative that the CRISPR spacer modulates the resistance of the cell. The present invention also provides methods for identifying a cas gene for use in modulating the resistance of a cell against a target nucleic acid or transcription product thereof comprising the steps of: (i) preparing a cell comprising at least one CRISPR spacer and at least two CRISPR repeats; (ii) [0 engineering the cell such that it comprises at least one cas gene; and (iii) determining if the cell modulates resistance against the target nucleic acid or transcription product thereof, wherein modulation of the resistance of the cell against the target nucleic acid or transcription product thereof is indicative that the cas gene can be used to modulate the resistance of the cell. The present invention also provides methods for identifying a CRISPR repeat for use in [5 modulating the resistance of a cell against a target nucleic acid or transcription product thereof comprising the steps of: (i) preparing a cell comprising at least one CRISPR spacer and at least one cas gene; (ii) engineering the cell such that it contains the CRISPR repeat; and (iii) determining if the cell modulates resistance against the target nucleic acid or transcription product thereof, wherein modulation of the resistance of the cell against the target nucleic acid or transcription product thereof is indicative !0 that the CRISPR repeat can be used to modulate resistance. The present invention also provides methods for identifying a functional combination of a cas gene and a CRISPR repeat comprising the steps of: (a) determining the sequences of the cas gene and the CRISPR repeat; (b) identifying one or more clusters of cas genes as determined by sequence comparison analysis; (c) identifying one or more clusters of CRISPR repeats; and (d) combining those cas gene and !5 CRISPR repeat sequences that fall within the same cluster, wherein the combination of the cas gene and CRISPR repeat sequences within the same cluster is indicative that the combination is a functional combination. The present invention also provides methods for modulating the lysotype of a bacterial cell comprising one or more cas genes or proteins and two or more CRISPR repeats comprising the steps of: 30 (i) identifying one or more pseudo CRISPR spacers in the genomic sequence of a bacteriophage against which resistance is to be modulated; and (ii) modifying the sequence of one or more CRISPR spacers of the bacterial cell such that the CRISPR spacer(s) of the bacterial cell has homology to the pseudo CRISPR spacer(s) of the bacteriophage against which resistance is to be modulated. The present invention also provides methods for modulating (e.g., conferring or increasing) the 35 resistance of a bacterial cell against a bacteriophage comprising the steps of: (i) identifying a sequence (e.g., a conserved sequence) in a bacteriophage (preferably, a sequence essential to the function or survival of the bacteriophage); (ii) preparing a CRISPR spacer which is homologous to the identified sequence; (iii) preparing a nucleic acid comprising at least one cas gene and at least two CRISPR repeats together with the CRISPR spacer; and (iv) introducing the nucleic acid into the bacterial cell thus to 40 render the bacterial cell resistant to the target nucleic acid or transcription product thereof.

10 5 The present invention also provides methods for modulating (e.g., conferring or increasing) the resistance of a bacterial cell against a target nucleic acid or transcription product in a bacteriophage thereof comprising the steps of: (i) identifying one or more pseudo CRISPR spacers in a bacteriophage genome that is capable of providing resistance to the target nucleic acid or transcription product thereof; (ii) preparing a recombinant nucleic acid comprising at least one cas gene and at least two CRISPR [0 repeats together with the identified one or more pseudo CRISPR spacers; and (iii) introducing the recombinant nucleic acid into the bacterial cell thus to render the bacterial cell resistant to the target nucleic acid or transcription product thereof. The present invention also provides methods for modulating the resistance of a bacterial cell comprising one or more cas genes or proteins and two or more CRISPR repeats against a target nucleic [5 acid or transcription product thereof in a bacteriophage comprising the steps of: (i) identifying one or more pseudo CRISPR spacers in a bacteriophage that is capable of providing resistance to a target nucleic acid or transcription product thereof; (ii) identifying one or more CRISPR spacers in a bacterial cell in which resistance is to be modulated; and (iii) modifying the sequence of the CRISPR spacer(s) in the bacterial cell in which resistance is to be modulated such that the CRISPR spacer(s) has a higher !0 degree of homology to the pseudo CRISPR spacer(s) of the bacteriophage against which resistance is to be modulated. The present invention also provides methods for determining the resistance of a cell against a target nucleic acid or a transcription product thereof comprising identifying one or more functional CRISPR repeat-cas combinations and one or more CRISPR spacers in the cell. !5 The present invention also provides cells obtained or obtained using the method(s) provided herein. In some embodiments, the present invention provides CRISPR spacers or pseudo CRISPR spacers obtained or obtainable by the method(s) described herein. In some embodiments, the present invention provides cas genes obtained or obtainable by the method(s) described herein. In some further embodiments, the present invention provides CRISPR 30 repeats obtained or obtainable by the method(s) described herein. In yet further embodiments, the present invention provides functional combinations obtained or obtainable by the method(s) described herein. In still further embodiments, the present invention provides recombinant CRISPR loci comprising at least one CRISPR spacer or pseudo CRISPR spacer, and/or at least one cas gene, and/or at least one CRISPR repeat and/or a functional combination. 35 In some embodiments, the present invention provides methods for the use of cells, at least one CRISPR spacer or pseudo CRISPR spacer, at least one cas gene, at least one CRISPR repeat, or a functional combination thereof for modulating the resistance of a cell against a target nucleic acid or a transcription product thereof. In some further embodiments, the present invention provides cell cultures comprising at least one 40 cell, at least one CRISPR spacer or pseudo CRISPR spacer, at least one cas gene, at least one CRISPR 11 5 repeat or a functional combination for modulating the resistance of a cell against a target nucleic acid or a transcription product thereof. In still further embodiments, the present invention provides food products and/or feed comprising cultures provided herein. In some additional embodiments, the present invention provides processes for preparing a food product and/or feed comprising cultures provided herein. In yet additional [0 embodiments, the present invention provides food products and/or feed obtained or obtainable by the methods provided herein. In some preferred embodiments, the present invention provides methods for the use of the cultures provided herein for preparing food products and/or feed. The present invention further provides nucleotide sequences comprising or consisting of the sequences set forth in any of SEQ ID NOS:7-10 and SEQ ID NOS:359-405, as well as variants, [5 fragments, homologues and derivatives thereof. The present invention also provides amino acids encoded by the nucleotide sequences set forth herein. In yet further embodiments, the present invention provides constructs and/or vectors comprising one or more of the nucleotide sequences provided herein. The present invention also provides host cells comprising at least one of the constructs and/or nucleotide sequences provided herein. !0 In some embodiments, the one or more cas genes or proteins are used in combination with two or more CRISPR repeats. In some further embodiments, the one or more cas genes or proteins and/or the two or more CRISPR repeats are derived from the same cell. In some additional embodiments, the one or more cas genes or proteins and the two or more CRISPR repeats naturally co-occur in the same cell. In some still further embodiments, the one or more cas genes or proteins are used in combination with !5 one or more CRISPR spacers. In some embodiments, the CRISPR spacer(s) is derived from a different organism than the cell from which the one or more cas genes or proteins and/or the two or more CRISPR repeats are derived. In some embodiments, the spacer is obtained from a cell which is resistant to a target nucleic acid. In some embodiments, the CRISPR spacer is a synthetic nucleic acid sequence. In some further 30 embodiments, the CRISPR spacer(s) have homology to the target nucleic acid. In some embodiments, the CRISPR spacer(s) have 100% identity to the target nucleic acid over at least the length of the CRISPR spacer core. In some embodiments, the one or more cas genes or proteins are used in combination with at least one or more CRISPR spacers and at least two or more CRISPR repeats. In some embodiments, the 35 target nucleic acid or transcription product thereof is derived from bacteriophage DNA. In yet further embodiments, the target nucleic acid or transcription product thereof is derived from at least one plasmid. In some further embodiments, the target nucleic acid or transcription product thereof is derived from at least one mobile genetic element DNA. In some embodiments, the target nucleic acid or transcription product thereof is derived from a transposable element and/or an insertion sequence. In some alternative 40 embodiments, the target nucleic acid or transcription product thereof is derived from an antibiotic/antimicrobial resistance gene. In some further embodiments, the target nucleic acid or 12 5 transcription product thereof is derived from a nucleic acid encoding at least one virulence factor. In some preferred embodiments, the virulence factor comprises toxins, internalins, hemolysins, and/or other virulence factors. In some embodiments of the present invention, the one or more cas genes and the two or more CRISPR repeats are derived from the same cell. In some alternative embodiments, the one or more cas [0 genes and the two or more CRISPR repeats naturally co-occur in the same cell. In yet further embodiments, the CRISPR spacers are derived from a different organism than the cell from which the one or more cas genes and/or the two or more CRISPR repeats are derived. In some embodiments, the cell is a recipient cell or a host cell. In some embodiments, the one or more cas genes or proteins and/or the two or more CRISPR [5 repeats are derived from the same cell. In some embodiments, the spacers are derived from a different organism than the cell comprising the one or more cas genes or proteins and/or the two or more CRISPR repeats. In some embodiments, the one or more cas genes or proteins and the two or more CRISPR repeats naturally co-occur in the same cell. !0 In some embodiments, the modification comprises inserting one or more CRISPR spacers and/or pseudo CRISPR spacers into the cell. In some embodiments, the modification comprises genetically engineering the CRISPR spacer of the cell. In some embodiments, the spacer of the cell has 100% homology to the CRISPR spacer or pseudo CRISPR spacer of the organism. In some embodiments, all or part of the spacer in the cell is modified. In some embodiments, the modification comprises the !5 modification of a recombinant spacer. In some embodiments, the modification occurs through spontaneous mutation or mutagenesis. In some embodiments, at least one or more CRISPR spacer(s) in the cell are deleted. In some embodiments, at least one or more CRISPR repeat(s) in the cell are deleted. In some embodiments, one or more cas genes are deleted. In some embodiments, CRISPR and/or one or more cas genes are deleted. In some embodiments, the one or more cas genes or proteins and/or two or 30 more CRISPR repeats in the cell are deleted. In some embodiments, the nucleotide sequences of the cas gene and the CRISPR repeat are derived from the same or different strains. In some embodiments, the nucleotide sequences of the cas gene and the CRISPR repeat are derived from the same or different species. In some embodiments, the nucleotide sequences of the cas gene and the CRISPR repeat are 35 derived from the same or different genera. In some embodiments, the nucleotide sequences of the cas gene and the CRISPR repeat are derived from the same or different organisms. In some embodiments of the present invention, the target nucleic acid in the bacteriophage is a highly conserved nucleic acid sequence. In some embodiments, the target nucleic acid in the bacteriophage encodes a host specificity protein. In some further embodiments, the target nucleic acid in 40 the bacteriophage encodes a protein that is essential for survival, replication or growth of the bacteriophage. In some embodiments, the target nucleic acid in the bacteriophage encodes a helicase, a 13 5 primase, a head or tail structural protein, a protein with a conserved domain (e.g., holin, lysin, etc.) or at least one conserved sequence amongst important phage genes. In some embodiments, the method for determining the resistance of a cell to a target nucleic acid or a transcription product thereof comprises the additional step of comparing the sequence of the one or more CRISPR spacers in the cell with the sequence of the target nucleic acid. In some alternative [0 embodiments, the method for determining the resistance of a cell to a target nucleic acid or a transcription product thereof comprises the additional step of determining the resistance profile of the cell. In some embodiments, the culture is a starter culture or a probiotic culture. The present invention also provides "labelled bacteria" that are resistant to phage (i.e., [5 "bacteriophage-insensitive mutants"; "BIMs"). In some embodiments, the present invention provides bacteria comprising one or more sequences originating from at least one bacteriophage genome that is/are integrated into the CRISPR locus of the bacteria. This phage-derived sequence provides a label, which is identifiable by its location and/or sequence and/or adjacent sequence. In some alternative embodiments, the present invention provides duplicated sequences (e.g., !0 duplicated CRISPR repeats) that originate from a parent bacterium and are also integrated iteratively, sequentially, simultaneously or substantially simultaneously along with the sequence originating from the bacteriophage genome. In addition, the present invention provides methods that facilitate the integration of one or more different bacteriophage sequences into the CRISPR locus of the bacterial strain. In some embodiments, !5 the integration of different bacteriophage sequences in the CRISPR locus of the bacterial strain is a random event. In some alternative embodiments, the integration of different bacteriophage sequences in the CRISPR locus of the bacterial strain is not a random event. Thus, it is not always the same locus of the bacteriophage genome which is integrated into the CRISPR locus of the bacterium. However, once it is integrated it is maintained and thus becomes a robust tag to label and/or track the bacterium. 30 Accordingly, the one or more sequences originating from the bacteriophage genome are not only new to the CRISPR locus of the parent bacterium but are also a label that is unique to each bacterium. There is therefore provided herein methods for labelling (e.g., tagging) and/or identifying bacteria. In some embodiments, the methods of the present invention are "natural" and do not result in the production of genetically modified organisms. In some preferred embodiments, the present invention 35 provides methods for labelling bacteria comprising the steps of: (a) exposing a parent bacterium to a bacteriophage; (b) selecting a bacteriophage insensitive mutant; (c) comparing a CRISPR locus or a portion thereof from the parent bacterium and the bacteriophage insensitive mutant; and (d) selecting a labelled bacterium comprising an additional DNA fragment in the CRISPR locus that is not present in the parent bacterium. 40 The present invention also provides labelled bacteria obtained using the methods of the present invention. In some embodiments, the present invention provides cell cultures comprising at least one 14 5 labelled bacterial strain. In still further embodiments, the present invention provides food and/or feed comprising labelled bacteria, including but not limited to cell cultures comprising such labelled bacteria. The present invention also provides methods for preparing food and/or feed comprising at least one labelled bacterial strain. In some embodiments, the methods comprise adding at least one labelled bacterial strain or cell culture to the food and/or feed. [0 The present invention also provides methods for generating CRISPR variants comprising the steps of: (a) exposing a parent bacterium to a bacteriophage; (b) selecting a bacteriophage resistant bacterium (i.e., a "bacteriophage insensitive mutant); (c) comparing the CRISPR locus or a portion thereof from the parent bacterium and the bacteriophage insensitive mutant; (d) selecting a labelled bacterium comprising an additional DNA fragment in the CRISPR locus that is not present in the parent [5 bacterium; and (e) isolating and/or cloning and/or sequencing the additional DNA fragment. The present invention also provides CRISPR variants produced using the methods set forth herein. In some particularly preferred embodiments, the CRISPR variants are phage resistant mutant strains that have a modified CRISPR locus with an additional spacer. In some additional embodiments, the present invention also provides methods for the use of at !0 least one nucleotide sequence obtained or obtainable from a bacteriophage for tagging and/or identifying bacteria, wherein the nucleotide sequence is integrated within the CRISPR locus of the parent bacterium. In still further embodiments, the present invention provides methods for the use of at least one nucleotide sequence for labelling and/or identifying a bacterium, wherein the nucleotide sequence is obtained or obtainable by: (a) exposing a parent bacterium to a bacteriophage; (b) selecting a !5 bacteriophage insensitive mutant; (c) comparing a CRISPR locus or a portion thereof from the parent bacterium and the bacteriophage insensitive mutant; and (d) selecting a labelled bacterium comprising an additional DNA fragment in the CRISPR locus that is not present in the parent bacterium. In yet additional embodiments, the present invention provides methods for identifying a labelled bacterium comprising the step of screening the bacterium for an additional DNA fragment within a CRISPR locus 30 of the bacterium is also provided in a further aspect of the present invention. In yet further embodiments, the present invention provides methods for identifying labelled bacteria comprising the steps of: (a) screening the bacteria for an additional DNA fragment in a CRISPR locus; (b) determining the nucleotide sequence of the additional DNA fragment; (c) comparing the nucleotide sequence of the additional DNA fragment with a database of labelled bacteria obtained or 35 obtainable by the method of the present invention; and (d) identifying a nucleotide sequence in the database of labelled bacteria that matches the additional DNA fragment. In some preferred embodiments, the 5' end and/or the 3' end of the CRISPR locus of the parent bacterium is compared with the labelled bacteria. In some alternative preferred embodiments, at least the first CRISPR repeat or the first CRISPR spacer (e.g., the first CRISPR spacer core) at the 5' end of the 40 CRISPR locus is compared. In yet further embodiments, at least the last CRISPR repeat or the last CRISPR spacer (e.g., the last CRISPR spacer core) at the 3' end of the CRISPR locus is/are compared.

15 5 In some preferred embodiments, the methods of the present invention comprise the step of selecting a labelled bacterium comprising an additional DNA fragment at the 5' end and/or at the 3' end of the CRISPR locus that is not present in the parent bacterium. In some alternative embodiments, the methods further comprise exposing the parent bacterium to two or more bacteriophages either simultaneously or sequentially. In yet further embodiments, the CRISPR locus or a portion thereof from [0 the parent bacterium and the bacteriophage insensitive mutant are compared by amplifying the CRISPR locus or a portion thereof from the parent bacterium and/or bacteriophage insensitive mutant. In some particularly preferred embodiments, the amplification is performed using PCR. In some alternative embodiments, the CRISPR locus or a portion thereof from the parent bacterium and the bacteriophage insensitive mutant are compared by sequencing the CRISPR locus or a portion thereof from the parent [5 bacterium and/or the bacteriophage insensitive mutant. In some preferred embodiments, the CRISPR locus or a portion thereof from the parent bacterium and the bacteriophage insensitive mutant are compared by amplifying and then sequencing the CRISPR locus or a portion thereof from the parent bacterium and/or the bacteriophage insensitive mutant. In some alternative preferred embodiments, the additional DNA fragment is at least 44 nucleotides in length. In some additional preferred embodiments, !0 the labelled bacteria comprise two or three or more additional DNA fragments is selected. In yet further embodiments, the additional DNA fragment comprises at least one nucleotide sequence that has at least about 95% identity, or preferably, 100% identity to a CRISPR repeat in the CRISPR locus of the parent bacterium. In still further embodiments, the additional DNA fragment comprises at least one nucleotide sequence that has at least about 95% identity, and in some embodiments, preferably about 100% identity !5 to a nucleotide sequence in the genome of the bacteriophage used for the selection of the labelled bacterium. In some embodiments, the present invention also provides at least one additional DNA fragment that comprises a first nucleotide sequence and a second nucleotide sequence wherein at least one of the nucleotide sequences have at least about 95% identity, or in some preferred embodiments, about 100% identity to a nucleotide sequence in the genome of the bacteriophage used for the selection of 30 the labelled bacteria. In some embodiments, the present invention provides parent bacteria that are suitable for use as starter cultures, probiotic cultures and/or dietary supplements. In some embodiments, the parent bacteria are selected any suitable genus, including but not limited to Escherichia, Shigella, Salmonella, Erwinia, Yersinia, Bacillus, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, 35 Agrobacterium, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Francisella, Brucella, Bifidobacterium, Brevibacterium, Propionibacterium, Lactococcus, Lactobacillus, Pediococcus, Leuconostoc, and Oenococcus. In some embodiments, the bacteriophage is selected from a suitable virus family, including but not limited to Corticoviridae, Cystoviridae, Inoviridae, Leviviridae, Microviridae, Myoviridae, Podoviridae, 40 Siphoviridae, and Tectiviridae. In some embodiments, the present invention provides cell cultures that are selected from starter cultures, probiotic cultures and/or dietary supplements. In some particularly 16 5 preferred embodiments, the present invention provides methods for identifying labelled bacteria, comprising the step of comparing at least one additional DNA fragment with a bacteriophage sequence database and/or a bacterial sequence database. The present invention also provides S. thermophilus strains comprising a sequence obtained or obtainable from a bacteriophage, wherein the sequence comprises the CRISPR spacer from Streptococcus [0 thermophilus strain DGCC7778, referred to herein as SEQ ID NO:680 (caacacattcaacagattaatgaagaatac; SEQ ID NO:680). In yet additional embodiments, the present invention provides S. thermophilus strains comprising a sequence obtained or obtainable from a bacteriophage, wherein the sequence comprises SEQ ID NO:680 downstream (e.g., directly downstream) of the first CRISPR repeat in at least one CRISPR locus. [5 In further embodiments, the present invention provides S. thermophilus strains comprising a sequence obtained or obtainable from a bacteriophage, wherein the sequence comprises CRISPR spacer (5'-3') from Streptococcus thermophilus strain DGCC7778 (tccactcacgtacaaatagtgagtgtactc; SEQ ID NO:68 1). In yet additional embodiments, the present invention provides S. thermophilus strains comprising a sequence obtained or obtainable from a bacteriophage, wherein the sequence comprises !0 SEQ ID NO:681 downstream (e.g., directly downstream) of the first CRISPR repeat in at least one CRISPR locus. In still further embodiments, the present invention provides S. thermophilus strains comprising a sequence obtained or obtainable from a bacteriophage, wherein the sequence comprises SEQ ID NO:683: !5 CRISPRI sequence (5'-3') of Streptococcus thermophilus strain DGCC7710-RH1 caaggacagttattgattttataatcactatgtgggtataaaaacgtcaaaatttcatttgag GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACtcaacaattgcaacatcttataacccactt GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACtgtttgacagcaaatcaagattcgaattgt ;0 GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACaatgacgaggagctattggcacaacttaca GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACcgatttgacaatctgctgaccactgttatc GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACacacttggcaggcttattactcaacagcga GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACctgttccttgttcttttgttgtatcttttc GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACttcattcttccgtttttgtttgcgaatcct 35 GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACgctggcgaggaaacgaacaaggcctcaaca GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACcatagagtggaaaactagaaacagattcaa GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACataatgccgttgaattacacggcaaggtca GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACgagcgagctcgaaataatcttaattacaag GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACgttcgctagcgtcatgtggtaacgtattta 40 GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACggcgtcccaatcctgattaatacttactcg GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACaacacagcaagacaagaggatgatgctatg GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACcgacacaagaacgtatgcaagagttcaag GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACacaattcttcatccggtaactgctcaagtg GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACaattaagggcatagaaagggagacaacatg 45 GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACcgatatttaaaatcattttcataacttcat GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACgcagtatcagcaagcaagctgttagttact GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACataaactatgaaattttataatttttaaga GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACaataatttatggtatagcttaatatcattg GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACtgcatcgagcacgttcgagtttaccgtttc 50 GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACtctatatcgaggtcaactaacaattatgct GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACaatcgttcaaattctgttttaggtacattt GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACaatcaatacgacaagagttaaaatggtctt GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACgcttagctgtccaatccacgaacgtggatg 17 5 GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACcaaccaacggtaacagctactttttacagt GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACataactgaaggataggagcttgtaaagtct GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACtaatgctacatctcaaaggatgatcccaga GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACaagtagttgatgacctctacaatggtttat ) GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACacctagaagcatttgagcgtatattgattg [0 GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACaattttgccccttctttgccccttgactag GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACaccattagcaatcatttgtgcccattgagt GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAGTTtgattcaacataaaaagccagttcaattg aacttggcttt (SEQ ID NO:683) [5 In yet additional embodiments, the present invention provides S. thermophilus strains comprising a sequence obtained or obtainable from a bacteriophage, wherein the sequence comprises SEQ ID NO:683 downstream (e.g., directly downstream) of the first CRISPR repeat in at least one CRISPR locus. S. thermophilus strains comprising a sequence obtained or obtainable from a bacteriophage, wherein the sequence comprises SEQ ID NO:685 (i.e., 5'-TACGTTTGAAAAGAATATCAAATCAATGA-3'). !0 In yet additional embodiments, the present invention provides S. thermophilus strains comprising a sequence obtained or obtainable from a bacteriophage, wherein the sequence comprises SEQ ID NO:685 downstream (e.g., directly downstream) of the first CRISPR repeat in at least one CRISPR locus. In some embodiments, the present invention provides methods and compositions that find use in the development and use of strain combinations and starter culture rotations. In some additional !5 embodiments, the use of one or more CRISPR BIMs simultaneously in a starter cultures (i.e., a combination of BIMs) is provided. In some further embodiments, the use of one or more CRISPR BIMs in a rotation scheme is provided. In some further embodiments, the use of one or more CRISPR BIMs combinations in a rotation scheme is provided. The present invention also provides means to analyze target organism CRISPRs, in order to ;0 allow comparisons between spacer sequences against biocontrol phage genome. In some embodiments, the present invention provides means to predict phage virulence and selection of at least one biocontrol phage against at least one target microorganism. The present invention also provides methods and compositions to utilize CRISPR-cas (i.e., natural mutagenesis, in some preferred embodiments) to construct at least one phage resistant CRISPR 35 variant of at least target microorganism which is then used to generate mutant phage that circumvent CRISPR-cas resistance via mutation within the phage corresponding to a sequence selected from spacer sequences, pseudospacer sequences, proximal sequence, recognition motifs, etc., to enhance the virulence of the phage. In some preferred embodiments, phage with enhanced virulence find use as biocontrol agents. 40 In some embodiments, the present invention provides compositions and methods suitable for the production of phage having enhanced virulence, as compared to the parent phage. In some embodiments, at least one cloned spacer is introduced into an active CRISPR-cas locus, to produce a phage-resistant cell variant for use in the generation of mutant phage. In some preferred embodiments, the methods comprise introducing a sequence that serves as a specific target of a phage genome sequence (e.g., a 45 region that is highly susceptible as a spacer target or recognition sequence for spacer host incorporation).

18 5 In some additional embodiments, the present invention provides methods and compositions for the direct engineering of phage, such that the genome sequence corresponding to the spacer is mutated accordingly. The present invention also provides methods to direct the evolution of a given phage using the acquired CRISPR phage resistance of a corresponding host strain to create a more virulent, therefore effiective, biocontrol agent. [0 DESCRIPTION OF THE DRAWINGS Figure 1 provides a schematic showing that the integration of a CRISPR spacer into the CRISPR locus of S. thermophilus provides resistance against a bacteriophage to which the CRISPR spacer shows identity. The parent DGCC7710 is phage sensitive, and the BIM DGCC7710RH1 is phage resistant. The [5 BIM DGCC7710RH1 has a new spacer (Sn) in the CRISPR locus, which shows 100% identity to phage sequence. As shown in step (B), the strain is challenged with phage 858 and a phage resistant mutant is selected. As shown in step (C), the CRISPR I locus of the mutant has an additional spacer which shares 100% identity with region 31.921-31.950bp of the phage. Figure 2 provides a schematic showing that integration of a CRISPR spacer into the CRISPR !0 locus of S. thermophilus provides resistance against a bacteriophage to which the CRISPR spacer shows identity. The parent DGCC7710 is phage sensitive, and the BIM DGCC7710RH2 is phage resistant. The BIM DGCC7710RH2 has a new spacer (Sn) in the CRISPR locus, which shows 100% identity to phage sequence. As shown in step (B), the strain is challenged with phage 858 and a phage resistant mutant is selected. As shown in step (C,) the experiment was independently repeated and another mutant !5 was selected. The CRISPR I locus of the mutant has an additional spacer (different from that in RHI) which shares 100% identity with region 17.125-17.244bp of the phage. Figure 3 provides a graphical representation illustrating the preparation of the CAS 1 KO construct in which the cas] gene is disrupted by homologous recombination. Figure 4 provides a graphical representation of the preparation of the RT construct using a 30 restriction enzyme to generate the RT construct from the S1S2 construct. There are BglI restriction sites within the repeats that allow the "middle" part of the construct to be cut. Following enzymatic digestion, a ligase was used to patch together the two end pieces, thus generating a new construct that has RT, but no spacers. Figure 5 provides a graphical representation of the integration of the RT construct. 35 Figure 6 provides a graphical representation illustrating the S1S2 construct engineering using specific primers and iterative PCR reactions. The first panel illustrates all primers used and the set up for the first two PCR reactions (reaction #1 with primers P1 and P2 and reaction #2 with primers P2 and P3). The second panel shows the PCR products obtained from the first two PCR reactions, with the product from reaction #1 on the left and the product from reaction #2 on the right. The third panel shows the 40 third PCR reaction, using a combination of the products from the first two PCRs as the template for the 19 5 third PCR reaction, and primer P1 from the first reaction along with primer P4 from the second reaction. The fourth panel shows the product of PCR#3, which technically generates the S1S2 construct. Figure 7 provides a graphical representation of the details for primer design for primers 2 and 3, which contain key sequences for the experiment, derived from spacers identical to phage sequences (the PCR products derived from these PCR primers will generate the spacers that will ultimately provide [0 resistance to the phages). Figure 8 provides a graphical representation of the integration of the S 1S2 construct. Figure 9 provides a graphical representation showing an overview of the S. thermophilus CRISPRi locus, the newly acquired spacers in phage-resistant mutants, and corresponding phage sensitivity. The CRISPRi locus of DGCC7710 (WT) is at the top. The repeat/spacer region of WT is in [5 the middle: repeats (black diamonds), spacers (numbered gray boxes), leader (L, white box) and terminal repeat (T, black diamond). At the bottom, the spacer content on the leader side of the locus in phage resistant mutants is detailed on the left, with newly acquired spacers (white boxes, S 1-S14). On the right, the sensitivity of each strain to phages 858 and 2972 is represented as a histogram of the efficiency of plaquing (EOP), which is the plaque count ratio of a mutant strain to that of the wild-type. !0 Figure 10 provides CRISPR spacer engineering, cas gene inactivation and corresponding phage sensitivity. I, mutant WT 858+s II, mutant WT 858+SiS2 CRISPRi where CRISPRi was deleted; III, mutant WT 8 5 8 +sis 2 ::pR where CRISPRi was displaced and replaced with a unique repeat; IV, WT 2972+S 4 ::pS 1S2, mutant of strain WT 2972+S4 where CRISPRi was displaced and replaced with a -Si S2 -4SS2 version containing S1 and S2; V, WT 858+S ::pcas5- with cas5 inactivated; VI, WT 858+S ::pcas7- with !5 cas7 inactivated. pORI indicates the integrated plasmid (12). The phage sensitivity of each strain to phages 858 and 2972 is represented at the bottom as a histogram of the efficiency of plaquing (EOP). Figure 11 provides a schematic showing the construction of the S1S2 construct. Figure 12 provides a schematic showing the construction of WT 858+Sis2 CRISPRi. Figure 13 provides an alignment of CRISPR spacer S1 with the corresponding genomic region of 30 phage 858 and the two mutant phages that have circumvented the CRISPR resistance of strain -S S2 WT 858+s2 Figure 14 provides a schematic representation of the construction of a first level phage resistant variant. Each variant has a single additional spacer within its CRISPR. Additional spacers are unrelated to each of the others (e.g., each has a different sequence). All spacers originate from phage P. 35 Figure 15 provides a schematic representation of second level of phage resistant variants presenting increased resistance to phages. Final variants (Al.n and A2.n) originate from strain A and have a sequential integration of additional spacers within its CRISPR, with all spacers being different from each of the others and originating from phage P. Figure 16 provides a schematic representation of second level of phage resistant variants 40 presenting enlarged resistance to phages. Final variant (AlPqr) originates from strain A and has a 20 5 sequential integration of additional spacers within its CRISPR originating from 3 different phages (i.e., from phage P, Q and R). Figure 17 provides a schematic representation of the CRISPRI locus (Panel A) and of the CRISPR3 locus (Panel B) of S. thermophilus strains described in Examples 7 to Example 16. Strain names are given on the left side of the Figure. Black arrows represent CRISPR repeats, "R" stands for [0 Repeat and "RT" stands for Terminal Repeat. Grey arrows numbered from 1 to 32 in part A and from 1 to 12 in part B represent CRISPRI spacers and CRISPR3 spacers, respectively, as they are in DGCC7710. White arrows numbered from S4 to S35 represent CRISPR additional spacers specific to the described strains. Figure 18 provides a schematic showing an embodiment of the present invention, in which a [5 tagging sequence and a CRISPR repeat are integrated at one end of the CRISPR locus. In Panel A, the CRISPR locus and elements, including repeats (R), spacers (S), the upstream leader and downstream trailer, with the terminal repeat (RT) adjacent to the trailer, and cas genes in the vicinity (4 cas genes named cas] to cas4 herein, not drawn to scale) are indicated. The cas genes can be on either end, or split and present on both ends. In addition, cas genes may be located on any of the two DNA strands. Panel B !0 shows the phage sequence, with a fragment of the sequence (Sn) being used as an additional spacer (i.e., tagging sequence). Panel C shows insertion of a new spacer (Sn) (i.e., tagging sequence) at one end of the CRISPR locus (close to the leader in this example at the 5' end of the CRISPR locus), between two repeats. Panel D provides a comparison of the CRISPR locus content between the parent and the mutant bacterium (i.e., labelled bacterium), with a new spacer (Sn) (i.e., tagging sequence) integrated at one end !5 of the CRISPR locus (close to the leader in this example), between repeats. The new spacer (Sn) constitutes the tagging sequence which is specific for the mutant bacterium (i.e., labelled bacterium). In some embodiments, use of this method results in the addition of one or more spacers from the phage sequence. Figure 19 provides a schematic showing an embodiment of the present invention, in which two 30 tagging sequences and two CRISPR repeats are integrated at one end of the CRISPR locus. In Panel A, (A) CRISPR locus and elements, including repeats (R), spacers (S), the upstream leader and downstream trailer, with the terminal repeat (RT) adjacent to the trailer, and cas genes in the vicinity (4 cas genes named cas] to cas4 herein, not drawn to scale) are indicated. The cas genes can be on either end, or split and present on both ends. cas genes may be located on any of the two DNA strands. Panel B shows the 35 phage sequence in black, with two fragments of the sequence (Sn and Sn') being used as additional spacers (i.e., tagging sequences). Panel C shows the insertion of the new spacers (i.e., tagging sequences) (Sn and Sn') at the same end of the CRISPR locus (close to the leader in this example at the 5' end), each of which is in between two repeats. Panel B provides a comparison of the CRISPR locus content between the parent and the mutant bacterium (i.e., labelled bacterium), with two new spacers (Sn and Sn') 40 integrated at the same end of the CRISPR locus (close to the leader in this example at the 5' end), with each located in between repeats. The new spacers Sn and Sn' constitute the tagging sequence which is 21 5 specific of the mutant. In some embodiments, this method results in the addition of one or more spacers from the phage sequence. Figure 20 provides a graph showing the evolution of phage count in milk containing 107 pfu/ml of D2972 during fermentation with DGCC7710 (black diamonds) or with DGCC9836 (open squares). Milk was 10% (w/v) milk powder in water. The incubation temperature was 42'C. [0 Figure 21 provides a graph showing the evolution of the cumulated phage count on WTphi 29 72

+S

2 0 and WThi 2972 +s21 in milk containing 107 pfu/ml of D2972 during fermentation inoculated with WTphi 2 97 2

+S

20 (dashed) or with WTphi 29 72 +S21 (light grey) or with both WTphi 2 97 2

+S

2 0 and WTphi 29 72

+S

2 1 (dark grey). Milk was 10% (w/v) milk powder in water. The incubation temperature was 42'C. Figure 22 provides a Web Logo for the CRISPRI motif NNAGAAW (SEQ ID NO:696). [5 Figure 23 provides an alignment of selected CRISPR3 protospacers and flanking regions and the web logo for the CRISPR3 motif NGGNG (SEQ ID NO:723). In this Figure, S42 DGCC7710phi 2972 40 phi 382 14s41s42 (SEQ ID NO:724), S41 DGCC7710phi 2972 40 phi 382 1s 4 1 s 42 , (SEQ ID NO:699) S41 DGCC7710phig 5 g+S1S2deltaCRSPR1 phi848+S43 (SEQ ID NO:700), and S78 LMD-9phi 4 24 14S 7 8 (SEQ ID NO:701) are provided. !0 DESCRIPTION OF THE INVENTION The present invention provides methods and compositions related to modulating the resistance of a cell against a target nucleic acid or a transcription product thereof. In some preferred embodiments, the present invention provides compositions and methods for the use of one or more cas genes or proteins for !5 modulating the resistance of a cell against a target nucleic acid or a transcription product thereof. In some embodiments, the present invention provides methods and compositions that find use in the development and use of strain combinations and starter culture rotations. In additional embodiments, the present invention provides methods for labelling and/or identifying bacteria. In some preferred embodiments, the present invention provides methods for the use of CRISPR loci to determine the 30 potential virulence of a phage against a cell and the use of CRISPR-cas to modulate the genetic sequence of a phage for increased virulence level. In still further embodiments, the present invention provides means and compositions for the development and use of phages as biocontrol agents. Streptococcus thermophilus is a low G+C Gram-positive bacterial species that is a key species exploited in the formulation of dairy culture systems for the production of yogurt and cheese. 35 Comparative genomics analyses of closely related S. thermophilus strains have previously revealed that genetic polymorphism primarily occurs at hypervariable loci, such as the eps and rps operons, as well as two clustered regularly interspaced short palindromic repeats (CRISPR) loci (See e.g., Jansen et al., Mol. Microbiol., 43:1565 [2002]; Bolotin et al., Microbiol., 151:2551 [2005]; and Bolotin et al., Nat. Biotechnol., 22:1554 [2004]). As described herein in greater detail, CRISPR loci typically consist of 40 several non-contiguous direct repeats separated by stretches of variable sequences called spacers, and are often times adjacent to cas genes (CRISPR-associated). Although the function of CRISPR loci has not 22 5 been established biologically, in silico analyses of the spacers have revealed sequence homology with foreign elements, including bacteriophage and plasmid sequences (See e.g., Bolotin et al., Microbiol., supra; Mojica et al., supra; and Pourcel et al., supra). Based exclusively on in silico analyses, several hypotheses have been put forward proposing roles for CRISPR and cas genes, that include providing immunity against foreign genetic elements via a mechanism based on RNA interference (See, Makarova [0 et al., Biol. Direct., 1:7 [2006]). However, it is not intended that the present invention be limited to any particular mechanism and/or means of action. Current strategies used in industry to minimize bacteriophage infection and the resultant failure of bacterial cultures, include the use of: (i) mixed starter cultures; and (ii) the use of alternating strains having different phage susceptibility profiles (i.e., strain rotation). Traditionally, starter cultures used in [5 the dairy industry are mixtures of lactic acid bacterial strains. The complex composition of mixed starter cultures ensures that a certain level of resistance to phage attack is provided. However, repeated sub culturing of mixed strain cultures leads to unpredictable changes in the distribution of individual strains and eventually often to undesired strain dominance. This in turn may lead to increased susceptibility to phage attack and risk of fermentation failures. !0 The rotation of selected bacterial strains which are sensitive to different phages is another approach currently used to limit phage development. However, it is difficult and cumbersome to identify and select a sufficient number of strains having different phage type profiles to provide an efficient and reliable rotation program. In addition, the continuous use of strains requires careful monitoring for new infectious phages and the need to quickly substitute an infected strain with a resistant bacterial strain. In !5 manufacturing plants where large quantities of bulk starter cultures are prepared long before use, such a quick response is usually not possible. Thus, several attempts have been made to improve the resistance of cultures for use in industry. In addition, although it would be useful to have starter cultures that are labelled such that their origin could be determined, this has not been done. Indeed, although it is feasible to insert a synthetic 30 oligonucleotide into a strain to tag or label it, using recombinant DNA technologies, the labelled strain would be considered to be a genetically modified organism and may thereby face regulatory issues in commercial applications. Thus, there is a need in the art for natural methods and compositions suitable for introducing a unique sequence into bacteria that could be used to identify and/or track bacteria.

23 5 Bacteriophages are arguably the most abundant biological entity on the planet (See, Breitbart and Rohwer, Trends Microbiol., 13:278 [2005]). Their ubiquitous distribution and abundance have an important impact on microbial ecology and the evolution of bacterial genomes (See, Chibani-Chennoufi et al., J. Bacteriol., 186:3677 [2004]). Consequently, bacteria have developed a variety of natural defense mechanisms that target diverse steps of the phage life cycle, notably blocking adsorption, preventing [0 DNA injection, restricting the incoming DNA and abortive infection systems. These antiviral barriers can also be engineered and manipulated to better control phage populations (See e.g., Chibani-Chennoufi et al., supra; and Sturino and Klaenhammer, Nat. Rev. Microbiol., 4:395 [2006]). Numerous bacteria have been selected by humans and used extensively for fermentation and biotechnology processes. Unfortunately, domesticated bacteria used in industrial applications are often [5 susceptible to phage attack, including those genera and species widely used as dairy cultures (See, Brussow, Ann. Rev. Microbiol., 55:283 [2001]). Accordingly, the industry has devised various strategies to combat phage based on strain diversity, bacteriophage insensitive mutants, and plasmids bearing phage-resistance mechanisms. !0 Definitions Unless defined otherwise herein, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. Although any methods and materials similar or equivalent to those described herein find use in the practice of what is described herein, exemplary methods and materials are described herein. As used !5 herein, the singular terms "a", "an," and "the" include the plural reference unless the context clearly indicates otherwise. Unless otherwise indicated, nucleic acids are written left to right in 5' to 3' orientation; amino acid sequences are written left to right in amino to carboxy orientation, respectively. It is to be understood that this invention is not limited to the particular methodology, protocols, and reagents described, as these may vary, depending upon the context they are used by those of skill in the 30 art. It is intended that every maximum numerical limitation given throughout this Specification includes every lower numerical limitation, as if such lower numerical limitations were expressly written herein. Every minimum numerical limitation given throughout this specification will include every higher numerical limitation, as if such higher numerical limitations were expressly written herein. Every 35 numerical range given throughout this specification will include every narrower numerical range that falls within such broader numerical range, as if such narrower numerical ranges were all expressly written herein. As used herein, the term "naturally occurring" refers to elements and/or process that occur in nature. 40 As used herein, the terms "construct," "conjugate," "cassette," and "hybrid," include a nucleotide sequence directly or indirectly attached to another sequence (e.g., a regulatory sequence, such as a 24 5 promoter). In some embodiments, the present invention provides constructs comprising a nucleotide sequence operably linked to such a regulatory sequence. The term "operably linked" refers to a juxtaposition wherein the components described are in a relationship permitting them to function in their intended manner. A regulatory sequence "operably linked" to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under condition compatible with the control [0 sequences. As used herein, the term "regulatory sequences" includes promoters and enhancers and other expression regulation signals. As used herein, the term "promoter" is used in the normal sense of the art, e.g. an RNA polymerase binding site. In some embodiments, constructs comprise or express a marker, which allows for the selection of the nucleotide sequence construct in, for example, a bacterium. Various markers exist which may be used, for example those markers that provide for antibiotic/antimicrobial [5 resistance. In some embodiments, the construct comprises a vector (e.g., a plasmid). In some further embodiments, the present invention provides vectors comprising one or more of the constructs or sequences described herein. As used herein, the term "vector" includes expression vectors, transformation vectors, and shuttle vectors. The term "transformation vector" means a construct capable !0 of being transferred from one entity to another entity, which may be of the same species or may be a different species. Constructs that are capable of being transferred from one species to another are sometimes referred to as "shuttle vectors. In some embodiments, the vectors are transformed into a suitable host cell as described herein. In some embodiments, the vectors are plasmid or phage vectors provided with an origin of replication, optionally a promoter for the expression of the polynucleotide, and !5 optionally a regulator of the promoter. In some embodiments, the vectors contain one or more selectable marker nucleotide sequences. The most suitable selection systems for industrial micro-organisms are those formed by the group of selection markers which do not require a mutation in the host organism. In some embodiments, the vectors are used in vitro (e.g., for the production of RNA or used to transfect or transform a host cell). In some embodiments, polynucleotides are incorporated into a recombinant 30 vector (typically a replicable vector), such as a cloning or expression vector. The vector finds use in the replication of the nucleic acid in a compatible host cell. Introduction of a nucleic acid (e.g., a phage, construct or vector) into a cell can be effected by various methods. For example, in some embodiments, transduction, transformation, calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid-mediated transfection, electroporation, 35 transduction or infection may find use. Indeed, any suitable method known in the art finds use in the present invention. In some embodiments, cells containing exogenous nucleic acid (introduced by means of phage, construct, or a vector) are selected for using any suitable method known in the art. Teachings on the transformation of cells are well documented in the art, for example see Sambrook et al (Molecular Cloning: A Laboratory Manual, 2nd edition, 1989, Cold Spring Harbor 40 Laboratory Press) and Ausubel et al., Current Protocols in Molecular Biology (1995), John Wiley & Sons, Inc.

25 5 In the context of introducing a nucleic acid into a cell, in some embodiments, it is preferred that the term "introducing" means one or more of transforming, transfecting, conjugating or transducing. In some particularly preferred embodiments, bacterial strains (e.g., parent bacterial strains, variant bacterial strains, etc.) are "exposed" to at least one phage, such that the phage nucleic acid is introduced into the cells of the bacterial strain. [0 As used herein, the terms "nucleic acid sequence," "nucleotide sequence," and "nucleic acid," refer to any nucleic acid sequence, including DNA, RNA, genomic, synthetic, recombinant (e.g., cDNA). It is intended that the terms encompass double-stranded and/or single-stranded sequences, whether representing the sense or antisense strand or combinations thereof. Recombinant nucleic acid sequences are prepared by use of any suitable recombinant DNA techniques. In some embodiments, as described [5 herein, nucleic acid sequences provided include gene sequences that encode CRISPR, Cas, and other sequences. Indeed, as used in context, the present invention encompasses nucleic acid sequences that encode various CRISPR sequences, including but not limited to spacers, pseudo-spacers, leaders, etc., as well as cas sequences, and other bacterial and phage ("bacteriophage") nucleic acid sequences. The terms "nucleic acid molecule encoding," "nucleic acid sequence encoding," "DNA sequence !0 encoding," and "DNA encoding," refer to the order or sequence of deoxyribonucleotides along a strand of deoxyribonucleic acid. The order of these deoxyribonucleotides determines the order of amino acids along the polypeptide (protein) chain. The DNA sequence thus codes for the amino acid sequence. As used herein in the context of introducing a nucleic acid sequence into a cell, the term "introduced" refers to any method suitable for transferring the nucleic acid sequence into the cell. Such !5 methods for introduction include but are not limited to protoplast fusion, transfection, transformation, conjugation, and transduction. In some particularly preferred embodiments, nucleic acid is introduced into recipient cells upon infection of the cells by bacteriophage(s). In some embodiments, the nucleic acid sequences and the nucleic acids provided herein are isolated or substantially purified. By "isolated" or "substantially purified" is intended that the nucleic 30 acid molecules, or biologically active fragments or variants, homologues, or derivatives thereof are substantially or essentially free from components normally found in association with the nucleic acid in its natural state. Such components include, but are not limited to other cellular material, culture media, materials from recombinant production, and various chemicals used in chemically synthesising the nucleic acids. 35 In some embodiments, an "isolated" nucleic acid sequence or nucleic acid is typically free of nucleic acid sequences that flank the nucleic acid of interest in the genomic DNA of the organism from which the nucleic acid was derived (e.g., coding sequences present at the 5 or 3 ends). However, the molecule may include some additional bases or moieties that do not deleteriously affect the basic characteristics of the composition. 40 As used herein, the term "modification" refers to changes made within nucleic acid and/or amino acid sequences. In some embodiments, modifications are accomplished using genetic engineering (e.g., 26 5 recombinant) methods, while in other embodiments, modifications are made using naturally-occurring genetic mechanisms. It is intended that all or part of a sequence will be modified using the methods of the present invention. In some preferred embodiments, the nucleic acids modified include one or more naturally-occurring or recombinantly produced CRISPR spacers, cas genes or proteins, CRISPR repeats, CRISPR loci, as well as bacteriophage nucleic acids. Any suitable method known in the art finds use in [0 the present invention, including but not limited to use of PCR, cloning, site-directed mutagenesis, etc. Indeed, commercially available kits find use in the present invention. In some embodiments, synthetic oligonucleotides are used. In some embodiments, methods such as homologous recombination find use (e.g., for insertion or deletion of CRISPR spacers). In some embodiments, genetic engineering includes the activation of one or more nucleic acid sequences (e.g., CRISPR loci, CRISPR repeats, CRISPR [5 spacers, cas genes or proteins, functional combinations of cas genes or proteins and CRISPR repeats, or combinations thereof). In some embodiments, one or more CRISPR spacers or pseudo CRISPR spacers are inserted into at least one CRISPR locus. In some further embodiments, the modification does not interrupt one or more cas genes of the at least one CRISPR locus. In other embodiments, the one or more cas genes !0 remain intact. In some additional embodiments, the modification does not interrupt one or more CRISPR repeats of the at least one CRISPR locus. In some embodiments, the one or more CRISPR repeats remain intact. In some further embodiments, one or more CRISPR spacers or pseudo CRISPR spacers are inserted into or within at least one CRISPR locus. In some further embodiments, one or more CRISPR spacers or pseudo CRISPR spacers are inserted at the 5' end of at least one CRISPR locus. !5 In some embodiments, the modification comprises inserting at least one CRISPR spacer or pseudo CRISPR spacers into a cell (e.g., a recipient cell). In some other embodiments, the modification comprises inserting one or more CRISPR spacers or pseudo CRISPR spacers into (e.g., to modify or replace) one or more CRISPR spacers of a recipient cell. In some embodiments, the CRISPR spacers of the cell are the same, while in other embodiments, they are different. In some embodiments, the 30 modification comprises inserting at least one CRISPR spacer or pseudo CRISPR spacer from a donor organism into a recipient cell. In some further embodiments, the modification comprises inserting one or more CRISPR spacers or pseudo CRISPR spacers from a donor organism into a recipient cell under conditions suitable to modify or replace one or more CRISPR spacers or pseudo CRISPR spacers of the recipient cell. In some embodiments, one or more CRISPR spacers or pseudo CRISPR spacers from a 35 donor organism are inserted into one or more, preferably, two or more CRISPR repeats of the cell. In some preferred embodiments, at least one functional CRISPR repeat-cas combination remains intact in the cell. In some further embodiments, insertion occurs adjacent to one or more (preferably two or more) CRISPR spacers or pseudo-spacers. As used herein, the term "adjacent" means "next to" in its broadest 40 sense and includes "directly adjacent." Thus, in some embodiments, one or more CRISPR spacers or pseudo CRISPR spacers from an organism are inserted "directly adjacent" to one or more CRISPR 27 5 spacers or pseudo CRISPR spacers of the recipient cell. (i.e., the CRISPR spacer(s) or pseudo CRISPR spacer(s) is inserted such that there are no intervening nucleotides between the spacers). In some additional embodiments, the CRISPR spacer(s) or pseudo CRISPR spacer(s) are inserted such that there are at least about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 15, about 20, about 25, about 30, about 35, about 40, about 45, about 50, about 55, about 60, about t0 65, about 70, about 75, about 80, about 85, about 90, about 95, about 100, about 200, about 300, about 400, about 500, about 600, about 700, about 800, about 900, about 1000, about 10,000, 1 about 00,000, or about 1,000,000 or more intervening nucleotides between the spacers. In some further embodiments, the intervening nucleotide is referred to as a "leader sequence." These terms are used interchangeably herein. The leader sequence can be of a different length in [5 different bacteria. In some embodiments, the leader sequence is at least about 20, about 25, about 30, about 35, about 40, about 45, about 50, about 55, about 60, about 65, about 70, about 75, about 80, about 85, about 90, about 95, about 100, about 200, about 300, about 400, or about 500 or more nucleotides in length. In some preferred embodiments, the leader sequence is between the last cas gene (at the 3' end) and the first CRISPR repeat (at the 5' end) of the CRISPR locus. In some embodiments, the leader !0 sequence is between about 20-500 nucleotides in length. In some embodiments, one or more CRISPR spacers or pseudo CRISPR spacers from a donor organism are inserted adjacent to one or more cas genes of a recipient cell, wherein the cas genes are the same or different. In some additional embodiments, one or more CRISPR spacers or pseudo CRISPR spacers from a donor organism are inserted adjacent to the same or different spacers of the recipient cell. !5 In another embodiment, one or more CRISPR spacers or pseudo CRISPR spacers - such as one or more CRISPR spacers or pseudo CRISPR spacers from a donor organism - are each inserted adjacent to the same or different CRISPR repeats of the cell. In another embodiment, one or more CRISPR spacers or pseudo CRISPR spacers - such as one or more CRISPR spacers or pseudo CRISPR spacers from a donor organism - are each inserted adjacent to the same or different cas genes of the recipient cell. 30 In some further embodiments, the sequence of the one or more CRISPR spacer(s) from a donor organism are provided under conditions that the recipient cell is modified such that the CRISPR spacer has homology to the CRISPR spacer or pseudo CRISPR spacer of the donor organism. In some embodiments, the CRISPR spacer has 100% homology to the CRISPR spacer of the donor organism. In some embodiments, the CRISPR spacer(s) or pseudo CRISPR spacers comprise DNA or RNA 35 of genomic, synthetic or recombinant origin. In some embodiments, the CRISPR spacer (s) or pseudo CRISPR spacers are double-stranded, while in other embodiments, they are single-stranded, whether representing the sense or antisense strand or combinations thereof. It is contemplated that the CRISPR spacer (s) or pseudo CRISPR spacers be prepared by use of recombinant DNA techniques (e.g. recombinant DNA), as described herein. 40 In some embodiments, the modification comprises inserting one or more CRISPR spacers or pseudo CRISPR spacers from a donor organism that is/are substantially resistant to a target nucleic acid 28 5 or a transcription product thereof into one or more CRISPR loci of a substantially sensitive cell. In some embodiments, the insertion occurs at or between a functional combination of at least two CRISPR repeats and at least one cas gene in a substantially sensitive cell. In some embodiments, the modification comprises modifying (e.g., mutating) the DNA of a recipient cell (e.g., plasmid DNA or genomic DNA), such that one or more cas genes are created in the DNA of the cell. In some embodiments, the cas genes [0 are cloned into a construct, a plasmid or a vector, etc., which is then transformed into the cell, using any suitable method. In some embodiments, the modification comprises modifying (e.g., mutating) the DNA of a recipient cell (e.g., such as plasmid DNA or genomic DNA), such that one or more, preferably, two or more CRISPR repeats are created in the DNA of the cell. In some embodiments, the CRISPR repeats [5 are cloned into a construct, a plasmid or a vector, etc., which is then transformed into the cell, using any suitable method. In some further embodiments, the modification comprises modifying (e.g., mutating) the DNA of a recipient cell (e.g., plasmid DNA or genomic DNA), such that one or more cas-CRISPR repeat functional combinations are created in the DNA of the cell. In some embodiments, the cas-CRISPR !0 repeat functional combinations may be cloned into a construct, a plasmid or a vector, which is then transformed into the cell, using any suitable method. In some embodiments, the modification comprises modifying (e.g., mutating) the DNA of a recipient cell (e.g., plasmid DNA or genomic DNA), such that one or more CRISPR spacers are created in the DNA of the cell. In some embodiments, the CRISPR spacers may be cloned into a construct, a !5 plasmid or a vector, which is then transformed into the cell, using any suitable method. In some preferred embodiments, a CRISPR spacer is flanked by two CRISPR repeats (i.e., a CRISPR spacer has at least one CRISPR repeat on each side). In some embodiments, the modification comprises inserting one or more CRISPR spacers (e.g., heterologous CRISPR spacers) in the vicinity of (e.g., adjacent to/directly adjacent to) one or more cas 30 genes and/or the leader sequence. Thus, in some embodiments, the organization of the naturally occurring CRISPR locus is maintained following insertion of the one or more CRISPR spacers. As used herein, the term "target nucleic acid" refers to any nucleic acid sequence or transcription product thereof, against which resistance in a cell (e.g., a recipient cell) is modulated. In some embodiments, the resistance is directed against the target nucleic acid sequence per se. Advantageously, 35 this confers resistance to a cell against a donor organism from which the target nucleic acid(s) is derivable. Thus, in some embodiments, the insertion of a pseudo-CRISPR spacer derived from a bacteriophage or a CRISPR spacer(s) which is/are complementary or homologous to the one or more pseudo CRISPR spacer(s) into a recipient cell confers resistance to the bacteriophage. Thus, in some preferred embodiments, insertion between two CRISPR repeats of a pseudo-CRISPR spacer derived from 40 a bacteriophage or CRISPR spacer(s) that is/are complementary or homologous to the one or more pseudo CRISPR spacer(s) into a recipient cell confers resistance to the bacteriophage.

29 5 In a further aspect, there is provided a method for modulating the resistance of a recipient cell against a target nucleic acid or a transcription product thereof. The present invention also provides methods for determining the resistance profile of a cell against a target nucleic acid. As used herein, the term "resistance profile" means one or more entities against which the cell is sensitive or resistant. Accordingly, in some embodiments, the resistance profile [0 of a cell reflects that the cell is resistant to a first bacteriophage, sensitive to a second bacteriophage, resistant to a first mobile genetic element, and sensitive to a first antibiotic resistance gene, etc. In some embodiments, one or more cas genes or proteins, one or more CRISPR repeats, one or more cas genes, one or more cas -CRISPR repeat functional combinations, one or more CRISPR spacers, and/or one or more CRISPR spacers etc., within a cell are detected and/or sequenced so as to [5 predict/determine the likely resistance profile of a particular cell. In some other embodiments, one or more CRISPR spacers within a cell are detected or sequenced so as to predict/determine the likely resistance profile of a particular cell. Suitable detection methods include, but are not limited to PCR, DNA-DNA hybridization, DNA-RNA hybridization, DNA microarrays, etc. Indeed, it is intended that any suitable method will find use in the present invention. In additional embodiments, the likely !0 resistance profile of a particular bacterial cell to one or more bacteriophage is used as a lysotype predictor for microbial selection. In some further embodiments, one or more Cas genes and/or one or more CRISPR repeats are sequenced in addition to one or more CRISPR spacers, in order to verify the compatibility of the cas gene-CRISPR repeat combination or to identify new pairs of compatible cas/repeat combinations. !5 As used herein, the term "modulating resistance" refers suppressing, reducing, decreasing, inducing, conferring, restoring, elevating, increasing or otherwise affecting the resistance of a cell to a target nucleic acid, as taken in context. As used herein, the term "resistance" is not meant to imply that a cell is 100% resistant to a target nucleic acid or a transcription product thereof, but includes cells that are tolerant of the target nucleic 30 acid or a transcription product thereof. As used herein the term "resistance to target nucleic acid or transcription product thereof' means that resistance is conferred against a cell or an organism (e.g., phage) that comprises or produces the target nucleic acid or transcription product thereof. In some embodiments, the minimal component required for conferring immunity or resistance against a target nucleic acid or expression product thereof 35 is at least one cas gene (or one Cas protein) and at least two CRISPR repeats flanking a spacer. In some embodiments, the present invention provides methods for modulating (e.g. conferring or increasing) the resistance of a cell against a target nucleic acid or a transcription product thereof comprising the steps of: identifying a sequence (e.g., a conserved sequence) in an organism (preferably, a sequence essential to the function or survival of the organism); preparing a CRISPR spacer which 40 comprises a sequence homologous (e.g., 100% identical), to the identified sequence; preparing a nucleic acid comprising at least one cas gene and at least two CRISPR repeats together with the CRISPR spacer; 30 5 and (iv) transforming a cell with the nucleic acid thus to render the cell resistant to the target nucleic acid or transcription product thereof. As used herein, the term "conserved sequence" in the context of identifying a conserved sequence in an organism does not necessarily have to be conserved in its strictest sense, as the knowledge of one sequence from a given organism is sufficient. Furthermore, the sequence does not need to be part [0 of an essential entity. However, in some embodiments, the conserved sequence is a sequence that is essential for function and/or survival and/or replication and/or infectivity and the like of an organism or a cell. In some embodiments, the conserved sequence comprises a helicase, a primase a head or tail structural protein, a protein with a conserved domain (e.g., holing, lysine, and others), or conserved sequences amongst important phage genes. [5 In some further embodiments, the present invention provides methods for modulating (e.g., conferring or increasing) the resistance of a cell against a target nucleic acid or a transcription product thereof comprising the steps of: identifying one or more CRISPR spacers in an organism resistant to the target nucleic acid or transcription product thereof; preparing a recombinant nucleic acid comprising at least one cas gene or protein and at least two CRISPR repeats together with the identified one or more !0 spacers; and transforming a cell with the recombinant nucleic acid thus to render the recipient cell resistant to the target nucleic acid or transcription product thereof. In some embodiments, the present invention provides methods for modulating (e.g., conferring or increasing) the resistance of a cell comprising at least one or more cas genes or proteins and one or more, preferably, two or more CRISPR repeats against a target nucleic acid or a transcription product thereof !5 comprising the steps of: identifying one or more CRISPR spacers in an organism resistant to the target nucleic acid or transcription product thereof; and modifying the sequence of one or more CRISPR spacer(s) in the cell such that the CRISPR spacer(s) has homology to the CRISPR spacer(s) in the organism. In some embodiments, one or more CRISPR spacers in a recipient cell are modified (e.g., genetically engineered) such that the CRISPR spacer(s) have homology to one or more CRISPR spacer(s) 30 in a donor organism that is substantially resistant to a target nucleic acid or a transcription product thereof, in order to render the cell resistant to the target nucleic acid. In some preferred embodiments, the one or more cas genes or proteins and one or more, preferably, two or more CRISPR repeats in the cell are a functional combination as described herein. The genetic engineering methods include any suitable methods known in the art, including but 35 not limited to, adding (e.g., inserting), deleting (e.g., removing) or modifying (e.g., mutating) the sequence of the one or more CRISPR spacers and/or one or more pseudo CRISPR spacers in a cell, such that the CRISPR spacer has homology (e.g., increased homology after the genetic engineering) to one or more CRISPR spacers of a donor organism. This engineering step results in a cell that was substantially sensitive to a target nucleic acid or a transcription product thereof being substantially resistant to the 40 target nucleic acid or a transcription product thereof.

31 5 In some additional embodiments, the present invention provides methods for decreasing or reducing the resistance of a recipient cell comprising at least one or more cas genes or proteins and one or more, preferably, two or more CRISPR repeats against a target nucleic acid or a transcription product thereof. In some embodiments, the methods comprise the steps of: identifying one or more CRISPR [0 spacers in an organism that is substantially resistant to the target nucleic acid or a transcription product thereof; and modifying the sequence of one or more CRISPR spacer(s) in the cell such that the CRISPR spacer(s) has a reduced degree of homology to the CRISPR spacer(s) in the organism. In other embodiments, the methods for modulating (e.g.,. decreasing) the resistance of a cell comprising one or more cas genes or proteins and one or more, preferably, two or more CRISPR repeats [5 against a target nucleic acid or transcription product thereof comprise the steps of: identifying a CRISPR spacer or a pseudo CRISPR spacer in an organism comprising a target nucleic acid or transcription product thereof against which resistance is to be modulated; and identifying the CRISPR spacer in the organism in which resistance is to be modulated; and (iii) adapting the sequence of the CRISPR spacer in the organism in which resistance is to be modulated such that the CRISPR spacer has a lower degree of !0 homology to the CRISPR spacer or pseudo CRISPR spacer of the organism comprising the target nucleic acid or transcription product thereof against which resistance is to be modulated. One or more CRISPR spacers in a substantially resistant cell are engineered in order to render the cell sensitive to a target nucleic acid. The genetic engineering methods that find use include, but are not limited to, the addition (e.g., insertion), deletion (e.g., removal) or modification of one or more functional !5 CRISPR repeat-cas combinations or portions or fragments thereof in the substantially resistant cell and/or the addition (e.g., insertion), deletion (e.g., removal) or modification of one or more CRISPR spacers or portions or fragments thereof in the substantially resistant cell. This engineering step results in a cell that was substantially resistant to a target nucleic acid or a transcription product thereof becoming substantially sensitive to a target nucleic acid or a transcription product thereof. 30 In some embodiments, in order to confer sensitivity to a cell, it is contemplated that one or more CRISPR spacers, one or more cas genes or proteins, one or more, preferably, two or more CRISPR repeats, and/or one or more functional CRISPR repeat-cas combinations from a substantially resistant cell will be removed, deleted or modified such that resistance is no longer conferred. In some embodiments, cells that are sensitive to a target nucleic acid or a transcription product thereof are 35 prepared such that their levels within a given culture (e.g., a starter culture) may be modulated (e.g., decreased) as desired. Thus, in some embodiments, starter cultures comprising two or more bacterial strains are developed such that all members of the culture are sensitive to the same agent (e.g., the same bacteriophage). Thus, when the time comes that it is no longer desired for the culture to be alive, the culture is contacted with the same single agent in order to kill all members of the culture. In some 40 embodiments, the sensitivity of cells are modulated to one or more agents (e.g., phages), such that the 32 5 agent kills only a certain proportion of the cells in a given culture (e.g., about 10, about 20, about 30, about 40, about 50, about 60, about 70, about 80, about 90, or about 95% of the cells in the culture). In some embodiments, a recipient cell is engineered such that it comprises a CRISPR spacer or a sequence corresponding to a pseudo CRISPR spacer, thereby rendering the cell resistant to a target nucleic acid or transcription product thereof. Suitably, the cell is engineered such that the CRISPR [0 spacer or sequence corresponding to the pseudo CRISPR spacer is used together with a functional cas gene-CRISPR repeat combination, as described herein. In some embodiments, a cell that is resistant to a target nucleic acid or transcription product thereof is engineered such that the CRISPR spacer conferring the immunity against the target nucleic acid or transcription product thereof is inserted into a cell that comprises a functional cas gene-CRISPR repeat [5 combination, thereby rendering the cell resistant to the target nucleic acid or transcription product thereof. In some further embodiments, the sequence of one or more CRISPR spacers or pseudo CRISPR spacers of a cell that is resistant to a target nucleic acid or transcription product thereof is determined. A recipient cell is then engineered such that it comprises the sequence of the CRISPR spacer and a !0 functional cas gene-CRISPR repeat combination, thereby rendering the cell resistant to the target nucleic acid or transcription product thereof. In some additional embodiments, a CRISPR spacer from a recipient cell and a functional cas gene-CRISPR repeat combination from the same or different cell (e.g., the same or different recipient cell) are prepared. A further recipient cell is then engineered such that is comprises the CRISPR spacer !5 sequence and functional cas gene-CRISPR repeat combination thereby rendering the cell resistant to the target nucleic acid or transcription product thereof. In some embodiments, the resistance is directed against a transcription product of the target nucleic acid sequence (e.g., a transcript of the target nucleic acid sequence, in particular an RNA or mRNA), a transcript (e.g., a sense or an antisense RNA transcript), or a polypeptide transcription product. 30 In some embodiments, this confers resistance to a cell against a donor organism from which the transcription product is derived. In some embodiments, the target nucleotide sequence comprises DNA or RNA of genomic, synthetic or recombinant origin. In some further embodiments, the nucleotide sequence is double stranded, while in other embodiment it is single-stranded, whether representing the sense or antisense 35 strand or combinations thereof. In yet additional embodiments, the nucleotide sequence is prepared by use of recombinant DNA techniques (e.g., recombinant DNA). In still further embodiments, the nucleotide sequence is the same as a naturally occurring form, while in other embodiments it is derived therefrom. In yet further embodiments, the target nucleic acid sequence is derived from a gene. In some other embodiments, the target nucleic acid sequence is derived from a variant, homologue, fragment or 40 derivative of a gene. In some preferred embodiments, the target nucleic sequence is or is derived from bacteriophage. In some embodiments, the target nucleic sequence is derived from plasmid DNA. In 33 5 some embodiments, the target nucleic sequence is derived from a mobile genetic element. In some additional embodiments, the target nucleic sequence is derived from a transposable element or an insertion sequence. In yet additional embodiments, the target nucleic sequence is derived from a gene that confers resistance. In some further embodiments, the target nucleic sequence is derived from a gene that confers resistance to an antibiotic or antimicrobial. In some embodiments, the target nucleic sequence is [0 derived from a virulence factor. In some additional embodiments, the target nucleic sequence is derived from a toxin, an internalin or a hemolysin. In some embodiments, the target nucleic sequence or a transcription product thereof is derived from one or more bacteria. Thus, in some preferred embodiments the resistance of bacterial cells is modulated using the methods and compositions of the present invention. In some preferred [5 embodiments, the target nucleotide sequence is derived from a gene associated with resistance to plasmid transfer in bacteria. In some embodiments, one or more CRISPR spacers in the cell are modified such that the CRISPR spacer of the cell has homology to the CRISPR spacer and/or pseudo CRISPR spacer contained in the plasmid DNA of the bacterial cell, thereby providing resistance against the particular plasmid(s). Thus, the transfer of foreign DNA into the cell is prevented. In some preferred !0 embodiments, particular regions within the plasmid DNA are targeted, so as to provide immunity against plasmid DNA. For example, in some embodiments, sequences within the plasmid's origin of replication or sequences within genes coding for replication proteins are targeted. In some embodiments, the present invention provides methods comprising the steps of: identifying a CRISPR spacer and/or pseudo CRISPR spacer derived from the plasmid DNA of a bacterial !5 cell against which resistance is to be modulated; and modifying the sequence of a CRISPR spacer in the cell in which resistance is to be modulated, such that the CRISPR spacer of the cell has homology to the CRISPR spacer and/or pseudo CRISPR spacer contained in the plasmid DNA of the bacterial cell. In still further embodiments, the present invention provides methods for conferring resistance to a cell against plasmid transfer, comprising the steps of: identifying a CRISPR spacer and/or pseudo 30 CRISPR spacer derived from plasmid DNA; identifying one or more functional CRISPR repeat-cas gene combinations in a cell that is substantially sensitive to the plasmid; and engineering the one or more CRISPR loci in the substantially sensitive cell such that they comprise one or more CRISPR spacers and/or pseudo CRISPR spacers from the plasmid, thereby rendering the cell resistant. In some embodiments, the target nucleotide sequence is derived from a gene associated with 35 rresistance to one or more mobile genetic elements. In some embodiments, particular CRISPR spacers and/or pseudo CRISPR spacers derived from one or more mobile genetic elements are added within a CRISPR locus of a cell so as to provide resistance against mobile genetic elements (e.g., transposable elements and insertion sequences), thus preventing transfer of foreign DNA and genetic drift. In some embodiments, particular regions within transposons and insertion sequences are targeted so as to provide 40 immunity against mobile genetic elements. For example, in some embodiments targets include, but are 34 5 not limited to conjugative transposons (Tn9]6), class II transposons (Tn501), insertion sequences (IS26), and transposase genes. In some embodiments, the present invention provides methods comprising the steps of: identifying a CRISPR spacer and/or pseudo CRISPR spacer derived from one or more mobile genetic elements of a cell against which resistance is to be modulated; and modifying the sequence of a CRISPR [0 spacer in a cell in which resistance is to be modulated such that the CRISPR spacer and/or pseudo CRISPR spacer of the cell has homology to the CRISPR spacer contained in the mobile genetic element(s) of the cell. In still a further embodiments, the present invention provides methods for conferring resistance to a cell against one or more mobile genetic elements comprising the steps of: identifying a CRISPR [5 spacer and/or pseudo CRISPR spacer derived from one or more mobile genetic elements; identifying one or more functional CRISPR repeat-cas combinations in a cell that is substantially sensitive to the one or more mobile genetic elements; and engineering the one or more CRISPR loci in the substantially sensitive cell such that they comprise or have homology to one or more CRISPR spacers and/or pseudo CRISPR spacers from the one or more mobile genetic elements to render the cell resistant. !0 In some embodiments the target nucleotide sequence is derived from a gene associated with resistance to antibiotics and/or antimicrobials. As used herein, the term "antimicrobial" refers to any composition that kills or inhibits the growth or reproduction of microorganisms. It is intended that the term encompass antibiotics (i.e., compositions produced by other microorganisms), as well as synthetically produced compositions. Antimicrobial resistance genes include, but are not limited to !5 bla,, blab, blash,, aadB, aacC], aacC2, aacC3, aacA4, mecA, vanA, vanH, vanX, satA, aacA-aphH, vat, vga, msrA sul, and/or int. The antimicrobial resistance genes include those that are obtained from bacterial species that include but are not limited to the genera Escherichia, Klebsiella, Pseudomonas, Proteus, Streptococcus, Staphylococcus, Enterococcus, Haemophilus, and Moraxella. The antimicrobial resistance genes also include those that are obtained from bacterial species that include but are not 30 limited to Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Proteus mirabilis, Streptococcus pneumoniae, Staphylococcus aureus, Staphylococcus epidermidis, Enterococcusfaecalis, Staphylococcus saprophyticus, Streptococcus pyogenes, Haemophilus influenzae, and Moraxella catarrhalis. In some embodiments, particular CRISPR spacers and/or pseudo CRISPR spacers derived from antimicrobial resistance encoding genes are added within a CRISPR locus of a recipient cell, under 35 conditions such that transfer of resistance genes is prevented. Thus, the risk of acquiring antimicrobial resistance genes (i.e., markers) is reduced. In some embodiments, targets also include vanR, (i.e., vancomycin resistance), tetR (i.e., tetracycline resistance), and/or resistance factors that provide beta lactamase resistance. In some embodiments, the present invention provides methods comprising the steps of: 40 identifying one or more CRISPR spacers and/or pseudo CRISPR spacers derived from a cell that comprises one or more antimicrobial resistance genes or markers; and modifying the sequence of the 35 5 CRISPR spacer in a cell that does not comprise or does not express the antimicrobial resistance genes or markers such that the CRISPR spacer of the cell has homology to the one or more CRISPR spacers and/or pseudo CRISPR spacers contained in the cell that comprises one or more antimicrobial resistance genes or markers. In still a further embodiments, the present invention provides methods for modulating the [0 acquisition of antimicrobial resistance markers in a cell comprising the steps of: identifying one or more CRISPR spacers and/or pseudo CRISPR spacers derived from a cell that comprises one or more antimicrobial resistance genes or markers; identifying one or more CRISPR loci in a cell that does not comprise or does not express the antimicrobial resistance genes or markers; and modifying the sequence of the CRISPR spacer in the cell that does not comprise or does not express the antimicrobial resistance [5 genes or markers such that the CRISPR spacer and/or pseudo CRISPR spacers has homology to the CRISPR spacer contained in the cell resistant to the transfer of genes conferring resistance to one or more antimicrobials. In some embodiments, the target nucleotide sequence is derived from at least one gene associated with virulence factor(s). In some embodiments, particular CRISPR spacers and/or pseudo CRISPR !0 spacers derived from genes encoding virulence factors are added within a bacterial CRISPR locus to provide resistance against the transfer of genes conferring virulence into the bacteria. In some embodiments, factors that commonly contribute to microbial virulence (e.g., in pathogens) are targeted, such as toxins, internalins, hemolysins and other virulence factors. The present invention also provides methods comprising the steps of: identifying one or more !5 CRISPR spacers and/or pseudo CRISPR spacers derived from a cell that comprises one or more virulence factors; and modifying the sequence of the CRISPR spacer in a cell that does not comprise or does not express the virulence factor(s) or marker(s) such that the CRISPR spacer of the cell has homology to the one or more CRISPR spacers and/or pseudo CRISPR spacers contained in the cell that comprises one or more virulence factors. 30 In still further embodiments, the present invention provides methods for conferring resistance to a cell against one or more virulence factor(s) or marker(s) comprising the steps of: identifying a CRISPR spacer and/or pseudo CRISPR spacer derived from one or more virulence factor(s) or marker(s); identifying one or more functional CRISPR repeat-cas combinations in a cell that is substantially sensitive to the one or more virulence factor(s) or marker(s); and engineering the one or more CRISPR 35 loci in the substantially sensitive cell such that they comprise one or more CRISPR spacers and/or pseudo CRISPR spacers from the one or more virulence factor(s) or marker(s) to render the cell resistant. The present invention encompasses the use of variants, homologues, derivatives and fragments thereof, including variants, homologues, derivatives and fragments of CRISPR loci, CRISPR spacers, pseudo CRISR spacers, cas genes or proteins, CRISPR repeats, functional CRISPR repeat-cas gene 40 combinations and target nucleic acid sequences or transcription products thereof.

36 5 The term "variant" is used to mean a naturally occurring polypeptide or nucleotide sequences which differs from a wild-type sequence. The term "fragment" indicates that a polypeptide or nucleotide sequence comprises a fraction of a wild-type sequence. It may comprise one or more large contiguous sections of sequence or a plurality of small sections. The sequence may also comprise other elements of sequence, for example, it may be a [0 fusion protein with another protein. Preferably the sequence comprises at least 50%, more preferably at least 65%, more preferably at least 80%, more preferably at least 85%, more preferably at least 90%, more preferably at least 95%, more preferably at least 96%, more preferably at least 97%, more preferably at least 98%, most preferably at least 99% of the wild-type sequence. Preferably, the fragment retains 50%, more preferably 60%, more preferably 70%, more [5 preferably 80%, more preferably 85%, more preferably 90%, more preferably 95%, more preferably 96%, more preferably 97%, more preferably 98%, or most preferably 99% activity of the wild-type polypeptide or nucleotide sequence. Preferably, a CRISPR spacer or pseudo CRISPR spacer comprises at least 50%, more preferably at least 65%, more preferably at least 80%, more preferably at least 85%, more preferably at least 90%, !0 more preferably at least 95%, more preferably at least 96%, more preferably at least 97%, more preferably at least 98%, most preferably at least 99% of the wild-type sequence. Preferably, a CRISPR spacer retains 50%, more preferably 60%, more preferably 70%, more preferably 80%, more preferably 85%, more preferably 90%, more preferably 95%, more preferably 96%, more preferably 97%, more preferably 98%, or most preferably 99% activity of the wild-type polypeptide or nucleotide sequence. !5 Preferably, a cas gene comprises at least 50%, more preferably at least 65%, more preferably at least 80%, more preferably at least 85%, more preferably at least 90%, more preferably at least 95%, more preferably at least 96%, more preferably at least 97%, more preferably at least 98%, most preferably at least 99% of the wild-type sequence. Preferably, a cas gene retains 50%, more preferably 60%, more preferably 70%, more preferably 80%, more preferably 85%, more preferably 90%, more 30 preferably 95%, more preferably 96%, more preferably 97%, more preferably 98%, or most preferably 99% activity of the wild-type polypeptide or nucleotide sequence. Preferably, a Cas protein comprises at least 50%, more preferably at least 65%, more preferably at least 80%, more preferably at least 85%, more preferably at least 90%, more preferably at least 95%, more preferably at least 96%, more preferably at least 97%, more preferably at least 98%, most 35 preferably at least 99% of the wild-type sequence. Preferably, a Cas protein retains 50%, more preferably 60%, more preferably 70%, more preferably 80%, more preferably 85%, more preferably 90%, more preferably 95%, more preferably 96%, more preferably 97%, more preferably 98%, or most preferably 99% activity of the wild-type polypeptide or nucleotide sequence. Preferably, a CRISPR repeat comprises at least 50%, more preferably at least 65%, more 40 preferably at least 80%, more preferably at least 85%, more preferably at least 90%, more preferably at least 95%, more preferably at least 96%, more preferably at least 97%, more preferably at least 98%, 37 5 most preferably at least 99% of the wild-type sequence. Preferably, a CRISPR repeat retains 50%, more preferably 60%, more preferably 70%, more preferably 80%, more preferably 85%, more preferably 90%, more preferably 95%, more preferably 96%, more preferably 97%, more preferably 98%, or most preferably 99% activity of the wild-type polypeptide or nucleotide sequence. Preferably, a functional CRISPR repeat-cas combination comprises at least 50%, more preferably t0 at least 65%, more preferably at least 80%, more preferably at least 85%, more preferably at least 90%, more preferably at least 95%, more preferably at least 96%, more preferably at least 97%, more preferably at least 98%, most preferably at least 99% of the wild-type sequence. Preferably, functional CRISPR repeat-cas combination retains 50%, more preferably 60%, more preferably 70%, more preferably 80%, more preferably 85%, more preferably 90%, more preferably 95%, more preferably [5 96%, more preferably 97%, more preferably 98%, or most preferably 99% activity of the wild-type polypeptide or nucleotide sequence. Preferably, a target nucleic acid sequence comprises at least 50%, more preferably at least 65%, more preferably at least 80%, more preferably at least 85%, more preferably at least 90%, more preferably at least 95%, more preferably at least 96%, more preferably at least 97%, more preferably at !0 least 98%, most preferably at least 99% of the wild-type sequence. Preferably, a target nucleic acid sequence retains 50%, more preferably 60%, more preferably 70%, more preferably 80%, more preferably 85%, more preferably 90%, more preferably 95%, more preferably 96%, more preferably 97%, more preferably 98%, or most preferably 99% activity of the wild-type polypeptide or nucleotide sequence. !5 In some embodiments, the fragment is a functional fragment. By a "functional fragment" of a molecule is understood a fragment retaining or possessing substantially the same biological activity as the intact molecule. In all instances, a functional fragment of a molecule retains at least 10% and at least about 25%, about 50%, about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99% of the biological activity of the intact molecule. 30 The term "homologue" means an entity having a certain homology with the subject amino acid sequences and the subject nucleotide sequences. Here, the term "homology" can be equated with "identity". In the present context, a homologous sequence is taken to include an amino acid sequence, which may be at least 75, 85 or 90 % identical, preferably at least 95%, 96%, 97%, 98 % or 99% identical to the 35 subject sequence. Although homology can also be considered in terms of similarity (i.e. amino acid residues having similar chemical properties/functions), in the context of the present invention it is preferred to express homology in terms of sequence identity. In the present context, a homologous sequence is taken to include a nucleotide sequence, which may be at least 75, 85 or 90% identical, preferably at least 95%, 96%, 97%, 98 % or 99% identical to the 40 subject sequence. Although homology can also be considered in terms of similarity (i.e. amino acid 38 5 residues having similar chemical properties/functions), in the context of the present invention it is preferred to express homology in terms of sequence identity. Homology comparisons may be conducted by eye, or more usually, with the aid of readily available sequence comparison programs. These commercially available computer programs can calculate % homology between two or more sequences. [0 Percent (%) homology may be calculated over contiguous sequences (i.e. one sequence is aligned with the other sequence and each amino acid in one sequence is directly compared with the corresponding amino acid in the other sequence, one residue at a time). This is called an "ungapped" alignment. Typically, such ungapped alignments are performed only over a relatively short number of residues. [5 Although this is a very simple and consistent method, it fails to take into consideration that, for example, in an otherwise identical pair of sequences, one insertion or deletion will cause the following amino acid residues to be put out of alignment, thus potentially resulting in a large reduction in % homology when a global alignment is performed. Consequently, most sequence comparison methods are designed to produce optimal alignments that take into consideration possible insertions and deletions !0 without penalising unduly the overall homology score. This is achieved by inserting "gaps" in the sequence alignment to try to maximise local homology. However, these more complex methods assign "gap penalties" to each gap that occurs in the alignment so that, for the same number of identical amino acids, a sequence alignment with as few gaps as possible - reflecting higher relatedness between the two compared sequences - will achieve a higher !5 score than one with many gaps. "Affine gap costs" are typically used that charge a relatively high cost for the existence of a gap and a smaller penalty for each subsequent residue in the gap. This is the most commonly used gap scoring system. High gap penalties will of course produce optimised alignments with fewer gaps. Most alignment programs allow the gap penalties to be modified. However, it is preferred to use the default values when using such software for sequence comparisons. For example, 30 when using the GCG Wisconsin Bestfit package the default gap penalty for amino acid sequences is -12 for a gap and -4 for each extension. Calculation of maximum % homology therefore firstly requires the production of an optimal alignment, taking into consideration gap penalties. A suitable computer program for carrying out such an alignment is the GCG Wisconsin Bestfit package (University of Wisconsin, U.S.A.; Devereux et al., 35 1984, Nucleic Acids Research 12:387). Examples of other software than can perform sequence comparisons include, but are not limited to, the BLAST package (see Ausubel et al., 1999 ibid - Chapter 18), FASTA (Atschul et al., 1990, J. Mol. Biol., 403-410), the GENEWORKS suite of comparison tools and CLUSTAL. Both BLAST and FASTA are available for offline and online searching (see Ausubel et al., 1999 ibid, pages 7-58 to 7-60). However, for some applications, it is preferred to use the GCG 40 Bestfit program. A new tool, called BLAST 2 Sequences is also available for comparing protein and 39 5 nucleotide sequence (see FEMS Microbiol Lett 1999 174(2): 247-50; FEMS Microbiol Lett 1999 177(1): 187-8). Although the final % homology can be measured in terms of identity, the alignment process itself is typically not based on an all-or-nothing pair comparison. Instead, a scaled similarity score matrix is generally used that assigns scores to each pairwise comparison based on chemical similarity or [0 evolutionary distance. An example of such a matrix commonly used is the BLOSUM62 matrix - the default matrix for the BLAST suite of programs. GCG Wisconsin programs generally use either the public default values or a custom symbol comparison table if supplied (see user manual for further details). For some applications, it is preferred to use the public default values for the GCG package, or in the case of other software, the default matrix - such as BLOSUM62. [5 Once the software has produced an optimal alignment, it is possible to calculate % homology, preferably % sequence identity. The software typically does this as part of the sequence comparison and generates a numerical result. Should Gap Penalties be used when determining sequence identity, then suitably the following parameters are used: !0 FOR BLAST GAP OPEN 0 GAP EXTENSION 0 FOR CLUSTAL DNA PROTEIN WORD SIZE 2 1 K triple GAPPENALTY 10 10 GAP EXTENSION 0.1 0.1 For polypeptide sequence comparison the following settings may be used: GAP creation penalty of 3.0 and GAP extension penalty of 0.1. Suitably, the degree of identity with regard to an amino acid 25 sequence is determined over at least 5 contiguous amino acids, determined over at least 10 contiguous amino acids, over at least 15 contiguous amino acids, over at least 20 contiguous amino acids, over at least 30 contiguous amino acids, over at least 40 contiguous amino acids, over at least 50 contiguous amino acids, or over at least 60 contiguous amino acids. The sequences may also have deletions, insertions or substitutions of amino acid residues, which 30 produce a silent change and result in a functionally equivalent substance. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues as long as the secondary binding activity of the substance is retained. For example, negatively charged amino acids include aspartic acid and glutamic acid; positively charged amino acids include lysine and arginine; and amino acids with 35 uncharged polar head groups having similar hydrophilicity values include leucine, isoleucine, valine, glycine, alanine, asparagine, glutamine, serine, threonine, phenylalanine, and tyrosine.

40 5 Conservative substitutions may be made, for example, according to the Table below. Amino acids in the same block in the second column and preferably in the same line in the third column may be substituted for each other: ALIPHATIC Non-polar G A P ILV Polar - uncharged C S T M N Q Polar - charged D E K R AROMATIC HFWY [0 The present invention also encompasses homologous substitution (substitution and replacement are both used herein to mean the interchange of an existing amino acid residue, with an alternative residue) may occur i.e. like-for-like substitution - such as basic for basic, acidic for acidic, polar for polar etc. Non-homologous substitution may also occur i.e. from one class of residue to another or alternatively involving the inclusion of unnatural amino acids - such as ornithine (hereinafter referred to [5 as Z), diaminobutyric acid ornithine (hereinafter referred to as B), norleucine ornithine (hereinafter referred to as 0), pyriylalanine, thienylalanine, naphthylalanine and phenylglycine. Replacements may also be made by unnatural amino acids include; alpha* and alpha disubstituted* amino acids, N-alkyl amino acids*, lactic acid*, halide derivatives of natural amino acids such as trifluorotyrosine*, p-Cl-phenylalanine*, p-Br-phenylalanine*, p-I-phenylalanine*, L-allyl !0 glycine*, B-alanine*, L-a-amino butyric acid*, L-y-amino butyric acid*, L-a-amino isobutyric acid*, L s-amino caproic acid#, 7-amino heptanoic acid*, L-methionine sulfone#*, L-norleucine*, L-norvaline*, p-nitro-L-phenylalanine*, L-hydroxyproline#, L-thioproline*, methyl derivatives of phenylalanine (Phe) - such as 4-methyl-Phe*, pentamethyl-Phe*, L-Phe (4-amino)#, L-Tyr (methyl)*, L-Phe (4-isopropyl)*, L-Tic (1,2,3,4-tetrahydroisoquinoline-3-carboxyl acid)*, L-diaminopropionic acid # and L-Phe (4 25 benzyl)*. The notation * has been utilised for the purpose of the discussion above (relating to homologous or non-homologous substitution), to indicate the hydrophobic nature of the derivative whereas # has been utilised to indicate the hydrophilic nature of the derivative, #* indicates amphipathic characteristics. Variant amino acid sequences include suitable spacer groups that are suitable for insertion 30 inserted between any two amino acid residues of the sequence including alkyl groups - such as methyl, ethyl or propyl groups - in addition to amino acid spacers - such as glycine or p-alanine residues. A further form of variation involves the presence of one or more amino acid residues in peptoid form will be well understood by those skilled in the art. For the avoidance of doubt, "the peptoid form" is used to refer to variant amino acid residues wherein the a-carbon substituent group is on the residue's nitrogen 35 atom rather than the a-carbon. Processes for preparing peptides in the peptoid form are well known in the art.

41 5 The nucleotide sequences for use in the present invention may include within them synthetic or modified nucleotides. A number of different types of modification to oligonucleotides are known in the art. These include methylphosphonate and phosphorothioate backbones and/or the addition of acridine or polylysine chains at the 3' and/or 5' ends of the molecule. For the purposes of the present invention, it is to be understood that the nucleotide sequences may be modified by any method available in the art. Such [0 modifications may be carried out to enhance the in vivo activity or life span of nucleotide sequences useful in the present invention. CRISPRs [5 CRISPRs (Clustered Regularly Interspaced Short Palindromic Repeats); also known as SPIDRs (SPacer Interspersed Direct Repeats) constitute a family of recently described DNA loci that are usually specific to a particular bacterial species. The CRISPR locus is a distinct class of interspersed short sequence repeats (SSRs) that were first recognized in E. coli (Ishino et al., J. Bacteriol., 169:5429-5433 [1987]; and Nakata et al., J. Bacteriol., 171:3553-3556 [1989]). Similar interspersed SSRs have been !0 identified in Haloferax mediterranei, Streptococcus pyogenes, Anabaena, and Mycobacterium tuberculosis (See, Groenen et al., Mol. Microbiol., 10:1057-1065 [1993]; Hoe et al., Emerg. Infect. Dis., 5:254-263 [1999]; Masepohl et al., Biochim. Biophys. Acta 1307:26-30 [1996]; and Mojica et al., Mol. Microbiol., 17:85-93 [1995]). The CRISPR loci differ from other SSRs by the structure of the repeats, which have been termed short regularly spaced repeats (SRSRs) (Janssen et al., OMICS J. Integ. Biol., !5 6:23-33 [2002]; and Mojica et al., Mol. Microbiol., 36:244-246 [2000]). The repeats are short elements that occur in clusters that are always regularly spaced by unique intervening sequences with a constant length (Mojica et al., [2000], supra). Although the repeat sequences are highly conserved between strains, the number of interspersed repeats and the sequences of the spacer regions differ from strain to strain (van Embden et al., J. Bacteriol., 182:2393-2401 [2000]). 30 CRISPR loci consist of short and highly conserved partially palindromic DNA repeats typically of 24 to 40 bp, containing inner and terminal inverted repeats of up to 11 bp. These repeats have been reported to occur from 1 to 140 times. Although isolated elements have been detected, they are generally arranged in clusters (up to about 20 or more per genome) of repeated units spaced by unique intervening 20-58 bp sequences. To date, up to 20 distinct CRISPR loci have been found within a single 35 chromosome. CRISPRs are generally homogenous within a given genome with most of them being identical. However, there are examples of heterogeneity in, for example, the Archaea (Mojica et al., [2000], supra). As used herein, the term "CRISPR locus" refers to the DNA segment which includes all of the CRISPR repeats, starting with the first nucleotide of the first CRISPR repeat and ending with the last 40 nucleotide of the last (terminal) CRISPR repeat.

42 5 Although the biological function of CRISPR loci is unknown, some hypotheses have been proposed. For example, it has been proposed that they may be involved in the attachment of the chromosome to a cellular structure, or in the chromosome replication and replicon partitioning (Jansen et al., OMICS 6:23-33 [2002]; Jansen et al., Mol. Microbiol., 43:1565-1575 [2002]; and Pourcel et al., Microbiol., 151:653-663 [2005]). Mojica et al. (Mojica et al., J. Mol. Evol., 60:174-182 [2005]) [0 hypothesize that CRISPR may be involved in conferring specific immunity against foreign DNA and Pourcel et al. (supra) hypothesize that CRISPRs are structures that are able to take up pieces of foreign DNA as part of a defense mechanism. Bolotin et al. (supra) suggest that the CRISPR spacer elements are the traces of past invasions by extrachromosomal elements, and hypothesize that they provide a cell with immunity against phage infection, and more generally foreign DNA expression, by coding an anti [5 sense RNA. Bolotin et al. (supra) also suggest that cas genes are necessary for CRISPR formation. However, it is not intended that the present invention be limited to any particular mechanism, function, theory, nor means of action. The genome of Streptococcus thermophilus LMG18311 contains 3 CRISPR loci; the 36-bp repeated sequences are different in CRISPRi (34 repeats), CRISPR2 (5 repeats), and CRISPR3 (a single !0 sequence). Nevertheless, they are perfectly conserved within each locus. CRISPRi and CRISPR2 repeats are respectively interspaced by 33 and 4 sequences of 30 bp in length. All these interspacing sequences are different from each other. They are also different from those found in strain CNRZ1066 (41 interspacing sequences within CRISPRi) and in strain LMD-9 (16 within CRISPRi and 8 within CRISPR3), which both are S. thermophilus. !5 Various methods for identifying CRISPR loci are known in the art. For example, Jensen et al. (Jensen et al., [2002], supra) describe a computer-based approach in which nucleotide sequences are searched for CRISPR motifs using the PATSCAN program at the server of the Mathematics and Computer Science Division at the Argonne National Laboratory, Argonne, IL, USA. The algorithm that was used for identifying CRISPR motifs was p1 = a ... b c ... dpi c... d p c ... d pI, where a and b 30 were the lower and upper size limit of the repeat and p1 and c and d were the lower and upper size limit of the spacer sequences. The values of a, b, c and d may be varied from about 15 to about 70 bp at increments of about 5 bp. In some preferred embodiments, CRISPR loci are identified using dotplots (e.g., by using the Dotter computer program). Any suitable method known in the art finds use in analyzing sequence similarity. For example, 35 analysis may be performed using NCBI BLAST with a microbial genomes database and GenBank, as known in the art. In addition, nucleotide sequences, including those provided herein are included in databases (e.g., GenBank or the JGI genome website). As used herein, "upstream" means in the 5' direction and "downstream" means in the 3' direction. In additional embodiments, the methods of the present invention utilize amplification procedures 40 (See e.g., Mojica et al., [2005], supra; and Pourcel et al., [2005], supra). Amplification of the desired region of DNA may be achieved by any method known in the art, including polymerase chain reaction 43 5 (PCR). "Amplification" refers to the production of additional copies of a nucleic acid sequence. This is generally carried out using PCR technologies well known in the art. The "polymerase chain reaction" ("PCR") is well-known to those in the art. In the present invention, oligonucleotide primers are designed for use in PCR reactions to amplify all or part of a CRISPR locus. The term "primer" refers to an oligonucleotide, whether occurring naturally as in a purified [0 restriction digest or produced synthetically, which is capable of acting as a point of initiation of synthesis when placed under conditions in which synthesis of a primer extension product which is complementary to a nucleic acid strand is induced (i.e., in the presence of nucleotides and an inducing agent - such as DNA polymerase and at a suitable temperature and pH). In some embodiments, the primer is single stranded for maximum efficiency in amplification, although in other embodiments, the primer is double [5 stranded. In some embodiments, the primer is an oligodeoxyribonucleotide. The primer must be sufficiently long to prime the synthesis of extension products in the presence of the inducing agent. The exact length of the primers depends on many factors, including temperature, source of primer, and the use of the method. PCR primers are typically at least about 10 nucleotides in length, and most typically at least about 20 nucleotides in length. Methods for designing and conducting PCR are well known in the !0 art, and include, but are not limited to methods using paired primers, nested primers, single specific primers, degenerate primers, gene-specific primers, vector-specific primers, partially mismatched primers, etc. In some preferred embodiments of the present invention, a CRISPR locus or a portion thereof from a parent bacterium and a labelled bacterium are compared using any suitable method known in the !5 art. In some preferred embodiments of the present invention, the CRISPR locus or a portion thereof from the parent bacterium and the labelled bacterium are compared by amplifying the CRISPR locus or a portion thereof. In addition to well-known cycling amplification methods (e.g., PCR, ligase chain reaction, etc.), other methods, including but not limited to isothermal amplification methods find use in the present invention. Well-known isothermal amplification methods that find use in the present 30 invention include, but are not limited to strand displacement amplification (SDA), Q-beta-replicase, nucleic acid-based sequence amplification (NASBA), and self-sustained sequence replication. In some other preferred embodiments of the present invention, the CRISPR locus or a portion thereof from the parent bacterium and the labelled bacterium are compared by sequencing the of the present invention, the CRISPR locus or a portion thereof from the parent bacterium and the labelled 35 bacterium are compared by amplifying and then sequencing the CRISPR loci or a portion thereof. In some embodiments, one end of the CRISPR loci are compared, while in other embodiments, both the 5' and 3' ends of the loci are compared. In some preferred embodiments, one end (e.g., the 5' end) of the CRISPR loci are compared. In yet other embodiments, at least the last CRISPR repeat at the 3' end of the CRISPR locus and/or at least the last CRISPR spacer (e.g., the last CRISPR spacer core) at the 3' end of 40 the CRISPR locus and/or at least the first CRISPR repeat at the 5' end of the CRISPR locus and/or at least the first CRISPR spacer (e.g., the first CRISPR spacer core) at the 5' end of the CRISPR locus are 44 5 compared. In some preferred embodiments, at least the first CRISPR repeat at the 5' end of the CRISPR locus and/or at least the first CRISPR spacer (e.g., the first CRISPR spacer core) at the 5' end of the CRISPR locus are compared. In some additional preferred embodiments, at least the last CRISPR spacer (e.g., the last CRISPR spacer core) at the 3' end of the CRISPR locus and/or at least the first CRISPR spacer (e.g., the first CRISPR spacer core) at the 5' end of the CRISPR locus are compared. In some [0 further preferred embodiments, at least the first CRISPR spacer (e.g., the first CRISPR spacer core) at the 5' ends of the CRISPR loci are compared. In some embodiments, the CRISPR loci comprise DNA, while in other embodiments, the CRISPR loci comprise RNA. In some embodiments, the nucleic acid is of genomic origin, while in other embodiments, it is of synthetic or recombinant origin. In some embodiments, the CRISPR loci are [5 double-stranded, while in other embodiments, they are single-stranded, whether representing the sense or antisense strand or combinations thereof. In some embodiments, CRISPR loci are prepared by use of recombinant DNA techniques (e.g., recombinant DNA), as described herein. The present invention also provides methods for generating CRISPR variants. These variants are expressed, isolated, cloned, and/or sequenced using any suitable method known in the art. In some !0 particularly preferred embodiments, the CRISPR variants are phage resistant mutant strains that have a modified CRISPR locus with an additional spacer. In some additional embodiments, these variants find use as targets for detection/identification purposes, or for engineering resistance against nucleic acid molecules. In still further embodiments, these variants find use in the development of biocontrol agents. In the context of the present invention, the CRISPR locus is oriented as described below. The !5 CRISPR leader is a conserved DNA segment of defined size. The orientation of the S. thermophilus CRISPRi locus is established using the following characteristics: The relative position of CRISPR to the neighbouring cas (CRISPR-associated sequences) genes; CRISPRi is located downstream of 4 cas genes (genes str0657, str0658, str0659, and str0660 within CNRZ1066 chromosome sequence); 30 This repeat sequence has the potential to form a hairpin secondary structure, although it is not fully palindromic, and the reverse complementary sequence; (5'-GTTGTACAGTTACTTAAATCTTGAGAGTACAAAAAC-3'; SEQ ID NO:695) is different from the direct sequence (5'-GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAAC-3'; SEQ ID NO: 1). Generally the 5' end of the direct sequence is richer in nucleotides G and T than the 5' end of the reverse 35 complementary sequence. Furthermore, as G-T base pairing is better than A-C base pairing, the hairpin structure is generally stronger on the direct strand; and As used herein, the position of the terminal repeat is the end repeat which shows sequence variation at its 3' end is generally the terminal repeat. The CRISPR leader is a conserved DNA segment of defined size which is located immediately 40 upstream of the first repeat. For example, the leader sequence of S. thermophilus CRISPRi is the DNA segment starting immediately after the stop codon of gene str0660, and ending just before the first repeat.

45 5 The CRISPR leader is located at the 5' end of the CRISPR locus. The CRISPR leader is located immediately upstream of the first CRISPR repeat of the CRISPR locus. The CRISPR trailer is a conserved DNA segment of defined size, which is located immediately downstream of the terminal repeat. For example, the trailer sequence of S. thermophilus CRISPRI is the DNA segment starting immediately after the terminal repeat, and ending just before the stop codon of [0 gene str0661 (located on the opposite DNA strand). The CRISPR trailer is located at the 3' end of the CRISPR locus. The CRISPR trailer is located immediately downstream of the terminal repeat. For example, the CRISPR leader and CRISPR trailer sequences in the CRISPRI locus of Streptococcus thermophilus strain CNRZ1066 are: CRISPR leader: [5 5' CAAGGACAGTTATTGATTTTATAATCACTATGTGGGTATAAAAACGTCAAAATTTCATTTGA G-3' (SEQ ID NO:688) CRISPR trailer: 5'-TTGATTCAACATAAAAAGCCAGTTCAATTGAACTTGGCTTT-3' (SEQ ID NO:691) !0 The CRISPR leader corresponds to positions 625038 to 625100, and the CRISPR trailer corresponds to positions 627845 to 627885 in the full genome (CP000024) of S. thermophilus. As used herein, the term "upstream" means in the 5' direction and "downstream" means in the 3' direction. As used herein the term "portion thereof" in the context of a CRISPR locus means at least about 10 nucleotides, about 20 nucleotides, about 24 nucleotides, about 30 nucleotides, about 40 !5 nucleotides, about 44 nucleotides, about 50 nucleotides, about 60 nucleotides, about 70 nucleotides, about 80 nucleotides, about 90 nucleotides, about 98 nucleotides or even about 100 or more nucleotides (e.g., at least about 44-98 nucleotides) of a CRISPR locus. In some preferred embodiments, the term "portion thereof" means at least about 10 nucleotides, about 20 nucleotides, about 24 nucleotides, about 30 nucleotides, about 40 nucleotides, about 44 nucleotides, about 50 nucleotides, about 60 nucleotides, 30 about 70 nucleotides, about 80 nucleotides, about 90 nucleotides, about 98 nucleotides or about 100 or more nucleotides (e.g., at least about 44-98 nucleotides) from one or both ends (i.e., the 5' and/or 3' ends) of a CRISPR locus. In some preferred embodiments, the term "portion thereof" refers to at least about the first 44 nucleotides at the 5' end of a CRISPR locus or about the last 44 nucleotides at the 3' end of a CRISPR locus. 35 In some further embodiments, the term "portion thereof" in the context of a CRISPR locus means at least the first about 10 nucleotides, about 20 nucleotides, about 24 nucleotides, about 30 nucleotides, about 40 nucleotides, about 44 nucleotides, about 50 nucleotides, about 60 nucleotides, about 70 nucleotides, about 80 nucleotides, about 90 nucleotides, about 98 nucleotides, or about 100 or more nucleotides (e.g., at least about 44-98 nucleotides) downstream from the first nucleotide of the first 40 CRISPR repeat at the 5' end of a CRISPR locus or upstream from the last nucleotide of the last CRISPR repeat at the 3' end of a CRISPR locus. In some preferred embodiments, the term "portion thereof" refers 46 5 to the at least about the first 44 nucleotides downstream from the first nucleotide of the first CRISPR repeat at the 5' end of a CRISPR locus or at least about 44 nucleotides upstream from the last nucleotide of the last CRISPR repeat at the 3' end of a CRISPR locus. In some embodiments, the minimum size of the duplicated sequence is about 24 nucleotides and minimum size of the tagging sequence is about 20 nucleotides. Thus, in some preferred embodiments, [0 the term "portion thereof" in the context of a CRISPR locus, means at least 44 nucleotides. In some embodiments, the maximum size of the duplicated sequence is about 40 nucleotides and the maximum size of the tagging sequence is about 58 nucleotides. Thus, in some embodiments, the term "portion thereof" when used in the context of a CRISPR locus means at least about 98 nucleotides. In some preferred embodiments, the term "portion thereof" in the context of a CRISPR locus means at least [5 about 44-98 nucleotides. When comparing the CRISPR locus or a portion thereof from the parent bacterium and a labelled bacterium, at least about 10 nucleotides, about 20 nucleotides, about 24 nucleotides, about 30 nucleotides, about 40 nucleotides, about 44 nucleotides, about 50 nucleotides, about 60 nucleotides, about 70 nucleotides, about 80 nucleotides, about 90 nucleotides, about 98 nucleotides, or about 100 !0 nucleotides (e.g., at least about 44-98 nucleotides) of a CRISPR locus are compared. In some preferred embodiments, at least about 10 nucleotides, about 20 nucleotides, about 24 nucleotides, about 30 nucleotides, about 40 nucleotides, about 44 nucleotides, about 50 nucleotides, about 60 nucleotides, about 70 nucleotides, about 80 nucleotides, about 90 nucleotides, about 98 nucleotides, or about 100 or more nucleotides (e.g., at least about 44-98 nucleotides) at one or both ends of a CRISPR locus are !5 compared. In some preferred embodiments, at least the first about 10 nucleotides, about 20 nucleotides, about 24 nucleotides, about 30 nucleotides, about 40 nucleotides, about 44 nucleotides, about 50 nucleotides, about 60 nucleotides, about 70 nucleotides, about 80 nucleotides, about 90 nucleotides, about 98 nucleotides or about 100 or more nucleotides (e.g., at least about 44-98 nucleotides) at the 5' 30 end of a CRISPR locus or at the 3' end of a CRISPR locus are compared. In some preferred embodiments, at least the first about 44 nucleotides at the 5' end of a CRISPR locus or the last about 44 nucleotides at the 3' end of a CRISPR locus are compared. In some embodiments, at least the first about 10 nucleotides, about 20 nucleotides, about 24 nucleotides, about 30 nucleotides, about 40 nucleotides, about 44 nucleotides, about 50 nucleotides, 35 about 60 nucleotides, about 70 nucleotides, about 80 nucleotides, about 90 nucleotides, about 98 nucleotides, or about 100 or more nucleotides (e.g., at least about 44-98 nucleotides) downstream from the first nucleotide of the first CRISPR repeat at the 5' end of a CRISPR locus or upstream from the last nucleotide of the last CRISPR repeat at the 3' end of a CRISPR locus are compared. In some preferred embodiments, at least about the first 44 nucleotides downstream from the first nucleotide of the first 40 CRISPR repeat at the 5' end of a CRISPR locus or about at least 44 nucleotides upstream from the last nucleotide of the last CRISPR repeat at the 3' end of a CRISPR locus are compared.

47 5 In some embodiments, the minimum size of the duplicated sequence is about 24 nucleotides and minimum size of the tagging sequence is about 20 nucleotides. In some preferred embodiments, at least 44 nucleotides are compared. In some alternative embodiments, the maximum size of the duplicated sequence is about 40 nucleotides and the maximum size of the tagging sequence is about 58 nucleotides. In some preferred embodiments, at least 98 nucleotides are compared. In some alternative preferred [0 embodiments, at least about 44-98 nucleotides are compared. As used herein, the term "CRISPR repeat" has the conventional meaning as used in the art (i.e., multiple short direct repeats, which show no or very little sequence variation within a given CRISPR locus). As used herein, in context, "CRISPR repeat" is synonymous with the term "CRISPR." A CRISPR locus comprises one or more CRISPR repeats than there are CRISPR spacers. Thus, [5 the CRISPR repeat corresponds to the repeated sequence within a CRISPR locus. For example, except for the terminal repeat, the typical repeat sequence of the S. thermophilus CRISPRI sequence is: 5'-GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAAC-3' (SEQ ID NO: 1) Point variations of this repeat sequence have been observed but they are very rare. Compared to this typical repeat sequence, the terminal repeat sequence always shows the same variation at its 3' end. !0 Point variations of this terminal repeat sequence have also been observed but they are rare. CRISPR repeats may naturally occur in the parent bacterium. Genbank accession numbers of CRISPRI sequences include: CP000023, CP000024, DQ072985, DQ072986, DQ072987, DQ072988, DQ072989, DQ072990, DQ072991, DQ072992, DQ072993, DQ072994, DQ072995, DQ072996, DQ072997, DQ072998, DQ072999, DQ073000, DQ073001, DQ073002, DQ073003, DQ073004, DQ073005, DQ073006, !5 DQ073007, DQ073008, and AAGS01000003. As described in further detail herein, a duplicated sequence is derived, derivable, obtained or obtainable from a parent bacterium. In some preferred embodiments, the sequence comprises the genomic DNA of a parent bacterium. In some particularly preferred embodiments, the duplicated CRISPR repeat (e.g., in the same CRISPR locus) is integrated iteratively, sequentially, simultaneously or 30 substantially simultaneously along with the tagging sequence into the parent bacterium to give rise to a labelled bacterium. The number of nucleotides in a repeat is generally about 20 to about 40 base pairs (e.g., 36 base pairs), but in other embodiments is about 20 to about 39 base pairs, about 20 to about 37 base pairs, about 20 to about 35 base pairs, about 20 to about 33 base pairs, about 20 to about 30 base pairs, about 21 to 35 about 40 base pairs, about 21 to about 39 base pairs, about 21 to about 37 base pairs, about 23 to about 40 base pairs, about 23 to about 39 base pairs, about 23 to about 37 base pairs, about 25 to about 40 base pairs, about 25 to about 39 base pairs, about 25 to about 37 base pairs, about 25 to about 35 base pairs, or about 28 or 29 base pairs. The number of nucleotides in a repeat is generally about 20 to about 40 base pairs, but may be 40 about 20 to about 39 base pairs, about 20 to about 37 base pairs, about 20 to about 35 base pairs, about 20 to about 33 base pairs, about 20 to about 30 base pairs, about 21 to about 40 base pairs, about 21 to about 48 5 39 base pairs, about 21 to about 37 base pairs, about 23 to about 40 base pairs, about 23 to about 39 base pairs, about 23 to about 37 base pairs, about 25 to about 40 base pairs, about 25 to about 39 base pairs, about 25 to about 37 base pairs, about 25 to about 35 base pairs, or about 28 or 29 base pairs. The number of repeats may range from about 1 to about 140, from about 1 to about 100, from about 2 to about 100, from about 5 to about 100, from about 10 to about 100, from about 15 to about 100, from t0 about 20 to about 100, from about 25 to about 100, from about 30 to about 100, from about 35 to about 100, from about 40 to about 100, from about 45 to about 100, from about 50 to about 100, from about 1 to about 135, from about I to about 130, from about I to about 125, from about I to about 120, from about 1 to about 115, from about I to about 110, from about 1 to about 105, from about I to about 100, from about 1 to about 95, from about 1 to about 90, from about 1 to about 80, from about 1 to about 70, [5 from about 1 to about 60, from about 1 to about 50, from about 10 to about 140, from about 10 to about 130, from about 10 to about 120, from about 10 to about 110, from about 10 to about 95, from about 10 to about 90, from about 20 to about 80, from about 30 to about 70, from about 30 to about 60, from about 30 to about 50, from about 30 to about 40, or about 32. In some other embodiments, the number of nucleotides in a repeat is about 20 to about 39 base !0 pairs, about 20 to about 37 base pairs, about 20 to about 35 base pairs, about 20 to about 33 base pairs, about 20 to about 30 base pairs, about 21 to about 40 base pairs, about 21 to about 39 base pairs, about 21 to about 37 base pairs, about 23 to about 40 base pairs, about 23 to about 39 base pairs, about 23 to about 37 base pairs, about 25 to about 40 base pairs, about 25 to about 39 base pairs, about 25 to about 37 base pairs, about 25 to about 35 base pairs, or about 28 or 29 base pairs. !5 In some embodiments, the number of repeats ranges from about 1 to about 144, from about 1 to about 100, from about 2 to about 100, from about 5 to about 100, from about 10 to about 100, from about 15 to about 100, from about 20 to about 100, from about 25 to about 100, from about 30 to about 100, from about 35 to about 100, from about 40 to about 100, from about 45 to about 100, from about 50 to about 100, from about I to about 135, from about 1 to about 130, from about I to about 125, from about 30 1 to about 120, from about 1 to about 115, from about I to about 110, from about 1 to about 105, from about 1 to about 100, from about 1 to about 95, from about 1 to about 90, from about 1 to about 80, from about 1 to about 70, from about 1 to about 60, from about 1 to about 50, from about 10 to about 140, from about 10 to about 130, from about 10 to about 120, from about 10 to about 110, from about 10 to about 95, from about 10 to about 90, from about 20 to about 80, from about 30 to about 70, from about 35 30 to about 60, from about 30 to about 50, from about 30 to about 40, or about 30, 31, 32, 33, 34 or 35 repeats. In some embodiments, the number of repeats ranges from about 2 to about 140, from about 2 to about 100, from about 2 to about 100, from about 5 to about 100, from about 10 to about 100, from about 15 to about 100, from about 20 to about 100, from about 25 to about 100, from about 30 to about 100, 40 from about 35 to about 100, from about 40 to about 100, from about 45 to about 100, from about 50 to about 100.

49 5 In some further embodiments, the number of repeats ranges from about 2 to about 135, from about 2 to about 130, from about 2 to about 125, from about 2 to about 120, from about 2 to about 115, from about 2 to about 110, from about 2 to about 105, from about 2 to about 100, from about 2 to about 95, from about 2 to about 90, from about 2 to about 80, from about 2 to about 70, from about 2 to about 60, from about 2 to about 50, from about 2 to about 40, from about 2 to about 30, from about 2 to about [0 20, from about 2to about 10, from about 2 to about 9, from about 2 to about 8, from about 2 to about 7, from about 2 to about 6, from about 2 to about 5, from about 2 to about 4, or from about 2 to about 3. In some embodiments, the CRISPR repeats comprise DNA, while in other embodiments, the CRISPR repeats comprise RNA. In some embodiments, the nucleic acid is of genomic origin, while in other embodiments, it is of synthetic or recombinant origin. In some embodiments, the CRISPR repeat [5 genes are double-stranded or single-stranded whether representing the sense or antisense strand or combinations thereof. In some embodiments, CRISPR repeat genes are prepared by use of recombinant DNA techniques (e.g., recombinant DNA), as described herein. In some embodiments, one or more of the CRISPR repeats are used to engineer a cell (e.g., a recipient cell). In some preferred embodiments, one or more, preferably, two or more CRISPR repeats !0 are used to engineer a cell (e.g., a recipient cell), that in combination with one or more cas genes or proteins and one or more CRISPR spacers modulates the resistance of a cell against a target nucleic acid or a transcription product thereof. For example, in some embodiments, the CRISPR repeat(s) are inserted into the DNA of a cell (e.g., plasmid and/or genomic DNA of a recipient cell), using any suitable method known in the art. In additional embodiments, the CRISPR repeat(s) find use as a template upon which to !5 modify (e.g., mutate) the DNA of a cell (e.g., plasmid and/or genomic DNA of a recipient cell), such that CRISPR repeat(s) are created or engineered in the DNA of the cell. In additional embodiments, the CRISPR repeat(s) are present in at least one construct, at least one plasmid, and/or at least one vector, etc. In further embodiments, the CRISPR repeats are introduced into the cell using any suitable method known in the art. 30 In additional embodiments, the present invention provides methods for identifying a CRISPR repeat for use in modulating the resistance of a cell against a target nucleic acid or transcription product thereof comprising the steps of: (i) preparing a cell comprising at least one CRISPR spacer and at least one cas gene; (ii) engineering the cell such that it contains a CRISPR repeat; and (iii) determining if the cell modulates resistance against the target nucleic acid or transcription product thereof, wherein 35 modulation of the resistance of the cell against the target nucleic acid or transcription product thereof is indicative that the CRISPR repeat can be used to modulate resistance. In some further embodiments, one or more cas genes or proteins are used together with or in combination with one or more, preferably, two or more CRISPR repeats and optionally one or more CRISPR spacers. In some particularly preferred embodiments, the cas gene(s) or protein(s) and CRISPR 40 repeat(s) form a functional combination as described below. In some embodiments, the CRISPR repeats comprise any of the nucleotides set forth in SEQ ID NOS: 1-22. SEQ ID NOS: 1-12 are from S.

50 5 thermophilus, while SEQ ID NOS:13-16 are from Streptococcus agalactiae, SEQ NO:17 is from S. mutans, and SEQ ID NOS: 18-22 are from S. pyogenes. GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAAC (SEQ ID NO:1) GTTTTTGTATTCTCAAGATTTAAGTAACTGTACAGT (SEQ ID NO:2) GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAGT (SEQ ID NO:3) t0 GTTTTTGTACTCTCAAGATTTAAGTAACCGTACAAC (SEQ ID NO:4) GTTTTTGTACTCTCAAGATTTAAGTAACTGTGCAAC (SEQ ID NO:5) GTTTTTGTACTCTCAAGATTTAAGTAGCTGTACAGT (SEQ ID NO:6) GTTTTTGTACTCTCAAGATATAAGTAACTGTACAAC (SEQ ID NO:7) GTTTTTGTACTCTCAAGATCTAAGTAACTGTACAAC (SEQ ID NO:8) [5 GTTTTTGTACTCTCAAGATGTAAGTAACTGTACAAC (SEQ ID NO:9) GTCTTTGTACTCTCAAGATTTAAGTAACTGTACAAC (SEQ ID NO: 10) AAAAAAGTCCCCTCTCGAGGTAATTAGGTTTATATC (SEQ ID NO: 11) GTTTCCGTCCCCTCTCGAGGTAATTAGGTTTATATC (SEQ ID NO: 12) GTTTTAGAGCTGTGTTGTTTCGAATGGTTCCAAAAC (SEQ ID NO: 13) !0 GTTTTAAAGCTGTGCTGTTATTATGCTAGGGCACCA (SEQ ID NO:14) GTTTTAGAGCTGTGCTGTTTCGAATGGTTCCAAAAC (SEQ ID NO: 15) GTTTTAGAGCTGTGCTGTTATTATGCTAGGACATCA (SEQ ID NO: 16) GTTTTAGAGCCATGTTAGTTACTGATTTACTAAAAT (SEQ ID NO: 17) GTTTTAGAGCTATGCTGTTTTGAATGGTCCCAAAAC SEQ ID NO:18 !5 GTTTTAGAGCTATGCTGTTTTGAATGGTCTCCATTC (SEQ ID NO: 19) CTTTCAATCCACTCACCCATGAAGGGTGAGACG (SEQ ID NO:20) ATTTCAATCCACTCACCCATGAAGGGTGAGACT (SEQ ID NO:21) ATTTCAATCCACTCACCCATGAAGGGTGAGACC (SEQ ID NO:22) ;0 CRISPR Spacer As used herein, "CRISPR spacer" encompasses non-repetitive spacer sequences that are found between multiple short direct repeats (i.e., CRISPR repeats) of CRISPR loci. In some embodiments of the present invention, a "CRISPR spacer" refers to the nucleic acid segment that is flanked by two CRISPR repeats. It has been found that CRISPR spacer sequences often have significant similarities to a ;5 variety of mobile DNA molecules (e.g., bacteriophages and plasmids). In some preferred embodiments, CRISPR spacers are located in between two identical CRISPR repeats. In some embodiments, CRISPR spacers are identified by sequence analysis at the DNA stretches located in between two CRISPR repeats. In some preferred embodiments, CRISPR spacer is naturally present in between two identical multiple short direct repeats that are palindromic. 40 Interestingly, cells carrying these CRISPR spacers are unable to be infected by DNA molecules containing sequences homologous to the spacers (Mojica et al. 2005). In some preferred embodiments, , the CRISPR spacer is homologous to the target nucleic acid or a transcription product thereof or an identified sequence. Although homology can also be considered in terms of similarity, in the context of the present invention it is preferred to express homology in terms of sequence identity. A homologous 45 sequence is taken to include a CRISPR spacer, which may be at least about 70, about 75, about 80, about 85, or about 90% identical, or at least about 91, about 92, about 93, about 94, about 95, about 96, about 97, about 98, or about 99 % identical to the target nucleic acid sequence or a transcription product thereof or an identified sequence. In some preferred embodiments, the CRISPR spacer is about 100% identical to the target nucleic acid sequence. It is also noted that the number of CRISPR spacers at a given 51 5 CRISPR loci or locus can vary between species. In addition, the number of spacers ranges from about 1 to about 140, from about 1 to about 100, from about 2 to about 100, from about 5 to about 100, from about 10 to about 100, from about 15 to about 100, from about 20 to about 100, from about 25 to about 100, from about 30 to about 100, from about 35 to about 100, from about 40 to about 100, from about 45 to about 100, or from about 50 to about 100. In some preferred embodiments, the number of spacers t0 ranges from about I to about 135, from about 1 to about 130, from about I to about 125, from about 1 to about 120, from about I to about 115, from about 1 to about 110, from about I to about 105, from about 1 to about 100, from about 1 to about 95, from about 1 to about 90, from about 1 to about 80, from about 1 to about 70, from about 1 to about 60, from about 1 to about 50, from about 1 to about 40, from about 1 to about 30, from about 1 to about 20, from about 1 to about 10, from about 1 to about 9, from about 1 to [5 about 8, from about 1 to about 7, from about 1 to about 6, from about 1 to about 5, from about 1 to about 4, from about 1 to about 3, or from about 1 to about 2. In some preferred embodiments, CRISPR spacers are identified by sequence analysis as the DNA stretches located in between two repeats. As described herein, the present invention provides methods and compositions that facilitate the use of one or more cas genes or proteins in combination with one or more, preferably, two or more !0 CRISPR repeats suitable to confer specificity of immunity to at least one CRISPR spacer in a recipient cell. In some preferred embodiments, at least one cas genes or proteins and at least one CRISPR repeat are used in functional combinations to confer specificity of immunity to at least one CRISPR spacer in a cell. As used herein, the term "specificity of immunity" means that immunity is conferred against a !5 specific nucleic acid sequence or transcription product thereof, using a specific CRISPR spacer or pseudo-CRISPR spacer sequence. As indicated herein, a given CRISPR spacer does not confer resistance against any nucleic acid sequence or transcription product thereof but only to those sequences against which the CRISPR spacer or pseudo-CRISPR spacer is homologous (e.g., those that are about 100% identical). 30 In some embodiments, the CRISPR spacer(s) are obtained from a donor organism that is different from the recipient cell. In some preferred embodiments, the donor and recipient cells are different bacterial strains, species, and/or genera. In some preferred embodiments, at least one cas genes or proteins and/or at least one CRISPR repeats are obtained from a different organism than the recipient organism. In some preferred embodiments, at least two CRISPR repeats are transferred. In some 35 additional preferred embodiments, the CRISPR spacers are obtained from an organism that is heterologous to the recipient or a further donor cell from which the at least one cas genes and/or proteins, and/or at least one CRISPR repeat are obtained. In some alternative preferred embodiments, the CRISPR spacers are obtained from an organism that is homologous to the recipient or a further donor cell from which the at least one cas genes and/or proteins, and/or at least one CRISPR repeat are obtained. In some 40 preferred embodiments, the CRISPR spacer(s) is/are designed and produced using recombinant methods 52 5 known in the art. Indeed, it is intended that the CRISPR spacers be produced using any suitable method known in the art. In some embodiments, the CRISPR spacers are heterologous to the recipient cell from which at least one cas genes or proteins and/or the at least one, and in some embodiments, preferably, two or more, CRISPR repeats are obtained. In some alternative embodiments, the CRISPR spacers are [0 homologous to the recipient cell from which at least one cas genes or proteins and/or the at least one, and in some embodiments, preferably, two or more, CRISPR repeats are obtained. Indeed, it is intended that any of the elements utilized in the methods be heterologous or homologous. In some embodiments, where multiple elements are used (e.g., any combination of CRISPR spacer(s), CRISPR repeat(s), cas gene(s), and Cas protein(s)), some elements are homologous with each other and some elements are [5 heterologous to each other (e.g., in some embodiments, the CRISPR spacer(s) and cas genes are homologous, but the CRISPR repeat(s) is/are heterologous). Thus, in some embodiments, the CRISPR spacer is not naturally associated with the CRISPR repeat and/or cas genes and/or functional CRISPR repeat-cas gene combination. Indeed, it is intended that any combination of heterologous and homologous elements find use in the present invention. In yet additional embodiments, the donor and !0 recipient cells are heterologous, while in further embodiments, they are homologous. It is also intended that the elements contained within the donor and recipient cells be homologous and/or heterologous. The elements (e.g., CRISPR spacers) are introduced into plasmid and/or genomic DNA of the recipient cell utilizing any suitable method known in the art. In some preferred embodiments, at least one CRISPR spacer is used to engineer a cell (e.g., a !5 recipient cell). In some additional embodiments, one or more CRISPR spacers are used in combination with one or more cas genes or proteins and/or one or more, preferably, two or more CRISPR repeats (in some preferred embodiments, one or more functional combinations thereof are used) to modulate the resistance of a cell against a target nucleic acid or a transcription product thereof, to produce an engineered cell. In some further embodiments, CRISPR spacers are used as a template upon which to 30 modify (e.g., mutate) the plasmid and/or genomic DNA of a cell (e.g., a recipient cell), such that CRISPR spacers are created in the DNA of the cell. In some embodiments, the CRISPR spacer(s) is/are cloned into at least one construct, plasmid or other vector, with which the recipient cell is then transformed, using any suitable method known in the art. In some further embodiments, the present invention provides methods for identifying a CRISPR 35 spacer for use in modulating the resistance of a cell against a target nucleic acid or a transcription product thereof, comprising the steps of: preparing a cell comprising at least two CRISPR repeats and at least one cas gene or protein; identifying at least one CRISPR spacer in an organism (e.g., a donor organism); modifying the sequence of the CRISPR spacer of the cell such that it has homology to the CRISPR spacer of the donor organism comprising the target nucleic acid; and determining whether the cell 40 modulates resistance against the target nucleic acid, wherein modulation of the resistance of the cell 53 5 against the target nucleic acid or transcription product thereof is indicative that the CRISPR spacer modulates the resistance of the cell against the target nucleic acid. In some preferred embodiments, the CRISPR spacers comprise or consist of the nucleotide sequence set forth any one or more of in any of SEQ ID NO:23-460 and/or SEQ ID NOS:522-665. SEQ ID NOS:23-339, 359-408, 522-665 are from S. thermophilus, while SEQ ID NOS:340-358 are from S. [0 vestibularis, SEQ ID NOS:409-446 are from S. agalactiae, SEQ ID NOS:447-452 are from S. mutans, and SEQ ID NOS:453-460 are from S. pyogenes. AGAACGTATTCCAAAACCTCTTTACGATTA (SEQ ID NO:23) TTAACTGTTATCAAAATGATAAGATAGTCT (SEQ ID NO:24) CGTTGATGTTTATTCAAGTAAAATAATTAA (SEQ ID NO:25) [5 TCCTTTCACGGGTAGCACACTAACATACAC (SEQ ID NO:26) GTTGGCAATGCAAACAACCTTTATGAACCG (SEQ ID NO:27) TTTATTTCCTTGCGATAACGTTCCACCTTT (SEQ ID NO:28) AGATTATAAGGAACACAACCAACTATATAG (SEQ ID NO:29) ACGACATCAAGCTGATTGTCTTCTACATAA (SEQ ID NO:30) !0 TTTGGAATACTGAATGTTTTACTGAAAATC (SEQ ID NO:31) ACACCACTATCTTTTCCTCCTGAAAATGAA (SEQ ID NO:32) GTAATTCCACGAAATTATCAACCTTATGCA (SEQ ID NO:33) TTGGAGGATTGCCCCATATTCCCAAGAGT (SEQ ID NO:34) GAGAGGCGTTAAATATAGAAATGCAAGATT (SEQ ID NO:35) !5 TTTTAACGTCATCAGTCCACCGCCTTAAAT (SEQ ID NO:36) CACCTCTTTCGATGGAAAGGTATCCTTCTA (SEQ ID NO:37) GACCAAAGTTTGATTATAGAGCTATACACC (SEQ ID NO:38) ACCATCATTCTTACCATTACAACTGTAATG (SEQ ID NO:39 ATACGAATTCGGTTCGCACAATTACAATTC (SEQ ID NO:40) ;0 TATCAACGCAATCATTACAACAACTTCAAACA (SEQ ID NO:41) ATCTACGTGTCAATACATATCACAAAACAG (SEQ ID NO:42) ATTTTTAGAAATTTCTGATATAATAATGA (SEQ ID NO:43) TTGTTGGAACAAGGACGACTTGGTAAACTA (SEQ ID NO:44) CATATTAAGCTGACTGGGCCTAATGCTTTT (SEQ ID NO:45) ;5 TTCATAGCATACCGTAGTTGTAAAATCTAT (SEQ ID NO:46) AACATTTAGGGAATGAAATTGATAAGACTG (SEQ ID NO:47) AACATGAGAAACTGTAGAAAACAAGCAATA (SEQ ID NO:48) TGGTGAAGATGGCAGTCATAAATGGCACATT (SEQ ID NO:49) AAGGGTTGAAAAATGTTGGTATATCAAACG (SEQ ID NO:50) 40 TTCTGGTAGTGGATTTAGTCAAACAGATGT (SEQ ID NO:51) TCCATAGAGCGTCTTAAACAAAGAATAGTC (SEQ ID NO:52) TTATGATTGAATGACATGGTTGTATAAGTA (SEQ ID NO:53) TTTCTTTAGGAATACCAGGGAGTTCAGCTT (SEQ ID NO:54) TGGCAGAGATTACACAGCAACGGAAACAGC (SEQ ID NO:55) 45 GGGTATCATTGTATCTAGTGATGGACCTGA (SEQ ID NO:56) ATTTGAAAAATGCACAACAGCGTTTGATAG (SEQ ID NO:57) GAGCTACCAGCTACCCCGTATGTCAGAGAG (SEQ ID NO:58) CGTTCCTTTTTTCAAGGTAATCTTTGAAAG (SEQ ID NO:59) AAGTCCGTAAGCACCAGTTCCAATCGTCAT (SEQ ID NO:60) 50 TTGAATACCAATGCCAGCTTCTTTTAAGGC (SEQ ID NO:61) AACCTCATACATGGGGAAAATTGGTAAGTA (SEQ ID NO:62) TAACTTCATTAGTGTAGTTGTAATTAGCAT (SEQ ID NO:63) TTAGCTACCCAAATATCTTCTGTTTTCCAA (SEQ ID NO:64) GAGTTTTCAATATTGGCACAGGAGACAATT (SEQ ID NO:65) 55 TGATACTATTTTAGTCAGATATGAAATATC (SEQ ID NO:66) TCATCAATGTTTAAAGCCCAACAATACATGA (SEQ ID NO:67) 54 5 TAGATTTAATCAGTAATGAGTTAGGCATAA (SEQ ID NO:68) AGGAAAATAGCATGAGCGTACAACAATCTA (SEQ ID NO:69) TGTCTATCACGCTTCCTAAGTGCATGAAAA (SEQ ID NO:70) ATGTCACCAATCACTAAAGAACCTACGCTG (SEQ ID NO:71) AACATCTTCCTCTCCGATTGCAAATAGTGC (SEQ ID NO:72) [0 CATATTTGGTGCCCGTTCGATAAAGAGTA (SEQ ID NO:73) CATTAAATCGCTTGAAGCAGACATTGAAGC (SEQ ID NO:74) GACTTATCTTGGAAGGTAGTGAAGGCACTT (SEQ ID NO:75) TCCTTGCCATCTGCACTGTAAGCCCAAGCA (SEQ ID NO:76) TAGTACGCATAATCAATTCATCAAGCTTGA (SEQ ID NO:77) [5 GTAGTGACCCAAAATTCTATGACCTTGAAA (SEQ ID NO:78) AGATTGTGGTGCTTACGGAAAATTCCTTGT (SEQ ID NO:79) TGGCAAGAAGTGTAAGAGATGCAATGGATA (SEQ ID NO:80) TTTATTATCATTATTCTTCTTCCCAAGCGT (SEQ ID NO:81) TTTTATAGAATTTGGTGGTGAACTTTTTCA (SEQ ID NO: 82) !0 AATGGGTCACAGATTGCCATAATAAGGAG (SEQ ID NO:83) CCGAGGTCACTTTAGAACCCACAAAATAAG (SEQ ID NO:84) ATGAGAGAACACAGTATAGACCCTGATACA (SEQ ID NO:85) CAGTATTAATGAGGTTTGGGTGGTCATTCC (SEQ ID NO:86) CCATACTCTCTATCAGTTCATTTAATTCTTC (SEQ ID NO:87) !5 TAATATGTCGCTCTACTGATTCCAAAACGG (SEQ ID NO:88) ATGAATTACATTCATGATTTTATCGAGTTT (SEQ ID NO:89) CGTGCCATTGTTTCGGTCGGACGTGGGCA (SEQ ID NO:90) CTTTCTAAGTTGAATTAAATTCAAGTTTTG (SEQ ID NO:91) TCGCTACTATGGTTAACGATGAGGAACTCT (SEQ ID NO:92) ;0 AGCAACTTTAAAACTAAAAGAGCTACTTGA (SEQ ID NO:93) AAAACCCTACACAGTGTGTGAGATGTGTCA (SEQ ID NO:94) AATGGGTCACAGATTGCCATAATAAGGAGG (SEQ ID NO:95) TTTTTTAAAATCCGTCATGCTATACTATAT (SEQ ID NO:96) AATTCAAACTTTCTCCAATAATACCCTCCA (SEQ ID NO:97) ;5 CATGCTTTCAGTTAATAAGACGTGGGACTA (SEQ ID NO:98) TGGAAGGGGTGTCTAGTGAAGAAATTGTCG (SEQ ID NO:99) CTCGAAGCGCTTCATTGCCCTATTCCTTTC (SEQ ID NO: 100) ATGTCTAAGGTATCCACTCGTGAAATCAT (SEQ ID NO: 101) ATATTAATGGAAATTTCATTCAAACGCAGT (SEQ ID NO:102) W. TAGAGAGTTTATATCCTGATGGAATCGATG (SEQ ID NO:103) TGGCGAATTAGAGAGCCAATGGCAAGCAAG (SEQ ID NO:104) AGAAGACCAATAAACTTGAGAAAAAGCAAG (SEQ ID NO:105) AAATGGTCGTTTAATTGTTAATGTCAAAGC (SEQ ID NO:106) CAATTGATTCTAAAATGCTTGGTACACGTA (SEQ ID NO:107) 45 TCTTCGTGTTATCACAGCTTCTACACGTTG (SEQ ID NO:108) GAAATCTCATTGAAACCAACTTCAAGACCA (SEQ ID NO:109) TGCTTGGTAGTTGATGCACTGCATTAGTAA (SEQ ID NO:110) AATGTACCGGAATAGCGTTACATTGCACAT (SEQ ID NO:111) TTCATAAATTCTCACTTTTCCTTGCTATTC (SEQ ID NO: 112) 50 TGTCGAAAAAATTACCTAGTCACGACAGAC (SEQ ID NO:113) CAACAATTACTTATGCATTAGGAACATCTG (SEQ ID NO:114) AATTCGTGAAAAACAATAAAAACAAAAAAA (SEQ ID NO:115) TAACATTTCTGTCCATTTCTTCCTTGATGC (SEQ ID NO: 116) CAAGGCAACTCAACCAACCAAATTGACC (SEQ ID NO:117) 55 CTAAAATCGTAAATGGTAAGTTGCACGATG (SEQ ID NO:118) AACGTAAGGAGTTTTTTTATTTCTTTGTTA (SEQ ID NO: 119) GTGGAAAATTTCACACCCTACATATATCAA (SEQ ID NO:120) CCTCTGCTAATGACTTAAACGGCTCGTTTT (SEQ ID NO: 121) AAAATCAAAGTTTTGGGTTTGTCTACGTTG (SEQ ID NO:122) 60 ATATGTACATACCTAAAGAAAACACGGGCA (SEQ ID NO:123) 55 5 CGTTGTCAAAATATGTGATTACTTTGTATT (SEQ ID NO: 124) CCATAGCTGTAATGTTGTTTGTGACTGCTT (SEQ ID NO: 125) CGCTAAGTTTGGCTTTAAGTATAACAAGCT (SEQ ID NO:126) AAAGTACGCTTCAAGGCACGTTGAAGACAT (SEQ ID NO:127) CTTTTTAACGTGTTAGCGTCTTTAGCTTTG (SEQ ID NO: 128) [0 TTGGCTTCGTGAATAATTTTTAAAACGCAT (SEQ ID NO: 129) TGTTGAATCAATACGCTGAAACACACTCCC (SEQ ID NO: 130) CGTTATCAGTTGAAAGTTTCAACTCGTAAG (SEQ ID NO:131) TAAACTAGTTGGCATCTATGCTCCAGGAAG (SEQ ID NO:132) TAGACCACCATAGCCGAGTTGTCTTTTTCG (SEQ ID NO: 133) [5 ACATCCCACTTTCTGGGTTTTTTAGCCATG (SEQ ID NO:134) AGTATGGCTATTGTCCTGATACTCATCCAC (SEQ ID NO: 135) CGCTCTTGACGTGGCTGGTGACATCTACGC (SEQ ID NO:136) GAGTACATGGAGTTTCTGCTAGATACACTA (SEQ ID NO:137) TAAGTTATGAAATATAAAGTTATTGTCTA (SEQ ID NO:138) !0 AACGTTATGACATTTAGGAGCTTCCAAATT (SEQ ID NO:139) AACACAGCAAGACAAAAGGATGACACTTT (SEQ ID NO: 140) CAACCATAACTTACGCATCAGGTACATCTG (SEQ ID NO: 141) ACACGCGCTTACCTCGTATATCAAATTCA (SEQ ID NO: 142) TGCCCGCAAACTAGCGATACACAACAGCAT (SEQ ID NO:143) !5 CTCAAGCTCTTCATCTGTGATAGGTGTTTTG (SEQ ID NO: 144) ATCACTCTTTGATAGTATCTCAAACGCTGG (SEQ ID NO: 145) GAAACAGTCAGACCAGCTAATTCGCCAATT (SEQ ID NO:146) ATATTTCGAAAGATACAAGGACACTTACAC (SEQ ID NO:147) GCGGATGAAACACAACTTCAATTGTATTCA (SEQ ID NO:148) ;0 TAATGCTACATCTCAAAGGATGATCCCAGA (SEQ ID NO:149) ACGTCTGTCTAACTGGAAAGTACCTGCTAAT (SEQ ID NO:150) CTGTTCTCTAATCGAGAGGCGCGTGATTGA (SEQ ID NO:151) AAACCTCACTAGTCACTTAGTGCGGTTAGG (SEQ ID NO:152) TATTAAGTTTAGTCCCAGGTTTCTTATCGT (SEQ ID NO: 153) ;5 AAACCAATAAACATACCGATTGCTGCCAAT (SEQ ID NO:154) GCAAACGTTAGCCCAGGAAAGCATCATGAA (SEQ ID NO:155) AAGAGCAAAAAATAACTCTAGCTCTCGTCC (SEQ ID NO:156) AAGAAACCTCTAAGTTGAGCATTTAATGAT (SEQ ID NO:157) ATATAGTTTTAAACTTTCTTGACCTTCTG (SEQ ID NO:158) W- ACGTTGATGAATATTGTTGATAAACTTTA (SEQ ID NO: 159) CAAGAAGTGAACAAAGTACACGCTGGAAGT (SEQ ID NO:160) GACAGCAAGATACACGTAGTTGATGAATTG (SEQ ID NO:161) TAAGAAATCAACGCAGATTTTTAGCCAACA (SEQ ID NO:162) TAACCCAATAATTACAGTGAAGCACAATAG (SEQ ID NO:163) 45 CAGGCGTAAGGTATGCTAATTATAACGAT (SEQ ID NO:164) GCTATCGAACTAATAGCTTAGAGGAACTCA (SEQ ID NO:165) GTGGAATATTAAGCCCGAATTGTTGCAGCA (SEQ ID NO:166) TATTGCAATATTTGCGTTTGGGAAACCTTC (SEQ ID NO:167) CGTCTGTCTAACTGGAAAGTACCGGCTAAT (SEQ ID NO:168) 50 AAAGAGATGTACCCATCCATTCTAACAGGT (SEQ ID NO:169) GGGGAGTTGATTTCTTACATCAAAACAATG (SEQ ID NO:170) CATCAAAGTTGAAAAGGACTACAACAGCCC (SEQ ID NO:171) CTTAAATTTAGAGCGTGGGATCTTGAATAT (SEQ ID NO:172) ATATACCGATGGCACATCTGAAACTGGCTG (SEQ ID NO:173) 55 TAACTCATATGTATCTTGACCAACTATTTT (SEQ ID NO: 174) AAATAGCACCTCTAAGCGTTAATGGTATTC (SEQ ID NO:175) AATATCTACAGGTCACTACAAAGCTACGCT (SEQ ID NO:176) GTTGGGGTGTGTTTGTAACGGCGTATGCTA (SEQ ID NO:177) TCAATCAGGTGACGGTGATGCTTATATTAA (SEQ ID NO: 178) 60 CATACATGATAGTTTGTCAACACTTTTGAT (SEQ ID NO: 179) 56 5 TCAGCATTTGGTTTACATGACCCACGTCTG (SEQ ID NO: 180) CAATCAACAGGTTTGACTGATTATAACGGT (SEQ ID NO:181) TAGCTACACATGAATTTTATTACAATGGTG (SEQ ID NO:182) CTTACGTTTGAAAAGAATATCAAATCAATG (SEQ ID NO:183) TTAAAAAAGGGCCTTTCTCTAAATCAAGTA (SEQ ID NO:184) to TGCTGAACGTATCTGTCCACTGTGTGGCCA (SEQ ID NO:185) CCGTTCTTCAAACGTTAAATTCCAAGGTGT (SEQ ID NO: 186) GCTGCGATTATGACAATGCTGTCTGTAAGG (SEQ ID NO:187) GAAGAATTTATTAATAAAGATGGTTCTGCT (SEQ ID NO:188) AGGCAGAAAAGAAGTATTTTGGTAAGTATG (SEQ ID NO:189) [5 AAATGGTTTATCGACAAGAAAATGAAGCT (SEQ ID NO:190) CCAAATTTGCATTATACAAAACGCTCCTTC (SEQ ID NO: 191) ATCCTAACTGCTTTGCTAACTACATCATGG (SEQ ID NO: 192) TAACAAGATAAGATTAGCGTCTTCAACAT (SEQ ID NO:193) AAAAGCCTATGTTTGCCCACTTTGTGGAAG (SEQ ID NO:194) !0 TGTCACTTTCTCTTTCTGGGTTGTGCCAAT (SEQ ID NO: 195) CATACTTTTCCATCTGTTTGTTGTTTGAAAA (SEQ ID NO: 196) TGAGAGTGTCTGATGGATTTATTGGCAGCC (SEQ ID NO:197) GGGGTTATTTTCCATTTTACCGTCTATCTA (SEQ ID NO: 198) TATCACGCCCATTTTCATTTCGCCATCTGT (SEQ ID NO: 199) !5 AACATTTTAATATAATTTCTAAATCTATTG (SEQ ID NO:200) TACAAAATTCCTTCAAACGCTATTTATTGA (SEQ ID NO:201) AGAGTTTGAAAATTATTTTTCAGTTTCTA (SEQ ID NO:202) TTCCTCATCTTTCTCCGCTTTTGCTAGCTT (SEQ ID NO:203) TTGAGCGTTCTAGTGTGTGGCTTGTAATGAA (SEQ ID NO:204) ;0 TGAAAGAAATACAATACAACGATAATGACC (SEQ ID NO:205) CTAGTTTTAAGAGATAGCTCTCTAAGTAGG (SEQ ID NO:206) AAATTCGACATAAGCACTACAGTTATATT (SEQ ID NO:207) CTATTTTCGAGAGAACGTCAGTCATTTTAA (SEQ ID NO:208) GTGCTAACTATATCAGTCGCATCAATAACA (SEQ ID NO:209) ;5 TTAGCGGTGATTGGAATAGAATAAGCGAAT (SEQ ID NO:210) CTTCTACAGCAGTTTAAGACACATTATCAT (SEQ ID NO:21 1) CGTATCGAAAACGGCGATAATCCAACAGT (SEQ ID NO:212) CAATACCTTTTTTTAATTCATCTTGATAAGT (SEQ ID NO:213) TTAAGAACAATATCATCAATACGACTTTCA (SEQ ID NO:214) W- CATCTATCAAATTCAAATTCGGATAAACTA (SEQ ID NO:215) TGAGAGTGTCTGATGGATTTATTGGTAACC (SEQ ID NO:216) ACCTCATACATGGGGAAAACTTGTAAGTA (SEQ ID NO:217) TATTTCACGAATTTCTACACTTTTCAACCT (SEQ ID NO:218) CTGAAACCTTGTTTTGAAGCGCTTGGAAGT (SEQ ID NO:219) 45 GTCAATTGATACTGCAATCTCTTTAACATT (SEQ ID NO:220) ACTTCAATATGGTCAACATCTTGATCACCGA (SEQ ID NO:221) TAAACTCGACAAAAGCACTACATGAATATT (SEQ ID NO:222) ATTTTTTAAGGAAAGGAGGAAAATAATATA (SEQ ID NO:223) CGTTCAAAACAGCGAAAACTTAACCCTAAC (SEQ ID NO:224) 50 CATTAAGTCGCTTGAGGCAGACATTGAAGC (SEQ ID NO:225) CCAAACTCAAATTGTCTATAATAATAACCG (SEQ ID NO:226) TATCTCTATTTCAGGTGGTTTAAAACATTC (SEQ ID NO:227) AAACGAAGATGGAAGCGTTGATGTTTATTC (SEQ ID NO:228) GATTGCATTTGCCAGTATTTCTTTTGATTA (SEQ ID NO:229) 55 TGAAGACAACGGAAACAATCAACCTATTA (SEQ ID NO:230) ACTTCTTTTTTAATGTCATCTAAGACAATA (SEQ ID NO:231) GCCAATGATGTTCAATTCGTTAATGGAATT (SEQ ID NO:232) TCAACATGGGATATTTCGTTGGTCAGGATG (SEQ ID NO:233) TATGGCTCTCTTGTTGGAATAAAGATGATT (SEQ ID NO:234) 60 ATAACATAGCAGTCTATTTCTTTGCTGATG (SEQ ID NO:235) 57 5 GTTACCACGCGCCCTACTGTATTAGTGGAG (SEQ ID NO:236) TACATACCCAAGGTTGTAAGTCGTTAAATT (SEQ ID NO:237) TGTAAGTAGTCAATATTCACTTCTGATAAC (SEQ ID NO:238) GATAGCAATAGCTTTCTTGACCTAAAAGAC (SEQ ID NO:239) GAGGTCTGTAATTTCATTCCCTCGTAATCT (SEQ ID NO:240) [0 AAAGGTTTCTCTAAACACATGCGGAATAT (SEQ ID NO:241) GTCATAGTACCAAGCACAAATAACGTTAGT (SEQ ID NO:242) GTGTATTTAGTAATGGTGATTTTTTAAATT (SEQ ID NO:243) CATTCATTTTTTATATATCAATAAAACTTT (SEQ ID NO:244) GGGGATTCTTATTTCACTGTAGTTACGATG (SEQ ID NO:245) [5 CAAAAATTGATGTCACAATTAATAAAGGTG (SEQ ID NO:246) CTATTTCTGACAATGGTTGAAATTGTGTTC (SEQ ID NO:247) CTTTTTTTAAATTAATTTATCGTAAGCAA (SEQ ID NO:248) AACAAACTTATGAGAACGGTTGAACGGCTT (SEQ ID NO:249) AGCCCGCTTATTGCTTCAGTTGGTTTATAT (SEQ ID NO:250) !0 TGGAGCAACAAGAATGATTAACTCTAATGC (SEQ ID NO:251) TTTGATGGATATCATTGATAAACTATACGA (SEQ ID NO:252) TAACGAAAGCAATACCAATCGTGCTAAAGC (SEQ ID NO:253) TATTCCTATGGTCGATATTCGAACAGTCAA (SEQ ID NO:254) CAGGGGACAAGGACTTTGACCCAACAGAAG (SEQ ID NO:255) !5 AGAAACACCTAATGGTCTCTTAGAACCCGA (SEQ ID NO:256) AAGAAGTTAAAGACAACTTTGTTAAAGACT (SEQ ID NO:257) GAAAAAGCATCCATGATAGTGCTTAGACCT (SEQ ID NO:258) CGGAATGGTATAAAGAATACAAAGAAAACG (SEQ ID NO:259) CCAAGTATCACGCAAAGAAATCAACGAGA (SEQ ID NO:260) ;0 TTGACCTGTTTATCCTTGTTAACTAGAATAG (SEQ ID NO:261) AGAGCACTAGCATACTGTTTAGTCCGAACG (SEQ ID NO:262) AGGCAAGGTATTTGATCCAACAGAAGCCAA (SEQ ID NO:263) CATGATTTACAACCACGCGCTAGACCAAG (SEQ ID NO:264) ACCTAGAAGCATTTGAGCGTATATTGATTG (SEQ ID NO:265) ;5 AATTTTGCCCCTTCTTTGCCCCTTGACTAG (SEQ ID NO:266) TAATAGTTTACCAAATCGTCCTTGTTCCAA (SEQ ID NO:267) ACCATTAGCAATCATTTGTGCCCATTGAGT (SEQ ID NO:268) ACGTCTGTCTAACTGGAAAGTACCTGTTAAT (SEQ ID NO:269) TTTTTATACTTTGGGTAATTACAAAATAG (SEQ ID NO:270) W- AAGAAAGAAATATTCTAGATATAGATATAA (SEQ ID NO:271) CAACGACCAACACAACAACTAAAGTTACTG (SEQ ID NO:272) TGATTATGGGTGTTAAACAAGGAGCTTATG (SEQ ID NO:273) TGAGTGGTAAGTACAAATACGCAGGACTGA (SEQ ID NO:274) TTATTTCCTCCTTTCCTTAAAAAAATTAGA (SEQ ID NO:275) 45 GGATGTATCTGTTGAAAGAGGTGTGTATAT (SEQ ID NO:276) AATAGGTGAAAAATATGCAAGTCACACAAA (SEQ ID NO:277) AAAATGGCATTAAAAATTAACATAGGAATA (SEQ ID NO:278) TATCAGCTCGTAAATGTTCGATAGACTCTT (SEQ ID NO:279) ATTCCATTAACGTATTTGACTTCACTAGCT (SEQ ID NO:280) 50 CTGTTACCGATCCAAGAGCAGACATCATAC (SEQ ID NO:281) AAGAAGCGGTTAAATGCTTCAACTGAATAG (SEQ ID NO:282) AATTGCTAAACATCTAAAAGACTTAACGGG (SEQ ID NO:283) GATGAAGATTTGACTGATGATAAAGAGAAA (SEQ ID NO:284) GACATCAGAAAGCAGTTTATAAATATTTTA (SEQ ID NO:285) 55 TTTGAATTTAACAACCTTGATTTTGATATC (SEQ ID NO:286) TGATACGGTCAAAGTTTTTCCACTAATAGCG (SEQ ID NO:287) ATGGTTTTCATTTCCTGAACCCCTAAGAGG (SEQ ID NO:288) AAGTTATTGAAAAACGCCAACATGATGAGT (SEQ ID NO:289) ATATAAGTCCTCCTATTAATATCCACAATA (SEQ ID NO:290) 60 TTGCCTCAAGAGATCCTGCTTGTTGCCAAG (SEQ ID NO:291) 58 5 TCCCATAGTTTTAATGAGTCGGTTAACTTA (SEQ ID NO:292) GTGTACTAAAAGTGTGCTAAGTTCATAAGG (SEQ ID NO:293) ATATAGTGATTGTATCCAGCTGCGGCGTAG (SEQ ID NO:294) AAAAGCAAATCGCGAGTATAAAGGATATA (SEQ ID NO:295) TTTTAATTGATCTAGACACCCTATGAAATA (SEQ ID NO:296) [0 ACAGAGGAGAGAAACCATGGCTATTTTAGA (SEQ ID NO:297) TGGCAGCAGTGAATTCGATGCCGAGCAAT (SEQ ID NO:298) CCAAGGAATACCAGGTCCTAAAGGTGCCGA (SEQ ID NO:299) CTAAATGAACTACAACAACAGCTTGATGA (SEQ ID NO:300) TACCTTAACATTTTCGATATTTTTCAAATT (SEQ ID NO:301) [5 TTTGACTGCTTTTTTATCTGAATTGTAATT (SEQ ID NO:302) CAGTAACCTAAAGCTCTATCAAGCCTATTT (SEQ ID NO:303) CGTCAAGCTGACAGACCTTGACAACAAATC (SEQ ID NO:304) AGGCATAAATAACATTGATAACCCTAACA (SEQ ID NO:305) GCCAACGAGGTCAAATATGTCAACGGCATT (SEQ ID NO:306) !0 GAAATAGGAACTTCAAAGGTAATTTCTTTA (SEQ ID NO:307) ATTTAGAGCAAGGAAAGCAGTACATCATTA (SEQ ID NO:308) CTGTAATCATTTTTAAATCAGGATTATCAA (SEQ ID NO:309) TTAAATGTATCCTAGTATTTTTGTACTATA (SEQ ID NO:310) CCATCAGCCAACTGTATCGGCTACTTTCTA (SEQ ID NO:311) !5 ATGCTCTTGGCGACTATCTCATGGAGCGTG (SEQ ID NO:312) AGGAAAAAACCCAAACAACCCAAAATGTTA (SEQ ID NO:313) TCTAATTCTGTCACCACGACTATATCGCCA (SEQ ID NO:314) AATCTGTGTGGGAAGTAAAGATTGAAGATG (SEQ ID NO:315) ATAGTTTGTTAAGTCATACCCATTAAATTG (SEQ ID NO:316) ;0 TCCACATGATTACAAAGCCACGCAAGACCT (SEQ ID NO:317) GAAGACCAAAATTTGACAATGAGTCCTGC (SEQ ID NO:318) ATTATATTTAAGTTGTAAATGTTGCTTTTC (SEQ ID NO:319) GCAGACATTGGCTCAACAAGTGATTATGAA (SEQ ID NO:320) TGTTCTCATAAATTGCCTTTCCTTTTTATG (SEQ ID NO:321) ;5 CTTATCAAACATCAAGGATTGTAGATGAGG (SEQ ID NO:322) ATTTCATTAGTAGCTTGATAAATGTTTCTA (SEQ ID NO:323) GAAAATACTATACTTTAAAAGAAATTTTAA (SEQ ID NO:324) TCTCCTCCGACATAATCTTTTGTCTTTCCG (SEQ ID NO:325) ACAAAAGCACTGCCACCTATAGAAGCATTT (SEQ ID NO:326) W- AAAAACTTTATGCTATCCGTGTCAGTATAT (SEQ ID NO:327) TTTTCAATGATTGAAAGCCCATAACTAACA (SEQ ID NO:328) CTTTCATAGTTGTTACGAAATGTTTGGCAT (SEQ ID NO:329) CGATTTGCAATATGATGATATTGATGAATT (SEQ ID NO:330) TTTAGATGCTAGTCCTAAGACTGTAGAGAC (SEQ ID NO:331) 45 GTAATCAAGCGTATATAAGTCAGGACTATC (SEQ ID NO:332) ATAACAGAAGGAGTAGGGGACGTAGGCGCG (SEQ ID NO:333) TTATTTGATAGGAATGTCAGTAATTTTTGA (SEQ ID NO:334) AACATTTCAGCGCTTACTTATCAATCTAAT (SEQ ID NO:335) GTATTAGTAGGCATACGATTATGGAAGTA (SEQ ID NO:336) 50 CATATATATATATATATTTATTTTAAATAT (SEQ ID NO:337) TTGTCATAATAATTAAATCCAATAGGACTT (SEQ ID NO:338) GAAAATTTCTGTTGTGTTCTTAATATTAGC (SEQ ID NO:339) GTACTTCAAAGGTTCTAACTACATAACACA (SEQ ID NO:340) TAAAACCAGATGGTGGTTCTTCTGATACTA (SEQ ID NO:341) 55 CATTTTCTTCAGTCAATTCGTTCTCAAGCG (SEQ ID NO:342) AAAGGACGGGGGCAATGAACAAACGACAAC (SEQ ID NO:343) TAATATCATTGATAGCTTCATCAAAGGCT (SEQ ID NO:344) TAAATTGTTCCTTGACTCCGAACTGCCCT (SEQ ID NO:345) AAACAATCGTTTATCTATCCTCAAAGGATG (SEQ ID NO:346) 60 ATAAAAAAACGCCTCAAAAACCGAGACAAC (SEQ ID NO:347) 59 5 TGGAAATCCCTTATATCGACAAATACGTTA (SEQ ID NO:348) TTCCCAGTCGTTGATTTTTATTGAATACCC (SEQ ID NO:349) GGACATCGAACAAGTCAATGCCGTAAGCTT (SEQ ID NO:350) AATCTTTAACCGGATTGTAGAACCGTTCGG (SEQ ID NO:351) TGCCTTTAAAATAACTAGATTTTACCATCA (SEQ ID NO:352) [0 GAGCAAGCACAAGCAAGCTTTACTATCCT (SEQ ID NO:353) CAGATTGGTTTATCGAACAAGGTCGCAAGT (SEQ ID NO:354) CAAAAGCTGTTGGTTAACGGTGCTTTGGGCA (SEQ ID NO:355) CTTGTTTTTCCTCTGGGGTCTCTGCGACTT (SEQ ID NO:356) GAAATAAACTGCCCAAACATTTTTATTTTC (SEQ ID NO:357) [5 TGAGTAAGCGACAAGCTAGAAATCAAGTCA (SEQ ID NO:358) ATAGCTAAGATGGAAGAAGCATCAAGCACC (SEQ ID NO:359) CAGTATCTCAAACGCTGGATACAACAAGAT (SEQ ID NO:360) CCTACTCAGTGGACACCTGCAATTGAAGAC (SEQ ID NO:361) CGATTGGAACGGGTGCTTATGGCCTTAAC (SEQ ID NO:362) !0 GCGAACAATTGAATTTGTTAGAAAATGTCG (SEQ ID NO:363) GAAGCATTTATTAATATAGATGGTTCTGCT (SEQ ID NO:364) TGCTGACGTATCTGTCCACTGTGTGCCA (SEQ ID NO:365) TTTTTATACTTTGGGTAAATTACAAAATAG (SEQ ID NO:366) TCAAGGTGTCGCCTTATGGAAAAGATGCTTG (SEQ ID NO:367) !5 TGTAAAAATTTCTAGACGTTTAGACACTTTA (SEQ ID NO:368) AAATGATGATTGAATGCTTGAGATAGCAGT (SEQ ID NO:369) AATAAGAAGTTCTTGACGACCAACCGACAT (SEQ ID NO:370) TCGTCAACGTCGATACAGAACAACGTGCTT (SEQ ID NO:371) TGATTAGCAAATTTAAAACAGGATATTTGG (SEQ ID NO:372) ;0 AAAGACAAGCCCAAGGGATTGAACTAGCAA (SEQ ID NO:373) CGAACAGTTGGCGAGAAATCCGTCTGGCGT (SEQ ID NO:374) CTACATTATTGATCATGTTTTTTCTCCTGT (SEQ ID NO:375) TAGAAGGCTCTGGAAATACAAAGCAATTCT (SEQ ID NO:376) TAGAAGGCTCTGGTAAATACAAAGCAATTCT (SEQ ID NO:377) ;5 TCTGATGGCTCTTGGTAGGGAACTGGATAT (SEQ ID NO:378) TTTGATGGCTCTTGGTAGGGAACTGGATAT (SEQ ID NO:379) TTTTGATGGCTCTTGGTAGGGAACTGGATAT (SEQ ID NO:380) ACAGAACAAAATGGTAGAATATATCATCT (SEQ ID NO:381) CCCTGGACAAGCTATCAGCACATATCCTTG (SEQ ID NO:382) W. CGCTGTTGATGTAACCCGCTTTATATATAT (SEQ ID NO:383) GAATGAATGTATTAGAGCAAGCACTTGACC (SEQ ID NO:384) TAGACGAAAAGGAAGGAAAATAGCATGAGC (SEQ ID NO:385) ATAACTCGATTGCTAACTTAAGCAAGCAGT (SEQ ID NO:386) CTGCATGTGTAACCATGACTTCTTCGTCGT (SEQ ID NO:387) 45 CTTCGCTGGAAACTTCGTAGTCATACATAC (SEQ ID NO:388) AAGACCGCTGTACTGGTTGGTATTCGTACC (SEQ ID NO:389) CAACCAAGCGAACACAGCAGTAGCACCGCA (SEQ ID NO:390) ATGATGATGAAGTATCGTCATCTACTAAC (SEQ ID NO:391) CTTCACCTCAAATCTTAGAGATGGACTAAA (SEQ ID NO:392) 50 AAAAGGTGCGTATGAAACTCATCCCAGCGG (SEQ ID NO:393) AAGGGTTTAAGTCCTTCATAGAGTGGAAAA (SEQ ID NO:394) CCTCAAAGCTTAAAATTGGGCTGAAGTAGA (SEQ ID NO:395) GCAATTTATTCGCTTGATGTACTCACGTTT (SEQ ID NO:396) TATTTATTGCAAATGGTTACCATATTTTTA (SEQ ID NO:397) 55 TATTTTAGCACTACGGTATCAGCGTATCTC (SEQ ID NO:398) TGCTACGTGCTCTGGACGGGCGCTATCAGC (SEQ ID NO:399) AAATGAACAGACAAGAAGCAACAGAAATTG (SEQ ID NO:400) AAGTTGATCGTATCTATTTAGAATATCGCA (SEQ ID NO:401) ATTCACTTTGACAGATACTAATGCTACATC (SEQ ID NO:402) 60 CAAGCAGTGTAAAGGTGGTTTATATGTTAA (SEQ ID NO:403) 60 5 CATAGTATAGCCGTCTTCTTTGATTGATTG (SEQ ID NO:404) CCATGGGTGCTAAAGGTGATGACTACCGCT (SEQ ID NO:405) TTTCTAGGAATGGGTAATTATAGCGAGCTAGAAAGC (SEQ ID NO:406) AGTTGGGAAGGTCTTGGAAAATCTATGGCAAAAAACCT (SEQ ID NO:407) TATATGGTTCAAATGCGATTCAAAGACTATTCAAA (SEQ ID NO:408) [0 TAATTGCCAATGCTTACAATATCTTCGTCA (SEQ ID NO:409) ATGTTCTGAATTACCTTTCTCGACACTCCG (SEQ ID NO:410) ACCATCAAGGCTCTTATCTGCAGATTGTTA (SEQ ID NO:41 1) AAATGGTTGCCAATGACTTTCTAGAGTGAT (SEQ ID NO:412) ACAAAATCTTTTGTTGCTCCTGGACGTATT (SEQ ID NO:413) [5 ATGTAAGGTATTGTAAAACTTCTTCTTGCG (SEQ ID NO:414) ACTGTTCCTATAATTAAAATAAAAGAGGTA (SEQ ID NO:415) TGTTCCAGTAAAAAGTAATTTTAAAGCATT (SEQ ID NO:416) CGCTCGATTGATGCTATCAACTATATTGAA (SEQ ID NO:417) TTCTTCAAGAGAACTTGTAGAACAGCTTCA (SEQ ID NO:418) !0 AAGGTACTTTTAGCTTGTTCTTGTGGTGTT (SEQ ID NO:419) ACAGCTACTGTAAATTCTGCTTTTACGGTT (SEQ ID NO:420) TAGTGCAGTTGTCAAGGAGATTGTGAGCGA (SEQ ID NO:421) TTTAACCTTTGAAAATGTGAAAGGCTCGTA (SEQ ID NO:422) GCGATGATGGTAAGTCATCATGGACAGCGT (SEQ ID NO:423) !5 TTTTACACACGATGTCAGATATAATGTCAA (SEQ ID NO:424) AGTACTGCACTAGGAATTGTAGAGATCAAA (SEQ ID NO:425) CGTACCATCTATCAATTTACCGCAAGCTGT (SEQ ID NO:426) TTAAAAGATTTAAACTATCAAGCGTCAATT (SEQ ID NO:427) TTCTAAATGCTGGTGACTGCTTTGCATAAA (SEQ ID NO:428) ;0 TTGCTGCTAGACCCAAACAGTTTATTTTTAG (SEQ ID NO:429) TCCTTTTTTAGATAATGTGCGATCACGGAC (SEQ ID NO:430) TTTTACCAATGCTTCCATATCGCTTATAT (SEQ ID NO:431) TGGTTATACATTTACTAATCCATCAGCATT (SEQ ID NO:432) AAGCTAATTCTCATCTCACCGAGATGGATA (SEQ ID NO:433) ;5 AAAAACTCTTACCACTTACATACATGTATG (SEQ ID NO:434) GCTGGAGATTTTACAAGCAGTTTGAATTTC (SEQ ID NO:435) ATCACACCAGTCGTTATGATGGATGACTAT (SEQ ID NO:436) TGTCAACAGTACGTGAGACGAGTGTGTAGG (SEQ ID NO:437) TGAAGTTGATGGATATGTTGATTTAGAGCT (SEQ ID NO:438) W. TAATCATTTTATGAGAGATACCGCCTCAAG (SEQ ID NO:439) TTTAAAGAGATATCTGTTTCATCTTGCGGA (SEQ ID NO:440) AATCACTTCTGCATAAATATCTTTTACTTC (SEQ ID NO:441) AAACATCCGCAACGGGATAAATAAAGCTAG (SEQ ID NO:442) AGTTTCTTGTGGGTTAGCTTGTCCACCGTA (SEQ ID NO:443) 45 GAACATGAAAGATTTTAAAAAAGAACATTT (SEQ ID NO:444) AGAGGGGAAAATATCAATGCCGAATGCTGA (SEQ ID NO:445) GATGGTACAAAATCATTTGTTGGTACTGAT (SEQ ID NO:446) AAAAGGAAACGCCATTAATTAATATGGTGA (SEQ ID NO:447) GATTGAACCAGCTAGCGCAGTTAGTGCTCT (SEQ ID NO:448) 50 CGCTAAAAGCTGTTGTGTCATCATAGTTAG (SEQ ID NO:449) TAAATATTTTCAATTAGACAATAGACAAAC (SEQ ID NO:450) TGCCTATGTATTCGGACATGACTTGCCACA (SEQ ID NO:451) ATGTGAAAAGAAAGTAACTACTACATTTGA (SEQ ID NO:452) TGCGCTGGTTGATTTCTTCTTGCGCTTTTT (SEQ ID NO:453) 55 TTATATGAACATAACTCAATTTGTAAAAAA (SEQ ID NO:454) AGGAATATCCGCAATAATTAATTGCGCTCT (SEQ ID NO:455) TAAATTTGTTTAGCAGGTAAACCGTGCTTT (SEQ ID NO:456) TTCAGCACACTGAGACTTGTTGAGTTCCAT (SEQ ID NO:457) CTGTGACATTGCGGGATGTAATCAAAGTAAAAA (SEQ ID NO:458) 60 AAAGCAAACCTAGCAGAAGCAGAAAATGACTT (SEQ ID NO:459) 61 5 TGATGTAATTGGTGATTTTCGTGATATGCTTTTT (SEQ ID NO:460) CAACACATTCAACAGATTAATGAAGAATAC (SEQ ID NO:522) TCCACTCACGTACAAATAGTGAGTGTACTC (SEQ ID NO:523) GCCCTTCTAATTGGATTACCTTCCGAGGTG (SEQ ID NO:524) CTCAGTCGTTACTGGTGAACCAGTTTCAAT (SEQ ID NO:525) [0 ATTGTCTATTACGACAACATGGAAGATGAT (SEQ ID NO:526) GAGTTTCTTTGTCAGACTCTAACACAGCCGC (SEQ ID NO:527) TTACTAGAGCGTGTCGTTAACCACTTTAAA (SEQ ID NO:528) TTCGTTAAAGTCACCTCGTGCTAGCGTTGC (SEQ ID NO:529) ATAACGGTAGCAAATATAAACCTGTTACTG (SEQ ID NO:530) [5 GAAGTAGCCATACAAGAAGATGGATCAGCA (SEQ ID NO:531) ATGTCACTGAGTGTCTAAGCATTGCGTAC (SEQ ID NO:532) TGAATAAGCAGTTCTTGACGACCAACCGAC (SEQ ID NO:533) TTACGTTTGAAAAGAATATCAAATCAATGA (SEQ ID NO:535) GCTCTACGACTTCTTCCACGAGTTCCTGCC (SEQ ID NO:536) !0 AACACAGCAAGACAAGAGGATGATGCTATG (SEQ ID NO: (SEQ ID NO:537) AAGTAGTTGATGACCTCTACAATGGTTTAT (SEQ ID NO:538) AATAATTTATGGTATAGCTTAATATCATTG (SEQ ID NO:539) AATCAATACGACAAGAGTTAAAATGGTCTT (SEQ ID NO:540) AATCGTTCAAATTCTGTTTTAGGTACATTT (SEQ ID NO:541) !5 AATGACGAGGAGCTATTGGCACAACTTACA (SEQ ID NO:542) AATTAAGGGCATAGAAAGGGAGACAACATG (SEQ ID NO:543) ACAATTCTTCATCCGGTAACTGCTCAAGTG (SEQ ID NO:544) ACACTTGGCAGGCTTATTACTCAACAGCGA (SEQ ID NO:545) ATAAACTATGAAATTTTATAATTTTTAAGA (SEQ ID NO:546) ;0 ATAACTGAAGGATAGGAGCTTGTAAAGTCT (SEQ ID NO:547) ATAATGCCGTTGAATTACACGGCAAGTCA (SEQ ID NO:548) CAACCAACGGTAACAGCTACTTTTTACAGT (SEQ ID NO:549) CATAGAGTGGAAAACTAGAAACAGATTCAA (SEQ ID NO:550) CGACACAAGAACGTATGCAAGAGTTCAAG (SEQ ID NO:551) ;5 CGATATTTAAAATCATTTTCATAACTTCAT (SEQ ID NO:552) CGATTTGACAATCTGCTGACCACTGTTATC (SEQ ID NO:553) CTGTTCCTTGTTCTTTTGTTGTATCTTTTC (SEQ ID NO:554) GAGCGAGCTCGAAATAATCTTAATTACAAG (SEQ ID NO:555) GCAGTATCAGCAAGCAAGCTGTTAGTTACT (SEQ ID NO:556) W0 GCTGGCGAGGAAACGAACAAGGCCTCAACA (SEQ ID NO:557) GCTTAGCTGTCCAATCCACGAACGTGGATG (SEQ ID NO:558) GGCGTCCCAATCCTGATTAATACTTACTCG (SEQ ID NO:559) GTTCGCTAGCGTCATGTGGTAACGTATTTA (SEQ ID NO:560) TCTATATCGAGGTCAACTAACAATTATGCT (SEQ ID NO:561) 45 TGCATCGAGCACGTTCGAGTTTACCGTTTC (SEQ ID NO:562) TGTTTGACAGCAAATCAAGATTCGAATTGT (SEQ ID NO:563) TTCATTCTTCCGTTTTTGTTTGCGAATCCT (SEQ ID NO:564) TGACTTAGCGAATTTAATCGCTAAGATATC (SEQ ID NO:565) TTTATACTTTATCTTTTTAAAGAATGTATT (SEQ ID NO:566) 50 CCTAAAATCATTTTCAACGAGTTGCGATAC (SEQ ID NO:567) AATAAATTGCTATGATACAGCGTACCGATA (SEQ ID NO:568) TGCTCTCTATGCGATTGGACGTCTGTCTAA (SEQ ID NO:569) AAGAAAGATAAGAAAAAAGTAACACTACTT (SEQ ID NO:570) TCTCTTTCCATCGGTACTGGTATATCTCAT (SEQ ID NO:571) 55 ATTGGTAGCCAAGTAAATATCACCATTGAT (SEQ ID NO:572) TTCTTCAAATTCACCGACTGCAAAATTACA (SEQ ID NO:573) GCTTCCTAAGTGCATGAAAATCGCAAACGG (SEQ ID NO:574) TATACCTGTCTATGTAAGGGAATTTAACTC (SEQ ID NO:575) GGTGTAGGTGCTGTTGGTAAGTTGTTTAAT (SEQ ID NO:576) 60 GTGAAACAGGTTATCAAAAAACGTATATTG (SEQ ID NO:577) 62 5 TTATTCTTGGAATTATTACAGACCCTACTA (SEQ ID NO:578) GCTTTCATTATATCACTTACTCATAAATCT (SEQ ID NO:579) TAATCACCCCTTTTTCTAGCTCTTGATTGA (SEQ ID NO:580) CAAGCAGTGTAAAGGTGGTTTAAATGTTAA (SEQ ID NO:581) AACCCGCGTGGTTATGGGCTTGAGGAGTGT (SEQ ID NO:582) [0 ATATTAATAGCGATTCTATGCTACAACGTG (SEQ ID NO:583) TCATCTTCTAAGTAAATACCACTGTCAGGG (SEQ ID NO:584) TTTTCGCAAAGTAAGCGAAGCTCTACGTG (SEQ ID NO:585) TTCTGTAGCCACTCCGTGGATGCCTTCAGC (SEQ ID NO:586) TTCTTTAGTTCGGACACCCTCAACACCTAT (SEQ ID NO:587) [5 GCTTTGATTGGACGGAAAATGGTATCCCTG (SEQ ID NO:588) TTCCTCATCTTTCTCCGCTTTTGCTAGACTT (SEQ ID NO:589) TTAGACCAGATGGACAGATATTCTTCATCG (SEQ ID NO:590) TCATCAGAGTCAACAATCACGGGAAAGACCT (SEQ ID NO:591) ACACTCATCCTTATCCTGTAGTTCAAAACA (SEQ ID NO:592) !0 CAGCACTAGCCGCAAGCCCTTGTATATTAA (SEQ ID NO:593) TAGAAATCAAGGAACTTGGATGAAAAGTAA (SEQ ID NO:594) ATATGAAAGGGAAATGATATGAAGAATGAA (SEQ ID NO:595) TTTTGGGATACAACACGCAGTCGTTGACTTG (SEQ ID NO:596) GTTTGAGATGCCAATGTTTTTCAATCCTTG (SEQ ID NO:597) !5 GTATCAAAAGACGCATTCATGAAGCGAGCT (SEQ ID NO:598) AAAAACAATTGAAATTCATAATCAGCGCTT (SEQ ID NO:599) GCTTTTAACGTTTTAAGAGAATACCCTCT (SEQ ID NO:660) GTGACGCTGCAATGACTTGCCATAGTAATT (SEQ ID NO:601) ATACTGGTATATAGTAATTCATACTTCATC (SEQ ID NO:602) ;0 TTGGTTTCATATTTACTCCTTTGTGTTTTG (SEQ ID NO:603) CTGATTTGGTCTTGTTCTTTTGTCCCTTTT (SEQ ID NO:604) GCAGCAGTTGAGAACTTTAGCGTCCAGTGG (SEQ ID NO:605) TGCTACTATGAAGGACGCTGTTGATACTTT (SEQ ID NO:606) TCTTCTTTAATCTTTTTTAACGTCAACGTT (SEQ ID NO:607) ;5 GTATCCATTAATATAGTAGCATTTCTATCA (SEQ ID NO:608) ATTCATTAATATCTGCAAGGATGTCTTGTT (SEQ ID NO:609) GAGAAAGTAGCCCATTCGGCCCATTCGGGG (SEQ ID NO:610) TACTTGAGTTAGCTCTGGAAGTCATTTATC (SEQ ID NO:611) CTGCATTTGTAACCATGACTTCTTCGTCGT (SEQ ID NO:612) W- AATTTGTCATCGACATCTACCAACGCCCAG (SEQ ID NO:613) ATAAAATTATGCCACGTTTTGGCACTAGAT (SEQ ID NO:614) ATGTCTCTGAGGCTGTAGTAATTTACTTGT (SEQ ID NO:615) CTTTAAAGAGTTGATTAAGTGCGTTACTGT (SEQ ID NO:616) AAATGGGTTATGCTGTTCAATATGCGTCCC (SEQ ID NO:617) 45 AAACTGAAAACAACACAGACAATTCAACAA (SEQ ID NO:618) GCCCAAAATGCTAGACGTTTGAATGACGGC (SEQ ID NO:619) ATGAAGAACGTGATTCACCTACGGTATGCT (SEQ ID NO:620) GCTTTTGCAGAATTGTCTCCAGTGCCGATTT (SEQ ID NO:621) TGTACTCTATTGATTGCTTCATCTTTATTA (SEQ ID NO:622) 50 CTTTCAAGATACTCATCAACCATTGATGTCA (SEQ ID NO:623) CTATGTCTTTACTGTTCTTCCAAAACCACC (SEQ ID NO:624) TGCTACGTGCTCTGTACGGGCGCTATCAGC (SEQ ID NO:625) CGTGGCAGCGTGGTCGGGTTTAATAGCCCG (SEQ ID NO:626) AAGCCCAAGTCAGAGCATCCGTCCAAGCC (SEQ ID NO:627) 55 ATTGGGTTTCGGTAAGAACTAAACATACCA (SEQ ID NO:628) CACAAAATAATTCGGTAGTTTTTACTAACT (SEQ ID NO:629) TTTGACCGTTTATTTAGACGTGCTAAAGT (SEQ ID NO:630) CTTCACCTCAAATCTTAGAGCTGGACTAAA (SEQ ID NO: 631) ATGTCTGAAAAATAACCGACCATCATTACT (SEQ ID NO:632) 60 GAAGCTCATCATGTTAAGGCTAAAACCTAT (SEQ ID NO:633) 63 5 TAGTCTAAATAGATTTCTTGCACCATTGTA (SEQ ID NO:634) ATTCGTGAAAAAATATCGTGAAATAGGCAA (SEQ ID NO:635) TCTAGGCTCATCTAAAGATAAATCAGTAGC (SEQ ID NO:636) TAAAAACATGGGGCGGCGGTAATAGTGTAAG (SEQ ID NO:637) ACAACCAGCAAAGAGAGCGCCGACAACATT (SEQ ID NO:638) [0 TATAACACAGGTTTAGAGGATGTTATACTT (SEQ ID NO:639) CTAGAAGCTCAAGCGGTAAAAGTTGATGGCG (SEQ ID NO:640) CTTTGAGGGCAAGCCCTCGCCGTTCCATTT (SEQ ID NO:641) AACTACCAAGCAAATCAGCAATCAATAAGT (SEQ ID NO:642) CTATAAGTGACAATCAGCGTAGGGAATACG (SEQ ID NO:643) [5 ATCAGTGCGGTATATTTACCCTAGACGCTA (SEQ ID NO:644) AACAGTTACTATTAATCACGATTCCAACGG (SEQ ID NO:645) AATTAGGGCGTCTTCCTTTATTCCGTGGTT (SEQ ID NO:646) ATAGCTTCATTGCGCTTTTTAATTTGACCT (SEQ ID NO:647) AACAACAAAGCAAATACAACAGTAACAACC (SEQ ID NO:648) !0 CTAAACTACGTTTGAAGGTCTCAACTCCGT (SEQ ID NO:649) GAGGTTGAATAGTGAGTGCACCATGTTTGT (SEQ ID NO:650) AGTAGAGAGACCAGCACACTACTGTACTAC (SEQ ID NO:651) CTTCGCACGAAAGTTTATTAGACAACTCGC (SEQ ID NO:652) TGATAGAGCTAGAATTGTCTTTTTTACCGA (SEQ ID NO:653) !5 AGATACTCTTGCTCGCCTCTGAACAACCAG (SEQ ID NO:654) GGTGAAAAAGGTTCACTGTACGAGTACTTA (SEQ ID NO:655) TCAATGAGTGGTATCCAAGACGAAAACTTA (SEQ ID NO:656) CCTTGTCGTGGCTCTCCATACGCCCATATA (SEQ ID NO:657) TGTTTGGGAAACCGCAGTAGCCATGATTAA (SEQ ID NO:658) ;0 ACAGAGTACAATATTGTCCTCATTGGAGACAC (SEQ ID NO:659) CTCATATTCGTTAGTTGCTTTTGTCATAAA (SEQ ID NO:660) AGAACTTTATCAAGATAAAACTACTTTAAA (SEQ ID NO:661) ATAGTATTAATTTCATTGAAAAATAATTGT (SEQ ID NO:662) GCTTTCTAGCTCGCTATAATTACCCATTCCTAGAAA (SEQ ID NO:663) ;5 TCAAAATATGTTATTACCTTGTATTTCATAATTCAATTAA (SEQ ID NO:664) CCACTTGCTGTGTACATCCTACCAGTTCCGCCTATGATG (SEQ ID NO:665) In particularly preferred embodiments, CRISPR spacers are flanked by two CRISPR repeats (i.e., a CRISPR spacer has at least one CRISPR repeat on each side). Although it is not intended that the 40 present invention be limited to any particular mechanism, theory, or hypothesis, it is contemplated that the further a given CRISPR spacer is from the 5' end of the CRISPR locus comprising the cas gene(s) and/or the leader sequence, the lower the resistance conferred by that CRISPR spacer is. Thus, in some embodiments of the present invention, one or more of the first 100 CRISPR spacers from the 5' end of the CRISPR locus are modified, while in other embodiments, one or more of the first 50 CRISPR spacers 45 from the 5' end of the CRISPR locus are modified. In some additional embodiments, one or more of the first 40 CRISPR spacers from the 5' end of the CRISPR locus are modified, while in some still further embodiments, one or more of the first 30 CRISPR spacers from the 5' end of the CRISPR locus are modified, and in yet additional embodiments, one or more of the first 20 CRISPR spacers from the 5' end of the CRISPR locus are modified, and in still more embodiments, one or more of the first 15 CRISPR 50 spacers from the 5' end of the CRISPR locus are modified. In some preferred embodiments, one or more of the first 10 CRISPR spacers from the 5' end of the CRISPR locus are modified. As indicated herein, 64 5 different bacteria have different numbers of CRISPR spacers, thus in some embodiments, various spacers are modified. CRISPR Spacer Core For a specific CRISPR type within a microbial species, the CRISPR spacer is typically [0 represented by a defined predominant length, although the size may vary. CRISPR types described to date have been found to contain a predominant spacer length of between about 20 bp and about 58 bp. As used herein, the term "CRISPR spacer core" refers to the length of the shortest observed spacer within a CRISPR type. Thus, for example, within S. thermophilus CRISPR Type 1 (CRISPRi), the dominant spacer length is 30 bp, with a minority of spacers between 28 bp and 32 bp in size. Thus, in [5 S. thermophilus CRISPR Type 1, the CRISPR spacer core is defined as a continuous stretch of 28 bp. In some preferred embodiments of the present invention, the CRISPR spacer core is homologous to the target nucleic acid, a transcription product thereof, or an identified sequence over the length of the core sequence. As indicated above, although homology can also be considered in terms of similarity, in some preferred embodiments of the present invention, homology is expressed in terms of sequence !0 identity. Thus, in some embodiments, a homologous sequence encompasses a CRISPR spacer core, which may be at least about 90% identical, or at least about 91, about 92, about 93, about 94, about 95, about 96, about 97, about 98 or about 99 % identical to the target nucleic acid sequence, a transcription product thereof, or an identified sequence over the length of the core sequence. In some particularly preferred embodiments, the CRISPR spacer core is about 100% identical to the target nucleic acid !5 sequence, transcription product thereof, or an identified sequence over the length of the core sequence. During the development of the present invention, the CRISPR sequences of various S. thermophilus strains, including closely related industrial strains and phage-resistant variants were analyzed. Differences in the number and type of spacers were observed primarily at the CRISPRi locus. Notably, phage sensitivity appeared to be correlated with CRISPRi spacer content. Specifically, the 30 spacer content was nearly identical between parental strains and phage-resistant derivatives, except for additional spacers present in the latter. These findings suggested a potential relationship between the presence of additional spacers and the differences observed in the phage sensitivity of a given strain. This observation prompted the investigation of the origin and function of additional spacers present in phage-resistant mutants. 35 Pseudo-CRISPR Spacer As used herein, the term "pseudo-CRISPR spacer" refers to a nucleic acid sequence present in an organism (e.g., a donor organism, including but not limited to bacteriophage), which is preferably essential for function and/or survival and/or replication and/or infectivity, etc., and which comprises a 40 CRISPR spacer sequence. In some embodiments, the pseudo-CRISPR spacers find use in producing 65 5 CRISPR spacer sequences that are complementary to or homologous to the pseudo-CRISPR spacer. In some particularly preferred embodiments, these sequences find use in modulating resistance. In some embodiments, at least one pseudo-CRISPR spacer and CRISPR spacer(s) that is/are complementary or homologous to at least one pseudo-CRISPR spacer(s) are used to engineer a recipient cell. In some preferred embodiments, at least one pseudo-CRISPR spacers or CRISPR spacer(s) that [0 is/are complementary or homologous to the at least one pseudo-CRISPR spacer(s) are used in combination with one or more cas genes or proteins and/or one or more CRISPR repeats (e.g., one or more functional combinations thereof), to engineer a recipient cell, such that the resistance of the recipient cell is modulated against a target nucleic acid or a transcription product thereof. In some embodiments, the pseudo-CRISPR spacers or CRISPR spacer(s) that is/are [5 complementary or homologous to the one or more pseudo-CRISPR spacer(s) are inserted into the plasmid and/or genomic DNA of a recipient cell using any suitable method known in the art. In some additional embodiments, the pseudo-CRISPR spacers are used as a template upon which to modify (e.g., mutate) the plasmid and/or genomic DNA of a recipient cell, such that CRISPR spacers are created in the plasmid and/or genomic DNA of the cell. In some further embodiments, the pseudo !0 CRISPR spacers or CRISPR spacer(s) that is/are complementary or homologous to the one or more pseudo-CRISPR spacer(s) are cloned into a construct, plasmid and/or vector, etc. is/are introduced into the host cell using any suitable method known in the art. CAS and cas Genes !5 As used herein, the term "cas gene" has the conventional meaning as used in the art and refers to one or more cas genes that are generally coupled, associated or close to or in the vicinity of flanking CRISPR loci. A comprehensive review of the Cas protein family is presented by Haft et al. (Haft et al., PLoS. Comput. Biol., 1(6): e60 [2005]), in which 41 newly recognized CRISPR-associated (cas) gene families are described, in addition to the four previously known gene families. As indicated therein, 30 CRISPR systems belong to different classes, with different repeat patterns, sets of genes, and species ranges. As indicated herein, the number of cas genes at a given CRISPR locus can vary between species. In some embodiments, the present invention provides methods and compositions for the use of one or more cas genes or proteins, alone or in any combination with one or more CRISPR spacers for modulating resistance in a cell (e.g., a recipient cell) against a target nucleic acid or a transcription 35 product thereof. In some embodiments, one or more of the cas genes and/or proteins naturally occur in a recipient cell and one or more heterologous spacers is/are integrated or inserted adjacent to the one or more of the cas genes or proteins. In some embodiments, one or more of the cas genes and/or proteins is/are heterologous to the recipient cell and one or more of the spacers is/are homologous or heterologous. In 40 some preferred embodiments, the spacers are integrated or inserted adjacent to the one or more of the cas gene or proteins.

66 5 In some further embodiments, the present invention provides methods and compositions for the use of one or more cas genes or proteins and at least two CRISPR repeats for modulating resistance in a cell (e.g., a recipient cell) against a target nucleic acid or a transcription product thereof. In yet additional embodiments, the present invention provides methods and compositions for the use of one or more cas genes or proteins, at least two CRISPR repeats and at least one CRISPR spacer [0 for modulating resistance in a cell (e.g., a recipient cell) against a target nucleic acid or a transcription product thereof. CRISPR structures are typically found in the vicinity of four genes named cas] to cas4. The mnost common arrangement of these genes is cas3-cas4-cas]-cas2. The Cas3 protein appears to be a helicase, whereas Cas4 resembles the RecB family of exonucleases and contains a cysteine-rich motif., [5 suggestive of DNA binding. CasI is generally highly basic and is the only Cas protein found consistently in all species that contain CRISPR loci. Cas2 remains to be characterized. cas1- 4 are typically characterized by their close proximity to the CRISPR loci and their broad distribution across bacterial and archaeal species. Although not all cas]--4 genes associate with all CRISPR loci, they are all found in multiple subtypes. !0 In addition, there is another cluster of three genes associated with CRISPR structures in many bacterial species, referred to herein as cas1B, cas5 and cas6 (See, Bolotin et al., [2005], supra). It is noted that the nomenclature of the cas genes is in flux. Thus, the text herein must be taken in context. In some embodiments, the cas gene is selected from cas], cas2, cas3, cas4, casIB, cas5 and/or cas6. In some preferred embodiments, the cas gene is cas]. In yet other embodiments, the cas gene is selected !5 from cas], cas2, cas3, cas4, cas1B, cas5 and/or cas6 fragments, variants, homologues and/or derivatives thereof. In some additional embodiments, a combination of two or more cas genes find use, including any suitable combinations, including those provided in WO 07/025097, incorporated herein by reference. In some embodiments, a plurality of cas genes is provided. In some embodiments, there is a plurality of different and/or same cas genes, or any combination thereof, as provided in WO 07/025097. 30 In some embodiments, the cas genes comprise DNA, while in other embodiments, the cas comprise RNA. In some embodiments, the nucleic acid is of genomic origin, while in other embodiments, it is of synthetic or recombinant origin. In some embodiments, the cas genes are double stranded or single-stranded whether representing the sense or antisense strand or combinations thereof. In some embodiments, cas genes are prepared by use of recombinant DNA techniques (e.g., recombinant 35 DNA), as described herein. As described herein, in some embodiments, the cas gene comprises a fragment of a cas gene (i.e., this fragment of the cas gene comprises a portion of a wild-type sequence). In some embodiments, the sequence comprises at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least 40 about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or least about 99% of the wild-type sequence.

67 5 In some embodiments it is preferred that the cas gene is the cas gene that is closest to the leader sequence or the first CRISPR repeat at the 5' end of the CRISPR locus- such as cas4 or cas6. In some embodiments, the Cas protein is selected from CasI, Cas2, Cas3, Cas4, CasIB, Cas5 and/or Cas6, as well as fragments, variants, homologues and/or derivatives thereof. In some further embodiments, the Cas protein is selected from CasI, Cas2, Cas3, Cas4, CasIB, Cas5 and/or Cas6, and [0 combinations thereof, as described in WO 07/025097. In yet additional embodiments, the Cas protein is selected from one or more of CasI, Cas2, Cas3, Cas4, CasIB, Cas5 and/or Cas6 or a plurality of same and/or different Cas proteins, in any suitable number and/or combination. The term "Cas protein" also encompasses a plurality of Cas proteins (e.g., between about 2 and about 12 Cas proteins, more preferably, between about 3 and about 11 Cas proteins, more preferably, [5 between about 4 and about 10 Cas proteins, more preferably, between about 4 and about 9 Cas proteins, more preferably, between about 4 and about 8 Cas proteins, and more preferably, between about 4 and about 7 proteins genes; such as 4, 5, 6, or 7 Cas proteins). In some embodiments, the Cas proteins are encoded by cas genes comprising DNA, while in other embodiments, the cas comprise RNA. In some embodiments, the nucleic acid is of genomic origin, !0 while in other embodiments, it is of synthetic or recombinant origin. In some embodiments, the cas genes encoding the Cas proteins are double-stranded or single-stranded whether representing the sense or antisense strand or combinations thereof. In some embodiments, cas genes are prepared by use of recombinant DNA techniques (e.g., recombinant DNA), as described herein. The present invention also provides methods for identifying a cas gene for use in modulating the !5 resistance of a cell against a target nucleic acid or transcription product thereof comprising the steps of: preparing a cell comprising at least one CRISPR spacer and at least two CRISPR repeats; engineering the cell such that it comprises at least one cas gene; and determining whether the cell modulates resistance against the target nucleic acid or transcription product thereof, wherein modulation of the resistance of the cell against the target nucleic acid or transcription product thereof is indicative that the cas gene is 30 useful in modulating the resistance of the cell. In some further embodiments, the present invention provides methods and one or more of the cas genes useful in the engineering of cells (e.g., recipient cells). In some preferred embodiments, one or more cas genes are used to engineer a cell (e.g., a recipient cell), that in combination with one or more, preferably, two or more CRISPR repeats and one or more CRISPR spacers finds use in modulating the 35 resistance of a cell against a target nucleic acid or a transcription product thereof. For example, in some embodiments the cas gene(s) is/are inserted into the DNA of a cell (e.g., plasmid and/or genomic DNA of a recipient cell) using any suitable method known in the art. In some additional embodiments, the cas genes are used as a template upon which to modify (e.g., mutate) the DNA of a cell (e.g., plasmid and/or genomic DNA of a recipient cell), such that cas genes are created or formed in the DNA of the cell. In 40 some embodiments, the cas genes are present in at least one construct, at least one plasmid, and/or at least one vector which is/are then introduced into the cell, using any suitable method known in the art.

68 5 In some embodiments, the cas genes comprise at least one cas cluster selected from any one or more of SEQ ID NOS:461, 466, 473, 478, 488, 493, 498, 504, 509, and 517. In further embodiments, the cas genes comprise any one or more of SEQ ID NOS:462-465, 467-472, 474-477, 479-487, 489-492, 494-497, 499-503, 505-508, 510-517, used alone or together in any suitable combination. In some preferred embodiments, the cluster(s) is/are used in combination with one or more, preferably, two or [0 more CRISPR repeats and optionally one or more CRISPR spacers. In some additional embodiments, one or more cas genes or proteins is/are used in suitable combinations. As indicated herein, a given set of cas genes or proteins is always associated with a given repeated sequence within a particular CRISPR locus. Thus, cas genes or proteins appear to be specific for a given DNA repeat (i.e., cas genes or proteins and the repeated sequence form a functional pair). [5 Accordingly, particular combinations of one or more cas genes or proteins and one or more, preferably, two or more CRISPR repeats are used in order for a CRISPR spacer to confer resistance against a target nucleic acid or transcription product thereof in a cell (e.g., a recipient cell). Accordingly, it has been surprisingly found that it is not possible to merely use any cas genes or proteins or any CRISPR repeat. Instead it is a feature of the present invention that the combination is functional. !0 In the context of the CRISPR repeat-cas gene or protein combination described herein, the term "functional" means that the combination is able to confer resistance to a target nucleic acid or a transcription product thereof when used together with a CRISPR spacer that aligns with or is homologous to a target nucleic acid or transcription product thereof. As used herein the terms "functional CRISPR repeat-cas combination" and "functional CRISPR repeat-cas gene combination" includes a functional !5 combination in which cas is a cas gene or a Cas protein. Suitably, the one or more cas genes or proteins and/or the one or more, preferably, two or more CRISPR repeats are derived from the same cell (e.g., the same recipient cell). In some embodiments, the term "derivable" is synonymous with the term "obtainable," as used in context. In some preferred embodiments, the term "derivable" is also synonymous with "derived," as used in context, as it is not 30 intended that the present invention be specifically limited to elements that are "derived." In some embodiments, the term "derived" is synonymous with the term "obtained," as used in context. In some embodiments, the one or more cas genes or proteins and/or the one or more, preferably, two or more CRISPR repeats are derived from the same CRISPR locus within a genome or plasmid, preferably a genome or plasmid of the same strain, species or genera. In some further embodiments, one 35 or more cas genes or proteins and/or one or more, preferably, two or more CRISPR repeats are derived from the same CRISPR locus within a single genome or plasmid, preferably a single genome or plasmid of the same strain, species or genera. In some embodiments, one or more cas genes or proteins and one or more, preferably, two or more CRISPR repeats naturally co-occur. In yet additional embodiments, the one or more cas genes or proteins and one or more, preferably, two or more CRISPR repeats naturally 40 co-occur in the same cell (e.g., recipient cell). In further embodiments, one or more cas genes or proteins and one or more, preferably, two or more CRISPR repeats naturally co-occur in the same genome of a 69 5 cell (e.g., recipient cell). In still additional embodiments, one or more cas genes or proteins and one or more, preferably, two or more CRISPR repeats naturally co-occur in the same genome of a strain, species or genera. In some further preferred embodiments, the present invention provides any suitable combination of nucleic acids consisting essentially of at least two CRISPR repeats and at least one cas gene or protein. [0 In some embodiments, the term "consists essentially of' refers to a combination of at least two CRISPR repeats and at least one cas gene or protein and excluding at least one further component of a CRISPR locus (e.g., the absence of one or more CRISPR spacer(s) and/or the absence of one or more common leader sequence(s) of a CRISPR locus). In some alternative embodiments, the term "consists essentially of' refers to a combination of at least two CRISPR repeats and at least one cas gene or protein [5 only and excluding all other components of a CRISPR locus (e.g., a naturally occurring CRISPR locus). In some further embodiments, the term "consists essentially of' refers to a combination of at least two CRISPR repeats and at least one cas gene or protein only and excluding at least one further component of a CRISPR locus, preferably excluding at least one further component of a naturally occurring CRISPR locus. In some still further embodiment, the term "consists essentially of' refers to a combination of at !0 least two CRISPR repeats and at least one cas gene or protein, with the proviso that at least one further component of the natural CRISPR locus is absent (e.g., substantially absent). Thus, it is intended that the term find use in context. In some embodiments, the present invention provides any suitable combination of at least two CRISPR repeats and at least one cas gene or protein, with the proviso that all other components of the CRISPR locus are absent (e.g., substantially absent), preferably that all other !5 components of the CRISPR locus of the natural combination of CRISPR repeat(s) and cas gene(s) are absent. In some further embodiments, one or more cas genes or proteins are used in combination or together with one or more CRISPR spacers. In some additional embodiments, one or more cas genes or proteins are used in combination or together with at least one or more CRISPR spacers and at least one or more, preferably, two or more CRISPR repeats. In some embodiments, the CRISPR spacer(s) are or are 30 derived from an organism (e.g., a donor organism) that is different than the cell (e.g., the recipient cell) from which the one or more cas genes or proteins and/or the one or more, preferably, two or more CRISPR repeats are derived. Various arrangements of CRISPR repeats(s) and cas gene(s) or protein(s), particularly functional CRISPR repeat-cas combinations, are provided. In some embodiments, the combination comprise, 35 consist or consist essentially of at least any of about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, or about 20 CRISPR repeat(s) in combination with any of about 1, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, or about 20 cas genes or proteins (e.g., 16 CRISPR repeat and 12 cas genes or proteins or 18 CRISPR repeats and 20 cas genes or 40 proteins or any other combinations thereof). The present invention provides CRISPR repeat(s) and cas gene(s) arranged in various ways, as provided in WO 07/025097. In some embodiments in which the 70 5 combination of a cas gene and a CRISPR repeat comprises more than one cas gene, it will be understood that the CRISPR repeat is inserted at the 3' end of the cas genes, the 5' end of the cas genes, or in between the cas genes, provided that at least one of the cas genes remains functional. In some embodiments, a first CRISPR repeat-cas gene or protein combination (comprising at least one cas gene or protein and at least two CRISPR repeats, wherein both are derived from the same [0 CRISPR locus within a genome) are used in combination with a second CRISPR repeat-cas gene or protein combination (comprising at least one cas gene or protein and at least two CRISPR repeats, wherein both are derived from the same or a different CRISPR locus within a genome). Accordingly, in these embodiments of the invention, the first and second combinations are derived from the same or different CRISPR loci within a genome. Thus, in some embodiments, the first and second CRISPR [5 repeat-cas gene or protein combinations are from different genomes (e.g., from different genomes within the same cluster), as described in further detail herein. In still further embodiments of the present invention, a first and/or a second CRISPR repeat-cas gene or protein combination (comprising at least one cas gene and at least two CRISPR repeats derived from the same CRISPR locus within a genome) are used in combination with about 3, about 4, about 5, !0 about 6, about 7, about 8, about 9, or about 10 or more CRISPR repeat-cas gene or protein combinations (each comprising at least one cas gene or protein and at least two CRISPR repeats derived from the same or a different CRISPR loci within a genome). Accordingly, in these embodiments of the invention, the combinations are derived from the same or different CRISPR loci within a genome. In some further embodiments of the invention, the combinations are from different genomes (e.g., different genomes !5 within the same cluster), as described in further detail herein. Thus, in some embodiments, for the CRISPR-repeat-cas gene or protein combination to confer resistance, the CRISPR-repeat(s) and cas gene(s) or protein(s) naturally co-occur within a given CRISPR locus of a genome. In some embodiments, the CRISPR-repeat(s) and cas gene(s) or protein(s) naturally co-occur within the same CRISPR locus of a genome. In some embodiments, these functional 30 combinations taken together, confer resistance against a target nucleic acid or a transcription product thereof. In some further embodiments, the present invention provides methods for identifying a functional combination of a cas gene or protein and a CRISPR repeat comprising the steps of: analyzing the sequences (e.g., nucleic acid or protein sequences) of the cas gene or protein and the CRISPR repeat; 35 identifying one or more clusters of cas genes or proteins; identifying one or more clusters of CRISPR repeats; and combining those cas gene or protein and CRISPR repeat sequences that fall within the same cluster. In some additional embodiments, the present invention provides methods for identifying a functional combination of a cas gene or protein and a CRISPR repeat for use in modulating the resistance 40 of a cell against a target nucleic acid or a transcription product thereof comprising the steps of: preparing a cell comprising a combination of one or more cas genes or proteins and one or more, preferably, two or 71 5 more CRISPR repeats; engineering the cell such that it contains one or more CRISPR spacers; and determining if the cell modulates resistance against a target nucleic acid, wherein modulation of the resistance of the cell against the target nucleic acid or a transcription product thereof is indicative that the combination can be used to modulate the resistance of the cell against the target nucleic acid. In some embodiments, the sequences of the cas gene and/or protein and/or the CRISPR repeat [0 are or derived from the same or different strains, species, genera, and/or organisms. In some embodiments, the combination comprises DNA and/or RNA of genomic, recombinant, and/or synthetic origin. In some embodiments, the CRISPR repeat(s) comprise(s) DNA and/or RNA of genomic, recombinant and/or synthetic origin. In some embodiments, the cas gene(s) comprise(s) DNA and/or RNA of genomic, recombinant and/or synthetic origin. Indeed it is intended that the present invention [5 encompass any combination of DNA and/or RNA for each of the elements (e.g., cas gene and/or CRISPR repeat). In some embodiments, the elements are analyzed using any suitable method known in the art. In some preferred embodiments, the analysis is conducted using dotplot analysis. In some embodiments, the CRISPR repeat and/or cas gene are double-stranded, while in other embodiments, either are single stranded, whether representing the sense or antisense strand or combinations thereof. !0 In some embodiments, one or more of the functional combinations described herein are used to engineer a cell (e.g., a recipient cell). In some preferred embodiments, one or more functional combinations are used to engineer a cell (e.g., a recipient cell), that in combination with one or more CRISPR spacers find use in modulating the resistance of a cell against a target nucleic acid or a transcription product thereof. In some embodiments, the functional combinations are inserted into the !5 DNA of a recipient cell (e.g., as plasmid or genomic DNA of a cell) using any suitable methods known in the art. In some additional embodiments, the functional combinations are used as a template upon which to modify (e.g., mutate) the DNA of a recipient cell (e.g., plasmid DNA or genomic DNA), such that functional combinations are created in the DNA of the cell. In yet additional embodiments, functional combinations are cloned into a construct, plasmid, or vector, etc., which is then transformed into the cell, 30 using methods such as those described herein and known in the art. In some embodiments, the functional combination is obtained or obtainable by a method comprising the steps of: analyzing the sequences of a cas gene and a CRISPR repeat; identifying one or more clusters of cas genes; identifying one or more clusters of CRISPR repeats; and combining those cas gene and CRISPR repeat sequences that fall within the same cluster, wherein the combination of the cas 35 gene and CRISPR repeat sequences within the same cluster is indicative that the combination is a functional combination. As indicated above, it was surprisingly found that it is not possible to merely exchange CRISPR repeat-cas combinations between any cells (e.g., any strains, species or genera of cells), as this does not necessarily result in functional CRISPR repeat-cas combinations. Indeed, for the CRISPR repeat-cas 40 combination(s) to be functional, they need to be compatible. Thus, it is contemplated that it is not possible to switch cas genes or CRISPR repeats between different CRISPR loci unless they are from the 72 5 same cluster. Even more surprising is that the clusters do not follow the "organism" phylogeny. Specifically, within one organism, there may be more than one CRISPR. These CRISPR(s) can belong to different clusters, even though they are present in the same organism. As a result, it is believed that a functional CRISPR repeat-cas combination requires that the combination be switched within a cluster as opposed to within an organism. [0 For the avoidance of doubt, the term "cluster" as used herein does not refer to a cluster of genes located at the same locus (typically forming an operon) but to the output from sequence comparison analysis (e.g., multiple sequence comparison analysis and/or multiple sequence alignments and/or dot plot analysis). Accordingly, in some embodiments, cluster analysis of CRISPR loci is performed using various methods that are known in the art (e.g., such as dot-plot analysis as described herein) or multiple [5 alignment followed by dendrogram calculation. In some embodiments, the cluster is a class, a family or a group of sequences. Advantageously, the use of naturally co-occurring CRISPR repeat-cas combination(s) provides for the interchange of the combination both within and between a given species, thereby making it possible to engineer the resistance of one strain using the combination from a different strain. !0 Bacteriophage As used herein, the term "bacteriophage" (or "phage") has its conventional meaning as understood in the art (i.e., a virus that selectively infects one or more bacterial species). Many bacteriophages are specific to a particular genus or species or strain of bacteria. In some preferred !5 embodiments, the phages are capable of infecting parent bacteria and/or host cells. In some embodiments, bacteriophages are virulent to the parent bacterium. In some embodiments, the phage are lytic, while in other embodiments, the phage are lysogenic. A lytic bacteriophage is one that follows the lytic pathway through completion of the lytic cycle, rather than entering the lysogenic pathway. A lytic bacteriophage undergoes viral replication leading to 30 lysis of the cell membrane, destruction of the cell, and release of progeny bacteriophage particles capable of infecting other cells. A lysogenic bacteriophage is one capable of entering the lysogenic pathway, in which the bacteriophage becomes a dormant, passive part of the cell's genome through prior to completion of its lytic cycle. 35 Bacteriophages that find use in the present invention include, but are not limited to bacteriophages that belong to any of the following virus families: Corticoviridae, Cystoviridae, Inoviridae, Leviviridae, Microviridae, Myoviridae, Podoviridae, Siphoviridae, or Tectiviridae. In some embodiments, bacteriophage that infect bacteria that are pathogenic to plants and/or animals (including humans) find particular use. In some particularly preferred embodiments, the resistance of a cell against 40 a bacteriophage is modulated.

73 5 In some particularly preferred embodiments, the bacteriophage of the present invention include, but are not limited to, those bacteriophage capable of infecting a bacterium that naturally comprises one or more CRISPR loci. CRISPR loci have been identified in more than 40 prokaryotes (See e.g., Jansen et al., Mol. Microbiol., 43:1565-1575 [2002]; and Mojica et al., [2005]) including, but not limited to Aeropyrum, Pyrobaculum, Sulfolobus, Archaeoglobus, Halocarcula, Methanobacterium, 10 Methanococcus, Methanosarcina, Methanopyrus, Pyrococcus, Picrophilus, Thermoplasma, Corynebacterium, Mycobacterium, Streptomyces, Aquifex, Porphyromonas, Chlorobium, Thermus, Bacillus, Listeria, Staphylococcus, Clostridium,. Thermoanaerobacter, Mycoplasma, Fusobacterium, Azarcus, Chromobacterium, Neisseria, Nitrosomonas, Desulfovibrio, Geobacter, Myxococcus, Campylobacter, Wolinella, Acinetobacter, Erwinia, Escherichia, Legionella, Methylococcus, Pasteurella, 15 Photobacterium, Salmonella, Xanthamonas,. Yersinia, Treponema and Thermotoga. In some embodiments, the bacteriophage include, but are not limited to, those bacteriophage capable of infecting bacteria belonging to the following genera: Escherichia, Shigella, Salmonella, Erwinia, Yersinia, Bacillus, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Agrobacterium, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium, !0 Mycobacterium, Treponema, Borrelia, Francisella , Brucella and Xanthomonas. In yet additional embodiments, the bacteriophage include, but are not limited to, those bacteriophage capable of infecting (or transducing) lactic acid bacteria, Bifidobacterium, Brevibacterium, Propionibacterium, Lactococcus, Streptococcus, Lactobacillus (e.g., L. acidophilus), Enterococcus, Pediococcus, Leuconostoc, and Oenococcus. !5 In still further embodiments, the bacteriophage include, but are not limited to, those bacteriophage capable of infecting Lactococcus lacti (e.g., L. lactis subsp. lactis and L. lactis subsp. cremoris, and L. lactis subsp. lactis biovar diacetylactis), Streptococcus thermophilus, Lactobacillus delbrueckii subsp. bulgaricus, Lactobacillus helveticus, Bifidobacterium lactis, Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium infantis, Lactobacillus paracasei, Lactobacillus 30 salivarius, Lactobacillus plantarum, Lactobacillus reuteri, Lactobacillus gasseri, Lactobacillus johnsonii or Bifidobacterium longum. In yet further embodiments, the bacteriophages include, but are not limited to, those bacteriophage capable of infecting any fermentative bacteria susceptible to disruption by bacteriophage infection, including but not limited to processes for the production of antibiotics, amino acids, and 35 solvents. Products produced by fermentation which have been known to experience bacteriophage infection, and the corresponding infected fermentation bacteria, include cheddar and cottage cheese (Lactococcus lactis subsp. lactis, Lactococcus lactis subsp. cremoris), yogurt (Lactobacillus delbrueckii subsp. bulgaricus, Streptococcus thermophilus), Swiss cheese (S. thermophilus, Lactobacillus lactis, Lactobacillus helveticus), blue cheese (Leuconostoc cremoris), Italian cheese (L. bulgaricus, S. 40 thermophilus), viili (Lactococcus lactis subsp. cremoris, Lactococcus lactis subsp. lactis biovar diacetylactis, Leuconostoc cremoris), yakult (Lactobacillus casei), casein (Lactococcus lactis subsp.

74 5 cremoris), natto (Bacillus subtilis var. natto), wine (Leuconostoc oenos), sake (Leuconostoc mesenteroides), polymyxin (Bacillus polymyxa), colistin (Bacillus colistrium), bacitracin (Bacillus licheniformis), L-glutamic acid (Brevibacterium lactofermentum, Microbacterium ammoniaphilum), and acetone and butanol (Clostridium acetobutylicum, Clostridium saccharoperbutylacetonicum). In some preferred embodiments, the bacteria that find use in the present invention include, but 10 are not limited to S. thermophilus, L. delbrueckii subsp. bulgaricus and/or L. acidophilus. In some particularly preferred embodiments, the bacteriophages include, but are not limited to, those bacteriophages capable of infecting bacteria that comprise one or more heterologous CRISPR loci. In some embodiments, the bacteria comprise one or more heterologous CRISPR loci, and/or one or more heterologous cas genes, and/or one or more heterologous CRISPR repeats, and/or one or more [5 heterologous CRISPR spacers. Infection of bacteria by phage results from the injection or transfer of phage DNA into cells. In some embodiments, infection leads to expression (i.e., transcription and translation) of the bacteriophage nucleic acid within the cell and continuation of the bacteriophage life cycle. In some embodiments involving recombinant bacteriophage, recombinant sequences within the phage genome (e.g., reporter !0 nucleic acids), are also expressed. It has been found that CRISPR spacer sequences in prokaryotes often have significant similarities to a variety of DNA molecules, including such genetic elements as chromosomes, bacteriophages, and conjugative plasmids. It has been reported that cells carrying these CRISPR spacers are unable to be infected by DNA molecules containing sequences homologous to the spacers (See, Mojica et al., [2005]). !5 In some embodiments of the present invention, one or more particular pseudo-spacers derived from bacteriophage DNA or CRISPR spacer(s) which is/are complementary or homologous to the one or more pseudo-CRISPR spacer(s) are added within a CRISPR locus of a cell (e.g., a recipient cell), in order to modulate (e.g., provide) resistance against a particular bacteriophage, thus substantially preventing phage attack. 30 In some preferred embodiments, particular regions within the phage genome are targeted to prepare the pseudo-spacers, including but not limited to genes coding for host specificity proteins, including those that provide particular phage-host recognition, such as helicases, primase, head or tail structural proteins, proteins with a conserved domain (e.g., holing, lysine, and others) or conserved sequences amongst important phage genes. 35 Any nucleic acid originating from the phage genome may confer immunity against the phage when inserted, for example, between two repeats in an active CRISPR locus. In some embodiments, immunity is more "efficient" when the CRISPR spacer corresponds to an internal sequence of a phage gene. In some particularly preferred embodiments, immunity is made even more "efficient" when the gene encodes an "essential" protein (e.g. the antireceptor). 40 In some preferred embodiments, the present invention provides methods for conferring resistance to a cell (e.g., a bacterial cell) against a bacteriophage comprising the steps of: (a) providing one or more 75 5 pseudo CRISPR spacers from at least one bacteriophage; (b) identifying one or more functional CRISPR repeat-cas combinations in at least one cell that is substantially sensitive to the bacteriophage; and (c) engineering the one or more CRISPR loci in the substantially sensitive cell such that they comprise one or more pseudo CRISPR spacers from a bacteriophage or one or more CRISPR spacer(s) which is/are complementary or homologous to the one or more pseudo CRISPR spacer(s) to render the cell resistant. [0 In yet additional embodiments, the present invention provides methods for conferring resistance to a cell (e.g., a bacterial cell) against a bacteriophage comprising the steps of: (a) providing one or more pseudo CRISPR spacers from at least one bacteriophage; (b) identifying one or more functional CRISPR repeat-cas combinations in at least one cell that is substantially sensitive to the bacteriophage; and (c) inserting one or more pseudo CRISPR spacers from the bacteriophage or one or more CRISPR spacer(s) [5 which is/are complementary or homologous to the one or more pseudo CRISPR spacer(s) into the substantially sensitive cell such that the cell is rendered substantially resistant to the bacteriophage. In yet additional embodiments, the present invention provides methods for modulating the lysotype of a bacterial cell comprising the steps of: (a) providing one or more pseudo CRISPR spacers from at least one bacteriophage; (b) identifying one or more functional CRISPR repeat-cas combinations !0 in at least one cell that is substantially sensitive to the bacteriophage; and (c) engineering the one or more CRISPR loci in the substantially sensitive cell such that they comprise one or more pseudo CRISPR spacers from a bacteriophage or one or more CRISPR spacer(s) which is/are complementary or homologous to the one or more pseudo CRISPR spacer(s). In still further embodiments, the present invention provides methods for modulating the lysotype !5 of a bacterial cell comprising the steps of: (a) providing one or more pseudo CRISPR spacers from at least one bacteriophage; (b) identifying one or more functional CRISPR repeat-cas combinations in at least one cell that is substantially sensitive to the bacteriophage; and (c) inserting one or more one or more pseudo CRISPR spacers from the bacteriophage or one or more CRISPR spacer(s) which is/are complementary or homologous to the one or more pseudo CRISPR spacer(s) into the substantially 30 sensitive cell. In some further preferred embodiments, the present invention provides methods for conferring resistance to a cell (e.g., a bacterial cell) against a bacteriophage comprising the steps of: (i) identifying a pseudo CRISPR spacer in a bacteriophage comprising a target nucleic acid or a transcription product thereof against which resistance is to be modulated; and (ii) modifying the sequence of the CRISPR 35 spacer of the cell such that the CRISPR spacer of the cell has homology to the pseudo CRISPR spacer of the bacteriophage comprising the target nucleic acid. In some further embodiments, the present invention provides methods for conferring resistance to a cell (e.g., a bacterial cell) against a bacteriophage comprising the steps of: (i) identifying a pseudo CRISPR spacer in a bacteriophage comprising a target nucleic acid or a transcription product thereof 40 against which resistance is to be modulated; and (ii) modifying the sequence of the CRISPR spacer of the 76 5 cell such that the CRISPR spacer of the cell has 100% homology or identity to the pseudo CRISPR spacer of the bacteriophage comprising the target nucleic acid. In yet additional embodiments, the present invention provides methods for modulating the lysotype of a bacterial cell comprising the steps of: comprising the steps of: (i) identifying a pseudo CRISPR spacer in a bacteriophage comprising a target nucleic acid or a transcription product thereof [0 against which resistance is to be modulated; and (ii) modifying the sequence of the CRISPR spacer of the cell such that the CRISPR spacer of the cell has homology to the pseudo CRISPR spacer of the bacteriophage comprising the target nucleic acid. In some further embodiments, the present invention provides methods for modulating the lysotype of a bacterial cell comprising the steps of: (i) identifying a pseudo CRISPR spacer in a [5 bacteriophage comprising a target nucleic acid or a transcription product thereof against which resistance is to be modulated; and (ii) modifying the sequence of the CRISPR spacer of the cell such that the CRISPR spacer of the cell has 100% homology or identity to the pseudo CRISPR spacer of the bacteriophage comprising the target nucleic acid. In some embodiments, the CRISPR spacer of the bacterial cell has 100% homology or identity to !0 a sequence (e.g., as a pseudo CRISPR spacer) in the bacteriophage comprising the target nucleic acid. In some alternative embodiments, the CRISPR spacer of the bacterial cell forms a component part of a CRISPR locus comprising a functional CRISPR repeat-cas combination as described herein. In some particularly preferred embodiments, the target nucleic acid or a transcription product thereof in the bacteriophage is a highly conserved nucleic acid sequence. In some further embodiments, !5 the target nucleic acid or transcription product thereof in the bacteriophage is a gene coding for a host specificity protein. In some additional embodiments, the target nucleic acid or transcription product thereof in the bacteriophage encodes an enzyme that is essential for survival, replication and/or growth of the bacteriophage. In yet additional embodiments, the target nucleic acid or transcription product thereof in the bacteriophage encodes a helicase, a primase, a head or tail structural protein, or a protein with a 30 conserved domain (e.g., holing, lysine, etc.). In some preferred embodiments, bacterial cells are prepared that have "reduced susceptibility to bacteriophage multiplication or infection." As used herein, this term refers to the bacteria as having a low or no susceptibility to bacteriophage multiplication or infection when compared to the wild-type bacteria when cultured (e.g., in a dairy medium). 35 In some embodiments, some bacterial cells exhibit "low susceptibility to bacteriophage multiplication." This term refers to the level of bacteriophage multiplication in a bacterium being below a level, which would cause a deleterious effect to a culture in a given period of time. Such deleterious effects on a culture include, but are not limited to, no coagulation of milk during production of fermented milk products (e.g., yogurt or cheese), inadequate or slow lowering of the pH during production of 40 fermented milk products (e.g., yogurt or cheese), slow ripening of cheese, and/or deterioration of a food's texture to the point where it is unappetizing or unsuitable for consumption.

77 5 For an equivalent set of culture conditions the bacterial susceptibility towards a bacteriophage of the present invention is generally expressed in comparison to the wild-type bacteria. In some embodiments, the bacteria have about 100 times lower (efficiency of plaquing [EOP] = 102), preferably about 1000 times lower (EOP = 10-'), more preferably 10,000 times lower (EOP = 10-4), and most preferably about 100,000 times lower (EOP=105). In some preferred embodiments, the level of [0 bacteriophage multiplication in a culture is measured after about 14 hours incubation of the culture, more preferably after about 12 hours, even more preferably after about 7 hours, still more preferably after about 6 hours, yet more preferably after about 5 hours, and most preferably after about 4 hours. In additional embodiments, the present invention provides methods for conferring sensitivity to a cell (e.g., a bacterial cell) against a bacteriophage comprising the steps of: (a) providing a pseudo [5 CRISPR spacer from at least one bacteriophage; (b) identifying one or more functional CRISPR repeat cas combinations in a cell that is substantially resistant to the bacteriophage; and (c) engineering the one or more CRISPR loci in the substantially sensitive cell such that they comprise one or more pseudo CRISPR spacers or one or more CRISPR spacer(s) which is/are complementary or homologous to the one or more pseudo CRISPR spacer(s) that have a reduced degree of homology as compared to the one or !0 more CRISPR loci in the substantially resistant cell. In further embodiments, the present invention provides methods for modulating (e.g., reducing) the lysotype of a cell (e.g., a bacterial cell), comprising one or more cas genes or proteins and one or more, preferably, two or more CRISPR repeats comprising the steps of: (i) identifying a pseudo CRISPR spacer in a bacteriophage against which resistance is to be modulated; and (ii) modifying the sequence of !5 the CRISPR spacer of the cell such that the CRISPR spacer of the cell has a reduced degree of homology to the pseudo CRISPR spacer of the bacteriophage comprising the target nucleic acid. In still a further embodiments, the present invention provides methods for modulating (e.g., reducing or decreasing) the resistance of a bacterial cell comprising one or more cas genes or proteins and one or more, preferably, two or more CRISPR repeats against a bacteriophage comprising the steps 30 of: (i) identifying one or more pseudo CRISPR spacers in a bacteriophage against which resistance is to be modulated; (ii) identifying a CRISPR spacer in the bacterial cell in which resistance is to be modulated that is homologous to the pseudo CRISPR spacer(s); and (iii) modifying the sequence of the CRISPR spacer in the bacterial cell in which resistance is to be modulated such that the CRISPR spacer has a lower degree of homology to the pseudo CRISPR spacer(s) of the bacteriophage against which 35 resistance is to be modulated. In some embodiments, the CRISPR spacer of the cell has a reduced degree of homology (e.g., about 1, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 15, about 20, about 25, about 30, about 35, about 40, about 45, about 50, about 55, about 60, about 65, about 70, about 75, about 80, about 90, or about 95% reduction in homology) as compared to the pseudo CRISPR 40 spacer(s) of the bacteriophage against which resistance is to be modulated.

78 5 In some embodiments, bacterial cells are prepared using the methods of the present invention such that the cells have an "increased susceptibility to bacteriophage multiplication." As used herein, this term refers to bacteria that have an increased or higher susceptibility to bacteriophage multiplication when compared to the wild-type bacteria when cultured (e.g., in a dairy medium). In some embodiments, the term "high susceptibility to bacteriophage multiplication" refers to the [0 level of bacteriophage multiplication in a bacterium being above a level, which would cause a deleterious effect to a culture in a given period of time. Such deleterious effects on a culture include, but are not limited to, no coagulation of milk during production of fermented milk products (e.g., yogurt or cheese), inadequate or slow lowering of the pH during production of fermented milk products (e.g., yogurt or cheese), slow ripening of cheese, and/or deterioration of a food's texture to the point where it is [5 unappetizing or unsuitable for consumption. For an equivalent set of culture conditions the bacterial susceptibility towards a bacteriophage of the present invention is generally expressed in comparison to the wild-type bacteria. In some embodiments, the bacteria have about 100 times lower (efficiency of plaquing [EOP] = 10-2), preferably about 1000 times lower (EOP = 10Of), more preferably 10,000 times lower (EOP = 10-4), and most !0 preferably about 100,000 times lower (EOP=10- 5 ). In some preferred embodiments, the level of bacteriophage multiplication in a culture is measured after about 14 hours incubation of the culture, more preferably after about 12 hours, even more preferably after about 7 hours, still more preferably after about 6 hours, yet more preferably after about 5 hours, and most preferably after about 4 hours. In some preferred embodiments, a CRISPR spacer is flanked by two CRISPR repeats (i.e., a !5 CRISPR spacer has at least one CRISPR repeat on each side). In some embodiments of the present invention, the parent bacterium (e.g., "parental bacterial strain") is exposed (e.g., iteratively, sequentially, simultaneously or substantially simultaneously) to more than one bacteriophage (e.g., a mixture of one or more phages). In some embodiments, the parental bacterial strain is sensitive to each of the bacteriophages that it is exposed to in the mixture, while in 30 other embodiments, the bacterial strain is sensitive to some of the bacteriophages, but resistant to others. As used herein, the term "tagging sequence" refers to the portion of an additional DNA fragment that is derived from the genome of one or more bacteriophage (e.g., the plus strand of the genome of the one or more bacteriophage) that the parent bacterium is exposed to in accordance with the methods of the present invention and is used as a label or a tag (e.g., providing a unique label or a unique tag). 35 The tagging sequence is typically a sequence that is a naturally occurring sequence in the bacteriophage. Preferably, the tagging sequence has at least about 90%, about 95%, about 96%, about 97%, about 98% or about 99% identity to the naturally occurring sequence in the bacteriophage (e.g., the genome of the bacteriophage from which it is derived). In some most preferred embodiments, the tagging sequence has about 100 % identity to the naturally occurring sequence in the bacteriophage (e.g., 40 the genome of the bacteriophage from which it is derived).

79 5 In some embodiments, the tagging sequence has less than about 40%, about 30%, about 20%, about 10%, about 5%, about 4%, about 3%, about 2%, about 1%, or about 0% identity to any other CRISPR spacers or CRISPR spacer cores in the one or more CRISPR loci of the labelled bacterium. In some embodiments, the tagging sequence has less than about 40%, about 30%, about 20%, about 10%, about 5%, about 4%, about 3%, about 2%, about 1%, or about 0% identity to any other [0 sequence in the one or more CRISPR loci of the labelled bacterium. In some additional embodiments, the tagging sequence has a sequence that is identical to a sequence (e.g., as a CRISPR spacer) in the CRISPR locus of the bacterium. In some further embodiments, the tagging sequence has a sequence that is identical to a sequence (e.g., a CRISPR spacer) in the CRISPR locus of the bacterium aside from one or more single nucleotide polymorphisms (e.g., one [5 or two single nucleotide polymorphisms). In some preferred embodiments, the tagging sequence is at least about 20 nucleotides in length, while in some particularly preferred embodiments it is about 20 to about 58 nucleotides in length In some particularly preferred embodiments, at least one tagging sequence is integrated into the parent bacterium. In some additional embodiments, at least one duplicated sequence (e.g., a duplicated !0 CRISPR repeat sequence) derived from the parent bacterium's genome or one or more of the parent bacterium's plasmids (e.g., megaplasmids) is also integrated. It is not intended that the present invention be limited to any particular mechanism or theory. However, it is believed that the at least one duplicated sequence is copied or replicated from the genome of the parent bacterium. In particular, it is believed that typically the CRISPR repeat sequence in a CRISPR locus is duplicated and the tagging sequence is !5 integrated in the bacterium's genome immediately after (i.e., downstream) the new duplicated CRISPR repeat. In some particularly preferred embodiments, the at least one duplicated sequence is a CRISPR repeat sequence that has at least about 90%, about 95%, about 96%, about 97%, about 98%, or about 99% identity to the CRISPR repeats in the one or more CRISPR loci of the parent bacterium and/or 30 labelled bacterium. Most preferably, the at least one duplicated sequence is a CRISPR repeat sequence that has at least about 100% identity to the CRISPR repeats in the one or more CRISPR loci of the parent bacterium and/or labelled bacterium. In some preferred embodiments, the duplicated sequence is at least about 24 nucleotides in length, while in some particularly preferred embodiments it is about 24 to about 40 nucleotides in length. 35 In some preferred embodiments, at least one tagging sequence and at least one duplicated sequence are integrated into the parent bacterium. It is not intended that the present invention be limited to any particular mechanism or theory. However, it is believed that each time a tagging sequence is integrated into the genome of the parent bacterium, this is accompanied by the iterative, sequential, simultaneous or substantially simultaneous integration of at least one duplicated sequence. Accordingly, 40 at least one pair of sequences comprising the tagging sequence and the duplicated sequence are integrated into the parent bacterium, thereby resulting in a labelled bacterium.

80 5 In some preferred embodiments, at least one tagging sequence and at least one duplicated sequence integrate adjacent to each other. More preferably, at least one tagging sequence and at least one duplicated sequence are integrated directly adjacent to each other such that there are no intervening nucleotides between the sequences. In some embodiments, the duplicated sequence is attached, linked or fused to one end (e.g., the 5' [0 or the 3' end) of the tagging sequence. Preferably, the duplicated sequence is attached, linked or fused to the 5' end of the tagging sequence. Accordingly, following the integration of a single pair of sequences, the duplicated sequence is the first sequence at the 5' end of the CRISPR locus and the tagging sequence will be the second (e.g., the next) sequence in the CRISPR locus, downstream of the duplicated sequence. In some preferred embodiments, the sequences are directly attached, directly linked or directly fused such [5 that there are no intervening nucleotides between the duplicated sequence and the tagging sequence. Thus, in some embodiments, a duplicated sequence and a tagging sequence pair are integrated into the genome of the parent bacterium to give rise to a labelled bacterium. The duplicated sequence is derived, derivable, obtained or obtainable from the parent bacterium's genome and the tagging sequence is derived, derivable, obtained or obtainable from the genome of the bacteriophage that is used to infect !0 the parent bacterium. Surprisingly, it has even been found that in some embodiments, multiple pairs of sequences are integrated into the genome of the parent bacterium. According to these embodiments, the multiple pairs comprise a first pair comprising a duplicated sequence and a tagging sequence, and a second pair comprising a second duplicated sequence and a second tagging sequence. The second duplicated !5 sequence typically comprises the same sequence (e.g., greater than about 95%, about 96,%, about 97%, about 98%, about 99%, or about 100% identity) as the first duplicated sequence. The tagging sequence typically comprises a different sequence (e.g., less than about 40%, about 30%, about 20%, about 10%, about 5%, about 4%, about 3%, about 2%, about 1%, or about 0% identity) to the first tagging sequence. This is also the case in embodiments in which additional pairs of sequences are integrated. 30 Accordingly, the configuration of the multiple pairs typically comprises: [duplicated sequence-tagging sequence], wherein n = 2, 3, 4, 5, 6, or more. Preferably, the configuration of the multiple pairs typically comprises: [CRISPR repeat-tagging sequence], 35 wherein n = 2, 3, 4, 5, 6, or more. In some embodiments, the configuration of the multiple pairs is: 5'-[duplicated sequence-tagging sequence],-3' wherein n = 2, 3, 4, 5, 6, or more. Preferably, the configuration of the multiple pairs is: 40 5'-[CRISPR repeat-tagging sequence],-3' wherein n = 2, 3, 4, 5, 6, or more.

81 5 Accordingly, in some embodiments, multiple pairs of sequences are integrated into the parent bacterium. In some embodiments, the tagging sequence integrates adjacent to: (i) a duplicated sequence that is homologous (e.g., identical) to a naturally occurring sequence in the parent bacterium; (ii) a duplicated sequence that is homologous (e.g., identical) to a naturally occurring sequence in the CRISPR [0 locus of the parent bacterium; or (iii) most preferably, a duplicated sequence that is homologous (e.g., identical) to a naturally occurring CRISPR repeat in the CRISPR locus of the parent bacterium. Following each exposure of a parent bacterium to a given bacteriophage in independent experiments, the tagging sequence in each of the labelled bacterium presents a different nucleotide sequence, thereby creating a sequence that is unique to each bacterium. Thus, without being bound by [5 any particular theory, it is believed that upon exposure of a parent bacterium to a given bacteriophage, the tagging sequence that is integrated into a parent bacterium is apparently randomly selected from the genome of the bacteriophage. However, it is not intended that the present invention be limited to random integration events. Advantageously, this surprising finding is utilized in the context of the present invention by !0 virtue of the fact that the randomly selected tagging sequence provides a unique tag or label in the labelled bacterium. Surprisingly, it has also be found that when the same parent bacterium is exposed to the same bacteriophage the tagging sequence that is integrated in independent/distinct experiments is of a different sequence, thereby resulting in a unique label in the labelled bacterium following each exposure. In some embodiments, the randomly selected tagging sequence is identified in the labelled !5 bacterium by virtue of one or more of the following properties of the tagging sequence: (1) The location of the tagging sequence in the one or more CRISPR loci of the bacteriophage insensitive mutant. As described herein, the tagging sequence is typically located at one and/or both ends (e.g., the 5' and/or 3' end, more preferably, the 5' end) of the CRISPR locus of the labelled bacterium (2) The tagging sequence has a high degree of homology or identity (e.g., 100 % identity) to a 30 sequence in the bacteriophage genome that the parent bacterium was exposed to; and/or (3) The tagging sequence is fused, linked or attached to (e.g., directly fused, linked or attached to) at least one sequence (e.g., a CRISPR repeat) that is duplicated from the genome of the parent bacterium. Typically, as described herein, this additional pair of sequences is located at one and/or both ends (e.g., the 5' and/or 3' end, preferably, the 5' end) of the CRISPR locus of the labelled bacterium. 35 In some tagging/labelling embodiments provided herein, one or more tagging sequences and/or the one or more duplicated sequences (eg. the duplicated CRISPR repeat from the parent bacterium) integrate into the CRISPR locus of the parent bacterium. In some preferred embodiments, one or more duplicated-sequence-tagging sequence pairs as described herein integrate into the CRISPR locus of the parent bacterium. In some embodiments, the tagging sequence(s) and/or the duplicated sequence(s) 40 integrate within the CRISPR locus of the parent bacterium. In some other embodiments, the tagging sequence(s) and/or the duplicated sequence(s) integrate at one or both ends of the CRISPR locus of the 82 5 parent bacterium. In yet further embodiments, the tagging sequence(s) and/or the duplicated sequence(s) integrate at both ends of the CRISPR locus of the parent bacterium such that the sequences are at the 5' end and the 3' end of the CRISPR locus. One of the duplicated sequences will typically be the first sequence at the 5' end of the CRISPR locus and the tagging sequence will be immediately downstream of the duplicated sequence. The other duplicated sequence will be the last sequence at the 3' end of the [0 CRISPR locus and the tagging sequence will be immediately upstream of the duplicated sequence. In some embodiments, the tagging sequence(s) and/or the duplicated sequence(s) integrate into one or more CRISPR loci. In yet further embodiments, the tagging sequence(s) and/or the duplicated sequence(s) integrate at one end of the CRISPR locus of the parent bacterium such that the sequence(s) are at the 3' end of the CRISPR locus. The duplicated sequence will be the last sequence at the 3' end of [5 the CRISPR locus and the tagging sequence will be immediately upstream of the duplicated sequence. Preferably, the tagging sequence(s) and/or the duplicated sequence(s) integrate at one end of the CRISPR locus of the parent bacterium such that the sequences are at the 5' end of the CRISPR locus. The duplicated sequence is the first sequence at the 5' end of the CRISPR locus and the tagging sequence is immediately downstream of the duplicated sequence. !0 As described herein, the tagging sequence(s) is a strain specific tag in the sense that the tagging sequence that is integrated or inserted from the bacteriophage into the parent bacterium is different each time the parent bacterium (e.g., the same parent bacterium) is exposed to the bacteriophage (e.g., the same bacteriophage). Hence the tagging sequence find use as a unique tag for a given bacterial strain. The tagging sequence(s) and/or the duplicated sequence(s) integrate into one or more different !5 CRISPR loci, while in other embodiments, two or more different tagging sequence(s) and/or duplicated sequence(s) integrate into one CRISPR locus, and is still further embodiments, two or more different tagging sequence(s) and/or duplicated sequence(s) each integrate into two or more different CRISPR loci. Each of the tagging sequences from each of the bacteriophage and/or each of the duplicated sequences (e.g., the duplicated CRISPR repeat) from the parent bacterium may integrate into the same CRISPR 30 locus. In some embodiments, each of the tagging sequences and/or each of the duplicated sequences integrate at one or both ends of the same CRISPR locus. In some further embodiments, each of the tagging sequences and/or each of the duplicated sequences integrate at the 5' and/or the 3' end of the same CRISPR locus. Preferably, each of the tagging sequences and/or each of the duplicated sequences 35 integrate at the 5' end of the same CRISPR locus. In some additional embodiments, each of the tagging sequences and/or each of the duplicated sequences from the parent bacterium integrate iteratively, simultaneously or substantially simultaneously. In some embodiments, each of the tagging sequences and/or each of the duplicated sequences integrate sequentially, whereby the first tagging sequence and/or the first duplicated sequence is integrated into the parent bacterium. A second tagging sequence from a 40 second bacteriophage and/or another duplicated sequence then integrates into the parent bacterium.

83 5 Suitably, the tagging sequence and/or the duplicated sequence integrate into the chromosomal DNA of the parent bacterium. In some embodiments, each of the tagging sequences and/or each of the duplicated sequences integrate into one end (e.g., the 5' end) of the same CRISPR locus adjacent (e.g., next to) each other. Thus, in some embodiments, each of the tagging sequences and/or duplicated sequences integrate [0 sequentially, whereby the first sequences are integrated into the parent bacterium at one end (e.g., within or at the 5' and/or the 3' end) of the CRISPR locus. A second tagging sequence and/or duplicated sequence may then integrate into the parent bacterium adjacent (e.g., directly adjacent) to the first pair of sequences. In some embodiments, the second sequences integrate into the parent bacterium adjacent (e.g., directly adjacent) to the 5' or the 3' end of the first sequences. Preferably, the second sequences 5 integrate into the parent bacterium adjacent (e.g., directly adjacent) to the 3' end of the first sequences and so on. In some embodiments, each of the sequences integrate adjacent (e.g., next to) each other within or at the 3' end and/or at the 5' end of the same CRISPR locus of the parent bacterium. In some preferred embodiments, each of the sequences integrate adjacent (e.g., next to) each other at the 5' end of the same CRISPR locus of the parent bacterium. More preferably, each of the sequences integrate !0 adjacent (e.g., next to) each other upstream of the 5' end of the CRISPR locus of the parent bacterium. More preferably, each of the sequences integrate adjacent (e.g., next to) each other upstream of the 5' CRISPR repeat of the CRISPR locus of the parent bacterium. Most preferably, each of the sequences integrate adjacent (e.g., next to) each other upstream of the first 5' CRISPR repeat of the CRISPR locus of the parent bacterium. Labelled Bacteria As used herein, the term "labelled bacteria" and "labelled bacterium" refers to a parent bacterium, parent bacteria, or parental bacterial strain in which one or more CRISPR loci or a portion thereof have been modified (e.g., mutated) in such a way that it is insensitive to the one or more 30 bacteriophage that it has been exposed to. As described in further detail herein, in some embodiments, the labelled bacterium is exposed to more than one bacteriophage (e.g., either iteratively, sequentially or simultaneously), such that it accumulates one or more genomic modifications within one or more CRISPR loci in such a way that it becomes insensitive to each of the bacteriophages to which it has been exposed 35 To infect cells, a bacteriophage injects or transfers its nucleic acid into the cell with the phage nucleic acid existing independently of the cell's genome. In some embodiments, infection results in the expression (i.e., transcription and translation) of the bacteriophage nucleic acid within the cell and continuation of the bacteriophage life cycle. In some embodiments of the present invention, following exposure to the bacteriophage, the 40 labelled bacterium has a reduced or no susceptibility to bacteriophage infection and/or multiplication when compared to the parent bacterium. As used herein, the term "reduced susceptibility to 84 5 bacteriophage infection and/or multiplication" means that the level of bacteriophage infection and/or multiplication in the labelled bacterium does not cause a deleterious effect to the labelled bacterium. Thus, in some embodiments of the present invention, a parent bacterium is not killed following exposure to the bacteriophage, due to mutation of the parent bacterium in such a way that it becomes insensitive to the bacteriophage. [0 In some embodiments, the labelled bacterium is insensitive or substantially insensitive to further infection and/or multiplication by the bacteriophage. In additional embodiments, the labelled bacterium is insensitive or substantially insensitive to one or more of the mechanisms that the bacteriophage uses to infect and/or multiply in a bacterium. In still further embodiments, the labelled bacterium is insensitive or substantially insensitive to all of the mechanisms that the bacteriophage uses to infect and/or multiply [5 in a bacterium. In yet additional embodiments, the labelled bacterium develops one or more mechanisms that attenuate, inactivate or destroy the bacteriophage during the infection cycle. In some further embodiments, the present invention provides labelled strains selected by standard screening procedures that are known in the art to isolate bacteriophage insensitive mutants. In some embodiments of the present invention, a labelled bacterium comprising a tagging !0 sequence in the CRISPR locus that is not present in the parent bacterium is selected following the comparison of the CRISPR locus or a portion thereof from the parent bacterium and the labelled bacterium. In some preferred embodiments, a labelled bacterium comprising an additional DNA fragment within or at the 5' and/or the 3' end of the CRISPR locus that is not present in the parent bacterium is !5 selected. More preferably, a labelled bacterium comprising a tagging sequence adjacent (e.g., directly adjacent) the 3' end of a newly duplicated sequence in the CRISPR locus of the labelled bacterium that is not present in the parent bacterium is selected. Most preferably, a labelled bacterium comprising a tagging sequence adjacent (e.g., directly adjacent) the 3' end of the first CRISPR repeat of the CRISPR locus in the labelled bacterium that is not present in the parent bacterium is selected. 30 In some embodiments, the tagging sequence (e.g., the one or more tagging sequences) is isolated and/or cloned. In some further embodiments, the tagging sequence (e.g., the one or more tagging sequences) is sequenced. These embodiments provide advantages, as they not only provide information about the location of the tagging sequence within the CRISPR locus, but also the specific sequence thereof, as well. In some embodiments, this information is stored in a database, thereby providing a 35 unique label for the given bacterium and also a means for subsequently tracking and/or identifying the bacterium. Once the sequence of the tagging sequence in the labelled bacterium is known, the tagging sequence alone finds use in identifying bacteria. Using various methods that are known in the art and described herein, the sequence and/or location of the tagging sequence are determined. This sequence is 40 then matched against, for example, a bacterial sequence database and/or a bacteriophage sequence database and/or a database or labels/tags in order to identify the bacterium.

85 5 Donor Organism As used in some embodiments herein, the term "donor organism" refers to an organism or cell from which the CRISPR repeat and/or cas gene and/or combination(s) thereof and/or CRISPR spacers are derived. These can be the same or different. In some embodiments, the term "donor organism" refers [0 to an organism or cell from which the one or more, preferably, two or more CRISPR repeats and/or one or more cas gene and/or combination(s) thereof and/or CRISPR spacers are derived. These can be the same or different. In some embodiments, the CRISPR spacer and/or pseudo CRISPR spacer is synthetically derived. In yet further embodiments, the donor organism or cell comprises one or more CRISPR spacers, which confers the specific of immunity against a target nucleic acid or transcription [5 product thereof. In additional embodiments, the donor organism or cell from which the cas gene and/or CRISPR repeat and/or combination thereof is derived is also the recipient cell/organism for the recombinant CRISPR locus. These can be the same or different. In other embodiments, the donor organism or cell from which the CRISPR spacer is derived is also the recipient cell/organism for the recombinant CRISPR locus. These can be the same or different. In embodiments in which the donor !0 organism is a bacterial cell then the donor organism typically comprises a CRISPR spacer which confers the specific immunity against the target nucleic acid or transcription product thereof. In some embodiments, the organism is a bacterial cell while in other embodiments it is a bacteriophage. Host Cell !5 As used herein, the term "host cell" refers to any cell that comprises the combination, the construct or the vector and the like according to the present invention. In some embodiments, host cells are transformed or transfected with a nucleotide sequence contained in a vector (e.g., a cloning vector). In some embodiments, a nucleotide sequence may be carried in a vector for the replication and/or expression of the nucleotide sequence. The cells are chosen to be compatible with the vector and in some 30 embodiments, prokaryotic (e.g., bacterial) cells. Recipient Cell As used herein, the term "recipient cell" refers to any cell in which resistance against a target nucleic acid or a transcription product thereof is modulated or is to be modulated. In some embodiments, 35 the recipient cell refers to any cell comprising the recombinant nucleic acid according to the present invention. In some embodiments, the recipient cell comprises one or more, preferably, two or more CRISPR repeats and one or more cas genes or proteins. Suitably, the CRISPR repeats and the cas genes or proteins form a functional combination in the recipient cell, as described herein. In some further embodiments, the recipient cell comprises one or more modified CRISPR repeats and/or one or more 40 modified cas genes or proteins. Suitably, the modified CRISPR repeats and/or the modified cas genes or proteins form a functional combination in the recipient cell, as described herein. In some embodiments, 86 5 the recipient cell comprises one or more genetically engineered CRISPR repeats and/or one or more genetically engineered cas genes or proteins. Suitably, the genetically engineered CRISPR repeats and/or the genetically engineered cas genes or proteins form a functional combination in the recipient cell, as described herein. In some alternative embodiments, the recipient cell comprises one or more recombinant CRISPR repeats and/or one or more recombinant cas genes or proteins. Suitably, the [0 recombinant CRISPR repeats and/or the recombinant cas genes or proteins form a functional combination in the recipient cell, as described herein. In yet additional embodiments, the recipient cell comprises one or more naturally occurring CRISPR repeats and one or more naturally occurring cas genes or proteins. Suitably, the CRISPR repeats(s) and the cas gene(s) or proteins form a functional combination. [5 In some embodiments, the recipient cell comprises combinations of one or more modified, genetically engineered, recombinant or naturally occurring CRISPR repeats and one or more modified, genetically engineered, recombinant or naturally occurring cas genes or proteins. Suitably, the one or more modified, genetically engineered, recombinant or naturally occurring CRISPR spacer(s) or the one or more modified, genetically engineered, recombinant or naturally occurring cas gene(s) or proteins !0 form a functional combination. In some embodiments, the recipient cell is a prokaryotic cell. In some preferred embodiments, the recipient cell is a bacterial cell. Suitable bacterial cells are described herein. In some embodiments, the bacterial cell is selected from a lactic acid bacteria species, a Bifidobacterium species, a Brevibacterium species, a Propionibacterium species, a Lactococcus species, a Streptococcus species, a !5 Lactobacillus species including the Enterococcus species, Pediococcus species, a Leuconostoc species and Oenococcus species. Suitable species include, but are not limited to Lactococcus lactis, including Lactococcus lactis subsp. lactis and Lactococcus lactis subsp. cremoris, Lactococcus lactis subsp. cremoris, Leuconostoc sp., Lactococcus lactis subsp. lactis biovar, Streptococcus thermophilus, Lactobacillus delbrueckii subsp. bulgaricus and Lactobacillus helveticus, Bifidobacterium lactis, 30 Lactobacillus acidophilus, Lactobacillus casei. In some embodiments, in which the cell's resistance is to be modulated, the bacterial cell is used for the fermentation of meat (including beef, pork, and poultry) including, but not limited to, lactic acid bacteria, Pediococcus cerevisiae, Lactobacillus plantarum, Lactobacillus brevis, Micrococcus species, Lactobacillus sakei, Lactobacillus curvatus, Pediococcus pentosaceus, Staphylococcus xylosus and 35 Staphylococcus vitulinus and mixtures thereof, as known in the art. In some alternative embodiments, the bacterial cell is used for the fermentation of vegetables (e.g., carrots, cucumbers, tomatoes, peppers, and cabbage) including, but not limited to, Lactobacillus plantatum, Lactobacillus brevis, Leuconostoc mesenteroides, Pediococcus pentosaceus, and mixtures thereof, as known in the art. In some alternative embodiments, the bacterial cell is used for the fermentation of dough formed from cereals (e.g., wheat, 40 rye, rice, oats, barley, and corn). In some further embodiments, the bacterial cell is used for the production of wine. Typically, this is achieved by the fermentation of fruit juice, typically grape juice.

87 5 In still further embodiments, the bacterial cell is used for the fermentation of milk to produce cheese (e.g., Lactobacillus delbrueckii subsp. bulgaricus, Lactobacillus helveticus, Streptococcus thermophilus, Lactococcus lactis subsp. lactis, Lactococcus lactis subsp. cremoris, Lactococcus lactis subsp. lactis biovar diacetylactis, Lactococcus, Bifidobacterium, and Enterococcus, etc. and mixtures thereof), as known in the art. In still further embodiments, the bacterial cell is used for the fermentation of egg (e.g., [0 Pediococcus pentosaceus, Lactobacillus plantarum, and mixtures thereof), as known in the art. In some further embodiments, the bacterial cell is used in cosmetic or pharmaceutical compositions. In some embodiments, the cell in which resistance is to be modulated is a bacterium that naturally comprises one or more CRISPR loci. CRISPR loci have been identified in more than 40 prokaryotes (See, Haft et al., 2005, supra) including, but not limited to Aeropyrum, Pyrobaculum, 15 Sulfolobus, Archaeoglobus, Halocarcula, Methanobacterium, Methanococcus, Methanosarcina, Methanopyrus, Pyrococcus, Picrophilus, Thermoplasma, Corynebacterium, Mycobacterium, Streptomyces, Aquifex, Porphyromonas, Chlorobium, Thermus, Bacillus, Listeria, Staphylococcus, Clostridium,. Thermoanaerobacter, Mycoplasma, Fusobacterium, Azarcus, Chromobacterium, Neisseria, Nitrosomonas, Desulfovibrio, Geobacter, Myxococcus, Campylobacter, Wolinella, Acinetobacter, !0 Erwinia, Escherichia, Legionella, Methylococcus, Pasteurella, Photobacterium, Salmonella, Xanthamonas, Yersinia, Treponema, and Thermotoga. Parent Bacterial Strain As used herein the terms "parent bacterium" "parent bacteria" and "parental strain" refer to any !5 bacterium/bacteria/strains that is/are exposed to one or more bacteriophage(s). In some embodiments, the bacteriophage are virulent for the parent bacterial strain, while in other embodiments, they are non virulent. In some particularly preferred embodiments, the parent bacteria are sensitive to the virulent phage. In some preferred embodiments, the parental strain is infected by the bacteriophage. In some particularly preferred embodiments, the infection by phage renders the parent bacterium/bacteria/strain or 30 a subpopulation thereof insensitive to further infection by the bacteriophage. In some preferred embodiments, the infection of a "parent bacterium" by one or more bacteriophage results in the creation of a labelled strain that can be selected based on its insensitivity to the bacteriophage. In some preferred embodiments, "bacteriophage resistant mutant" are bacteria that are tagged or labelled according to the methods of the present invention. In some embodiments, the parent bacteria are wild-type bacterial 35 strains. In some preferred embodiments, the parent bacteria are wild-type strains of bacteria that have not been previously infected with any bacteriophage. In some preferred embodiments, the parent bacteria are wild-type strains of bacteria that have not been previously tagged or labelled, while in some alternative embodiments, the patent bacteria are bacteriophage resistant mutants that have been previously tagged or labelled. 40 In some particularly preferred embodiments, the parent bacterium is selected from any bacterium that naturally comprises one or more CRISPR loci. As indicated above, CRISPR loci have been 88 5 identified in more than 40 prokaryotes (See, Haft et al., [2005], supra) including, but not limited to Aeropyrum, Pyrobaculum, Sulfolobus, Archaeoglobus, Halocarcula, Methanobacterium, Methanococcus, Methanosarcina, Methanopyrus, Pyrococcus, Picrophilus, Thermoplasma, Corynebacterium, Mycobacterium, Streptomyces, Aquifex, Porphyromonas, Chlorobium, Thermus, Bacillus, Listeria, Staphylococcus, Clostridium,. Thermoanaerobacter, Mycoplasma, Fusobacterium, 10 Azarcus, Chromobacterium, Neisseria, Nitrosomonas, Desulfovibrio, Geobacter, Myxococcus, Campylobacter, Wolinella, Acinetobacter, Erwinia, Escherichia, Legionella, Methylococcus, Pasteurella, Photobacterium, Salmonella, Xanthamonas, Yersinia, Treponema, and Thermotoga. In some embodiments, the parent bacterium comprises one or more heterologous CRISPR spacers, one or more heterologous CRISPR repeats, and/or one or more heterologous cas genes. In some [5 alternative embodiments, the parent bacterium comprises one or more heterologous CRISPR loci, preferably, one or more complete CRISPR loci. In some further embodiments, the parent bacterium naturally comprises one or more CRISPR loci and also comprises one or more heterologous CRISPR spacers, one or more heterologous CRISPR repeats, and/or one or more heterologous cas genes. In some additional embodiments, the parent bacterium naturally comprises one or more CRISPR loci and also !0 comprises one or more heterologous CRISPR loci, preferably, one or more complete CRISPR loci. In some preferred embodiments, the phage-resistant subpopulation created by exposure of the parent bacteria to at least one phage is a pure culture. However, it is not intended that the present invention be limited to pure cultures of bacterial strains, variants, or phage. Indeed, it is intended that the present invention encompasses mixed cultures of cells and phage. In some embodiments, the mixed !5 culture is a mix of different mutants corresponding to different integration events at the same and/or at different CRISPR loci. Although it is not intended that the present invention be so limited, preferred parental bacterial genera are Streptococcus and Lactobacillus. Indeed, it is intended that any bacterial species will find use in the present invention, including but not limited to Escherichia, Shigella, Salmonella, Erwinia, 30 Yersinia, Bacillus, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Agrobacterium, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Francisella, Brucella, Bifidobacterium, Brevibacterium, Propionibacterium, Lactococcus, Lactobacillus, Enterococcus, Pediococcus, Leuconostoc, Oenococcus, and/or Xanthomonas. In some embodiments, the parent bacteria are or are derived from lactic acid 35 bacteria, including but not limited to Bifidobacterium, Brevibacterium, Propionibacterium, Lactococcus, Streptococcus, Lactobacillus (e.g., L. acidophilus), Enterococcus, Pediococcus, Leuconostoc, and/or Oenococcus. In further embodiments, the parent bacteria are or are derived from Lactococcus lactis (e.g., L. lactis subsp. lactis and L. lactis subsp. cremoris, and L. lactis subsp. lactis biovar diacetylactis), L. delbrueckii subsp. bulgaricus, L. helveticus, L. acidophilus, L. casei, L. paracasei, L. salivarius, L. 40 plantarum, L. reuteri, L. gasseri, L. johnsonii, Bifidobacterium lactis, B. infantis, B. longum, and/or Streptococcus thermophilus.

89 5 In some embodiments of the present invention, the parent bacterium is a "food-grade bacterium" (i.e., a bacterium that is used and generally regarded as safe for use in the preparation and/or production of food and/or feed). In some preferred embodiments, the parent bacterium is suitable for use as a starter culture, a probiotic culture, and/or a dietary supplement. In additional embodiments, the parent bacterium finds use in the fermentation of meat (e.g., beef, pork, lamb, and poultry) including, but not 10 limited to, lactic acid bacteria, Pediococcus cerevisiae, Lactobacillus plantarum, L. brevis, L. sakei, L. curvatus, Micrococcus species, Pediococcus pentosaceus, Staphylococcus xylosus, S. vitulinus and mixtures thereof (See e.g., Knorr (ed.), Food Biotechnology, at 538-39 [1987]; and Pederson, Microbiology of Fermented Foods, at 210-34, 2d ed., [1979]; and U.S. Pat. No. 2,225,783, herein incorporated by reference in its entirety). In yet additional embodiments, the parent bacterium finds use [5 in the fermentation of vegetables (e.g., carrots, cucumbers, tomatoes, peppers, and cabbage) including, but not limited to, L. plantatum, L. brevis, Leuconostoc mesenteroides, Pediococcus pentosaceus, and mixtures thereof (See e.g., Knorr, supra; Pederson, supra; and U.S. Pat. Nos. 3,024,116, 3,403,032, 3,932,674, and 3,897,307). In yet further embodiments, the parent bacterium finds use in the fermentation of dough formed from cereals (e.g., wheat, rye, rice, oats, barley, and corn). In still further !0 embodiments, the parent bacterium finds use in the production of wine through fermentation of fruit juice (e.g., grape juice). In some additional embodiments, parent bacterium finds use in the fermentation of milk (e.g., L. delbrueckii subsp. bulgaricus, L. acidophilus, S. thermophilus, and mixtures thereof (See, Knorr, supra; and Pederson supra, at pages 105-35). In some preferred embodiments, the parent bacterium find use in the production of cheese, including but not limited to L. delbrueckii subsp. !5 bulgaricus, L. helveticus, L. lactis subsp. lactis, L lactis subsp. cremoris, L. lactis subsp. lactis biovar diacetylactis, S. thermophilus, Bifidobacterium Enterococcus, etc., and mixtures thereof (See e.g., Knorr, supra, and Pederson, supra, at 135-51). In yet further embodiments, the parent bacterium finds use in the fermentation of eggs, including but not limited to Pediococcus pentosaceus, Lactobacillus plantarum, and mixtures thereof (See, Knorr, supra). In some embodiments, the parent bacterium is finds use in 30 fermentation to produce various products, including but not limited to cheddar and cottage cheese (e.g., L. lactis subsp. lactis, L. lactis subsp. cremoris), yogurt (L. delbrueckii subsp. bulgaricus, and S. thermophilus), Swiss cheese (e.g., S. thermophilus, L. lactis, and L. helveticus), blue cheese (Leuconostoc cremoris), Italian cheese (L. bulgaricus and S. thermophilus), viili (L. lactis subsp. cremoris, L. lactis subsp. lactis biovar diacetylactis, Leuconostoc cremoris), yakult (L. casei), casein (L. 35 lactis subsp. cremoris), natto (Bacillus subtilis var. natto), wine (Leuconostoc oenos), sake (Leuconostoc mesenteroides), polymyxin (Bacillus polymyxa), colistin (Bacillus colistrium), bacitracin (Bacillus licheniformis), L-Glutamic acid (Brevibacterium lactofermentum and Microbacterium ammoniaphilum), and acetone and butanol (Clostridium acetobutyricum, and Clostridium saccharoperbutylacetonicum). In some preferred embodiments, the parent bacterial species are selected from S. thermophilus, L. 40 delbrueckii subsp. bulgaricus and/or L. acidophilus.

90 5 In yet additional embodiments, the parent bacteria find use in methods including but not limited to antibiotic production, amino acid production, solvent production, and the production of other economically useful materials. In still other embodiments the parent bacteria find use in cosmetic, therapeutic, and/or pharmaceutical compositions. In some embodiments the compositions have particular activities, including but not limited to regenerating the skin, including but not limited to anti-wrinkle [0 properties, erasing old scars, repairing burn-damaged tissues, promoting skin healing, eliminating pigmentary spots, etc. In some embodiments, the compositions either promote or inhibit the growth of nails, hair or hairs. In some additional embodiments, the compositions comprise at least one microbial culture and/or labelled bacterium and/or a cell culture produced using the methods and compositions of the present invention [5 In further embodiments, the parent bacteria are bacteriophage insensitive mutants. Thus, in some embodiments, the parent bacteria are insensitive to one or more bacteriophage. In some preferred embodiments, the parent bacterium is not a bacteriophage insensitive mutant for the bacteriophage that it is to be exposed to during use of the present invention. !0 Starter Cultures Starter cultures are used extensively in the food industry in the manufacture of fermented products including milk products (e.g., yoghurt and cheese), as well as meat products, bakery products, wine and vegetable products. Starter cultures used in the manufacture of many fermented milk, cheese and butter products !5 include cultures of bacteria, generally classified as lactic acid bacteria. Such bacterial starter cultures impart specific features to various dairy products by performing a number of functions. Commercial non-concentrated cultures of bacteria are referred to in industry as "mother cultures," and are propagated at the production site, for example a dairy, before being added to an edible starting material, such as milk, for fermentation. The starter culture propagated at the production site for 30 inoculation into an edible starting material is referred to as the "bulk starter." Suitable starter cultures for use in the present invention include any organism which is of use in the food, cosmetic or pharmaceutical industry (i.e., "industrially useful cultures" or "industrially useful strains"). Starter cultures are prepared by techniques well known in the art (See e.g., US Pat. No. 35 4,621,058, incorporated herein by reference). In some embodiments, starter cultures are prepared by the introduction of an inoculum, for example a bacterium, to a growth medium (e.g., a fermentation medium or product) to produce an inoculated medium and incubating the inoculated medium to produce a starter culture. Dried starter cultures are prepared by techniques well known in the art (See e.g., US Pat. Nos. 4, 40 423,079 and 4,140,800). Any suitable form of dried starter cultures find use in the present invention, including solid preparations (e.g., tablets, pellets, capsules, dusts, granules and powders) which are 91 5 wettable, spray-dried, freeze-dried or lyophilized. In some embodiments, the dried starter cultures for use in the present invention are in either a deep frozen pellet form or freeze-dried powder form. Dried starter cultures in a deep frozen pellet or freeze-dried powder form are prepared according to any suitable method known in the art. In some embodiments, the starter cultures used in the present invention are in the form of [0 concentrates which comprise a substantially high concentration of one or more bacterial strains. In some embodiments, the concentrates are diluted with water or resuspended in water or other suitable diluents, (e.g., an appropriate growth medium, mineral oil, or vegetable oil). The dried starter cultures of the present invention in the form of concentrates are prepared according to the methods known in the art (e.g., centrifugation, filtration or a combination of such techniques). [5 In some embodiments, the starter culture is suitable for use in the dairy industry. When used in the dairy industry the starter culture is often selected from a lactic acid bacteria species, a Bifidobacterium species, a Brevibacterium species, a Propionibacterium species. Suitable starter cultures of the lactic acid bacteria group include commonly used strains of a Lactococcus species, a Streptococcus species, a Lactobacillus species including the Lactobacillus acidophilus, Enterococcus species, !0 Pediococcus species, a Leuconostoc species and Oenococcus species. Cultures of lactic acid bacteria are commonly used in the manufacture of fermented milk products (e.g., buttermilk, yoghurt or sour cream), and in the manufacture of butter and cheese (e.g., brie or havarti). Lactococcus species include the widely used Lactococcus lactis, including Lactococcus lactis subsp. lactis and Lactococcus lactis subsp. cremoris. !5 Other lactic acid bacteria species include Leuconostoc sp., Streptococcus thermophilus, Lactobacillus delbrueckii subsp. bulgaricus and Lactobacillus helveticus. In addition, probiotic strains (e.g., Lactococcus species), include the widely used Lactococcus lactis, including Lactococcus lactis subsp. lactis, and Lactococcus lactis subsp. cremoris. Mesophilic cultures of lactic acid bacteria commonly used in the manufacture of fermented milk 30 products such as buttermilk, yoghurt or sour cream, and in the manufacture of butter and cheese (e.g., brie or havarti). Other Lactococcus species include Lactococcus lactis subsp. cremoris, Lactococcus lactis, Leuconostoc sp., Lactococcus lactis subsp. lactis biovar, Streptococcus thermophilus, Lactobacillus delbrueckii subsp. bulgaricus and Lactobacillus helveticus. In addition, in some embodiments, probiotic strains such as Bifidobacterium lactis, Lactobacillus acidophilus, Lactobacillus 35 casei are added during manufacturing to enhance flavour or to promote health. Cultures of lactic acid bacteria commonly used in the manufacture of cheddar and monterey jack cheeses include Streptococcus thermophilus, Lactococcus lactis subsp. lactis and Lactococcus lactis subsp. cremoris or combinations thereof. Thermophilic cultures of lactic acid bacteria commonly used in the manufacture of Italian 40 cheeses such as pasta filata or parmesan, include Streptococcus thermophilus and Lactobacillus 92 5 delbrueckii subsp bulgaricus. Other Lactobacillus species (e.g.., Lactobacillus helveticus) are added during manufacturing to obtain a desired flavour. In some preferred embodiments , the starter culture organism comprises or consists of a genetically modified strain prepared according to the methods provided herein, of one of the above lactic acid bacteria strains or any other starter culture strain. [0 The selection of organisms for the starter culture of the invention will depend on the particular type of products to be prepared and treated. Thus, for example, for cheese and butter manufacturing, mesophillic cultures of Lactococcus species, Leuconostoc species and Lactobacillus species are widely used, whereas for yoghurt and other fermented milk products, thermophillic strains of Streptococcus species and of Lactobacillus species are typically used. [5 In some embodiments, the starter culture is a dried starter culture, a dehydrated starter culture, a frozen starter culture, or a concentrated starter culture. In some embodiments, the starter culture is used in direct inoculation of fermentation medium or product. In some embodiments, the starter culture comprises a pure culture (i.e., comprising only one bacterial strain). In some alternative embodiments, the starter culture is a mixed culture (i.e., comprising !0 at least two different bacterial strains). Lactic Acid Bacteria Particularly suitable starter cultures, in particular dried starter cultures, for use in the present invention comprise lactic acid bacteria. !5 As used herein the term "lactic acid bacteria" refers to Gram positive, microaerophillic or anaerobic bacteria which ferment sugar with the production of acids including lactic acid as the predominantly produced acid, acetic acid, formic acid and propionic acid. The industrially most useful lactic acid bacteria are found among Lactococcus species, such as Lactococcus lactis, Lactobacillus species, Bifidobacterium species, Streptococcus species, Leuconostoc species, Pediococcus species and 30 Propionibacterium species. The starter cultures of the present invention may comprise one or more lactic acid bacteria species such as, Lactococcus lactis, Lactobacillus delbrueckii subsp. bulgaricus and Streptococcus thermophilus or combinations thereof. Lactic acid bacteria starter cultures are commonly used in the food industry as mixed strain 35 cultures comprising one or more species. For a number of mixed strain cultures, such as yoghurt starter cultures comprising strains of Lactobacillus delbrueckii subsp. bulgaricus and Streptococcus thermophilus, a symbiotic relationship exists between the species wherein the production of lactic acid is greater compared to cultures of single strain lactic acid bacteria (See e.g., Rajagopal et al., J.Dairy Sci., 73:894-899 [1990]). 40 Products 93 5 Suitable products for use in the present invention include, but are not limited to, a foodstuffs, cosmetic products or pharmaceutical products. Any product, which is prepared from, or comprises, a culture is contemplated in accordance with the present invention. These include, but are not limited to, fruits, legumes, fodder crops and vegetables including derived products, grain and grain-derived products, dairy foods and dairy food-derived products, meat, poultry, seafood, cosmetic and [0 pharmaceutical products. The term "food" is used in a broad sense and includes feeds, foodstuffs, food ingredients, food supplements, and functional foods. As used herein the term "food ingredient" includes a formulation, which is or can be added to foods and includes formulations which can be used at low levels in a wide variety of products that require, for [5 example, acidifying or emulsifying. As used herein, the term "functional food" means a food which is capable of providing not only a nutritional effect and/or a taste satisfaction, but is also capable of delivering a further beneficial effect to consumer. Although there is no legal definition of a functional food, most of the parties with an interest in this area agree that there are foods marketed as having specific health effects. !0 The term "food" covers food for humans as well as food for animals (i.e., a feed). In a preferred aspect, the food is for human consumption. In some embodiments, the cells described herein comprise or are added to a food ingredient, a food supplement, or a functional food. In some embodiments, the food is in a liquid form (e.g., a solution), gel, emulsion, or solid, as called for by the mode of application and/or administration. !5 The cells described herein find use in the preparation of food products such as one or more of: confectionery products, dairy products, meat products, poultry products, fish products and bakery products. In some embodiments, the bacteria find use as ingredients to soft drinks, fruit juices, beverages comprising whey protein, health teas, cocoa drinks, milk drinks, lactic acid bacteria drinks, yoghurt, drinking yoghurt, and wine, etc. 30 There is also provided a method of preparing a food, the method comprising admixing the cells according to the present invention with a food ingredient (such as a starting material for a food). The method for preparing a food is also another aspect of the present invention. Suitably a food as described herein is a dairy product. In some preferred embodiments, the dairy product is yoghurt, cheese (e.g., acid curd cheese, hard cheese, semi-hard cheese, cottage cheese, etc.), 35 buttermilk, quark, sour cream, kefir, creme fraiche, fermented whey-based beverage, koumiss, milk drink, or yoghurt drink. As used herein the term term "food" is very broad sense, as it is intended to cover food for humans as well as food for non-human animals (i.e., feed). In some preferred embodiments, the food is for human consumption. The term "feed ,"as used herein includes raw and processed plant material and 40 non-plant material. The term encompasses any feed suitable for consumption by an animal, including, but not limited to livestock, poultry, fish, crustacean, and/or pets.

94 5 Development of Phage-Resistant Strains and Starter Cultures During the development of the present invention, phage resistance involving the CRISPR-cas genes, as well as their role in resistance to incoming alien DNA and on the role of the spacers inserted within the CRISPR on the specificity of this resistance, have been elucidated. Importantly, the present [0 invention provides methods and compositions for the development of phage-resistant strains and starter cultures. In some embodiments, a parental strain "A" is exposed to phage "P" and a phage resistant variant (Variant "A1.O") selected. Variant A1.0 is analyzed (for example by PCR, and/or DNA sequencing) to confirm the presence of an additional inserted spacer within a CRISPR locus. The nucleotide sequence of the additional spacer (Spacer Spl.0) is then determined. Typically, spacer Spi.0 [5 is a fragment of approximately 30 nucleotides in size from the phage P, and gives resistance to phage P and related phages ("related phages" are those containing the sequence of the spacer in their genomes, and define a family of phages). Independently from the first phage exposure, the same parental strain A is exposed to the same phage P and a second phage resistant variant (Variant A2.0) is selected. Variant A2.0 is selected in order !0 to also have an additional spacer inserted (Spacer Sp2.0) within a CRISPR locus but with the sequence of spacer Sp2.0 being different from that of spacer Spi.O. Typically, spacer Sp2.0 is a fragment of approximately 30 nucleotides in size from the phage P, and gives resistance to phage P and related phages. Similarly, in some embodiments, variant A3.0 to variant Ax.0 are generated through the exposure of the same strain A to the same phage P. All the "A" variants are selected in order to also have !5 an additional spacer inserted (Spacer Sp3.0 to Spx.0) within a CRISPR locus but with the sequence of all the "Sp" spacers being different from each of the others. Typically, "Sp" spacers are fragments of approximately 30 nucleotides in size from the phage P, and all give resistance to phage P and related phages. Although these variants are useful, they are limited in terms of the scope of their resistance. 30 Thus, in some embodiments, it is advantageous to develop second level phage resistant strains. Indeed, it is advantageous to further develop these phage resistant variants by increasing and expanding their resistance to phages. Typically, it can be estimated that the level of resistance will be approximately that of a single mutation occurring within the phage genome within the sequence corresponding to the spacer (i.e., roughly 104 to 10-6). Consequently, phage resistant strains that accumulate different spacers within 35 the CRISPR locus have an increased level of resistance to the phage containing the sequence of these spacers within their genome (i.e., since multiple single mutations need to occur within the phage genome). In some embodiments, the second level variants are produced by isolating a mutated phage through exposure of variant A1.0 to phage P. Typically, this mutated phage (phage P1.0) has a mutation 40 (deletion, point mutation, etc.) in its genome within the region containing the sequence of spacer Spi.0. Variant A1.0 is sensitive to phage P1.0. Then, variant A1.0 is exposed to phage P1.0 and a phage 95 5 resistant variant (Variant A1.1) selected (See, Figure 15). Variant A1.1 is also selected such that it has an additional spacer inserted (Spacer Spl.1) within a CRISPR locus but with the sequence of spacer Spi.1 being different from that of spacers Spl.0, Sp2.0 to Spx.0. Typically, spacer Spi.1 is a fragment of approximately 30 nucleotides in size from the phage P1.0, and will give resistance to phage P1.0 and related phages. Variant A1.1 is resistant to phage P1.0 and preferably, has an increased resistance to [0 phage P because of the accumulation of spacer Sp1.0 and Sp1.1. In additional embodiments, a newly mutated phage (phage Pl.1) is generated through exposure of variant A1.1 to phage P1.0. Then, upon exposure of variant A1.1 to phage P1.1 a new variant A1.2 is obtained that contains one new additional spacer (Spl.2). This spacer gives resistance to phage P1.1 and preferably increases the resistance to phage P1.0 and P (i.e., due to the accumulation of spacers Spl.0, [5 Spl.1, Spl.2). In yet additional embodiments, different spacers (e.g., 2, 3 or 4) are iteratively accumulated within strain A through variant A1, then variant A1.1, then variant A1.2, etc to obtain a variant highly resistant to phages (variant Al.n). In still further embodiments, additional different spacers can be accumulated in the same strain through variant A2, then variant A2.1, then variant A2.2, etc to generate another variant of strain A highly resistant to phages (variant A2.n) in parallel. The same !0 strategy finds use with variants A3.0 to Ax.0 In some embodiments, strains that are resistant to more than one family of phages are provided. As a given strain can be sensitive to more than one family of phages, in some embodiments, it is desired to enlarge the strain resistance to multiple phage families by introducing additional spacer(s) within a CRISPR locus originating from the other families of phages (See, Figure 16). For example, phages P, Q, !5 and R are representative phages from three families of phages able to infect strain A. Using the method outlined above and herein, variants resistant to all three phage families are produced. In some embodiments, phage P is used to generate variant A1p (containing spacer Spl) that is resistant to phage P. Then, variant A1P is exposed to phage Q and a phage resistant variant (Variant A1Pq) is selected. Variant A1pq has one additional spacer (Sql) inserted within a CRISPR locus. Typically, spacer Sql is a 30 fragment of approximately 30 nucleotides in size from the phage Q, and gives resistance to phage Q and related phages. Variant A1p t is resistant to both P and Q phages. Next, variant A1p t is exposed to phage R and a phage resistant variant (Variant A1Pq') is selected. Variant A1 p'has a third additional spacer (Sri) inserted within a CRISPR locus. Typically, Sri is a fragment of approximately 30 nucleotides in size from the phage R, and also gives resistance to phage R and related phages. Variant A 1 P r is resistant 35 to all three phages. In some particularly preferred embodiments, the variant is also resistant to related phages. In additional embodiments, the above methods are used in combination to produce increased and expanded resistance to phages. In some particularly preferred embodiments, these variants have high resistances to multiple phage families. In still further embodiments, strains are produced that are resistant 40 to particular phages or families of phages that are problematic in particular factories and/or fermenters.

96 5 CRISPR-Mediated Immunity and Applications for Phage-Resistant Strains In contrast to the teachings of the prior art which hypothesize that CRISPR or CRISPR spacers could be involved in conferring specific immunity, the present invention is based, in part, on the surprising finding that cas genes or proteins are required for immunity against a target nucleic acid or a transcription product thereof. However, it is not intended that the present invention be limited to any [0 particular mechanism, function, nor means of action. Even more surprisingly, during the development of the present invention, it was found that one or more cas genes or proteins are associated with two or more CRISPR repeats within CRISPR loci. In other words, cas genes or proteins appear to be specific for a given DNA CRISPR repeat, meaning that cas genes or proteins and the repeated sequence form a functional pair. Accordingly, one or more [5 CRISPR spacers find use together with one or more of these functional pairs (i.e., CRISPR repeats and cas genes) in order to modulate the resistance of a cell against a target nucleic acid or a transcription product thereof. In one embodiment, for one or more CRISPR spacers to confer immunity to the cell, the CRISPR repeat(s) and the cas gene(s) or proteins form a functional combination (i.e., the CRISPR repeat(s) and !0 the cas gene(s) or proteins are compatible). In additional preferred embodiments, the present invention provides cas genes/proteins that influence resistance of bacteria to phages. In additional further preferred embodiments, the present invention provides at least two CRISPR repeats and at least one cas gene/protein useful in predicting, determining and/or modifying bacterial resistance to phages. Indeed, the present invention provides !5 methods for modifying the lysotype (i.e., the resistance/sensitivity to various phages) of bacteria. Consequently, identification and detection of CRISPR loci in cells and phages provides means to determine, predict and modify the resistance profile of cells, as well as phage-host interactions. Advantageously, the application of one or more CRISPR loci, two or more CRISPR repeats, one or more cas genes or proteins and/or one or more CRISPR spacers in genetic engineering provides means 30 to produce resistant or sensitive variants of cells for use within a wide variety of applications in the biotechnology industry. As discussed in greater detail below, phages are natural parasites of bacteria that may develop during fermentation. Upon infection by phages, bacteria are killed, which impairs the fermentation process. In dairy fermentation, these phage infections often have major economic impacts, ranging from 35 a reduced quality of the fermented product up to the complete loss of the product. To overcome phage problems, starter culture companies have developed various strategies. Traditional starter culture programs have depended on phage defence rotation strategies (PDRS) to minimize failures due to phage attack (See e.g., Klaenhammer, Adv. Appl. Microbiol., 30:1 [1984]; Lawrence et al., J. Dairy Res. 43:141 [1976); and Whitehead and Hunter, J. Dairy Res., 15:112 [1947]). 40 These strategies rely on multiple genetically unrelated strains that are likely to present different spectrum of phage sensitivity (i.e., different lysotypes). When a phage appears during a fermentation process using 97 5 a defined strain, a strain which is ideally of a different lysotype (i.e., with a different sensitivity pattern to phages) is use in replacement for the fermentation. History has proven, however, that it is difficult to identify sufficient numbers of different lysotypes to successfully utilize these strategies. Indeed, many strains of industrial interest present rare functional traits (e.g., fast acidifying texturing S. thermophilus). In addition, not all of the strains present appropriate traits for being produced as starter cultures. Further, [0 because of their rareness and the increase of the size of dairy factories, these strains are intensively used. There are additional problems with traditional starter culture rotation strategies. Although some stains are not attacked by existing phages when introduced, phage often eventually appear due to phage mutation, modification, and build-up that attack the newly introduced strain (See e.g., Heap and Lawrence, N.Z.J. Dairy Sci. Technol., 11:16 [1976]; Limsowtin and Terzaghi, N.Z.J. Dairy Sci. [5 Technol., 11:251 [1976]; Pearce, N.Z.J. Dairy Sci. Technol., 13:166 [1978]; and Sanders and Klaenhammer, Appl. Environ. Microbiol., 40:500 [1980]). Moreover, in many cases, the longevity and starter activity of complex strain rotations is unpredictable and often leads to early failure (See e.g., Limsowtin et al., N.Z.J. Dairy Sci. Technol.,13:1 [1977]; and Thunell et al., J. Dairy Sci., 64, 2270 [1981]). Furthermore, prolonged rotations involving numerous strains increase the level and diversity of !0 phage contaminating the plant (See e.g., Heap and Lawrence, N.Z.J. Dairy Sci. Technol., 12:213 [1981]; Lawrence et al., J. Dairy Sci., 61:1181 [1978]; and Thunell et al., J. Dairy Sci. 64, 2270 [1981]). In order to fight phage proliferation, traditional starter culture programs have depended on the use of strains presenting the same or similar technological functionalities but different phage sensitivities. The strains are used in rotation to perform successive fermentation. These programs traditionally rely on !5 multiple genetically unrelated strains that consequently presents different spectrum of phage sensitivity (lysotype). Alternative approaches (See e.g., US Patent 5,593,885) utilizes starter culture programs based on the use of sets of isogenic strains that present different phage sensitivity, instead of genetically unrelated strains presenting different lysotypes. The term "set of isogenic strains" as used herein defines strains that are identical from a chromosomal point of view but that each differs by the presence of one or 30 more phage resistance mechanisms that are plasmid-borne. In such starter culture rotation program, when a phage appears during a fermentation process using a defined strain, a strain which is ideally of a different lysotype (i.e., with a different spectrum of sensitivity to phages) is used in replacement for the fermentation. Due to this different lysotype, the second strain is not affected by the phages that stay dormant in the environment. Most of the population of dormant phages are then be washed out by 35 successive fermentation and sanitation, and eradicated by the time the first strain is used again for the fermentation, if the system works as intended. The present invention provides improved methods and compositions suitable for addressing these problems in the fermentation industry. Indeed, the present invention provides methods and compositions for the fermentation industry, and in particular the dairy industry with a selection of strains suitable to 40 fulfill the needs of phage defence rotation strategies. In addition, the present invention provides methods and compositions suitable to customize strains having lysotypes that are adapted to a particular phage 98 5 environment. In particular, the present invention provides methods and compositions suitable for directing the evolution of a given strain to various lysotypes, in order to produce strains that differ from each others only by their spectrum of phage sensitivity (lysotype). This difference of lysotype is a function of the CRISPR-cas system, as described herein. In some preferred embodiments, different lysotypes are obtained through the "modulation" of phage resistance. In some particularly preferred [0 embodiments, although the lysotypes are different, strains of this type have identical metabolism (e.g., of carbon, nitrogen, etc.) and thus identical functionalities (e.g., acidification, flavour, texture, etc.). This provides means for amplifying the construction of starter rotation. In addition, industrial processability of the phage resistant strain are identical (e.g., nutrition needs, resistance to processing operation, etc.), thus reducing the need of development of specific production processes. Indeed, the present invention [5 provides methods and compositions suitable for minimizing fermentation failures due to phage attack. In some embodiments, methods and compositions are provided for the production of highly phage resistant starter cultures, by the association of multiple phage resistant strains differing by their lysotype. In some alternative embodiments, methods and compositions are provided to produce starter cultures with strictly identical industrial functionalities to be used in rotation dairy fermentation. In further embodiments, !0 methods and compositions are provided that are suitable to replace existing starters by preventing frequent phage attacks in dairy plants, by introducing a new bacterial strain that is resistant to the phages involved in these phage attack. In some embodiments, these methods and compositions are used iteratively, in order to combat sequential phage attacks. In some additional embodiments, the starter culture is a mixed bacterial culture. In some !5 particularly preferred embodiments, the starter comprises equal amounts of multiple (i.e., at least 2) phage resistant variants that only differ in their CRISPRs and their sensitivity to phages. In some embodiments, these variants are of the first level of phage resistant variants (e.g., variants A1.0 plus A2.0, as described above). In some preferred embodiments, the variants are selected from those in the second level of phage resistant variants (e.g., variants A1.4 plus A2.4, as described above). In some 30 particularly preferred embodiments, the variants are selected among the third level of phage resistant variants. In such mixed bacterial cultures, when one of the variants is attacked by a given phage the other variants are not be attacked by the phage, due to their different phage sensitivities and the fermentation is not adversely affected. In some further embodiments, a principal starter and a back-up starter are used. The principal 35 starter is composed of a single strain. In some embodiments, this strain is of the first level of phage resistant variants, while in other preferred embodiments the strain is of the second level, and in still other more preferred embodiments, the strain is of the third level. In some preferred embodiments, the back up starter is based on a phage resistant variant obtained independently from the same parental strain. This second phage resistant variant differs from the other variant by its CRISPRs and is of the first level of 40 phage resistant variants, while in other preferred embodiments the strain is of the second level, and in still other more preferred embodiments, the strain is of the third level. For example, in some embodiments, 99 5 the principal starter is made of variant A1.4 and the back-up starter is made of strain A2.4. Upon first appearance of a phage during fermentation with the principal starter, this starter is discarded and replaced by the back up starter. In some more preferred embodiments, a third starter is also prepared as the back up starter that will serve as a back up for the back up. In some preferred embodiments, the starters are each made of multiply phage-resistant variants. [0 In yet further embodiments, the present invention provides methods and compositions suitable in rotation strategies. In some embodiments, instead of discarding the starter often attacked by phages, the starters are used in a cyclic way even if phage attack is observed. This strategy limits the number of starters to be developed. In some particularly preferred embodiments, the starters are each made of multiple phage resistant strains instead of a single one. This provides increased robustness to emerging [5 phage. In still further embodiments, customized starters are provided. In some preferred embodiments, the phage resistant variants are produced to specifically combat phages that are present in a given fermentation plant or facility. TYPING !0 In a further aspect of the present invention, there is provided a method for identifying (eg. typing) a labelled bacterium. In one embodiment, the identification step is performed by amplifying (eg. PCR amplifying) the CRISPR locus or a portion thereof. A first primer may be designed to hybridize to a sequence that is located upstream of the first !5 CRISPR repeat of a CRISPR locus. By way of example, the first primer may hybridize to part of the common leader sequence of the CRISPR locus. By way of further example, the first primer may hybridize to a neighboring gene that is located upstream of the CRISPR locus. The second primer may hybridize downstream from at least the first CRISPR spacer or the at least first CRISPR spacer core. The second primer may hybridize as far as in the trailer or even in a 30 downstream neighboring gene. Preferably, the second primer hybridizes within the CRISPR locus. Preferably, the second primer hybridizes at least partially to a downstream CRISPR spacer or CRISPR spacer core. Following amplification, the tagging sequence may be identified using various methods that are known in the art. 35 By way of example, the tagging sequence may be identified by determining the amplification product restriction pattern. Accordingly, once the DNA comprising the CRISPR locus or a portion thereof has been amplified, it may be digested (eg. cut) with one or more restriction enzymes. As used herein, the term "restriction enzymes" refers to enzymes (eg. bacterial enzymes), each of which cut double-stranded DNA at or near a specific nucleotide sequence. Restriction enzymes are well 40 known in the art and may be readily obtained, for example, from variety of commercial sources (for example, New England Biolabs, Inc., Beverly, Massachusetts). Similarly, methods for using restriction 100 5 enzymes are also generally well known and routine in the art. Restriction enzymes that produce between 10 and 24 fragments of DNA when cutting the CRISPR locus or a portion thereof may be used. Examples of such enzymes include, but are not limited to, AluI, MseI, and Tsp5091. Fragments of DNA obtained using restriction enzymes may be detected, for example, as bands by gel electrophoresis. Restriction enzymes may be used to create Restriction Fragment Length Polymorphisms (RFLPs). [0 RFLPs are generated by cutting ("restricting") a DNA molecule with a restriction endonuclease. Many hundreds of such enzymes have been isolated, as naturally made by bacteria. In essence, bacteria use such enzymes as a defensive system, to recognise and then cleave (restrict) any foreign DNA molecules that might enter the bacterial cell (e.g., a viral infection). Each of the many hundreds of different restriction enzymes has been found to cut (i.e., "cleave" or "restrict") DNA at a different [5 sequence of the 4 basic nucleotides (A, T, G, C) that make up all DNA molecules, e.g., one enzyme might specifically and only recognise the sequence A-A-T-G-A-C, while another might specifically and only recognise the sequence G-T-A-C-T-A, etc. Depending on the unique enzyme involved, such recognition sequences may vary in length, from as few as 4 nucleotides to as many as 21 nucleotides. The larger the recognition sequence, the fewer restriction fragments will result, as the larger the '0 recognition site, the lower the probability that it will repeatedly be found throughout the DNA. By way of further example, the tagging sequence may be identified by determining or also determining the difference in size of the amplification product. Separation may be achieved by any method suitable for separating DNA, including, but not limited to, gel electrophoresis, high performance liquid chromatography (HPLC), mass spectroscopy, and !5 use of a microfluidic device. In one embodiment, the amplification products or DNA fragments are separated by agarose gel electrophoresis. Gel electrophoresis separates different sized charged molecules by their rate of movement through a stationary gel under the influence of an electric current. These separated amplification products or DNA fragments can easily be visualised, for example, by staining with ethidium bromide and by viewing the gel under UV illumination. The banding pattern reflects the 30 sizes of the restriction digested DNA or the amplification products. By way of further example, the tagging sequence may be identified by sequencing the amplification products. The sequence of the amplified products may be obtained by any method known in the art, including automatic and manual sequencing methods. See, for example, Sambrook et al. (1989) 35 Molecular Cloning: A Laboratory Manual (2d ed., Cold Spring Harbor Laboratory Press, Plainview, New York; Roe et al. (1996) DNA Isolation and Sequencing (Essential Techniques Series, John Wiley & Sons). Hybridisation methods are also within the scope of the present invention, either using a nucleic acid molecule as a probe, or a nucleic acid molecule capable of hybridising to a particular nucleotide 40 sequence. See, for example, Sambrook et al. (1989) Molecular Cloning: Laboratory Manual (2d ed., Cold Spring Harbor Laboratory Press, Plainview, New York).

101 5 In hybridisation techniques, the hybridisation probe(s) may be genomic DNA fragments, PCR amplified products, or other oligonucleotides, and may comprise all or part of a known nucleotide sequence. In addition, it may be labelled with a detectable group such as 1P, or any other detectable marker, such as other radioisotopes, a fluorescent compound, an enzyme, or an enzyme co-factor. The term "labelled," with regard to the probe, is intended to encompass direct labelling of the probe by [0 coupling (i.e., physically linking) a detectable substance to the probe, as well as indirect labelling of the probe by reactivity with another reagent that is directly labelled. Examples of indirect labelling include end-labelling of a DNA probe with biotin such that it can be detected with fluorescently labelled streptavidin. Methods that encompass hybridisation techniques to detect or differentiate bacterial strains are [5 also encompassed. These include, but are not limited to, Southern blotting (see, for example, Van Embden et al. (1993) J. Clin. Microbiol. 31:406-409), shift mobility assays (see, for example, U.S. Published Application No. 20030219778), sequencing assays using oligonucleotide arrays (see, for example, Pease et al. (1994) Proc. Natl. Acad. Sci. USA 91:5022-5026), spoligotyping (see, for example, Kamerbeek et al. (1997) J. Clin. Microbiol. 35:907-914), Fluorescent In Situ Hybridization (FISH) (see, !0 for example, Amann et al. (1990) J. Bacteriol. 172:762-770) and heteroduplex tracking assays or heteroduplex mobility analysis (see, for example, White et al. (2000) J. Clin. Micro. 38:477-482). The tagging sequence that is identified may be compared to with a phage sequence database and/or a bacterial sequence database. Typically, the tagging sequence will match with one or more sequences in the phage sequence database but not with the bacterial sequence database. !5 As new labeled bacteria are prepared using the methods described herein, a database of labels may be created allowing for the specific identification of bacteria that have been labeled. In one aspect there is provided the use of a sequence obtained or obtainable from a bacteriophage (e.g., in the manufacture of a labelled bacterium) for labelling and/or identifying a bacterium, wherein said sequence is integrated at one end of the CRISPR locus of the parent bacterium. 30 In a further aspect there is provided the use of a sequence obtained or obtainable from a bacteriophage (eg. in the manufacture of a labelled bacterium) for labelling and/or identifying a bacterium, wherein said sequence comprises: (i) at least one sequence that is homologous (eg. identical) to a CRISPR repeat in the CRISPR locus of said bacterium; and (ii) a tagging sequence. In a further aspect, there is provided the use of a sequence for labelling and/or identifying a 35 bacterium (eg. in the manufacture of a labelled bacterium), wherein said sequence is obtained or obtainable by: (a) exposing a parent bacterium to a bacteriophage; (b) selecting a bacteriophage insensitive mutant; (c) comparing the CRISPR locus or a portion thereof from the parent bacterium and the bacteriophage insensitive mutant; and (d) selecting a sequence in the CRISPR locus or a portion thereof of the bacteriophage insensitive mutant that is not present in the parent bacterium. 40 102 5 CRISPR and Eukaryotes As detailed herein, CRISPR has been shown to provide resistance against incoming nucleic acid in prokaryotes. Specifically, it was shown that CRISPR spacers showing homology to viral DNA (e.g., bacteriophage nucleic acid) provide resistance against the virus sharing sequence identity with at least one spacer sequence. However, it is also contemplated that the CRISPR system, including cas genes [0 and/or proteins along with spacers, repeats, leader and trailer to cells not currently containing CRISPR loci will find use in providing resistance against nucleic acid de novo. Indeed in some embodiments, such manipulations find use with various eukaryotes, including but not limited to humans, other animals, fungi, etc. It is contemplated that the CRISPR system be transferred into eukaryotic cells utilizing any suitable method known in the art, including, but not limited to transformation via plasmids. In these [5 embodiments, the CRISPR loci, as well as necessary transcription/translation signals are included in the plasmid DNA, to all for expression and function of the sequences in eukaryotic cells. In some additional embodiments, the spacer sequences are engineered such that they have identity with viral sequences of interest infect the host involved. In some preferred embodiments, these methods and compositions provide resistance to the host cell against viruses that share sequence identity !0 with the CRISPR spacer introduced into the cell. In some particularly preferred embodiments, the viruses include, but are not limited to HIV, orthomyxoviruses, paramyxoviruses, pseudomyxoviruses, RSV, influenza, rubeola, varicella, rubella, coronaviruses, hepatitis viruses, caliciviruses, poxviruses, herpesviruses, adenoviruses, papovaviruses, papillomaviruses, enteroviruses, arboviruses, rhabdoviruses, arenaviruses, arboviruses, rhinoviruses, reoviruses, coronaviruses, reoviruses, rotaviruses, retroviruses, !5 etc. In further embodiments, specific targeting of highly conserved nucleic acid sequences in CRISPR spacers provides increased resistance against such viruses in eukaryotic cells. In some particularly preferred embodiments, the eukaryotic cells are human cells. CRISPR and Generation of Phage-Resistant Mutants 30 During the development of the present invention, experiments were conducted to determine whether CRISPR loci are altered during the natural generation of phage-resistant mutants. A phage-host model system was selected, consisting of a phage-sensitive wild-type S. thermophilus strain widely used in the dairy industry, DGCC7710 (WT) and two distinct, but closely related virulent bacteriophages isolated from industrial yogurt samples, namely phage 858 and phage 2972 (Levesque et al., Appl. 35 Environ. Microbiol., 71:4057 [2005]). Nine phage-resistant mutants were independently generated by challenging the WT strain with phage 858, phage 2972 or simultaneously with both, and their CRISPR loci were analyzed. Differences were consistently observed at the CRISPRI locus, where 1 to 4 additional spacers were inserted next to the 32 spacers present in the WT strain (See, Figure 9). The addition of new spacers in response to phage infection appeared to be polarized towards one end of the 40 CRISPRI locus. This is consistent with previous observations of spacer hypervariability at the leader end of the CRISPR locus in various strains (See e.g., See, Pourcel et al., Microbiol., 151:653 [2005]; and 103 5 Lillestol et al., Archaea 2:59 [2006]). Sequence analysis of the additional spacers inserted in the CRISPRi locus of the various phage-resistant mutants revealed similarity to sequences found within the genomes of the phages used in the challenge. Similarities were observed throughout the phage genomes, in most functional modules, both on the coding and non-coding strands. No particular sequence, gene or functional group seemed to be targeted specifically. These results indicate that upon becoming resistant [0 to bacteriophages, the CRISPRi locus was modified by the integration of novel spacers apparently derived from phage DNA. However, it is not intended that the present invention be limited to any specific mechanism. Surprisingly, it was observed that some strains were resistant to both phages while others were resistant only to the phage used in the challenge (See, Figure 9). The phage-resistance profile seemed to [5 be correlated to the spacer content whereby strains with spacers showing 100% identity to sequences conserved in both phages were resistant to both phages, such as spacers S3, S6 and S7. In contrast, when nucleotide polymorphisms were observed between the spacer and the phage sequence (from 1 to 15 SNPs over 29 or 30 nucleotides), the spacer did not seem to provide resistance, such as spacers S1, S2, S4, S5 and S8 (See, Figure 9). !0 Additionally, when several spacers were inserted (S9-S14), phage-resistance levels were higher. These findings indicate that the CRISPRi locus is subject to dynamic and rapid evolutionary changes driven by phage exposure. These results indicate that CRISPR loci can indeed be altered during the generation of phage-resistant mutants and establish a link between CRISPR content and phage sensitivity. Thus, it is contemplated that the presence of a CRISPR spacer identical to a phage sequence !5 provides resistance against phages containing this particular sequence. To determine whether CRISPR spacer content defines phage resistance, the CRISPRi locus was altered by adding and deleting spacers, and the strain sensitivity to phages was tested. All constructs were generated and integrated into the S. thermophilus chromosome using methods known in the art (See e.g., Russell and Klaenhammer, Appl. Environ. Microbiol., 67:4361 [2001]). The spacers and repeats in 30 the CRISPRi locus of strain WT 858Ssis2 were removed and replaced with a single repeat without any spacer. The resulting strain WT 858+S iS2 CRISPRi was sensitive to phage 858, indicating that the phage resistance of the original phage-resistant mutant (WT 858+S 2) was probably linked to the presence of S1 and S2 (See, Figure 10). In addition, to determine whether adding spacers provides novel phage resistance, the CRISPRi 35 locus of strain WT 2972+S4 was replaced with a version only containing spacers S1 and S2. The phage sensitivity of the resultant construct was then tested. The resulting strain WT 2972+S4 ::pS 1S2 gained resistance to phage 858, suggesting that these two spacers have the ability to provide phage resistance de novo (See, Figure 10). These observed modifications establish a link between the CRISPR spacer content and phage resistance. 40 In the process of generating strain WT 8 5 8 +SiS2 CRISPRi, WT 858+S is2::pR, a variant that contains the integration vector with a single repeat inserted between the cas genes and the native 104 5 CRISPRI locus was created (See, Figure 10). Unexpectedly, strain WT 858+S is2::pR was sensitive to phage 858, although spacers Si and S2 remained present on the chromosome (See, Figure 10). Similarly, the WT 2972+S4 ::pS1S 2 construct lost the resistance to phage 2972, although spacer S4 is present in the chromosome (See, Figure 10). These results indicated that spacers alone did not provide resistance, and perhaps they have to be in a particular genetic context to be effective. [0 Although early experiments suggested involvement in DNA repair (Makarova et al., Nucl. Acids Res., 30:482 [2002]), the current hypothesis is that cas genes (Jansen et al., Mol. Microbiol., 43:1565 [2002]; and Haft et al., PloS Comput. Biol., 1:e60 [2005]) are involved in CRISPR-mediated immunity (Makarova et al., Biol. Direct. 1:7 [2006]). In additional experiments, two cas genes in strain WT 858+Sis2 were inactivated, namely cas5 (COG3513) and cas7, which are equivalent to [5 strO657/stuO657 and str0660/stuO660, respectively (See, Bolotin et al., Nat. Biotechnol., 22:1554 [2004]; and Bolotin et al., Microbiol., 151:2551 [2005]). The cas5 inactivation resulted in loss of the phage resistance (See, Figure 10). In addition, it is possible that Cas5 acts as a nuclease, since it contains a HNH-type nuclease motif. In contrast, inactivating cas7 did not alter the resistance to phage 858 (See, Figure 10). However, it is not intended that the present invention be limited to any particular mechanism. !0 In addition, experiments to generate CRISPRI phage-resistant mutants from the cas7 knockout did not work. Although it is not intended that the present invention be limited to any particular mechanism, this may be because Cas7 is involved in the synthesis and/or insertion of new spacers and additional repeats. Upon testing sensitivity of the phage-resistant mutants, it was found that plaque formation was dramatically reduced, but that a relatively small population of bacteriophage retained the ability to infect !5 the mutants. Phage variants derived from phage 858 that retained the ability to infect WT 858+Si s 2 were further analyzed. In particular, the sequences of the genome region corresponding to additional spacers S1 and S2 in two virulent phage variants were investigated. In both cases, the genome sequence of the phage variant was mutated and two distinct single nucleotide polymorphisms were identified in the sequence corresponding to spacer S1 (See, Figure 13). 30 Overall, prokaryotes appear to have evolved a nucleic-acid based "immunity" system whereby specificity is dictated by the CRISPR spacer content, while the resistance is provided by the Cas enzymatic machinery. Additionally, it was speculated that some of the cas genes that do not directly provide resistance are actually involved in the insertion of additional CRISPR spacers and repeats, as part of an adaptive "immune" response. This nucleic-acid based system contrasts with amino-acid based 35 counterparts in eukaryotes whereby adaptative immunity is not inheritable. The inheritable nature of CRISPR spacers supports the use of CRISPR loci as targets for evolutionary, typing and comparative genomic studies (See, Pourcel et al., supra; Groenen et al., Mol. Microbiol., 10:1057 [1993]; Mongodin et al., J. Bacteriol., 187:4935 [2005]; and DeBoy et al., J. Bacteriol., 188:2364 [2006]). Because this system is reactive to the phage environment, it likely plays a significant role in prokaryotic evolution and 40 ecology and provides a historical perspective of phage exposure, as well as a predictive tool for phage sensitivity. However, it is not intended that the present invention be limited to any particular mechanism.

105 5 Nonetheless, the present invention provides methods and compositions for utilizing the CRISPR/cas system as a virus defense means, and also potentially to reduce the dissemination of mobile genetic elements and the acquisition of undesirable traits such as antimicrobial resistance genes and virulence markers. In some embodiments, it is further contemplated from a phage evolution perspective, the integrated phage sequences within CRISPR loci also provide additional anchor points to facilitate [0 recombination during subsequent phage infections, thus increasing the gene pool to which phages have access (See, Hendrix et al., Proc. Natl. Acad. Sci. USA 96:2192 [1999]). Since CRISPR loci are found in the majority of bacterial genera, and are ubiquitous in Archaea (See, Jansen et al., supra; Lillestol et al., supra; and Goode and Bickerton J. Mol. Evol., 62:718 [2006]), they provide new insights in the relationship and co-directed evolution between prokaryotes and their predators. -5 Biocontrol Phages The present invention also provides methods and compositions for the development of phages as biocontrol agents. As indicated herein, bacteria can become resistant to phage attack by incorporating phage derived sequences (spacers) into an active CRISPR loci. Phage can escape this resistance by !0 mutation within the genome sequence corresponding to the spacer or the CRISPR motif recognition sequence that corresponds to a given Cas-CRISPR system. Through iterative rounds of phage challenge to create host strain CRISPR-mediated phage resistant derivatives and isolation of phage escape mutants, the present invention provides phages that have been altered within CRISPR target sequences and/or putative CRISPR recognition sites that direct spacer insertion. Further, the present invention provides !5 phages that have been synthetically designed such that the CRISPR motif sequence for a given Cas CRISPR system has been eliminated. These "altered" phages, applied as a cocktail or in a "sequential rotation scheme" reduce the ability of target bacteria to adapt resistance via the CRISPR system. Indeed, the present invention provides a diverse set of virulent phage for use as biocontrol agents. In particularly preferred embodiments, this diversity is targeted at the CRISPR directed mechanism of phage resistance, 30 such that the ability of the host organism to rapidly evolve against phage attack (via CRISPR) is severely reduced or eliminated. The administration of the diverse phage, either as a cocktail or in a sequential rotation further reduces the possibility of the host organism to adapt or evolve CRISPR-directed phage resistance. Phages are natural antimicrobial agents that have been extensively studied as an alternative 35 therapeutic agent to antibiotics. This interest has been recently renewed, due to the proliferation of multiple-antibiotic resistant pathogens. As with antibiotics, bacteria have developed multiple mechanisms to overcome phage attack. The present invention provides methods and compositions involving the use of Cas-CRISPR in mediating phage resistance to generate a diverse phage population, to create synthetic phages devoid of CRISPR motif sequences, as well as methods for administering such 40 phage that will reduce the ability of a target organism to develop resistance against the phage.

106 5 As detailed herein, Cas-CRISPR systems have been described in a wide range of organisms which include examples of pathogenic genera. Upon phage infection, bacteria escaping lysis can be found to contain new spacer sequence(s) within a CRISPR locus. The new spacer is typically of a defined length that is characteristic for a given CRISPR locus and derived from the attacking phage genome to which it confers resistance. As the level of resistance conferred by a single spacer is often not complete, [0 phage can escape the mechanism. Analysis of "escape-phages" indicated that the genomes were mutated in or proximal to the corresponding spacer sequence found in the resistant host variant. Furthermore, the "escape-phages" are fully virulent to the CRISPR-mediated host variant from which they were derived. One unique aspect of therapeutic phage, distinguishing it from traditional antibiotics, is the ability to propagate exponentially in conjunction with the infected bacteria. While this can be [5 advantageous from a pharmacological perspective, it also provides unique opportunities for the phage to evolve towards adaptive response of the targeted bacteria to phage attack. Bacteria have developed several defense mechanisms against virulent phage. As indicated herein, the Cas-CRISPR loci play a role in conferring bacterial phage resistance. Following phage infection, analysis of surviving bacteria found that some isolates had inserted a new spacer element !0 within their resident CRISPR locus, the sequence of which was identical to that found in the corresponding phage genome. When challenged with phage, these first generation CRISPR-mediated phage resistant variants give rise to plaques; the phage of which were found to be fully infective on both parent and derivative. Analysis of these "CRISPR-escape" phage indicated that their genomes were mutated in the sequence corresponding to the CRISPR spacer harbored by the phage resistant variant or !5 in a proximal sequence believed to direct spacer insertion and identified as the CRISPR motif specific to a given Cas-CRISPR system. Therefore the "CRISPR-escape" phage is potentially more virulent than the parent and first-generation variants, as this phage is capable of infecting both the parent strain and the first generation CRISPR variant. As indicated above, CRISPR loci have been identified in several genera/species of bacteria that 30 include examples of known pathogens and spoilage microorganisms. Also as described herein, the present invention provides methods and compositions for utilization of CRISPR loci in combination with Cas proteins to confer "immunity" to invading foreign DNA, in particular, bacteriophages. Also as described herein, bacterial strains harbouring "active" CRISPR-cas loci containing a spacer that is identical to a corresponding sequence within a phage genome (i.e., a "protospacer"), confers upon that 35 bacterial strain, resistance to the phage. In some preferred embodiments, the genome sequences of the biocontrol phage are known. In some particularly preferred methods, the isolated target microorganism is examined for the presence of CRISPR loci. In some preferred embodiments, PCR using specific primers for conserved sequences that flank CRISPR loci of the target microorganism finds use. In some preferred embodiments, amplification product(s) are sequenced compared with the genome sequence of 40 the biocontrol phage. In some preferred embodiments, the generation of CRISPR phage resistant variants and analysis of the spacer / protospacer provides means to identify the specific CRISPR motif. Once 107 5 identified, the sequence information is used to design and synthesize a phage devoid of the CRISPR motif. Thus, the resulting phage is insensitive to CRSPR-cas mediated resistance. In these assessments, the absence of spacers with similarity to the phage genome indicates the susceptibility of the target microorganism to the biocontrol phage. Thus, the biocontrol phage has a greater degree of virulence and efficacy as a biocontrol agent. [0 The present invention provides methods and compositions suitable for use in the food, feed, medical and veterinary industries to generate phage with broader host range and method of application for more effective biocontrol of bacteria. The present invention provides means to produce a sufficient number of altered phage (in response to CRISPR) to significantly reduce the ability of the native bacteria to evolve an effective CRISPR-mediated resistance. The present invention also provides methods of [5 application/administration designed such that the rate of evolution by the native bacteria is significantly reduced. EXPERIMENTAL !0 The following examples are provided in order to demonstrate and further illustrate certain preferred embodiments and aspects of the present invention and are not to be construed as limiting the scope thereof. In the experimental disclosure which follows, the following abbreviations apply: 'C (degrees Centigrade); rpm (revolutions per minute); H 2 0 (water); HCl (hydrochloric acid); aa (amino acid); bp !5 (base pair); kb (kilobase pair); kD (kilodaltons); gm (grams); g and ug (micrograms); mg (milligrams); ng (nanograms); 1 and ul (microliters); ml (milliliters); mm (millimeters); nm (nanometers); m and um (micrometer); M (molar); mM (millimolar); M and uM (micromolar); U (units); V (volts); MW (molecular weight); sec (seconds); min(s) (minute/minutes); hr(s) (hour/hours); MOI (multiplicity of infection); EOP (efficiency of plaquing); PFU (plaque-forming units); MgCl 2 (magnesium chloride); 30 NaCl (sodium chloride); OD 4 20 (optical density at 420 nm); PAGE (polyacrylamide gel electrophoresis); EtOH (ethanol); PBS (phosphate buffered saline [ 150 mM NaCl, 10 mM sodium phosphate buffer, pH 7.2]); SDS (sodium dodecyl sulfate); Tris (tris(hydroxymethyl)aminomethane); w/v (weight to volume); v/v (volume to volume); Amicon (Amicon, Inc., Beverly, MA); ATCC (American Type Culture Collection, Manassas, VA); Amersham (Amersham Biosciences, Inc., Piscataway, NJ); NEB (New 35 England Biolabs, Beverly, MA); Becton Dickinson (Becton Dickinson Labware, Lincoln Park, NJ); BioRad (BioRad, Richmond, CA); Clontech (CLONTECH Laboratories, Palo Alto, CA); Difco (Difco Laboratories, Detroit, MI); GIBCO BRL or Gibco BRL (Life Technologies, Inc., Gaithersburg, MD); Sigma (Sigma Chemical Co., St. Louis, MO); and Sorvall (Sorvall Instruments, a subsidiary of DuPont Co., Biotechnology Systems, Wilmington, DE).

108 5 The present invention utilizes, unless otherwise indicated, conventional techniques of chemistry, molecular biology, microbiology, recombinant DNA and immunology, which are within the capabilities of a person of ordinary skill in the art. Such techniques are well known to those of skill in the art. As used herein, DGCC7710 is also referred to as "WT"; DGCC7710RH1 is also referred to as "DGCC7710-RH1" and "RHI"; DGCC7710RH2 is also referred to as "DGCC7710-RH2" and "RH-2"; [0 DGCC7778cas1 is also referred to as "DGCC7778cas1KO," "CASIKO," and "cas1 KO"; DGCC7778cas4 is also referred to as "DGCC7778cas4KO"; DGCC7778 is also referred to as "WT 858+S1S2"; DGCC7778RT is also referred to as "WT 858+S1S2::pR "; DGCC7778RT'is also referred to as "WT 858+S1S2 CRISPRI"; DGCC7710-R2 is also referred to as "WT 2972+S4"; and DGCC7710-R2S1S2 is also referred to as "WT 2 97 2 +S4::pS1S 2 ." [5 EXAMPLE 1 Manipulation of Phage-Specific Spacers !0 In this Example, experiments conducted to manipulate phage-specific spacers are described. In some experiments, a phage specific spacer was inserted into an existing, functional CRISPR to provide resistance to the corresponding phage are described. The bacterial strain used was Streptococcus thermophilus ST0089 and the phage was phage 2972. S. thermophilus ST0089 is an industrially important strain used in the manufacture of yogurt. It is genetically amenable to manipulation, and !5 susceptible to the well-known virulent phage 2972. The CRISPR loci were determined in strain ST0089. This was determined preferentially by sequencing the entire genome of ST0089. Alternatively, the CRISPR loci are identified via PCR using primer sets with sequences identical to S. thermophilus CRISPR elements previously identified. Once identified, the CRISPR loci sequences were determined as well as the proximal regions ;0 containing the relevant cas genes. At least one particular CRISPR-cas locus was selected for further manipulation. Functionality of this locus was ascertained through in silico analysis of the spacer regions and their homologies to phage DNA sequences (i.e., absence and/or presence of spacer sequences and correlation to phage infectivity with strain ST0089). In the absence of this correlation, functionality was assumed, based on 35 the presence of all documented elements (i.e., repeats, spacers, leader sequences, and cas genes that putatively encode full length proteins). A suitable spacer sequence(s) was chosen from the genome of phage 2972. The criteria used to select the spacer were generally based on the length of the spacers within the selected CRISPR locus and the identity (preferably approximately 100%) to the phage sequence. Indeed, any suitable phage 40 sequence finds use in various embodiments of the present invention. In some embodiments, a CRISPR unit consisting of a phage 2972 spacer sequence, flanked by two repeating elements (identical to the selected CRISPR locus) was chemically synthesized. By 109 5 definition, this synthetic "CRISPR unit" is approximately 100 bp in length and is too short for ensuring integration into the CRISPR locus. Therefore, additional flanking DNA was constructed along with the CRISPR unit. A minimum of 500 bp of homologous DNA, identical to the targeted CRISPR locus that flanks the synthetic CRISPR unit, was produced in order to facilitate integration. [0 In additional embodiments, there are multiple approaches. In one embodiment, a construct emulates the addition of a new spacer onto the existing CRISPR. In some alternative embodiments, the entire CRISPR locus is replaced with the synthetic CRISPR unit. The resulting CRISPR integrant was verified through DNA sequencing of the CRISPR locus prior to biological testing. In addition, phage sensitivity patterns of the CRISPR integrant against phage [5 2972 were tested and compared with the parental strain. The constructed CRISPR integrant successfully demonstrated the direct correlation between the presence of a specific spacer within the proper context of CRISPR-cas. In additional experiments, insertion of a spacer homologous to a phage DNA into a recipient cell was performed. In these experiments, a new CRISPR spacer was designed from phage DNA (with 100% !0 identity to phage DNA) within the anti-receptor gene and inserted into the cell in a CRISPR locus. The anti-receptor gene was targeted because CRISPR spacers from other strains have been found to show similarity to phage anti-receptor genes. Four strains bearing spacers showing identity to phage anti receptor genes were resistant to the particular phage. The mutant was exposed to phage and found to be resistant. !5 In additional experiments, a spacer was inserted into an original host, but not in a CRISPR locus. The resulting mutant retained its sensitivity to the phage. Thus, these experiments showed that the spacer needs to be in a particular environment within the context of a CRISPR and cas genes. In other experiments, a particular CRISPR spacer was deleted from a naturally occurring CRISPR locus. This deletion removed immunity against a given phage and the host became sensitive 30 (i.e., loses resistance) to the phage to which the spacer was homologous. Results from these experiments are provided in Figure 10. In yet additional experiments, whole CRISPR repeat-cas combinations were inserted into a recipient cell in order to provide immunity against incoming nucleic acid. In additional experiments, a plasmid comprising a CRISPR spacer was prepared using the 35 methods set forth herein. Attempts to transfer this plasmid into cells that contain the same spacer were unsuccessful However, plasmids that do not contain the spacer can be transformed into cells. Figures 11 and 12 illustrate these results. In further experiments, CRISPR-cas combinations present in two different strains were exchanged. This exchange of spacers was shown to modify their phenotypes (phage 40 sensitivity/resistance). As indicated herein when S1S2 is introduced into a strain with S4, phage sensitivity was switched (See, Figure 10).

110 5 In additional experiments, different cas-CRISPR-repeat combinations are prepared. Not only are cas genes or proteins required, but specific cas-CRISPR repeat pairs are required for functionality. When cas genes or proteins are provided from another CRISPR locus, the strain remains sensitive to the phage. In still additional experiments, one or more cas genes (from a functional CRISPR-cas unit) were deleted. Cas genes are necessary for immunity to be provided. Cas mutants are still sensitive to the [0 phage, despite the presence of the spacer identical to phage DNA. In these experiments, cas5 (formerly known as cas]) and cas7 (formerly known as cas4) were deleted. Cas5 was shown to be required for resistance. In addition, cas7 was shown to be required for integration of new spacers. In additional experiments, cas genes are provided in trans to the host. Where the cas gene is knocked out, immunity is restored. [5 EXAMPLE 2 Integration of CRISPR Spacer(s) In these experiments, integration of a CRISPR spacer into the CRISPR locus was shown to provide resistance against a bacteriophage to which the CRISPR spacer shows identity. In these !0 experiments, S. thermophilus strain DGCC7710RH1 was produced. Streptococcus thermophilus strain DGCC7710 (deposited at the French "Collection Nationale de Cultures de Microorganismes" under number CNCM 1-2423) possesses at least 3 CRISPR loci: CRISPRI, CRISPR2, and CRISPR3. In S. thermophilus strains CNRZ1066 and LMG18311 for which the complete genome sequence is known (Bolotin et al., Microbiol., 151:2551-1561 [2005] . CRISPRI is !5 located at the same chromosomal locus: between str0660 (or stu0660) and str0661 (or stu0661). In strain DGCC7710, CRISPRI is also located at the same chromosomal locus, between highly similar genes. CRISPRI of strain DGCC7710 contains 33 repeats (including the terminal repeat), and thus 32 spacers. All these spacers are different from each other. Most of these spacers are new (i.e, not previously 30 described within CRISPR loci), but four spacers close to the CRISPRI trailer are identical to already known CRISPRI spacers: - the 2 8 h spacer of DGCC7710 is 100% identical to the 31't CRISPRI spacer of strain CNRZ1575 (Genbank accession number DQ072991); - the 3 0 h spacer of DGCC7710 is 100% identical to the 2 7 h CRISPRI spacer of strain CNRZ703 35 (Genbank accession number DQ072990); - the 31sV spacer of DGCC7710 is 100% identical to the 2 8 h CRISPRI spacer of strain CNRZ703 (Genbank accession number DQ072990); - the 3 2 "d spacer of DGCC7710 is 100% identical to the 3 0 h CRISPRI spacer of strain CNRZ703 (Genbank accession number DQ072990). 40 111 5 During the development of the present invention, S. thermophilus strain DGCC7710RH1 was isolated as a natural phage resistant mutant using DGCC7710 as the parental strain, and phage D858 as the virulent phage. D858, a bacteriophage belonging to the Siphoviridae family of viruses was used. CRISPRI of strain DGCC771O-RH1 contains 34 repeats (including the terminal repeat), and thus 33 spacers. When compared to the CRISPRI sequence of S. thermophilus strain DGCC7710, the [0 CRISPRI sequence of S. thermophilus strain DGCC7710-RH1 possesses one additional new spacer (and one additional repeat which flanks the new spacer) at one end of the CRISPR locus (i.e., close to the leader, at the 5' end of the CRISPR locus). All the other spacers of CRISPRI locus remained unchanged. The CRISPRI sequence (5'-3') of strain DGCC7710-RH1 is provided below: [5 caaggacagttattgattttataatcactatgtgggtataaaaacgtcaaaatttcatttgag GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACtcaacaattgcaacatcttataacccactt tgtttgacagcaaatcaagattcgaattgt aatgacgaggagctattggcacaacttaca cgatttgacaatctgctgaccactgttatc !0 Gacacttggcaggcttattactcaacagcga ctgttccttgttcttttgttgtatcttttc ttcattcttccgtttttgtttgcgaatcct gctggcgaggaaacgaacaaggcctcaaca catagagtggaaaactagaaacagattcaa !5 Gataatgccgttgaattacacggcaaggtca gagcgagctcgaaataatcttaattacaag gttcgctagcgtcatgtggtaacgtattta ggcgtcccaatcctgattaatacttactcg aacacagcaagacaagaggatgatgctatg ;0 Gcgacacaagaacgtatgcaagagttcaag acaattcttcatccggtaactgctcaagtg aattaagggcatagaaagggagacaacatg cgatatttaaaatcattttcataacttcat gcagtatcagcaagcaagctgttagttact ;5 Gataaactatgaaattttataatttttaaga aataatttatggtatagcttaatatcattg tgcatcgagcacgttcgagtttaccgtttc tctatatcgaggtcaactaacaattatgct aatcgttcaaattctgttttaggtacattt 40 G G T T T T aatcaatacgacaagagttaaaatggtctt gcttagctgtccaatccacgaacgtggatg caaccaacggtaacagctactttttacagt ataactgaaggataggagcttgtaaagtct taatgctacatctcaaaggatgatcccaga 45 Gaagtagttgatgacctctacaatggtttat GTTacctagaagcatttgagcgtatattgattg aattttgccccttctttgccccttgactag GAA AC accattagcaatcatttgtgcccattgagt GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAGT 50 Ttgattcaacataaaaagccagttcaattgaacttggcttt (SEQ ID NO:682) In the above sequence, the leader has the sequence: 5' caaggacagttattgattttataatcactatgtgggtataaaaacgtcaaaatttcatttgag 3' (SEQ ID NO:688) 55 The integrated sequence (GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACtcaacaattgcaacatcttataacccactt; SEQ ID NO:689) comprising a CRISPR repeat is shown in upper case and a CRISPR spacer (i.e., tagging 112 5 sequence) in lower case; both are shown above in gray. The terminal repeat and trailer sequences of the CRISPR repeat are shown below: Terminal repeat: 5' gtttttgtactctcaagatttaagtaactgtacagt 3' (SEQ ID NO:3) Trailer sequence: 5' ttgattcaacataaaaagccagttcaattgaacttggcttt 3' (SEQ ID NO:691) -0 The sequence of the new spacer 5-TCAACAATTGCAACATCTTATAACCCACTT (SEQ ID NO:534) exists within the D858 phage genome. The sequence of the spacer is found between positions 31921 and 31950 bp (i.e., on the plus strand) of D858's genome (and has 100% identity to the D858 genomic sequence over 30 nucleotides): [5 Spacer 1 tcaacaattgcaacatcttataacccactt 30 (SEQ ID NO:534) |||||||||||||||||||||||||||||| D858 31921 tcaacaattgcaacatcttataacccactt 31950 (SEQ ID NO:534) !0 The new spacer that is integrated into the CRISPRI locus of S. thermophilus strain DGCC7710 RHI confers resistance to phage D858 to this strain, as shown in Figure 1 and Table 2-1. Table 2-1. Phiage 272 Phage 258 Strains B|m Pn acrF- f PS erh on' sensitliit i4nnoh~ , enitivty hnnooy C Ctrt Ctr DCC07778 85 S > 10 SNPs O 2saas DGCC7T~1-RH11 BS 0% 0% DGC?710-RM2 52 R10 R 1& DGCC?77ERT -52 S 10SNPS S '0%! 1tet DGeC7778RT' 853 R I 10 SNi 3 o 5Npmeslf DlCC771-R2~ 2972 R 1 A( pce) R5C~ ________________ ______ next to a icientical to phage 858 In addition, during the development of the present invention, S. thermophilus strain DGCC77 10 RH2 was isolated as a natural phage resistant mutant using S. thermophilus strain DGCC7710 as the parental strain, and phage D858 as the virulent phage.

113 5 CRISPRI of S. thermophilus strain DGCC7710-RH2 contains 34 repeats (including the terminal repeat), and thus 33 spacers. When compared to the CRISPRI sequence of S. thermophilus strain DGCC7710, the CRISPRI sequence of S. thermophilus strain DGCC7710-RH2 possesses one additional new spacer (and one additional repeat which flanks the new spacer) at one end of the CRISPR locus (i.e., close to the leader, at the 5' end of the CRISPR locus). All the other spacers of CRISPRI locus remained [0 unchanged. The CRISPRI sequence (5'-3') of strain DGCC7710-RH2 is shown below: caaggacagttattgattttataatcactatgtgggtataaaaacgtcaaaatttcatttgag GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACttacgtttgaaaagaatatcaaatcaatga 5 GTtgtttgacagcaaatcaagattcgaattgt aatgacgaggagctattggcacaacttaca cgatttgacaatctgctgaccactgttatc acacttggcaggcttattactcaacagcga ctgttccttgttcttttgttgtatcttttc !0 Gttcattcttccgtttttgtttgcgaatcct gctggcgaggaaacgaacaaggcctcaaca catagagtggaaaactagaaacagattcaa ataatgccgttgaattacacggcaaggtca gagcgagctcgaaataatcttaattacaag !5 Ggttcgctagcgtcatgtggtaacgtattta ggcgtcccaatcctgattaatacttactcg aacacagcaagacaagaggatgatgctatg cgacacaagaacgtatgcaagagttcaag acaattcttcatccggtaactgctcaagtg 0 Gaattaagggcatagaaagggagacaacatg cgatatttaaaatcattttcataacttcat gcagtatcagcaagcaagctgttagttact ataaactatgaaattttataatttttaaga aataatttatggtatagcttaatatcattg ;5 Gtgcatcgagcacgttcgagtttaccgtttc tctatatcgaggtcaactaacaattatgct aatcgttcaaattctgttttaggtacattt aatcaatacgacaagagttaaaatggtctt gcttagctgtccaatccacgaacgtggatg 40 G G T T T T caaccaacggtaacagctactttttacagt ataactgaaggataggagcttgtaaagtct taatgctacatctcaaaggatgatcccaga GTTaagtagttgatgacctctacaatggtttat GTTacctagaagcatttgagcgtatattgattg 45 GCCaattttgccccttctttgccccttgactag 45TCaccattagcaatcatttgtgcccattgagt GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAGT Ttgattcaacataaaaagccagttcaattgaacttggcttt (SEQ ID NO:777) 50 In the above sequence, the leader sequence is: 5'-caaggacagttattgattttataatcactatgtgggtataaaaacgtcaaaatttcatttgag-3' (SEQ ID NO:688) The integrated sequence comprising a CRISPR repeat is shown in upper case and a CRISPR 55 spacer (i.e., tagging sequence) in lower case; both are shown above in gray (GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACttacgtttgaaaagaatatcaaatcaatga; SEQ ID NO:694). The terminal repeat and trailer sequences of the CRISPR repeat are shown below: 114 5 Terminal repeat: 5'-gtttttgtactctcaagatttaagtaactgtacagt-3' (SEQ ID NO:3) Trailer sequence: 5'-ttgattcaacataaaaagccagttcaattgaacttggcttt-3' (SEQ ID NO:691) [0 It has been shown that the sequence of the new spacer exists within the D858 phage genome. The sequence of the spacer (SEQ ID NO:535) is found between positions 17215 and 17244 bp (i.e., on the plus strand) of D858's genome (and has 100% identity to the D858 genomic sequence over 30 nucleotides): [5 Spacer 1 ttacgtttgaaaagaatatcaaatcaatga 30 (SEQ ID NO:535) D858 17215 ttacgtttgaaaagaatatcaaatcaatga 17244 (SEQ ID NO:690) The new spacer that is integrated into the CRISPRI locus of S. thermophilus strain DGCC7710 !0 RH2 confers resistance against phage D858 to S. thermophilus strain DGCC7710-RH2, as shown in Figure 2 and Table 2-1 (See also, Figure 10). EXAMPLE 3 Construct Integration and Knockout !5 In this Example, methods used for construct integration and knockout are described. The strains used in these experiments were: S. thermophilus DGCC7710 parent strain, sensitive to phages 858 and 2972 S. thermophilus DGCC7778 CRISPR mutant resistant to 858 S. thermophilus DGCC7778cas1KO ;0 S. thermophilus DGCC7778cas4KO S. thermophilus DGCC7778RT S. thermophilus DGCC7778RT' S. thermophilus DGCC7710R2 CRISPR mutant resistant to 2972 S. thermophilus DGCC7710R2S 1S2 35 E. coli EC1,000 provided pORI28 (See, Russell and Klaenhammer, Appl. Environ. Microbiol., 67:43691 4364 [2001]) Escherichia coli pCR2. ITOPO provided pTOPO (See, Invitrogen catalog #K4500-01) The following plasmids were used in these experiments: pTOPO, a plasmid used for sub-cloning of the various constructs 40 pTOPOcaslko contains an integral fragment of cas] pTOPOcas4ko contains an integral fragment of cas4 pTOPOS1S2 contains the S1S2 spacer construct pTOPO RT contains the RT terminal repeat construct 115 5 pORI28 is a plasmid used for integration of the various constructs in the chromosome of S. thermophilus strains. pORIcaslko contains an integral fragment of cas] pORIcas4ko contains an integral fragment of cas4 pORIS1S2 contains the S1S2 spacer construct [0 purist contains the RT terminal repeat construct The following primers were used in these experiments: Cas1 5'-caaatggatagagaaacgc-3' (SEQ ID NO:670) and 5'-ctgataaggtgttcgttgtcc-3' (SEQ ID NO:671) [5 Cas4 5'-ggagcagatggaatacaagaaagg-3' (SEQ ID NO:672) and 5'-gagagactaggttgtctcagca-3' (SEQ ID NO:673) S1S2 and RT P1 5'-acaaacaacagagaagtatctcattg-3' (SEQ ID NO:666) !0 P2 5'-aacgagtacactcactatttgtacg-3' (SEQ ID NO:667) P3 5'-tccactcacgtacaaatagtgagtgtactcgtttttgtattctcaagatttaagtaactgtacagtttgattcaacataaaaag-3' (SEQ ID NO:668) P4 5'-ctttccttcatcctcgctttggtt-3' (SEQ ID NO:669) !5 Strains and phages were obtained from the Danisco Culture Collection, or from referenced material (Russell and Klaenhammer, Appl. Environ. Microbiol., 67:43691-4364 [2001]; and Levesque et al., Appl. Environ. Microbiol., 71:4057-4068 [2005]). Phage preparation, purification and tests were carried out using methods known in the art (See e.g., Duplessis et al., Virol., 340:192-208 [2005]; and Levesque et al., Appl. Environ. Microbiol., 30 71:4057-4068 [2005]). S. thermophilus strains were grown at 37 0 C or 42'C in M17 (Difco) supplemented with 0.5 % lactose or sucrose. For phage infection, 1OmM CaCl 2 were added to the medium prior to phage infection, as known in the art (See e.g., Duplessis et al., supra; and Levesque et al., supra). Enzymes used to carry out restriction digests and PCR were purchased from Invitrogen and used 35 according to the manufacturer's instructions. PCRs were carried out on an Eppendorf Mastercycler Gradient thermocycler as known in the art (See e.g., Barrangou et al., Appl. Environ. Microbiol., 68:2877-2884 [2002]). Gene inactivation and site-specific plasmid insertion via homologous recombination in the S. thermophilus chromosome were carried out by sub-cloning into the Invitrogen pCR2. ITOPO system, 40 subsequent cloning in the pORI system using E. coli as a host and the constructs were ultimately purified and transformed into S. thermophilus as previously described (Russell and Klaenhammer, supra).

116 5 RT Construct Integration Using the RT construct engineered as shown in Figure 4, the construct was inserted just after cas4, as shown in Figure 5. The parent DGCC7778 is resistant to phage 858. The parent has two spacers (SI and D2) which are identical to phage 858 DNA. The resulting strain (RT) lost resistance to phage t0 858. This result indicates that cas genes need to be in the immediate vicinity of the spacer(s) to confer resistance. As shown in Figure 3, the parent DGCC7778 was engineered such that the cas] gene is disrupted, resulting in a loss of resistance, meaning that cas] is needed to confer resistance. As shown in Figure 3, the parent DGCC7778 was engineered such that the cas4 gene is disrupted. In addition, the S1S2 construct was integrated into the parent DGCC77 10, as shown in Figures 6-8. [5 EXAMPLE 4 Isolation of Phage-Resistant Mutants and Confirmation of CRISPR Sequences In this Example, methods used in the isolation of phage-resistant mutants and confirmation of CRISPR sequences are described. S. thermophilus phage-resistant mutants were obtained by challenging !0 the wild-type host strain DGCC7710 (also called "RD534") with phage 2972 and/or phage 858 (Levesque et al., Appl. Environ. Microbiol., 71:4057 [2005]). The host strain was grown at 42'C in 10 ml of M17 broth supplemented with 0.5% lactose (LM17). When the optical density (600 nm) reached 0.3, phages and calcium chloride 1OmM were added at a final concentration of 10 7 pfu/ml and 50 mM, respectively. The phage-containing culture was incubated at 42'C for 24 hours and monitored for lysis. !5 Then, 100 pl of the lysate were inoculated into 10 ml of fresh LM17. The remaining lysate was centrifuged and the pellet was inoculated into another tube containing 10 ml of fresh LM17. These two cultures were incubated at 42'C for 16 hours. Finally, these cultures were diluted and plated on LM17. Isolated colonies were tested for phage sensitivity as known in the art (See, Moineau et al., Can. J. Microbiol., 38:875 [1992]). The CRISPR loci of the resistant isolates were verified by sequencing PCR 30 products, and using relevant phage genome information known in the art (See, Levesque et al., Appl. Environ. Microbiol., 71:4057 [2005]). EXAMPLE 5 CRISPR Spacer Engineering 35 In this Example, methods used in some embodiments for CRISPR spacer engineering are described. Enzymes used to carry out restriction digests and PCR were purchased from Invitrogen and used according to the manufacturer's instructions. PCRs were carried out on an Eppendorf Mastercycler Gradient thermocycler, using methods known in the art. Gene inactivation and site-specific plasmid insertion via homologous recombination in the 40 S. thermophilus chromosome were carried out by sub-cloning into the pCR2.1-TOPO system (Invitrogen), by subsequent cloning in the pORI system using E. coli as a host, and the constructs were 117 5 ultimately purified and transformed into S. thermophilus as known in the art (See, Russell and Klaenhammer, Appl. Environ. Microbiol.., 67:4361 [2001]). DNA from mutant WT 858sis2 was used as a template to amplify two distinct PCR fragments using P1 (5'-acaaacaacagagaagtatctcattg-3'; SEQ ID NO:666) and P2 (5'-aacgagtacactcactatttgtacg-3'; SEQ ID NO:667) in one reaction, and P3 t0 (5'-tccactcacgtacaaatagtgagtgtactcgtttttgtattctcaagatttaagtaactgtacagtttgattcaacataaaaag-3'; SEQ ID NO:668) and P4 (5'-ctttccttcatcctcgctttggtt-3'; SEQ ID NO:669) in another reaction. Both PCR products were subsequently used as templates in another PCR reaction using primers P1 and P4 to generate the S1S2 construct according to Figure 11. The S1S2 construct was sub-cloned into the Invitrogen pCR2.1-TOPO system. This construct [5 was digested with NotI and HindIII and subsequently cloned into pORI at the NotI and HindIII sites, providing the pS1S2 construct. Integration of pS1S2 into the CRISPRI locus of WT 2972+S4 occurred via homologous recombination at the 3' end of cas7, to generate WT 29 72 +S4::pS1S2. The pR construct was generated using the pS1S2 construct as a template. Specifically, the S1S2 construct subcloned into pCR2.1-TOPO was digested using BsrGI, which cuts within the CRISPR repeat. !0 Then, the digest was religated and a plasmid containing a single repeat and no spacer was used subsequently for cloning into pORI using NotI and HindIl, generating pR. Integration of pR into the chromosome of WT 858+S is2 at the 3' end of cas7 via homologous recombination generated WT 858+S is2::pR, a mutant where the CRISPRI locus is displaced and a unique repeat is inserted in its place. !5 The mutant WT 858+Sis2: :pR was subsequently grown in the absence of erythromycin, and antibiotic-sensitive variants were analyzed to find a mutant that had a complete deletion of the CRISPRI locus. The deletion was derived from homologous recombination occurring at the 3' end of ORF (as opposed to a recombination event occurring at the 3' end of cas7, which would have resulted in restoration of the WT 858+S iS2 strain), generating WT 858+Sis2 CRISPRI (See, Figure 12), a mutant where 30 the CRISPRI locus is deleted (See also, Figure 10) EXAMPLE 6 Inactivation of cas Genes For cas5 inactivation, a 801-bp internal piece of cas5 was amplified by PCR using primers 35 5'-caaatggatagagaaacgc-3' (SEQ ID NO:670) and 5'-ctgataaggtgttcgttgtcc-3' (SEQ ID NO:671) and subcloned into E. coli pCR2.1-TOPO (Invitrogen). This construct was digested with EcoRV and HindIl and subsequently cloned into pORI at the EcoRV and HindIII sites. Integration of this construct into the cas5 gene of WT 858+Sis2 occurred via homologous recombination of the internal piece of the gene, resulting into WT 858+S is2: :pcas5-. 40 Similarly, a 672-bp internal piece of cas7 was amplified by PCR using primers 5'-ggagcagatggaatacaagaaagg-3' (SEQ ID NO:672) and 5'-gagagactaggttgtctcagca-3' (SEQ ID NO:673) 118 5 and subcloned into E. coli pCR2. 1-TOPO (Invitrogen). This construct was digested with EcoRV and HindIl and subsequently cloned into pORI at the EcoRV and HindIl sites. Integration of this construct into the cas7 gene of WT 858Ssis2 occurred via homologous recombination of the internal piece of the gene, resulting into WT 858+S is2::pcas7- (See, Figures 10-12). [0 EXAMPLE 7 Natural Methods For Inserting an Additional Sequence in a CRISPR Locus In this Example, methods used to naturally provoke the insertion of an additional sequence within a CRISPR locus of a bacterial strain are described. "Additional sequence" as used herein is defined as a spacer sequence associated with CRISPR repeat sequence. More particularly, the [5 "additional sequence" originates partly from a donor phage able to infect the targeted bacterium and partly from the duplication of the CRISPR repeat sequence. The introduction of the donor phage DNA into the bacterial cell results from the infection of the cell by the donor phage. The selection of cells that contain additional sequence is made through selection pressure with the donor phage such that the selected modified cells are resistant to the phage. !0 In these experiments, a parental strain was exposed to a donor phage and a phage resistant variant of the parental strain (i.e., a variant strain) selected. The variant strain was analyzed (e.g., by PCR and/or DNA sequencing) to confirm the presence of an additional sequence within a CRISPR locus. The nucleotide sequence of the additional sequence was determined. Typically, the additional sequence is a fragment of approximately 30 nucleotides in size from the donor phage associated (fused) to a CRISPR !5 repeat sequence, and confers resistance to the donor phage. In some experiments, the parental strain was pre-cultivated overnight in a milk based medium at 42 0 C. A milk-based medium was then inoculated at 0.1% (v/v) with the pre-culture of the parental strain and with a suspension of the donor phage at an MOI of 10. After 6 h of incubation at 42 'C, dilutions of the culture were plated on a nutritional medium, in order to obtain isolated colonies. Isolates were then 30 tested for their resistance to the donor phage (any suitable method known in the art find use in these experiments). Variant strains were then analyzed for the presence of an additional sequence within one of their CRISPR loci. CRISPR loci were amplified by PCR and the nucleotide sequences of the resulting PCR products were determined by DNA sequencing using standard PCR and sequencing methods known in the art. 35 These sequence were then compared to that of the parental strain using standard methods known in the art. In some experiments, DGCC7710 was used as the parental strain and D2972 was used as a donor phage. The parental S. thermophilus strain DGCC7710 was exposed to the donor phage D2972 as described above. A variant strain named WTphi2972+s 6 was obtained (See, Table 7-1). Table 7-1 also 40 includes results for variant strains described in other Examples. In Table 7-1, the EOP is expressed 119 5 relatively to phage D2972. Positioning of the additional sequence in the phage genome is given relatively to phage D2972, unless specified otherwise. Table 7.1 Description of CRISPR-Modified Variant Strains of DGCC7710 Variant Parental Donor Additional Sequence EOP Strain Strain Phage Sequence - DGCC7710 - - 1 WTphi 29 72 +s6 DGCC7710 D2972 34521-34492 GCCCTTCTAATTGGATTACCTTCC 10-4 GAGGTG (SEQ ID NO:524) WTphi858+sis2 WTphi858+sis2 D858 33824-33853 TGTAGATAGCGTGGGTGCAGAGA 10-5 ::pcas5 ::pcas5 TGCACGG phi858+S19 (SEQ ID NO:702) WThi 29 72 +s 4 DGCC7710 D2972 31582-31611 CTCAGTCGTTACTGGTGAACCAG 10-5 TTTCAAT (SEQ ID NO:525) WTphi 29 72 +s 20 DGCC7710 D2972 25693-25722 TCTAATCCCACTAGGAATAGTGG 10-5 GTAGTAA (SEQ ID NO:703) WTphi 29 72 +s21 DGCC7710 D2972 27560-27589 TCGATAAATCAGCCAAAGTATTA 10-5 AGTGGTT (SEQ ID NO:704) WThi 29 72 +s22 DGCC7710 D2972 24624-24653 CAGCTTGAAATGTTTATTGAAGC 10-4 AGCAGTG (SEQ ID NO:705) WTrai,2972+s6P WTri2972+s6 D4724 1113-1142 TTATATCGAAGAACGACTGAAAG <108 hi4724+S15 AGCTTGA (SEQ ID NO:706) WTrai,2972+s6P WTri2972+s6 D4724 33968-33997 TCCAAGTTATTTGAGGAGTTATTA <108 hi4724+S17 AGACAT (SEQ ID NO:707) WTrap2972+se, WTri2972+s6 D4724 30803-30832 TACCGAAACGACTGGTTTGAAAA <108 hi4724 +S24 ATTCAAG (SEQ ID NO:708) WTrai2972+s6 , WTri2972+s D4733 29923-29894 AGTTGATTGCGTAATCAACCATC <108 hi4724+S15 phi4724+S15 TCCATAA phi4733 +S16 (SEQ ID NO:709) WTri,2972+s4 P WTri2972+s4 D4720 33968-33997 TCCAAGTTATTTGAGGAGTTATTA 10-6 hi4720+S17 AGACAT (SEQ ID NO:707) WTrai2972+S4p WTri2972 +S4 D858 30338-30367 CTTCAAATGTACTGCAAGGCTGC <108 hi8581S18 (relatively to AAAAGTA D858) (SEQ ID NO:710) WTrai2972+s4 WTri2972 +S4 D858 33886-33915 ATTGTCTATTACGACAACATGGA <10 7 hi858+S25 (relatively to AGATGAT D858) (SEQ ID NO:526) WT 8pi297 DGCC7710 D2972 + 7874-7903 TTACTAGAGCGTGTCGTTAACCA <10-7 2+S9 12 D858 CTTTAAA 20650-20621 (SEQ ID NO:528) TTCGTTAAAGTCACCTCGTGCTAG 8360-8389 CGTTGC (SEQ ID NO:529) 18998-19027 ATAACGGTAGCAAATATAAACCT

GTTACTG

120 Table 7.1 Description of CRISPR-Modified Variant Strains of DGCC7710 Variant Parental Donor Additional Sequence EOP Strain Strain Phage Sequence (SEQ ID NO:530) GAAGTAGCCATACAAGAAGATGG ATCAGCA (SEQ ID NO:531) WTphi858phi297 DGCC7710 D2972 + 33602-33631 GATGTCACTGAGTGTCTAAGCAT 108 2 *S13S14 D858 TGCGTAC 4830-4801 (SEQ ID NO:776) TGAATAAGCAGTTCTTGACGACC AACCGAC (SEQ ID NO:533) WThi 29 72 +s26 DGCC7710 D2972 29647-29-618 TTTTCCGTCTTCTTTTTTAGCAAA <108 S27 GATACG 16681-16652 (SEQ ID NO:711) TGTTTCAAGGTTTCGGGTCCAAG' ATCATT (SEQ ID NO:712) DGCC9705 DGCC7710 D2972 25582-25611 AAATCAGTTTTTTGTTCAGAAACT <108 TGTTCT 18079-18108 (SEQ ID NO:713) TAGAGGTAATGACGGCTTACCGG GTAAAGA (SEQ ID NO:714) DGCC9726 DGCC9705 D3821 26530-26559 GAAGTATTAGGTCTCTCAAAAGA <108 TGATATT (SEQ ID NO:715) DGCC9733 DGCC9726 D3288 5339-5363 TAAACTATGAAATTTTATAATTTT <108 (relatively to TGAACA 7201) (SEQ ID NO:716) DGCC9836 DGCC9733 D4753 15562-15590 AACCCAATAATTACAGTGAAGCA <108 (relatively to CAATAG D858) (SEQ ID NO:717) 362-333 AATTGTGTCGGTCTTTTTTATTGT TTTTACC 24083-24112 (SEQ ID NO:718) (relatively to CTCGTTAATTGCAAGTTTGGTCGG D858) CACGTT 30059-30088 (SEQ ID NO:719) (relatively to TTGTGGCACAAACAAAATGAATT D858) AAAGATT (SEQ ID NO:720) 5 This variant exhibited resistance to D2972, as the efficiency of plaquing (EOP) of D2972 on WTrai2972+s6 was reduced by 4 logs. DNA was extracted from WTphi 2972 +s 6 and the CRISPRI locus was analyzed by PCR as known in the art (See e.g., Bolotin et al. [2005], supra) using combination of one forward primer (either YC70 and/or SPIDR-ups (5'-gTCTTTAgAAACTgTgACACC-3'; SEQ ID 10 NO:674) and one reverse primer (either YC31 and/or SPIDR-dws (5'-TAAACAgAgCCTCCCTATCC; SEQ ID NO:675). The sequence of the PCR product was determined and compared to that of the CRISPRI locus of DGCC7710. Compared to DGCC7710, WTphi 2 97 2

*S

6 was found to differ by the 121 5 addition of a single spacer sequence of 30 bp at the 5' end of its CRISPRI region and by the duplication of the repeat sequence, as shown in Figure 14. Comparison of the additional sequence with the sequence of D2972 genome shows that the new spacer sequence is 100% identical to that of the D2972 genome from nucleotide 34521 to nucleotide 34492. In some additional experiments, WTphi 85 8 +sis2 ::pcas5 was used as the parental strain and D858 [0 was used as a donor phage. The resulting variant strain named WTi 8 58 +sis2 ::pcas5phi858+s 1 9 (See, Table 7 1) was resistant to D858, with an EOP reduced by 5 logs. DNA was extracted from WTi 8 5 8 +sis2 ::pcas5phi858+s 19 and its CRISPR3 locus was analyzed by PCR using one forward primer (CR3_leadF1, 5'-CTGAGATTAATAGTGCGATTACG; SEQ ID NO:676) and one reverse primer (CR3_trailR2, 5'-GCTGGATATTCGTATAACATGTC; SEQ ID NO:677). The sequence of the PCR [5 product was determined and compared to that of the CRISPR3 locus of WThi 8 5 8 +sis 2 ::pcas5. Compared to WTi 8 5 8 +sis2 ::pcas5, WTi 8 58 +sis2 ::pcas5phi858+s 1 9 differs by the addition of a single spacer sequence of 30 bp at the 5' end of its CRISPR3 region and by the duplication of the repeat sequence. Comparison of the additional sequence with the sequence of D858 genome showed that the new spacer sequence is 100% identical to that of the D858 genome from nucleotide 33824 to nucleotide 33853. !0 In other additional experiments, DGCC7809 was used as the parental strain and D3743 was used as the donor phage. The resulting variant strain named DGCC7809phiD 3743

+S

28 (See, Table 7-2) was resistant to D3743 with an EOP reduced by 8 logs. DNA was extracted from DGCC7809phiD 374 3+S 28 and its CRISPR3 locus was analyzed by PCR using one forward primer (CR3_leadFl, 5' CTGAGATTAATAGTGCGATTACG; SEQ ID NO:676) and one reverse primer (CR3_trailR2, 5' !5 GCTGGATATTCGTATAACATGTC; SEQ ID NO:677). The sequence of the PCR product was determined and compared to that of the CRISPR3 locus of ST0189. Compared to DGCC7809, DGCC7809phiD 3743

+S

2 8 differs by the addition of a single spacer sequence of 29 bp at the 5' end of its CRISPR3 region and by the duplication of the repeat sequence. The sequence of the phage D3743 is unknown; however comparison of the additional sequence with the sequence of other streptococcal phage 30 genome shows that the new spacer sequence is 100% identical to that of the phage DT1 genome from nucleotide 6967 to nucleotide 6996. In other additional experiments, DGCC3198 was used as the parental strain and D4241 was used as the donor phage. The resulting variant strain named DGCC3198phi 424 14s 29 (See, Table 7-2) was resistant to D4241 with an EOP reduced by 8 logs. DNA was extracted from DGCC3198phi 4 24 1*si and its CRISPRI 35 locus was analyzed by PCR using one forward primer (either YC70 and/or SPIDR-ups (5' gTCTTTAgAAACTgTgACACC-3'; SEQ ID NO:674) and of one reverse primer (either YC31 and/or SPIDR-dws (5'-TAAACAgAgCCTCCCTATCC; SEQ ID NO:675). The sequence of the PCR product was determined and compared to that of the CRISPRI locus of DGCC3198. Compared to DGCC3198, DGCC3198phi 424 14s 29 differs by the addition of a single spacer sequence of 30 bp at the 5' end of its 40 CRISPRI region and by the duplication of the repeat sequence. The sequence of the phage D4241 is unknown; however comparison of the additional sequence with the sequence of other streptococcal phage 122 5 genome shows that the new spacer sequence is 100% identical to that of the DT1 phage genome from nucleotide 3484 to nucleotide 3455. Table 7-2 below provides a description of CRISPR-modified variant strains from DGCC7809 and from DGCC3198. In this Table, EOP is expressed relatively to the donor phages. Positioning of the additional sequence in the phage genome is given relatively to the phage DT 1. [0 Table 7-2. Description of CRISPR-Modified Variant Strains from DGCC7809 and DGCC3198 Variant Strain Parental Donor Additional Sequence EOP Strain Phage sequence DGCC7809 - - - 1 6967-6996 ACAAGCAAAGATTACAACCG DGCC7809phi 374 3

S

2 S DGCC7809 D3743 (relative to CTGGTGCTA <10 DTl) (SEQ ID NO:721) DGCC3198 - - 1 3484-3455 ACCAAGTAGCATTTGAGCAAA DGCC3198phi 42 41

S

29 DGCC3198 D4241 (relative to GATAGATTG <108 DTl) (SEQ ID NO:722) EXAMPLE 8 Selection of a Set of CRISPR-Modified Variant Strains [5 From the Same Parental Strain In this Example, methods used for the selection of a set of variant strains from the same parental strain differing by their additional sequence originating from the same phage are described. As various portions of a donor phage find use as sources for additional sequences, multiple different variant strains can be generated from given donor phage. Furthermore, each variant strain has a different additional 20 sequence. Consequently, multiple strains were developed from the same parental strain in addition to the variant strain described in Example 7. In some experiments, these additional strains were generated by exposing the recipient strain to the same donor phage. The various resulting variant strains were contemplated to present different spectrum of phage sensitivity. In independent cultures, the parental strain was submitted to the same donor phage. For each 25 culture, a single phage resistant variant was isolated as described in Example 7 and then analyzed. Additional sequences in each of the variant strains were compared to each other. The spectrum of sensitivity of the variant strains to donor phage and other phages was determined using classical microbiological methods known in the art. The sensitivity spectra of the various strains were then compared. The selected variant strains were those presenting different additional sequence(s) and 30 different spectra of phage sensitivity. In some experiments, the selection of various variant strains of DGCC7710 using D2972 as a single donor phage was conducted. The parental strain DGCC7710 was exposed to the donor phage D2972 in four independent cultures as described in Example 7. From each of the cultures, a variant 123 5 strain was isolated and was respectively named WTphi2972+s, WTPi 297 2 +s 2 O, WThi 29 7 2 +s 2 1 and WTphi 2 97 2 +s 22 (See, Table 7-1). These variant strains exhibited resistance to D2972, as the efficiency of plaquing (EOP) of D2972 on the four phage resistant variants was reduced by 3 to 5 logs. DNA was extracted from S4 ~ -4S20S2S2 WTri2972+s4, WTri2972+2, WTri2972+s1 and WTphi 2 97s 2 2 and was analyzed by PCR using methods known [0 in the art (See e.g., Bolotin at al. [2005], supra), using combination of one forward primer (either YC70 and/or SPIDR-ups (5'-gTCTTTAgAAACTgTgACACC; SEQ ID NO:674) and of one reverse primer (either YC31 and/or SPIDR-dws (5'-TAAACAgAgCCTCCCTATCC; SEQ ID NO:675). The sequence of the PCR products were determined and compared to that of the CRISPRi locus of DGCC7710. Compared to DGCC7710, WTphi 2 97 2 *S4, WTphi29 7 2 +s 20 , WTphi 2 9 72 +s 2 1 and WTphi 29 72 +s 22 differ by the addition [5 of a spacer sequence of 30 bp at the 5' end of its CRISPRi region and by the duplication of the repeat sequence, as shown in Figure 17). Comparison of these new spacer sequences with the sequence of the D2972 genome shows that the new spacer sequences are 100% identical to that of the D2972 genome from nucleotide 31582 to nucleotide 31611, from nucleotide 25693 to nucleotide 25722, from nucleotide 27560 to nucleotide 27589, and from nucleotide 24624 to nucleotide 24653, respectively. All four !0 additional spacers were found to be different from each other and different from the spacers described in Example 7. EXAMPLE 9 Natural Methods Used for the Insertion of a Second Additional Sequence in a !5 CRISPR Locus In this Example, natural methods used to provoke the insertion of a second additional sequence in CRISPR locus are described. Upon insertion of an additional sequence from a given donor phage in a bacterial CRISPR locus, the variant strain becomes resistant or at least less sensitive to this phage. Therefore, the method described in Example 7 is no more efficient for the insertion of additional 30 sequences in the CRISPR locus of this variant strain. For example, the method cannot be applied to variant strain WThi 2972 +s6 (as a parental strain) using D2972 as a donor phage, because WTphi 29 72

+S

6 has significantly decreased sensitivity to D2972 (See, Example 7). In some experiments, this problem was overcome by the use of a mutated donor phage derived from D2972 that includes at least one specific modification within its genome (i.e., a "mutated phage"). 35 This mutated phage was selected by exposing the donor phage to the variant strain, such that the modification (i.e., mutation) of the parental phage rendered it virulent for the variant strain. In some experiments, the mutated phage had a mutation in its genome within the region containing the sequence of the additional spacer that is part of the additional sequence in the variant strain. The variant strain was sensitive to this mutated phage. The variant strain was exposed to the 40 mutated phage and a new phage resistant variant ( 2 nd generation variant) of the variant strain was selected. The 2 nd generation variant was analyzed using suitable methods known in the art (e.g., PCR and sequencing), to confirm the presence of an additional sequence within a CRISPR locus. The nucleotide 124 5 sequence of the additional sequence was determined. In some experiments, the additional sequence was found to contain a fragment of approximately 30 nucleotides in size from the mutated phage which gives resistance to the mutated phage. In some experiments, the variant strain was pre-cultivated overnight in an appropriate milk-based medium at 42 0 C. A suitable milk-based medium was then inoculated with the pre-culture of the variant [0 strain at a concentration of about 106 cfu/ml and with a suspension of the donor phage at an MOI greater than 100. The culture was incubated over night at 42 0 C, and then centrifuged. The supernatant was harvested and filtered using a 0.45 pm filter. Dilutions of the filtrated supernatant were used to inoculate a nutritive agar media seeded with the variant strain in order to obtain isolated phage plaques, using any suitable method known in the art. Isolated plaques were cultivated on the variant strain in liquid nutritive [5 media, using any suitable method known in the art. A suspension of the mutated phage was obtained by filtering the culture through a 0.45 pm filter. The mutated phage was then used as described above (See, Example 7) to provoke the insertion of a second additional spacer sequence in the CRISPR locus of the variant strain. In some experiments, WTphi 2972 +s6 (See, Example 7, and Table 7-1) was used as the parental strain !0 and D4724 was used as the donor phage. The variant strain WThi 29 72 +s 6 was cultivated in the presence of high concentration of phage D2972. A mutated phage named D4724 was isolated by plaquing the supernatant from this culture on strain WTPhi2972+S 6 using the methods described above. The virulence of the mutated phage D4724 on WTphi 2972 +s6 was verified. The variant strain WTphi 2972 +s6 was exposed to the mutated phage D4724 in a culture as described in Example 7. A phage resistant variant strain named ±SS6 .5 WVTphi2972+sphi4724si (See, Table 7-1) was obtained. Compared to WTPhi2972S 6 , this variant strain exhibited an increased resistance to D2972, as the efficiency of plaquing (EOP) of D2972 on WTphi 2972 +s6 phi4724+sis was reduced by more than 8 logs (instead of 4 logs); in addition, its resistance was also enlarged compare to WTphi2972+s 6 as its displays some resistance to D4724 (See, Table 9-1). DNA was extracted from WThi 2972 +s 6 pi4724+sis and its CRISPRi 30 locus was analyzed by PCR as described above using the same combinations of primers as described above. The sequence of the PCR product was determined and compared to that of the CRISPRi locus of S6 6 S56 -S-15 WThi 2972 +s . Compared to WThi 2972 +s, WTphi2972+ phi4724+ differs by the addition of a spacer sequence of 30 bp at the 5' end of its CRISPRi region and by the duplication of the repeat sequence, as shown in Figure 17. Comparison of this additional spacer sequence with the sequence of D2972 genome showed 35 that the second additional spacer sequence is 100% identical to that of the D2972 genome from nucleotide 1113 to nucleotide 1142. From independent cultures using identical experimental conditions, WTphi 2972 +s6 phi4724+s17 and WTri2972+s6 phi4724+s24 variant strains were isolated and analyzed (See, Table 7-1). As compared to WTphi2972+s, these variant strains exhibited an increased resistance to D2972, as the efficiency of 40 plaquing (EOP) of D2972 on WTphi 2972 +s6 phi4724+s 17 and WTphi 2972 +s6 phi4724+s24 was reduced by more than 8 logs for both variant strains; and their resistance was also enlarged, as compared to WTphi2972+s 6 as they 125 5 displayed some resistance to D4724 (See Table 9-1). In addition, these variant strains display additional spacer sequences in CRISPRI that are 100% identical to that of the genome of D2972 from nucleotide 33968 to nucleotide 33997 and nucleotide 30803 to nucleotide 30832, respectively. In additional experiments, WThi 2 97 2

+S

6 phi 4 72 4 +Si 5 was used as the parental strain and D4733 was used as the donor phage. The methods described above were used to generate the mutated phage D4733 [0 from phage D4724. Then, phage D4733 was used to obtain a phage resistant variant strain from ±S6 S15S6 -4S15 ±S16 WTrhi 2972 + phi4724+ . The resulting variant strain was named WTrhi 2972 + phi4724+ phi4733 (See, Table 7 1). This variant strain contains one additional sequence including a spacer sequence that is 100% identical to a sequence from D2972 genome, nucleotide 29923 to nucleotide 29894. It exhibited an increased resistance to D2972, as the efficiency of plaquing (EOP) of D2972 on 5 WTrSi2972+s6 phi4724+Si5 S+16 was reduced by more than 8 logs and it resistance was expanded to phage D4733 (See Table 9-1). Table 9-1 provides a description of the phage resistance of some CRISPR modified variant strains from DGCC7710. In this Table, "nd" indicates that results were not determined. Table 9-1: Description of the Phage Resistance of Some CRISPR-Modified Variant Strains from DGCC7710 Variant Parental Donor EOP EOP EOP EOP EOP Strain Strain Phage D2972 D4724 D4720 D858 D4733 DGCC7710 - 1 1 1 1 1 WTphi 2 97 2

+S

6 DGCC7710 D2972 10-4 1 1 nd nd WTri2972+s 6 phi4724+sis WTphi 2 97 2

+S

6 D4724 <10-8 <10-7 1 nd nd WTrSi2972+s 6 phi4724+S 1 7 WTphi 2 97 2

+S

6 D4724 <10-8 <10-7 nd nd nd WTrSi2972+s 6 phi4724+S 2 4 WTphi 2 97 2

+S

6 D4724 <10-8 <10-7 nd nd nd WThi 2 97 2

+S

6 phi 4 72 4 +Si 5 WTphi 2 97 2

+S

6 D4733 <10-8 <10-7 <10-6 nd nd +S16 +S15 phi4733 phi4724 WTphi 2 97 2

+S

4 DGCC7710 D2972 10-5 nd nd 1 nd WTphi 2 97 2

+S

4 phi 4 72 0+S1 7 WTphi 2 97 2

+S

4 D4720 10-6 nd nd 10-5 nd WTphi 2 97 2 +S4 phi 85 8 +Si 8 WTphi 2 97 2

+S

4 D858 <10-8 nd nd nd 10-5 WTphi 2 97 2 +S4 phi 8 5 8

+S

2 5 WTphi 2 97 2

+S

4 D858 <10-7 nd nd nd 10-3 20 In still further experiments, WTphi 2 97 2 +s4 was used as the parental strain and D4720 was used as the donor phage. Using the same methods as described above, mutated phage D4720 was generated from phage D2972. Phage D4720 was used to obtain a phage resistant variant from WTphi 29 72

+S

4 . The resulting variant strain was named WTphi 29 72

+S

4 phi 47 2 0+S 17 (See Table 7-1). This variant strain contains one additional sequence including a spacer sequence that is 100% identical to a sequence from D2972 genome from 25 nucleotide 33968 to 33997. It exhibits an increased resistance to D2972, as the efficiency of plaquing (EOP) of D2972 on WTphi 2 9 72 +S4phi4724+S17 was reduced by 6 logs (compared to 5 logs); and its resistance was enlarged to the phage D4720 (See, Table 9-1).

126 5 EXAMPLE 10 Alternative Natural Methods to Insert Second Additional Sequence(s) in CRISPR Loci In this Example, alternative natural methods useful for inserting a second additional sequence in [0 a CRISPR locus are described. It is known that a given parental strain may be sensitive to more than one family of phages. This diversity of sensitivity was advantageously used to insert additional sequences in a CRISPR locus of a variant strain, as described herein. In these experiments, the second donor phage was selected by testing the virulence of a selection of phages on the parental strain and on the variant strain(s). Second donor phages of interest were those that were virulent to both strains. It was [5 contemplated that these phages would be likely to represent a different family of phages than those represented by the initial donor phage. Following its selection, the second donor phage was used to infect the variant strain. As described in the methods above, a second generation phage resistant variant strain was isolated and tested for an additional sequence within the CRISPR locus. In these experiments, a collection of phages (or phage-containing samples) was tested against the !0 parental strain using classical microbiological methods known in the art. Phages (or samples) that are virulent to the parental strain were then tested against the variant strain using the same methods. One phage (or sample) that was virulent to the variant strain was selected as a second donor phage. In the case of phage containing samples, the one virulent phage was purified to homogeneity on the variant strain using classical microbiological methods known in the art. In some experiments, the sequence of !5 the second donor phage was determined. In some experiments, the second donor phage was then used as described above (See, Example 7) to provoke the insertion of a second additional sequence in the CRISPR locus of the variant strain. In some experiments, WTrai2972+s4 (See, Example 8 and Table 7-1) was used as the parental strain and D858 was used as the donor phage. Upon testing of various phages, strain DGCC7710 was found to 30 be sensitive to both phage D2972 and phage D858. In addition, D858 was found to be virulent against variant strain WThi 2972 + . Phage D858 was therefore chosen as a second donor phage in some experiments. The variant strain WThi 2972 +s4 was exposed to the second donor phage D858, as described in Example 7. A phage resistant variant strain named WTphi 29 72 +S4 phi 85 8 +sis (See, Table 7-1) was obtained that 35 is resistant to D858 (See Table 9-1). This strain exhibits an increased resistance to D2972, as the efficiency of plaquing of D2972 on WTphi 29 72 +S4 phi 85 8 +Si 8 was reduced by more than 8 logs (compared to 5 logs for WTphi29 72

+S

4 ; See Table 9-1). DNA was extracted from WTphi 2 97 2 +S4 phi 85 8 +si 8 and its CRISPRI locus was analyzed by PCR using the same methods and primers as described above. The sequence of the PCR product was determined and compared to that of the CRISPR locus of WTphi29 7 2 +s 4 . Compared S4-S4 40 to WTphi 2972 + , WTrhi2972+ phi858+si differs by the addition of a spacer sequence of 30 bp at the 5' end of its CRISPRI region and by the duplication of the repeat sequence, as shown in Figure 17. Comparison of 127 5 this additional spacer sequence with the sequence of D858 genome showed that the second additional spacer sequence is 100% identical to that of the D858 genome from nucleotide 30338 to nucleotide 30367. Another variant strain named WTphi 29 72 +s4 phi4720+s2s (See, Table 7-1) was also obtained using this method in independent experimental work. This variant strain contains one additional sequence including [0 a spacer sequence that is 100% identical to a sequence from D858 genome from nucleotide 33886 to 33915. It exhibits an increased resistance to D2972, as the efficiency of plaquing of D2972 on WTri2972+s4 phi4724+s2s was reduced by more than 7 logs (See, Table 9-1). EXAMPLE 11 [5 Genesis of a CRISPR-Modified Variant Strain Resistant to Multiple Phages by Multiple Insertions of Additional Sequences in CRISPR Loci In this Example, the development of a multi-phage resistant strain is described through the iterative addition of phage sequences in CRISPR loci, as addition of 2 phage sequences in the CRISPR loci is not enough to confer resistance to all phages to a given strain. For example, strain !0 WThi 2 97 2 +S4 phi 85 8 +si (described in Example 10) was found to be sensitive to multiple other phages. In the process of developing a multi-phage resistant strain, the parental strain was submitted to a first phage to select a variant strain, then the variant strain was submitted to a second phage to select a second generation variant strain that is resistant to both phages. Then, the last variant strain was submitted iteratively to the phages to which it was still sensitive, until a final variant strain was obtained that was !5 resistant to all available phages. Using methods known in the art, a set of 10 reference phages were identified that are representative of the diversity of phages that are able to develop on strain DGCC7710, namely phages D858, D1126, D2766, D2972, D3288, D3821, D4083, D4752, D4753, and N1495. As described in Example 7, DGCC7710 was exposed to phage D2972 to generate the variant strain DGCC9705. 30 DGCC9705 was found to be resistant to phage D2766 and D4752 in addition to phage D2972, but was still sensitive to the other phages as shown in Table 11-1. DGCC9705 is described in Table 11-1 and in Figure 17. DGCC9705 presents 1 additional sequence in CRISPRI and 1 additional sequence in CRISPR3. Analysis of the sequence of the CRISPRI locus and of the CRISPR3 locus was done accordingly to the methods described in Example 7. The sequence of the PCR products were determined 35 and compared to that of the CRISPRI and 3 loci of DGCC7710. DGCC9705 presents 1 additional spacer in its CRISPRI locus and one additional spacer in its CRISPR3 locus. The spacer sequences are identical to sequences from phage D2972 Using the same methods, DGCC9705 was then exposed to phage D3821 and variant strain DGCC9726 was then isolated. In addition to being resistant to D2972, DGCC9726 has resistance to phages D858, D3821, D4083 and N1495 (See, Table 11-1). DGCC9726 has 40 1 additional spacer sequence in its CRISPRI locus as compared to DGCC9705 (See, Table 7-1 and Figure 17). The additional spacer sequence is identical to a sequence from D2972. Through the exposure 128 5 of strain DGCC9726 to phage D3288, DGCC9733 was isolated. Strain DGCC9733 is additionally resistant to phage D3288 and D 1126 (See, Table 11-1). DGCC9733 has 1 additional spacer sequence in its CRISPRI locus comparatively to DGCC9726 (See, Table 7-1 and Figure 17). This spacer sequence has some identity (25/30 base pair identity) to a sequence of the streptococcal phage 7201. Finally, by a last iterative exposure to phage D4753, DGCC9836 was isolated that is resistant to all phages (See, Table [0 11-1). DGCC9836 has 2 additional spacer sequences in its CRISPRI locus and 2 additional spacer sequences in its CRISPR3 locus (See, Table 7-1 and Figure 17). One spacer sequence is identical to a sequence in phage D2972 and the 3 other spacer sequences are identical to sequences in phage D858. Table 11-1 provides data regarding the phage sensitivity of the CRISPR-modified variant strain DGCC9836 and intermediate CRISPR-modified variant strains. In this Table, "S" indicates sensitivity [5 and "R" indicates resistance. Table 11-1. Phage Sensitivity of the CRISPR-modified Variant Strain DGCC9836 and Intermediate CRISPR-Modified Variant Strains. Strain Parental Donor Phage Strain Phage ~] 00 00 ON 00 N ] r DGCC7710 S S S S S S S S S S DGCC9705 DGCC7710 D2972 R R R S S S S S S S DGCC9726 DGCC9705 D3821 R R R R R R R S S S DGCC9733 DGCC7710 D3288 R R R R R R R R R S DGCC9836 DGCC7710 D4753 R R R R R R R R R R 20 EXAMPLE 12 Natural Method to Insert Multiple Additional Sequence(s) in a CRISPR Locus In this Example, methods are described to insert multiple additional sequences in CRISPR loci. In these methods, rather than using the various phages iteratively, the parental strain was exposed to a mix containing multiple phages. A collection of phages was tested against multiple strains using 25 classical microbiological methods, in order to determine their host spectrum. Phages that were virulent to the parental strain but that have different host spectrum were selected. The selected phages were mixed and used in the methods provided above (See, Example 7) to provoke the insertion of additional sequences in the CRISPR loci of the variant strain. In some experiments, DGCC7710 was used as the parental strain and D858 and D2972 were 30 used as the donor phages. Upon testing of various phages, strain DGCC7710 was found to be sensitive to both phage D2972 and phage D858. However, D2972 and D858 presented different host spectra when tested on strain DGCC7778, suggesting that the two phages were different.

129 5 The parental strain DGCC7710 was exposed to a mix of phage D858 and D2972 as described in Example 7. A phage resistant variant strain named WThi 85 8 phi 2 97 2

+S

9 SIOS11S1 2 (See, Table 7-1) was obtained. It exhibits resistance to D858, as the efficiency of plaquing of D858 on WThi 85 8 phi29 7 2

+S

9 SIOS11S1 2 was reduced by more than 7 logs, as well as resistance to D2972, as the efficiency of plaquing of D2972 on WTphi858phi2972+s9sIOS11S12 was reduced by more than 7 logs. DNA was extracted from [0 WThi 8 5 8 phi 29 72

+S

9 SIOS11S1 2 and its CRISPR loci were analyzed by PCR using the same methods and primers as described above. The sequence of the PCR products were determined and compared to that of the CRISPRI locus and of the CRIPR3 locus of DGCC7710. Compared to DGCC7710, WThi 85 8 phi 2 9 7 2

+S

9 SIOS11S1 2 differs by the addition of 4 spacer sequences of 30 bp at the 5' end of its CRISPRI region and by duplication of the repeat sequences, as shown in Figure 17. Comparison of the 5 additional spacer sequences with the sequence of the D2972 genome showed that the additional spacer sequences are 100% identical to that of the D2972 from nucleotide 7874 to nucleotide 7903, from nucleotide 20650 to nucleotide 20621, from nucleotide 8360 to nucleotide 8389, and from nucleotide 18998 to nucleotide 19027. In further experiments, strain WT phi858phi2972+s1s14 (See, Table 7-1) was also obtained following !0 these methods. It exhibits resistance to D858, as the efficiency of plaquing of D858 on WT phi858phi2972+S13S14 was reduced by 7 logs, and resistance to D2972, as the efficiency of plaquing of D2972 on WT phi858phi2972+s13s14 was reduced by 8 logs. Comparison of the additional spacer sequences with the sequence of D2972 genome showed that the additional spacer sequences are 100% identical to that of the D2972 from nucleotide 33602 to nucleotide 33631, and from nucleotide 4830 to nucleotide 4801. EXAMPLE 13 Fighting Phages in Fermentation Using a CRISPR-Modified Variant Strain In this Example methods of fighting phages in fermentation by the use of a variant strain rather than a parental (i.e., wild-type, recipient) strain are described. Thus, this Example provides yet another 30 description of the benefits provided by variant strains. In some experiments, comparison of strain DGCC7710 to strain WTphi 2972

+S

20 and to strain WTrai2972+s26s27 in milk fermentation in the presence of phage D2972 was performed. DGCC7710 is an industrial strain used in milk fermentation. Strain WThi 2972 +s 20 is described in Table 7-1 and in Example 8 and displays in its CRISPRI locus an additional spacer, as compared to strain DGCC7710. Strain 35 WThi 2972 +s 20 exhibits improved resistance to D2972, as compared to DGCC7710. WThi 2972 +s 26 s 27 is another variant exhibiting some resistance to D2972 (described in Table 7-1) and displays 2 additional spacers in its CRISPRI locus. Serial fermentations were performed with each strain. First, 10% milk powder medium (w/v) was seeded with 1% (v/v) of a pre-culture of the tested strain and with 104 pfu/ml of phage D2972. The 40 culture was incubated at 42'C for 6 h. Following the first fermentation, a second fermentation was set up. The exact same fermentation conditions were used except that 0.1% volume of the fermentate of the 130 5 preceding fermentation was added (before addition, the fermentate was filtrated using a 0.45 pm filter). Then, successive fermentations were performed with the same experimental conditions as those used for the second fermentation. All fermentations were recorded by impedimetry. At the end of each of the fermentation, the clotting of the milk was tested and titration of phages was performed using methods known in the art. [0 In the case of milk fermentation in the absence of phage, variation of impedance with DGCC7710 was above 2500 pS within 6 hours. In the presence of D2972, (DGCC7710 being very sensitive to phages), D2972 phages reached high level of population during first culture and fermentation failed to clot the milk. Variation of impedance at 6 hours was always below 500 pS. On the contrary, milk fermentation with WTphi 29 72

+S

2 0 in the presence of D2972 allowed clotting of milk at least until the [5 3 rd sub-culture and slow evolution of phage level was noted. Variation of impedance increased to more than 2500 pS also until the 3 rd sub-culture. This demonstrates that the variant strain WTrai2972+s20 is more appropriate than the parental strain DGCC7710 for milk acidification in the presence of phages. Furthermore, fermentation of milk with WTphi 29 72

+S

2 6

S

2 7 in the presence of D2972 allowed clotting of milk until the last sub-culture without phage development. In addition, variation of impedance increased to !0 more than 2500 p S also until the last sub-culture. This demonstrates that the variant strain WTphi 29 72

+S

26

S

2 7 is more appropriate than the parental strain DGCC7710 and even more appropriate than WTphi 2 97 2

+S

20 for milk acidification in the presence of phages. The experiments were duplicated; the results are presented in Table 13-1.

131 Table 13-1. Comparison of Milk Fermentation with DGCC7710 or with Variant Strains in the Presence of phage D2972 Strain Subcultures Clotting of Phage Level on Variation of Impedance Milk Within Fermenting Strain Within 6 h (in pS) 6h DGCC7710 Control Yes No 3246 DGCC7710 1 No High 319 First trial 2 No High 23 DGCC7710 1 No High 287 Second trial 2 No High 16 WTphi 297 2+S 2 0 1 Yes No 3281 First trial 2 Yes Low 3148 3 Yes Low 3251 4 Yes High 3101 WTphi 297 2+S 2 0 1 Yes Low 3371 Second trial 2 Yes Medium 3265 3 Yes High 2780 4 No High 223 WTphi 297 2+S 26

S

27 1 Yes No 3322 First trial 2 Yes No 3208 3 Yes No 3467 4 Yes No 3182 WTphi 297 2+S 26

S

27 1 Yes No 3260 Second trial 2 Yes No 3021 3 Yes No 3377 4 Yes No 3246 5 In a second set of experiments, comparison of strain DGCC7710 to strain WTrhi 2972 +s 20 and to strain WTphi 297 2

+S

2 6

S

2 7 in milk fermentation in the presence of phage D2972 was reproduced. In addition, strain DGCC9836 was studied. Strain DGCC9836 is an even more evolved variant strain of DGCC7710 10 that is the result of multiple phage challenge. This strain presents 5 additional spacers in its CRISPRI locus and 3 additional spacers in its CRISPR3 locus (See, Example 11 and Figure 17). DGCC9836 is resistant to all tested phages. Experiments were conducted as described above. The results are displayed in Table 13-2. As for the first set of experiments, fermentation of milk with WTphi29 7 2

+S

20 in the presence of D2972 allowed 15 clotting of milk until the 5 h sub-culture and slow evolution of phage level was measured. Variation of impedance increased to more than 2500 pS during the 5 first sub-cultures, demonstrating that milk acidification is unaffected by phages. At the 6 h sub-culture, phage level increased significantly and the milk fermentation was impaired. For the 2 other variant strains, milk fermentation was unaffected all along the 6 sub-cultures, phages never developed and the recorded variation of impedance was always 20 above 2500 pS.

132 5 These experiments demonstrate that strains containing at least one additional spacer sequence in its CRISPRi locus allow milk fermentation even in the presence of phages. Milk fermentation is even more secured when strains have more than one additional spacer sequence in its CRISPR loci. Table 13-2. Comparison of Milk Fermentation with Variant Strains of DGCC7710 in the Presence of Phage D2972 Strain Subcultures Clotting of Phage Level on Variation of Impedance Milk Within Fermenting Strain Within 6 h (in pS) 6 h WTphi 2 9 72+S 2 0 1 Yes No 3171 2 Yes No 2991 3 Yes Low 2871 4 Yes Medium 2934 5 Yes Medium 2906 6 No High 661 WTphi 29 72+S 26

S

2 7 1 Yes No 2970 2 Yes No 2945 3 Yes No 2617 4 Yes No 2721 5 Yes No 2660 6 Yes No 2605 DGCC9836 1 Yes No 3028 2 Yes No 3115 3 Yes No 2708 4 Yes No 2817 5 Yes No 2845 6 Yes No 2813 [0 EXAMPLE 14 Fighting Phages in Fermentation Using a Combination of CRISPR-Modified Variant Strains In this Example, methods for fighting phages in fermentation through the use of a combination of 15 variant strains instead of using a single strain are described. Thus, this Example illustrates the simultaneous use of more than one variant strains (i.e., a combination of variant strains). Indeed, mixtures of strains exhibiting the same functionalities, yet different phage sensitivity patterns find use in such applications. For example, 2 or 3 or even more variant strains as described herein find use in such applications. Using a combination of variant strains with different added spacer sequences in their 20 CRISPR loci allows the fermentation to more easily resist any emerging mutant phages. In some experiments, comparisons were made between strain WThi 2972 +s21 alone and a combination of 3 strains (namely WTphi2972+S 20 , WTphi 29 72 +S21 and WTPhi2972+S 22 ) used in milk fermentation in the presence of phage D2972. Strains WTphi2972+ 0 , WTPhi2972 + 1 and WTPhi2972 + 2 are described in Table 7-1 and in Example 8. They are independent variant strains of DGCC7710. Each variant strain 133 5 displays in its CRISPRi locus a distinct additional spacer sequence (which originated from phage D2972) as compared to strain DGCC77 10. Serial fermentations were performed either with strain WTphi2972

+

s21 alone or in the threes strain combination. First, 10% milk powder medium (w/v) was seeded with 1% (v/v) of a pre-culture of the strain alone or the combination of strains and with 104 pfu/ml of phage D2972. The culture was incubated [0 at 42 0 C for 6 h. Following the first fermentation, a second fermentation was set up. The exact same fermentation conditions were used except that 0.1% volume of the fermentate of the preceding fermentation was added (before addition, the fermentate was filtrated using a 0.45 pm filter). Then successive fermentations were performed using the same experimental conditions as those used for the second fermentation. All fermentations were recorded by impedimetry. At the end of each of the [5 fermentation the clotting of the milk was tested and titration of phages was performed using methods known in the art. The experiments were duplicated; the results are provided in Table 14-1. Table 14-1. Comparison of Milk Fermentation with WTphi2972+S21 or with a Three Strain Combination in the Presence of Phage D2972 Strain Subcultures Clotting of Phage Level on Variation of Impedance Milk Within 6 Fermenting Strain Within 6 h (in pS) h DGCC7710 Control No High 46 WTphi2972+S 2 1 1 Yes Low 3367 First trial 2 Yes High 3312 3 No High 555 4 No High 33 5 No High 25 WTphi2972+S 2 1 1 Yes Low 3450 Second trial 2 Yes High 3293 3 No High 1071 4 No High 29 5 No High 26 WTphi 2 9 72+S 2 0 1 Yes Very low 3242 WTphi 2 9 72+S 2 1 2 Yes Low 3233 WTphi 29

?+S

2 2 3 Yes High 3319 4 Yes High 3169 First trial 5 Yes High 3261 WTphi 2 9 72+S 2 0 1 Yes Very low 3384 WTphi 2 9 72+S 2 1 2 Yes Low 3178 +S22 3 Yes High 3206 4 Yes High 3295 Second trial 5 Yes High 3209 134 5 Milk fermentation done with WTphi 29 72 +s21 in the presence of phages failed at the third subculture in both trials. This was shown by an absence of clotting of the milk and by a highly reduced variation of impedance following 6 hours of fermentation. On the contrary, despite some development of phage D2972, the fermentations were successfully conducted until the fifth subculture when the mix of the three strains was used. Clotting of milk was recorded in all cultures and variation of impedance within 6 hours [0 of incubation was never below 3000 pS. These experiments demonstrate that the use of combination of variant strains having at least one additional distinct spacer sequence in its CRISPRi locus allows milk fermentation in the presence of phages, as compared to the use of single variant strain. [5 EXAMPLE 15 Fighting Phages in Fermentation Using a Rotation of CRISPR-Modified Variant Strains In additional experiments, the variant strains were used in rotation. In some experiments, the strains had the same functionalities, but different phage sensitivity patterns. Thus, in this Example, !0 experiments conducted on the iterative/subsequent use of several different strains (i.e., CRISPR-modified variant strains) sequentially in a rotation scheme are described. In some experiments, comparisons were made between strain WTphi 2972 +s21 alone and strains S4-20 S521S2 WTri2972+s2, WTphi 2972 + and WTphi297 2+ 2 used successively (in rotation) in milk fermentation in the presence of phage D2972. The first milk fermentation was conducted with strain WTphi 2972 +s20 . Then, !5 strain WTphi2972+s22 was used for the second fermentation, and strain WTphi 2972 +s21 was used for the third fermentation. The fourth fermentation was then again done using strain WThi2972+s 20 ; followed by a S522 S21S2 fermentation with strain WTphi 2972 + , then strain WTphi 2972 + 21, and so on.. Strains WTphi2 9 72+ 20 , WThi 2972 +s 21 and WThi 2972 +s 22 are described above in Table 7-1. They are independent variant strains of strain DGCC7710. Each variant strain displays a distinct additional spacer sequence in its CRISPRi 30 locus, as compared to strain DGCC77 10, which originated from phage D2972. Serial fermentations were performed using the same experimental methods as described in Example 14. Experiments were done in triplicate; the results are displayed in Table 15-1. Serial fermentations inoculated with WThi 2972 +s 20 alone were successful until the 3 rd subculture, as shown by values of variation of impedance above 3000 pS and by milk clotting. The next subcultures failed to clot 35 the milk and high phage values were recorded. In contrast, serial fermentations made by inoculating the milk in rotation with 3 different variant strains (WThi 2972 +s 20 , WThi 2972 +s 21 and WThi 2972 +s 22 ) were successful up to the tenth subculture. Under these experimental conditions, phages failed to propagate and remained at low levels. The results indicate that using a rotation of variant strains provides improved phage resistance during fermentation, as compared to the use of a single variant strain. 40 135 Table 15-1. Successive Milk Fermentation with Rotation of Strains in the Presence of Phage D2972 Trial Fermentation Clotting of Phage Level on Variation of Impedance Milk Fermenting Strain Within 6 h (in pS) Within 6 h ) Control 1" fermentation WTphi2972+S20 Yes No 3464 2 " fermentation WTphi 29 72+S20 Yes Low 3203 3 d fermentation WTphi 29 72+S20 Yes Medium 3300 4th fermentation WTphi 29 72+S20 No High 235 5th fermentation WTphi 2 9 72+S20 No High 249 First 1" fermentation WTphi2972+S20 Yes No 3134 trial 2 fermentation WTphi 29 72+S22 Yes No 3253 3rd fermentation WTphi2972+S21 Yes No 3076 4h fermentation WTphi 29 72+S20 Yes No 3103 5th fermentation WTphi2972+S22 Yes No 2930 6h fermentation WTphi 2 9 72+S21 Yes Low 3127 7th fermentation WTphi2972+S20 Yes No 3160 8th fermentation WTphi 2 9 72+S22 Yes Low 2969 9th fermentation WTphi2972+S21 Yes Low 2967 16th fermentation WTphi 29 72+S20 Yes Low 3051 Second 17t fermentation WTphi 2 9 72+S20 Yes No 3168 trial 2"d fermentation WTphi2972+S22 Yes No 3063 3d fermentation WTphi 29 72+S21 Yes No 2992 4th fermentation WTphi2972+S20 Yes No 3186 5th fermentation WTphi 2 9 72+S22 Yes Low 3070 6th fermentation WTphi 2 9 72+S21 Yes Low 2932 7th fermentation WTphi2972+S20 Yes Low 3181 8th fmentation WTphi2972+S22 Yes Low 2920 9th fermentation WTphi2972+S21 Yes Low 2863 10Oth fermentation WTphi2972+S20 Yes Low 2995 Third 1't fermentation WTphi2972+S20 Yes No 3308 trial 2 fermentation WTphi 29 72+S22 Yes No 3290 3rd fermentation WTphi2972+S21 Yes No 3023 4th fermentation WTphi2972+S20 Yes No 3039 5th fermentation WTphi 2 9 72+S22 Yes Low 2994 6th fermentation WTphi2972+S21 Yes Low 2945 7th fermentation WTphi 2 9 72+S20 Yes Low 3184 8th fermentation WTphi 2 9 72+S22 Yes Low 3048 9th fermentation WTphi 29 72+S21 Yes Low 3063 17th fermentation WTphi 29 72+S20 Yes No 3016 5 EXAMPLE 16 Reduction and Control of Phage Population Using CRISPR-Modified Variant Strains In this Example, experiments conducted to determine the ability of a CRISPR-modified strain to 10 destroy phages that it has been made resistant to are described. In particular, experiments were designed to determine whether a phage population will be decreased to an undetectable level during fermentation of a CRISPR-modified strain.

136 5 In some experiments, DGCC9836 (described in Example 11 and in Figure 17) was used to perform milk fermentation in the presence of phage D2972, in comparison to fermentations made with its parental strain DGCC7710 in the presence of D2972. Ten-percent milk powder medium (w/v) was seeded with about 106 cfu/ml of a pre-culture of the tested strain and with 107 pfu/ml of phage D2972. The culture was incubated at 42'C for 24 h. At various time points, an aliquot was taken and the phage [0 population was measured using double-layer agar plate seeded with DGCC7710 using standard methods known in the art. The results are presented in Figure 20. In fermentation of milk by DGCC7710, phage D2972 developed to reach a population of above 108 pfu/ml. In contrast, during the fermentation with DGCC9836, the D2972 phage population gradually decreased to very low level (120 pfu/ml) after 6 hours of incubation, and was almost undetectable after 24 hours of incubation. This last result suggests [5 that phages were destroyed during the process of fermentation with the variant strain DGCC9836. The property of a variant strain to destroy phages, as well as not being sensitive to the phages represents an additional benefit, as compared to the traditional starter culture rotation program for which the strains are not sensitive, but are harmless to phages. Indeed, by using variant strains, eradication of dormant phages will occur through the combination of washing out the phages (as for rotation using !0 traditional starter culture) and of destroying the phages. In other experiments, variant strains presenting some but incomplete resistance to phage D2972 were associated in milk fermentation in the presence of D2972. Selected variant strains included WTphi 2 97 2

+S

20 and WTphi29 7 2

+S

21 , as described in Example 8 and in Table 7-1. These strains display EOP reductions for the phage D2972 of about 5 logs. Milk fermentations were performed as described above !5 (bacterial inoculation rate of 106 cfu/ml; phage inoculation rate of 107 pfu/ml). Milk fermentations were made either with WTphi 29 7 2

+S

20 or with WTphi 29 72

+S

21 or a mix of the two strains. At various time points, the population of phages was recorded. For this purpose, an aliquot was taken and phage population was measured using double-layer agar plate seeded either with WTphi 29 72 +s 2 0 or with WThi 29 72 +s 21 , using standard methods known in the art. The results are presented in Figure 21, which indicates the sum of 30 phages detected on WTphi 29 72

+S

2 0 and on WTphi 29 72

+S

2 1 for each of the milk fermentations. When a single strain was used for the fermentation (WTphi 29 72

+S

2 0 or WTphi 2 97 2

+S

2 1 ), the number of detected phages at inoculation time was about 100 pfu/ml (due to the 5 logs of EOP reduction). Upon cultivation, this number of phages rose to 106 or 107 (respectively), corresponding to a multiplication of the phages by 4 to 5 logs. The multiplication factor of the phages was much lower (2 logs) for the milk fermentation 35 inoculated with the 2 strains. Indeed, the number of phages rose from 100 pfu/ml to a maximum of about 104 pfu/ml. These results conclusively show that during a co-culture of 2 variant strains the propagation rate of the phages is significantly reduced compare to the propagation rate of the phages in a culture made with a single variant strains. 40 137 5 EXAMPLE 17 Insertion of Spacers In this Example, methods and compositions used to insert two spacers in S. thermophilus DGC7710 are described. S. thermophilus strain DGCC7710 (deposited at the French "Collection Nationale de Cultures de Microorganismes" under number CNCM 1-2423) possesses at least 3 CRISPR [0 loci: CRISPRI, CRISPR2, and CRISPR3. In strains CNRZ1066 and LMG18311, for which the complete genome sequence is known (See, Bolotin et al., [2004], supra), CRISPRI is located at the same chromosomal locus: between str0660 (or stu0660) and str0661 (or stu0661) (See, Figure 18). In strain DGCC7710, CRISPRI is also located at the same chromosomal locus, between highly similar genes. CRISPRI of strain DGCC7710 contains 33 repeats (including the terminal repeat), and thus 32 spacers [5 (See, Figure 19). All of these spacers are different from each other. Most of these spacers have not previously been described as being within CRISPR loci, but four spacers close to the CRISPRI trailer are identical to known CRISPRI spacers. For example, the 2 8 h spacer of DGCC7710 is 100% identical to the 31't CRISPRI spacer of strain CNRZ1575 (Genbank accession number DQ072991); the 3 0 h spacer of DGCC7710 is 100% identical to the 2 7 h CRISPRI spacer of strain CNRZ703 (Genbank accession !0 number DQ072990); the 31sV spacer of DGCC7710 is 100% identical to the 2 8 h CRISPRI spacer of strain CNRZ703 (Genbank accession number DQ072990); and the 32 "d spacer of DGCC7710 is 100% identical to the 30 CRISPRI spacer of strain CNRZ703 (Genbank accession number DQ072990). The CRISPRI sequence (5'-3') of strain DGCC7710 is shown in SEQ ID NO:678, below: !5 caaggacagttattgattttataatcactatgtgggtataaaaacgtcaaaatttcatttgag GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACtgtttgacagcaaatcaagattcgaattgt GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACaatgacgaggagctattggcacaacttaca GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACcgatttgacaatctgctgaccactgttatc GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACacacttggcaggcttattactcaacagcga ;0 GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACctgttccttgttcttttgttgtatcttttc GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACttcattcttccgtttttgtttgcgaatcct GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACgctggcgaggaaacgaacaaggcctcaaca GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACcatagagtggaaaactagaaacagattcaa GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACataatgccgttgaattacacggcaaggtca 35 GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACgagcgagctcgaaataatcttaattacaag GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACgttcgctagcgtcatgtggtaacgtattta GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACggcgtcccaatcctgattaatacttactcg GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACaacacagcaagacaagaggatgatgctatg GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACcgacacaagaacgtatgcaagagttcaag 40 GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACacaattcttcatccggtaactgctcaagtg GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACaattaagggcatagaaagggagacaacatg GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACcgatatttaaaatcattttcataacttcat GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACgcagtatcagcaagcaagctgttagttact GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACataaactatgaaattttataatttttaaga 45 GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACaataatttatggtatagcttaatatcattg GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACtgcatcgagcacgttcgagtttaccgtttc GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACtctatatcgaggtcaactaacaattatgct GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACaatcgttcaaattctgttttaggtacattt GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACaatcaatacgacaagagttaaaatggtctt 50 GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACgcttagctgtccaatccacgaacgtggatg GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACcaaccaacggtaacagctactttttacagt GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACataactgaaggataggagcttgtaaagtct GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACtaatgctacatctcaaaggatgatcccaga GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACaagtagttgatgacctctacaatggtttat 138 5 GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACacctagaagcatttgagcgtatattgattg GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACaattttgccccttctttgccccttgactag GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACaccattagcaatcatttgtgcccattgagt GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAGT Ttgattcaacataaaaagccagttcaattgaacttggcttt (SEQ ID NO:678) -0 D858, the phage used in these experiments is a bacteriophage belonging to the Siphoviridae family of viruses. Its genome sequence has been completely determined, it apparently remains to be published. This phage is virulent to S. thermophilus strain DGCC7710. S. thermophilus strain DGCC7778 was isolated as a natural phage resistant mutant using DGCC7710 as the parental strain, and [5 phage D858 as the virulent phage. The CRISPRI of strain DGCC7778 contains 35 repeats (including the terminal repeat), and thus 34 spacers. When compared to the CRISPRI sequence of DGCC7710, the CRISPRI sequence of DGCC7778 possesses two additional, adjacent, new spacers (and of course two additional repeats which flank the new spacers) at one end of the CRISPR locus (i.e., close to the leader). All the other spacers of the CRISPRI locus are unchanged. The CRISPRI sequence (5'-3') of strain !0 DGCC7778 is shown in SEQ ID NO:679, below: caaggacagttattgattttataatcactatgtgggtataaaaacgtcaaaatttcatttgag GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACcaacacattcaacagattaatgaagaatac GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACtccactcacgtacaaatagtgagtgtactc GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACtgtttgacagcaaatcaagattcgaattgt !5 GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACaatgacgaggagctattggcacaacttaca GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACcgatttgacaatctgctgaccactgttatc GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACacacttggcaggcttattactcaacagcga GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACctgttccttgttcttttgttgtatcttttc GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACttcattcttccgtttttgtttgcgaatcct ;0 GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACgctggcgaggaaacgaacaaggcctcaaca GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACcatagagtggaaaactagaaacagattcaa GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACataatgccgttgaattacacggcaaggtca GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACgagcgagctcgaaataatcttaattacaag GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACgttcgctagcgtcatgtggtaacgtattta ;5 GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACggcgtcccaatcctgattaatacttactcg GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACaacacagcaagacaagaggatgatgctatg GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACcgacacaagaacgtatgcaagagttcaag GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACacaattcttcatccggtaactgctcaagtg GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACaattaagggcatagaaagggagacaacatg 40 GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACcgatatttaaaatcattttcataacttcat GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACgcagtatcagcaagcaagctgttagttact GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACataaactatgaaattttataatttttaaga GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACaataatttatggtatagcttaatatcattg GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACtgcatcgagcacgttcgagtttaccgtttc 45 GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACtctatatcgaggtcaactaacaattatgct GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACaatcgttcaaattctgttttaggtacattt GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACaatcaatacgacaagagttaaaatggtctt GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACgcttagctgtccaatccacgaacgtggatg GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACcaaccaacggtaacagctactttttacagt 50 GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACataactgaaggataggagcttgtaaagtct GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACtaatgctacatctcaaaggatgatcccaga GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACaagtagttgatgacctctacaatggtttat GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACacctagaagcatttgagcgtatattgattg GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACaattttgccccttctttgccccttgactag 55 GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACaccattagcaatcatttgtgcccattgagt GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAGT Ttgattcaacataaaaagccagttcaattgaacttggcttt (SEQ ID NO:679) 139 5 In the case of DGCC7778, the first spacer (5'-caacacattcaacagattaatgaagaatac-3'; SEQ ID NO:680) and the second spacer (5'-tccactcacgtacaaatagtgagtgtactc-3'; SEQ ID NO:681) constitute the strain-specific tag which identifies this labelled strain. It was determined that the sequence of both new spacers exists within the D858 phage genome. The sequence of the second new spacer is found between t0 positions 25471 and 25442 bp (i.e., on the minus strand) of D858's genome, with one mismatch (96.7% of identical nucleotides over 30 nucleotides): spacer 2 1 tccactcacgtacaaatagtgagtgtactc 30 (SEQ ID NO:681) [5 D858 25471 tccactcacgtacaaatagtgagcgtactc 25442 (SEQIDNO:686) The sequence of the first spacer is found between positions 31481 and 31410 bp (i.e., on the plus strand) of D858's genome (100% of identical nucleotides over 30 nucleotides): 0 spacer 1 1 caacacattcaacagattaatgaagaatac 30 (SEQIDNO:3) D858 31481 caacacattcaacagattaatgaagaatac 31410 (SEQ ID NO:687) Although it is not intended that the present invention be limited to any particular mechanism nor theory, it is contemplated that two new spacers present in the CRISPRI locus of DGCC7778 was needed to confer to strain DGCC7778 a new resistance to phage D858). Spacer "2' (as found in DGCC7778) was first inserted into the CRISPRI locus of DGCC7710 (33 repeats and 32 spacers), at one end of this 30 CRISPR locus, together with one repeat. This insertion gave rise to a bacteriophage insensitive mutant (intermediate strain), tagged by this additional new spacer (thus bearing 34 repeats and 33 spacers). This spacer was derived from the D858 genome, but a replication error or reverse transcription error likely occurred during the insertion process, leading to a point mutation. Due to the imperfect match (i.e., the 1 mismatch) between this newly acquired spacer and the targeted phage sequence, the efficiency of 35 resistance of this intermediate strain to phage D858 was low. A second event of spacer insertion occurred in this intermediate strain (more resistant to phage D858 than parental strain DGCC7710, but not "fully" resistant because of the mismatch), leading to the insertion of a second new spacer (i.e., spacer "1" as found in DGCC7778) at the same end of CRISPRI locus, together with one repeat. This second insertion gave rise to a new bacteriophage insensitive mutant, which was isolated and named 40 DGCC7778. DGCC7778 is more resistant to D858 than the intermediate strain, and of course much more 140 5 resistant than parental strain DGCC7710, due to the presence of spacer "1," which is 100% identical to the targeted phage sequence. EXAMPLE 18 Method for Tagging DGCC7710 and Selection of Labelled Strain DGCC7778 [0 In this Example, methods used to tag DGCC7710 and selection of the labelled DGCC7778 strain are described. Strain DGCC7710 was infected/challenged by phage D858 by inoculating pasteurised milk with strain DGCC7710 at about 2.106 cfu/ml and with phage D858 at about 1.105 pfu/ml. The inoculated milk was cultivated for 12 hours at 35'C. After incubation, viable bacteria (i.e., those that are likely to be bacteriophage insensitive mutants) were isolated on non-selective medium (milk agar plates) [5 at 35'C, using an appropriate dilution of the infected culture. One isolate, named DGCC7778, was propagated in M17-glucose liquid medium at 35'C and its DNA was extracted using a classical DNA extraction protocol, as known in the art. The DNA extract was amplified using PCR as known in the art (See e.g., Bolotin et al. [2005], supra) using combination of one forward primer (either yc70 and/or SPIDR-ups !0 [5'-gTCTTTAgAAACTgTgACACC]; SEQ ID NO:674) and of one reverse primer (either yc31 and/or SPIDR-dws [5'-TAAACAgAgCCTCCCTATCC]; SEQ ID NO:675). The sequence of the PCR products was determined and compared to that of the CRISPR locus of DGCC77 10. EXAMPLE 19 !5 Production of a Second Tagged Strain In this Example, methods used to produce a second tagged strain are described. S. thermophilus strain DGCC771O-RH1 was isolated as a natural phage resistant mutant using DGCC7710 as the parent strain and phage D858 as the virulent phage. The CRISPRI of strain DGCC7710-RH1 contains 34 repeats (including the terminal repeat), and 30 thus 33 spacers. When compared to the CRISPRI sequence of S. thermophilus strain DGCC7710, the CRISPRI sequence of S. thermophilus strain DGCC7710-RH1 possesses one additional new spacer (i.e., tagging sequence) (and of course one additional repeat which flanks the new spacer) at one end of the CRISPR locus (i.e., close to the leader, at the 5' end of the CRISPR locus). All of the other spacers of CRISPRI locus are unchanged. The CRISPRI sequence (5'-3') of strain DGCC7710-RH1 is: 35 caaggacagttattgattttataatcactatgtgggtataaaaacgtcaaaatttcatttgag GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACtcaacaattgcaacatcttataacccactt tgtttgacagcaaatcaagattcgaattgt aatgacgaggagctattggcacaacttaca 40 GTcgatttgacaatctgctgaccactgttatc acacttggcaggcttattactcaacagcga ctgttccttgttcttttgttgtatcttttc ttcattcttccgtttttgtttgcgaatcct gctggcgaggaaacgaacaaggcctcaaca 45 GTcatagagtggaaaactagaaacagattcaa ataatgccgttgaattacacggcaaggtca 141 5 G T C C T A C A gagcgagctcgaaataatcttaattacaag G T A T G T T T C gttcgctagcgtcatgtggtaacgtattta GTGC CGTA AGC ggcgtcccaatcctgattaatacttactcg GTGC CGTA AGC aacacagcaagacaagaggatgatgctatg ) TT A C A T AA GC cgacacaagaacgtatgcaagagttcaag [0 GCTCacaattcttcatccggtaactgctcaagtg GTGC CGTA AGC aattaagggcatagaaagggagacaacatg GTGC CGTA AGC cgatatttaaaatcattttcataacttcat GTGC CGTA AGC gcagtatcagcaagcaagctgttagttact GTGC CGTA AGC ataaactatgaaattttataatttttaaga [5 GCTCaataatttatggtatagcttaatatcattg GTGC CGTA AGC tgcatcgagcacgttcgagtttaccgtttc GTGC CGTA AGC tctatatcgaggtcaactaacaattatgct GTGC CGTA AGC aatcgttcaaattctgttttaggtacattt GTGC CGTA AGC aatcaatacgacaagagttaaaatggtctt !0 GCTCgcttagctgtccaatccacgaacgtggatg GTGC CGTA A GC caaccaacggtaacagctactttttacagt GTGC CGTA AGC ataactgaaggataggagcttgtaaagtct GTGC CGTA AGC taatgctacatctcaaaggatgatcccaga GTGC CGTA AGC aagtagttgatgacctctacaatggtttat !5 Gacctagaagcatttgagcgtatattgattg GTGC CGTA AGC aattttgccccttctttgccccttgactag GTGC CGTA AGC accattagcaatcatttgtgcccattgagt GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAGT Ttgattcaacataaaaagccagttcaattgaacttggcttt (SEQ ID NO:682) ;0 The leader sequence is 5' caaggacagttattgattttataatcactatgtgggtataaaaacgtcaaaatttcatttgag 3' (SEQ ID NO:688). The integrated sequence (GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACtcaacaattgcaacatcttataacccactt; SEQ ID NO:689) is shown in gray, comprising a CRISPR Repeat (upper case) and a CRISPR spacer (i.e., tagging ;5 sequence), which is shown in lower case. The terminal repeat (5' gtttttgtactctcaagatttaagtaactgtacagt 3' (SEQ ID NO:3)) trailer sequence: 5' ttgattcaacataaaaagccagttcaattgaacttggcttt3' (SEQ ID NO:691) are shown. Accordingly, in the case of S. thermophilus strain DGCC7710-RH1, the spacer (5' tcaacaattgcaacatcttataacccactt-3'; SEQ ID NO:534) constitutes the strain-specific tagging sequence which 40 identifies this mutant strain (i.e., the labelled bacterium). The sequence of the new spacer (i.e., tagging sequence) exists within the D858 phage genome. The sequence of the spacer is found between positions 31921 and 31950 bp (i.e., on the plus strand) of the D858 genome (and has 100% identity to the D858 genomic sequence over 30 nucleotides): 45 spacer 1 tcaacaattgcaacatcttataacccactt 30 (SEQ ID NO:534) D858 31921 tcaacaattgcaacatcttataacccactt 31950 (SEQ ID NO:534) The new spacer (i.e., tagging sequence) that is integrated into the CRISPRI locus of 50 Streptococcus thermophilus strain DGCC7710-RH1 confers to this strain a new resistance to phage D858.

142 5 EXAMPLE 20 Production of a Third Tagged Strain In this Example, methods used to produce a third tagged strain are described. S. thermophilus strain DGCC7710-RH2 was isolated as a natural phage resistant mutant using S. thermophilus strain DGCC7710 as the parental strain, and phage D858 as the virulent phage. The CRISPRI of S. [0 thermophilus strain DGCC7710-RH2 contains 34 repeats (including the terminal repeat), and thus 33 spacers. When compared to the CRISPRI sequence of S. thermophilus strain DGCC7710, the CRISPRI sequence of S. thermophilus strain DGCC7710-RH2 possesses one additional new spacer (i.e., tagging sequence) (and of course one additional repeat which flanks the new spacer) at one end of the CRISPR locus (i.e., close to the leader, at the 5' end of the CRISPR locus). All the other spacers of CRISPRI locus [5 are unchanged. The CRISPRI sequence (5'-3') of strain DGCC7710-RH2 is: caaggacagttattgattttataatcactatgtgggtataaaaacgtcaaaatttcatttgag GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACttacgtttgaaaagaatatcaaatcaatga !0 Gtgtttgacagcaaatcaagattcgaattgt aatgacgaggagctattggcacaacttaca cgatttgacaatctgctgaccactgttatc acacttggcaggcttattactcaacagcga ctgttccttgttcttttgttgtatcttttc !5 Gttcattcttccgtttttgtttgcgaatcct gctggcgaggaaacgaacaaggcctcaaca catagagtggaaaactagaaacagattcaa ataatgccgttgaattacacggcaaggtca gagcgagctcgaaataatcttaattacaag ;0 Ggttcgctagcgtcatgtggtaacgtattta ggcgtcccaatcctgattaatacttactcg aacacagcaagacaagaggatgatgctatg cgacacaagaacgtatgcaagagttcaag acaattcttcatccggtaactgctcaagtg ;5 Gaattaagggcatagaaagggagacaacatg cgatatttaaaatcattttcataacttcat gcagtatcagcaagcaagctgttagttact ataaactatgaaattttataatttttaaga aataatttatggtatagcttaatatcattg 40 G G T T T T tgcatcgagcacgttcgagtttaccgtttc tctatatcgaggtcaactaacaattatgct aatcgttcaaattctgttttaggtacattt aatcaatacgacaagagttaaaatggtctt gcttagctgtccaatccacgaacgtggatg 45 G G T T T T caaccaacggtaacagctactttttacagt ataactgaaggataggagcttgtaaagtct taatgctacatctcaaaggatgatcccaga GTTaagtagttgatgacctctacaatggtttat GT AAC acctagaagcatttgagcgtatattgattg 50 GCCaattttgccccttctttgccccttgactag 5CTCaccattagcaatcatttgtgcccattgagt GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAGT Ttgattcaacataaaaagccagttcaattgaacttggcttt (SEQ ID NO:684) 55 The leader sequence is 5' caaggacagttattgattttataatcactatgtgggtataaaaacgtcaaaatttcatttgag 3' (SEQ ID NO:688).

143 5 The integrated sequence (GTTTTTGTACTCTCAAGATTTAAGTAACTGTACAACttacgtttgaaaagaatatcaaatcaatga; SEQ ID NO:694) is shown in gray, comprising a CRISPR Repeat (upper case) and a CRISPR spacer (i.e., tagging sequence), which is shown in lower case. The terminal repeat (5' gtttttgtactctcaagatttaagtaactgtacagt (SEQ ID NO:3)) trailer sequence: 5' ttgattcaacataaaaagccagttcaattgaacttggcttt3' (SEQ ID NO:691) are [0 shown. Thus, in the case of Streptococcus thermophilus strain DGCC7710-RH2, the spacer (5' ttacgtttgaaaagaatatcaaatcaatga-3'; SEQ ID NO:697) constitutes the strain-specific tag which identifies this mutant strain (i.e., labelled bacterium). The sequence of the new spacer was shown to exist within D858 phage genome. The sequence of the spacer is found between positions 17215 and 17244 bp (i.e., on the [5 plus strand) of D858's genome (and has 100% identity to the D858 genomic sequence over 30 nucleotides): spacer 1 ttacgtttgaaaagaatatcaaatcaatga 30 (SEQ ID NO:697) !0 D858 17215 ttacgtttgaaaagaatatcaaatcaatga 17244 (SEQ ID NO:698) The new spacer integrated into the CRISPRI locus of S. thermophilus strain DGCC7710-RH2 confers a new resistance to phage D858 to S. thermophilus strain DGCC7710-RH2. !5 EXAMPLE 21 Construction of "CRISPR-Escape" Phage from Phage-Resistant Bacterial Variants In this Example, methods for construction of CRISPR-escape phages are described. Phage resistant host variants are first constructed as described in the Examples above. In these experiments, a parental strain "A" is exposed to phage "P" and a phage resistant variant (Variant "A1.0") selected. ;0 Variant A1.0 is analyzed (for example by PCR, and/or DNA sequencing) to confirm the presence of an additional inserted spacer within a CRISPR locus. The nucleotide sequence of the additional spacer (Spacer Spi.0) is then determined. Typically, spacer Spi.0 is a fragment of approximately 30 nucleotides in size from the phage P, and gives resistance to phage P and related phages ("related phages" are those containing the sequence of the spacer in their genomes, and define a family of phages). 35 Independently from the first phage exposure, the same parental strain A is exposed to the same phage P and a second phage resistant variant (Variant A2.0) is selected. Variant A2.0 is selected in order to also have an additional spacer inserted (Spacer Sp2.0) within a CRISPR locus but with the sequence of spacer Sp2.0 being different from that of spacer SpI.0. Typically, spacer Sp2.0 is a fragment of approximately 30 nucleotides in size from the phage P, and gives resistance to phage P and related 40 phages. Similarly, in some embodiments, variant A3.0 to variant Ax.0 are generated through the exposure of the same strain A to the same phage P. All the "A" variants are selected in order to also have an additional spacer inserted (Spacer Sp3.0 to Spx.0) within a CRISPR locus but with the sequence of all the "Sp" spacers being different from each of the others. Typically, "Sp" spacers are fragments of 144 5 approximately 30 nucleotides in size from the phage P, and all give resistance to phage P and related phages. Typically, it can be estimated that the level of resistance will be approximately that of a single mutation occurring within the phage genome within the sequence corresponding to the spacer (i.e., roughly 10-4 to 10-6). Thus, phage that escape the CRISPR-mediated resistance are easy to isolate. The [0 mutated phage are generated through exposure of variant A1.0 to phage P. Typically, the mutated "CRISPR-escape" phage (P1.0) harbors at least one mutation within its genome corresponding to the sequence of spacer Sp1.0 (e.g., deletion(s), point mutation(s), etc.), or in some preferred embodiments, the region flanking Spl.0, plus or minus 20 bp corresponding to the CRISPR motif. Variant A1.0 would be sensitive to phage P1.0. Similarly, independently generated phage P resistant variants (Variant A2.0, [5 A3.0, to Ax.0) that harbor unique spacers (Sp 2 .0, Sp3.0, to Spx.0, respectively) are likewise challenged with phage P to generate the corresponding mutant phages (P2.0, P3.0, to Px.0, respectively). Subsequently, a pool of mutant virulent phage, whose genomes have been specifically mutated to a sequence anticipated to be a CRISPR spacer, can be generated. Indeed, phage D2792 represents a fully virulent biocontrol phage against S. thermophilus strain !0 DGCC7710 (WT). In contrast, analysis of the CRISPR locus of related strains WTphi 29 72 + s, WThi 2 97 2 +4 4S20 -4S21S2 WTri2972+s2, WTri2972+s1, and WTphi 29 72 +s 22 , indicate the presence of a spacer sequence that is similar to sequences found in phage D2972 which indicate that phage D2972 has reduced virulence upon these strains. Plaquing data (See, Table 7-1) confirms the reduced virulence of phage D2972 on these strains. In regards to strain WTphi 29 72 + s, which has been characterized to be resistant to phage D2972 due to the !5 presence of a corresponding CRISPR spacer, screening of D2972-related phages for full increased virulence identify phages D4724 and D4733 as candidate agents as biocontrol agents (See, Table 7-1). In additional experiments, strain DGCC7710 was exposed to phage D2972 to generate resistant 4S6 -4S6 variant WThi 2972 + . When strain WThi 2972 + was exposed to phage D2972, it was possible to isolate mutant phage, such as D4724. This D4724 phage was found to be fully virulent upon DGCC7710 and 4S6 -4S6 30 WThi 2972 + . In a second iteration, WThi 2972 + was exposed to phage D4724, to generate resistant variant 4S6 -4S15 WTri2972+s phi4724+ . Upon exposure of this strain to D4724, mutant phages were identified such as D4733, that are fully virulent towards DGCC7710 and WTphi 2 97 2

*S

6 . In some embodiments successive iterations are used to generate phage with the desired level of virulence. Additional phage mutant examples are provided in Figure 13. In this Figure, mutant phage 858 35 A and 858-B derived from parent phage D858 are shown. The mutations correspond to spacer S1 from WT 858+S1S2 challenged with phage D858. In yet further examples, fully virulent phage mutants where the mutation is identified in the CRISPR motif are shown in Table 20-1. In this Table, nucleotide sequences in wild-type and mutant phages that correspond to the newly acquired spacers by the S. thermophilus strains are shown. The 40 AGAAW motif is highlighted in grey. Each mutation is in bold and underlined. *, indicates a deletion. This Table provides sequences for phage resistant CRISPR variant and virulent phage mutant pairs: 145 5 DGCC7710s 8 5 8 ss 3 / phage 2972.S3C, DGCC7710 2 97 2

*S

4 / phage 2972.S4A or phage 2972.S4C, DGCC7710 2 97 2

*S

6 / phage 2972.S6A, and DGCC7710 2972

S

4 s 5 8 +s 3 2 / phage 858.S32A or phage 858.S32D. In this Table, the new spacer corresponds to SEQ ID NO:535 (DGCC7710 85 8

S

3 ). Table 20-1. Nucleotide Sequences in Wild-Type and Mutant Phages That Correspond to Newly Acquired Spacers by S. thermophilus Strains Source Sequence SEQ ID NO: DGCC7710 s 5 ssS 3 TTACGTTTGAAAAGAATATCAAATCAATGA SEQ ID NO:535 Phage 2972 TTACGTTTGAAAAGAATATCAAATCAATGACGAGAAAGA SEQ ID NO:725 Phage 2972, S3A TTACGTTTGAAAAGAATATCAAATTAATGACG AGAAGA SEQ ID NO:726 Phage 2972, S3B TTACGTTTGAAAAGAATATCAAATCAACGACGAGAGA SEQ ID NO:727 Phage 2972, S3C TTACGTTTGAAAAGAATATCAAATCAATGACG.|ANA. GA SEQ ID NO:728 Phage 2972, S3D TTACGTTTGAAAAGAATATCAAATCTATGACG|A|AAAGA SEQ ID NO:729 Phage 2972, S3E TTACGTTTGAAAAGAATATCAATTCAATGACGM||A|*iA GA SEQ ID NO:730 Phage 2972, S3F TTACGTTTGAAAAGAATATCAAATTAATGGCG|GAAAGA SEQ ID TTACGTTTGAAAAGAATATCAAATTAATGGCGAEAAAGA NO:731 Phage 2972, S3G TTACGTTTGAAAAGAACATCAAATTAATGACGA*AAGA SEQ ID TTACGTTTGAAAAGAACATCAAATTAATGACGA*|A-GA NO:732 DGCC77102972*S4 CTCAGTCGTTACTGGTGAACCAGTTTCAAT SEQ ID NO:525 Phage 2972 CTCACGCGTTACTGGTGAACCAGTTTCAATTGG||AA SEQ ID NO:733 Phage 2972, S4A CTCAGTCGTTACTGGTGAACCAGTTTCAATTGAA AAAA SEQ ID NO:734 Phage 2972, S4B CTCAGTCGTTACTGGTGAACCAGTTTCGATTGANAAAA SEQ ID NO:735 Phage 2972, S4C CTCAGTCGTTACTGGTGAACCAGTTTCAATTGAGA AA SEQ ID NO:736 Phage 2972, S4D CTCAGTCGTTACTGGTGAACCGGTTTCAATTG AAAAA SEQ ID CTCAGTCGTTACTGGTGAACCGGTTTCAATTGAAAAAA NO:737 DGCC77 10 4 2 97 2*S6 GCCCTTCTAATTGGATTACCTTCCGAGGTG SEQ ID NO:524 Phage 2972 GCCCTTCTAATTGGATTACCTTCCGAGGTGTTAGAATTC SEQ ID NO:738 Phage 2972, S6A GCCCTTCTAATTGGATTACCTTCCGAGGTGTT AGTTC SEQ ID NO:739 Phage 2972, S6B GCCCTTCTAATTGGATTACCTTCCGATGTGTTAGA ATC SEQ ID NO:740 Phage 2972, S6C GCCCTTCTAATTGGATTACCTTCCGAGTTGTTAQAATTC SEQ ID NO:741 Phage 2972, S6D GCCCTTCTAATTGGATTACCTTCCGA*GTGTTAGAATTC SEQ ID NO:742 DGCC77102972*S4 ATTGTCTATTACGACAACATGGAAGATGAT SEQ ID 58S32 NO:526 146 Table 20-1. Nucleotide Sequences in Wild-Type and Mutant Phages That Correspond to Newly Acquired Spacers by S. thermophilus Strains Source Sequence SEQ ID NO: Phage 858 ATTGTCTATTACGACAACATGGAAGATGATGTM3AAATT SEQ ID NO:743 Phage 858.S32A ATTGTCTATTACGACAACATGGAAGATGATGTATAAATT SEQ ID NO:744 Phage 858.S32B ATTGTCTATTACGACAACATGGAAGATTATGTA*.. ATT SEQ ID NO:745 Phage 858.S32C ************************************|TT SEQ ID NO:746 Phage 858.S32D ATTGTCTATTACGACAACATGGAAGATGATGTAAAA TT SEQ ID NO:747 DGCC77 10 4 2 97 2*S6 TTATATCGAAGAACGACTGAAAGAGCTTGA SEQ ID 42972.S6B+S20 NO:706 Phage 2972 TTATATCGAAGAACGACTGAAAGAGCTTGAGAAGAA AA SEQ ID NO:748 Phage 2972.S20A TTATATCGAAGAACGACTGAAAGAGCTTGAGAATAAAAA SEQ ID NO:749 5 EXAMPLE 22 Second Level "CRISPR-Escape" Phage In this Example, experiments for construction of second-level (i.e., with multiple mutations directed at multiple spacers) CRISPR-escape phages are described. [0 Through an iterative process of creating CRISPR-mediated phage resistant variants followed by isolation of mutated ("CRISPR-escape") phage capable of overcoming the cas-CRISPR mechanism, it is possible to create phage that have "pre-adapted" with multiple mutations against potential CRISPR mediated resistance. In some embodiments, the second level variants are produced by isolating a mutated phage [5 through exposure of variant A1.0 to phage P. Typically, this mutated phage (phage P1.0) has a mutation (deletion, point mutation, etc.) in its genome within the region containing the sequence of spacer SpI.0 or within the region flanking Spl.0, plus or minus 20 bp corresponding to the CRISPR motif. Variant A1.0 is sensitive to phage P1.0. Then, variant A1.0 is exposed to phage P1.0 and a phage resistant variant (Variant A1.1) selected (See, Figure 15). Variant A1.1 is also selected such that it has an additional 20 spacer inserted (Spacer Sp1.1) within a CRISPR locus but with the sequence of spacer Spl.1 being different from that of spacers Spl.0, Sp2.0 to Spx.0. Typically, spacer Spi.1 is a fragment of approximately 30 nucleotides in size from the phage P1.0, and will give resistance to phage P1.0 and related phages. Variant A1.1 is resistant to phage P1.0 and preferably, has an increased resistance to phage P because of the accumulation of spacer Sp1.0 and Sp1.1. 25 In additional embodiments, a newly mutated phage (phage Pl.1) is generated through exposure of variant A1.1 to phage P1.0. Then, upon exposure of variant A1.1 to phage P1.1 a new variant A1.2 is obtained that contains one new additional spacer (Spl.2). This spacer gives resistance to phage P1.1 and preferably increases the resistance to phage P1.0 and P (i.e., due to the accumulation of spacers Spl.0, Sp1.1, Sp1.2). Phage P1.1 is fully infective towards parental strain A, as well as variants A1.0 and A1.1.

147 5 In yet additional embodiments, different spacers (e.g., 2, 3 or 4) are iteratively accumulated within strain A through variant A1, then variant Al.1, then variant A1.2, etc to obtain a variant highly resistant to phages (variant Al.n). In still further embodiments, additional different spacers can be accumulated in the same strain through variant A2, then variant A2. 1, then variant A2.2, etc to generate another variant of strain A highly resistant to phages (variant A2.n) in parallel. The same strategy finds [0 use with variants A3.0 to Ax.0. Following an iterative process of creating CRISPR phage resistant variants and isolation of mutant "CRISPR-escape" phage (e.g., exposure of variant Al .1 to phage Pl.1 creating new variant A1.2 that contains one new additional spacer (Spl.2) from which a mutant phage is isolated (P1.2) that is fully virulent on variant A1.2, Al.1, A1.0 and parent strain A. 5 In some embodiments, combinatorial mutations are accumulated by iterative construction of bacterial variants combining different spacers (e.g., Sp2.0. Sp3.0 to Spx.0), exposure to the corresponding first level mutant phage (P2.0, P3.0 to Px.0), and isolation of second level mutant phages. An example of iterative combinatorial mutations creating CRISPR phage resistant variants and mutant "CRISPR-escape" phage is shown in Table 22-1. This table provides a list of new spacers found !0 in CRISPR1 and the corresponding region in phages 2972, 858, or DT1. In this Table, the "a" indicates DNA regions that are 100% identical between phages 858 and 2972. The "5' Position" refers to the 5' position of the proto-spacer in the phage genome. Underlined and shaded nucleotides in the proto-spacer sequence indicate mismatches between the phage and the spacer. An asterisk (*) indicates a deletion. In the "3' Flanking Region" indicates the 3' flanking sequence in the phage genome. Mismatches in the !5 AGAAW motif are underlined and shaded in grey. In the column designated "Strand/Module," the transcription modules are "E" (early expressed genes); "M" (middle expressed genes); and "L" (late expressed genes).

148 < Ln 0n 0n 0n 0n L nr-r 00 0 0 ~ E ~5 00 0ina 00 CA t4 enF- C 00 0 H a- n Hn n C5 U- HM- 0 0 0 S Ln Hn Ln E- H- Ln r- r- r- r b '' (J ~H 0H CA HA CA C H 0 N r- c r- c 00 U - Un 0 c c H Hr m CA Hn c. Ln N c H- Ic Uc H I' U l n U- 0U c m 0U m 00 U w m H- 00 - mU 00 H- H- H U- r- H- r- H- U- r- H- r- r- H on U U H ol ol Ul ol ol Ul Ul Hl ol l l C0 00U ~~~~L H- 00 U H U H U Ln H- U0 U - H U H U U - 149 05 0 -< - - - oo 0.L D 0D 0JC1) C CD m 0 0 0 00 0 0 mL 0- LnL 0 00 0 00 Z 00- 0 - 00 00- 150 5 DGCC7710 was exposed to phage 2972 to create CRISPR phage resistant variant DGCC7710 2972

*S

6 from which CRISPR-escape mutant phage 2972.S6B was generated. Exposure of DGCC7710 2972

*S

6 to phage 2972.S6B created CRISPR phage resistant variant DGCC77102972S62972.sB+S20 from which CRISPR-escape mutant phage 2972.S20A was isolated. [0 In some embodiments, strains that are resistant to more than one family of phages are provided. As a given strain can be sensitive to more than one family of phages, in some embodiments, it is desired to enlarge the strain resistance to multiple phage families by introducing additional spacer(s) within a CRISPR locus originating from the other families of phages (See, Figure 16). For example, phages P, Q, and R are representative phages from three families of phages able to infect strain A. Using the method [5 outlined above and herein, variants resistant to all three phage families are produced. In some embodiments, phage P is used to generate variant A1p (containing spacer Spl) that is resistant to phage P. Then, variant A1P is exposed to phage Q and a phage resistant variant (Variant A1Pq) is selected. Variant A1pq has one additional spacer (Sql) inserted within a CRISPR locus. Typically, spacer Sql is a fragment of approximately 30 nucleotides in size from the phage Q, and gives resistance to phage Q and !0 related phages. Variant A1p t is resistant to both P and Q phages. Next, variant A1p t is exposed to phage R and a phage resistant variant (Variant A1Pq') is selected. Variant A1 p'has a third additional spacer (Sri) inserted within a CRISPR locus. Typically, Sri is a fragment of approximately 30 nucleotides in size from the phage R, and also gives resistance to phage R and related phages. Variant A 1 P r is resistant to all three phages. In some particularly preferred embodiments, the variant is also resistant to related !5 phages. These CRISPR-escape phages find use as biocontrol/therapeutic phages. As described above, through the process of creating CRISPR-mediated phage resistant variants, exposure to phage and isolation of virulent "CRISPR-escape" phage, a mixture of phage species that harbor single and/or multiple mutations targeted against single and/or multiple phage genome sequences that are potential 30 CRISPR spacer targets is generated. As target host bacteria can become resistant to phage through the incorporation of a single or multiple spacers and that the Cas-CRISPR mechanism can be overcome through a mutation within the phage genome corresponding to such spacers, the use of a mixture of phage harboring various mutations reduces the rate of an individual bacterium to successfully acquire new spacers and proliferate. 35 In an additional embodiment, analysis of the protospacer and flanking regions, as determined from the spacers in the corresponding CRISPR phage resistant variants, facilitates identification of the CRISPR motif for a specific CRISPR. In the example of DGCC7710 CRISPR 1 phage-resistant variants containing spacers Si - S33, were generated following challenge with phage 2972 or 858. Alignment of the protospacer and flanking regions, from the genome of phages 2972 or 858 that correspond to spacers 40 SI - S33, using the software program Clustal X, identified the CRISPR 1 motif as NNAGAAW (SEQ ID NO:696), and is visualized using WebLogo (Figure 22).

151 5 In a further example, CRISPR 3 phage resistant variants were derived from DGCC7710 following challenge with phages 858 and 3821, and LMD-9 following challenge with phage 4241. Alignment of the protospacers and flanking region from the respective phage genomes with the corresponding spacers of the respective CRISPR 3 phage resistant variants, identified the CRISPR 3 motif as NGGNG (SEQ ID NO:723) (Figure 23). [0 Analysis for the presence of a specific CRISPR motif provides means to identify the location of putative protospacers within a genome or other specified sequence (e.g., a plasmid or another mobile genetic element). In the example of sequenced phages 858, 2972, and DT1, analysis for the distribution of the AGAAW CRISPR 1 motif identified the location of potential protospacers within the respective genomes. Utilizing the degeneracy of the genetic code and/or the use of conservative amino acid [5 substitutions, each AGAAW motif was eliminated in the process of chemically synthesizing a genome as described for phage OX174, as known in the art. Thus, the phage became insensitive to the Cas-CRISPR 1 resistance system. Thus, a DNA molecule, devoid of specific CRISPR motifs is insensitive to the corresponding Cas-CRISPR system. These phages and "cocktails" of multiple phage types find use in rotation strategies (e.g., defined !0 sequential administration of phage). As an extension to the use of a single cocktail, composed of phage harboring different spacer mutations, in some embodiments, multiple virulent phage, each harboring a different spacer mutation in a defined sequential manner are used. For example, using a set of "CRISPR escape" phages (P1.0, P2.0, and P3.0, or P1.0, P1.1, P1.2, or some combination thereof), each phage is applied individually and in a defined sequence and rotation (P.10 > P2.0 > P3.0 > P1.0, P2.0 > etc) so as !5 to minimize the probability of the target bacteria developing CRISPR-mediated resistance to the phage. Likewise, a set of phage cocktails (i.e., each phage within the cocktail as well as each cocktail possesses a unique combination of mutations) finds use in sequence and rotation. In some embodiments, the phage and/or cocktail is comprised of a single phage family, while in other embodiments, the phage and/or cocktail is comprised of multiple phage families. 30 EXAMPLE 23 Functional Combinations This Example provides various functional combinations that find use in the present invention. 35 By way of example only, the following functional combinations may be used in accordance with the present invention. Functional Combination #1: cas sequences: SEQ ID NO:461 to SEQ ID NO:465 and SEQ ID NO:473 to SEQ ID NO:477 40 (all of which are S. thermophilus sequences), as set forth below: 152 5 SEQ ID NO:461: ATGAGTGACTTAGTTTTAGGACTTGATATCGGTATAGGTTCTGTTGGTGTAGGTATCCTTAAC AAAGTGACAGGAGAAATTATCCATAAAAACTCACGCATCTTCCCAGCAGCTCAAGCAGAAA ATAACCTAGTACGTAGAACGAATCGTCAAGGAAGACGCTTGACACGACGTAAAAAACATCG TATAGTTCGTTTAAATCGTCTATTTGAGGAAAGTGGATTAATCACCGATTTTACGAAGATTT [0 CAATTAATCTTAACCCATATCAATTACGAGTTAAGGGCTTGACCGATGAATTGTCTAATGAA GAACTGTTTATCGCTCTTAAAAATATGGTGAAACACCGTGGGATTAGTTACCTCGATGATGC TAGTGATGACGGAAATTCATCAGTAGGAGACTATGCACAAATTGTTAAGGAAAATAGTAAA CAATTAGAAACTAAGACACCGGGACAGATACAGTTGGAACGCTACCAAACATATGGTCAAT TACGTGGTGATTTTACTGTTGAGAAAGATGGCAAAAAACATCGCTTGATTAATGTCTTTCCA [5 ACATCAGCTTATCGTTCAGAAGCCTTAAGGATACTGCAAACTCAACAAGAATTTAATCCACA GATTACAGATGAATTTATTAATCGTTATCTCGAAATTTTAACTGGAAAACGGAAATATTATC ATGGACCCGGAAATGAAAAGTCACGGACTGATTATGGTCGTTACAGAACGAGTGGAGAAAC TTTAGACAATATTTTTGGAATTCTAATTGGGAAATGTACATTTTATCCAGAAGAGTTTAGAG CAGCAAAAGCTTCCTACACGGCTCAAGAATTCAATTTGCTAAATGATTTGAACAATCTAACA !0 GTTCCTACTGAAACCAAAAAGTTGAGCAAAGAACAGAAGAATCAAATCATTAATTATGTCA AAAATGAAAAGGCAATGGGGCCAGCGAAACTTTTTAAATATATCGCTAAGTTACTTTCTTGT GATGTTGCAGATATCAAGGGATACCGTATCGACAAATCAGGTAAGGCTGAGATTCATACTTT CGAAGCCTATCGAAAAATGAAAACGCTTGAAACCTTAGATATTGAACAAATGGATAGAGAA ACGCTTGATAAATTAGCCTATGTCTTAACATTAAACACTGAGAGGGAAGGTATTCAAGAAG !5 CCTTAGAACATGAATTTGCTGATGGTAGCTTTAGCCAGAAGCAAGTTGACGAATTGGTTCAA TTCCGCAAAGCAAATAGTTCCATTTTTGGAAAAGGATGGCATAATTTTTCTGTCAAACTGAT GATGGAGTTAATTCCAGAATTGTATGAGACGTCAGAAGAGCAAATGACTATCCTGACACGA CTTGGAAAACAAAAACGACTTCGTCTTCAAATAAAACAAAATATTTCAAATAAAACAAAAT ATATAGATGAGAAACTATTAACTGAAGAAATCTATAATCCTGTTGTTGCTAAGTCTGTTCGC ;0 CAGGCTATAAAAATCGTAAATGCGGCGATTAAAGAATACGGAGACTTTGACAATATTGTCA TCGAAATGGCTCGTGAAACAAATGAAGATGATGAAAAGAAAGCTATTCAAAAGATTCAAAA AGCCAACAAAGATGAAAAAGATGCAGCAATGCTTAAGGCTGCTAACCAATATAATGGAAA GGCTGAATTACCACATAGTGTTTTCCACGGTCATAAGCAATTAGCGACTAAAATCCGCCTTT GGCATCAGCAAGGAGAACGTTGCCTTTATACTGGTAAGACAATCTCAATCCATGATTTGATA ;5 AATAATCCTAATCAGTTTGAAGTAGATCATATTTTACCTCTTTCTATCACATTCGATGATAGC CTTGCAAATAAGGTTTTGGTTTATGCAACTGCTAACCAAGAAAAAGGACAACGAACACCTT ATCAGGCTTTAGATAGTATGGATGATGCGTGGTCTTTCCGTGAATTAAAAGCTTTTGTACGT GAGTCAAAAACACTTTCAAACAAGAAAAAAGAATACCTCCTTACAGAAGAAGATATTTCAA AGTTTGATGTTCGAAAGAAATTTATTGAACGAAATCTTGTAGATACAAGATACGCTTCAAGA 40 GTTGTCCTCAATGCCCTTCAAGAACACTTTAGAGCTCACAAGATTGATACAAAAGTTTCCGT GGTTCGTGGCCAATTTACATCTCAATTGAGACGCCATTGGGGAATTGAGAAGACTCGTGATA CTTATCATCACCATGCTGTCGATGCATTGATTATTGCCGCCTCAAGTCAGTTGAATTTGTGGA AAAAACAAAAGAATACCCTTGTAAGTTATTCAGAAGAACAACTCCTTGATATTGAAACAGG TGAACTTATTAGTGATGATGAGTACAAGGAATCTGTGTTCAAAGCCCCTTATCAACATTTTG 45 TTGATACATTGAAGAGTAAAGAATTTGAAGACAGTATCTTATTCTCATATCAAGTGGATTCT AAGTTTAATCGTAAAATATCAGATGCCACTATTTATGCGACAAGACAGGCTAAAGTGGGAA AAGATAAGAAGGATGAAACTTATGTCTTAGGGAAAATCAAAGATATCTATACTCAGGATGG TTATGATGCCTTTATGAAGATTTATAAGAAGGATAAGTCAAAATTCCTCATGTATCGTCACG ACCCACAAACCTTTGAGAAAGTTATCGAGCCAATTTTAGAGAACTATCCTAATAAGCAAAT 50 GAATGAAAAAGGAAAAGAGGTACCATGTAATCCTTTCCTAAAATATAAAGAAGAACATGGC TATATTCGTAAATATAGTAAAAAAGGCAATGGTCCTGAAATCAAGAGTCTTAAATACTATG ATAGTAAGCTTTTAGGTAATCCTATTGATATTACTCCAGAGAATAGTAAAAATAAAGTTGTC TTACAGTCATTAAAACCTTGGAGAACAGATGTCTATTTCAATAAGGCTACTGGAAAATACGA AATCCTTGGATTAAAATATGCTGATCTACAATTTGAGAAAGGGACAGGAACATATAAGATT 55 TCCCAGGAAAAATACAATGACATTAAGAAAAAAGAGGGTGTAGATTCTGATTCAGAATTCA AGTTTACACTTTATAAAAATGATTTGTTACTCGTTAAAGATACAGAAACAAAAGAACAACA GCTTTTCCGTTTTCTTTCTCGAACTTTACCTAAACAAAAGCATTATGTTGAATTAAAACCTTA TGATAAACAGAAATTTGAAGGAGGTGAGGCGTTAATTAAAGTGTTGGGTAACGTTGCTAAT

GGTGGTCAATGCATAAAAGGACTAGCAAAATCAAATATTTCTATTTATAAAGTAAGAACAG

153 5 ATGTCCTAGGAAATCAGCATATCATCAAAAATGAGGGTGATAAGCCTAAGCTAGATTTTTA ATATTAATTGTTAGAAAGTGTTGCAATTATAGTTATCATATGCTATAATAATCGTGTAAGGG ACGCCTTACACAGTTACTTAAATCTTGCAGAAGCTACAAAGATAAGGCTTCATGCCGAAATC AACACCCTGTCATTTTATGGCAGGGTGTTTTCGTTATTTAAAGAGGAGAAGAAATGACTTGG AGAGTTGTACATGTCAGTCAAAGTGAGAAGATGCGCTTAAAGCTTGATAACTTATTAGTGCA 0 AAAAATGGGACAAGAGTTTACGGTGCCACTAAGTGATATTTCGATAATCGTTGCAGAAGGT GGGGATACAGTTGTTACCCTTCGTCTATTAAGTGCCTTAAGTAAATATAATATTGCCTTGGTC GTTTGTGATAACGAACATTTACCAACAGGAATTTATCACTCACAAAATGGGCACTTTAGAGC GTACAAGCGCTTGAAAGAACAGCTGGATTGGTCTCAGAAACAAAAGGACAAGGCATGGCA GATTGTAACTTATTATAAAATCAATAACCAAGAGGATGTTCTAGCCATGTTTGAAAAAAGTC [5 TGGACAACATTAGATTACTTTCAGACTATAAAGAGCAGATAGAACCTGGTGATAGAACGAA TAGAGAGGGACATGCTGCCAAGGTCTACTTTAATGAGCTCTTTGGTAAACAATTTGTCAGAG TAACTCAGCAAGAAGCTGATGTCATCAATGCTGGTTTAAACTATGGCTATGCTATCATGAGG GCTCAGATGGCTAGAATAGTGGCGGGTTATGGTTTAAATGGCCTATTAGGAATCTTCCATAA AAATGAATACAATCAGTTTAATTTGGTTGACGATTTGATGGAGCCATTTAGACAGATTGTAG !0 ATGTTTGGGTATATGATAATCTACGAGATCAGGAATTCCTTAAGTATGAGTATAGGTTGGGA TTGACAGATTTACTCAATGCTAAAATCAAATATGGCAAAGAGACTTGCTCAGTGACAGTTGC TATGGACAAATATGTCAAAGGCTTTATCAAATATATTTCGGAAAAAGATAGTAGTAAATTTC ACTGCCCAGTGGTATCAAGTTTAGAGTGGAGAAAATAAGATGAGGTATGAAGCATTGAGAT TATTATGTTTTTTTGATTTACCAATGGAATCCAAGGATGAAAAAAGAATATATCGTAATTTT !5 CGTAAAGAATTAATTTCAAATGGGTTTGAAATGTTACAATTTTCGGTCTACTATCGCACTTGT CCTAATAGAAGCTTTGCAAATAAATTTTATAAGAAGTTAAAGATTAGCAATCTTCCTGCTGG GAATGTGAGACTTTTGGCAGTTACTGAAAAACAATTTTCAGAGATGACATTAATTATAGGTG GTAAAACTAAGCAAGAAGAAATCGTCAGTGATAATAAGTTGGTGGTTATATGAAATATTTT GTACAACATCCTTACAAAGAACGTATTGAATTAAATATTGGTGCAATCACACAAATTGTTGG ;0 TCAGAATAAAGAACTCAAATATTATATTTGGCAAATTTTGAGCTGGTATTTTGGCGGAAAAA AATACTCAAGTGAGGACTTAAGTATTTTTGATTATGAGGAACCTACTATACTTGATGAGTCT GGAGAAATAGTGAAGCGAAGTAGCTATCACTATATCGACATTTCAAGTTTTAAGGATTTACT GGAGCAGATGGAATACAAGAAAGGAACACTTGCTCAGGGTTACCTTAGTAAAATTCTCAAT CAGGTTGATATTGTAGGCCATTTGGAGAAAATTAATGAACAAGTAGAGCTTATAGAAGGAG ;5 CAATGAATCAGCATATAAACTTAAACTGTGGTCAGGTGGAGTACCATTTGGAGAATCACCCT CTAACACTAGACCAATTACTTTCAAAAAATTTTAGTCCCTTTTTTGCTATCGAGAATAAGAA TTTATCTTTTGAATGGGTTTCAAATACTGATAAACTTTCTCTCTTTCTAGAAATGTTAGACCG CCTTCTGTCACAAACAACAGAGAAGTATCTCATTGTGCTAAAAAATATTGATGGCTTTATCT CAGAAGAATCTTATACTATTTTTTATAGGCAAATCTGTCATCTGGTCAAGAAGTATCCAAAT W- CTAACCTTTATTTTGTTTCCTAGTGACCAAGGCTATTTAAAAATTGATGAAGAAAATAGTAG GTTCGTCAATATTTTATCTGACCAGGTGGAGCATTTGTATGATGTTGAGTTTATGTATGAAA GAGTAATGAAATATTATCCAAGTAATGATTTTCCGACGAGAGAAGGTTTTAGGATGTCTTTA GAAACTGTGACACCTTATTTATTGACAAAAATGCTGAGACAACCTAGTCTCTCACTTGTTGA TTCAGTAATATTGAATATCCTAAATCAGTTGTTTCATTTTAGTTACCGTATAAGATATTCTCA 45 GACACCTGATAAGGAACTATTACATAAATTTTTAGAAAGTAAGGATTGA (SEQ ID NO:461) SEQ ID NO:462: ATGAGTGACTTAGTTTTAGGACTTGATATCGGTATAGGTTCTGTTGGTGTAGGTATCCTTAAC AAAGTGACAGGAGAAATTATCCATAAAAACTCACGCATCTTCCCAGCAGCTCAAGCAGAAA 50 ATAACCTAGTACGTAGAACGAATCGTCAAGGAAGACGCTTGACACGACGTAAAAAACATCG TATAGTTCGTTTAAATCGTCTATTTGAGGAAAGTGGATTAATCACCGATTTTACGAAGATTT CAATTAATCTTAACCCATATCAATTACGAGTTAAGGGCTTGACCGATGAATTGTCTAATGAA GAACTGTTTATCGCTCTTAAAAATATGGTGAAACACCGTGGGATTAGTTACCTCGATGATGC TAGTGATGACGGAAATTCATCAGTAGGAGACTATGCACAAATTGTTAAGGAAAATAGTAAA 55 CAATTAGAAACTAAGACACCGGGACAGATACAGTTGGAACGCTACCAAACATATGGTCAAT TACGTGGTGATTTTACTGTTGAGAAAGATGGCAAAAAACATCGCTTGATTAATGTCTTTCCA ACATCAGCTTATCGTTCAGAAGCCTTAAGGATACTGCAAACTCAACAAGAATTTAATCCACA GATTACAGATGAATTTATTAATCGTTATCTCGAAATTTTAACTGGAAAACGGAAATATTATC

ATGGACCCGGAAATGAAAAGTCACGGACTGATTATGGTCGTTACAGAACGAGTGGAGAAAC

154 5 TTTAGACAATATTTTTGGAATTCTAATTGGGAAATGTACATTTTATCCAGAAGAGTTTAGAG CAGCAAAAGCTTCCTACACGGCTCAAGAATTCAATTTGCTAAATGATTTGAACAATCTAACA GTTCCTACTGAAACCAAAAAGTTGAGCAAAGAACAGAAGAATCAAATCATTAATTATGTCA AAAATGAAAAGGCAATGGGGCCAGCGAAACTTTTTAAATATATCGCTAAGTTACTTTCTTGT GATGTTGCAGATATCAAGGGATACCGTATCGACAAATCAGGTAAGGCTGAGATTCATACTTT 0 CGAAGCCTATCGAAAAATGAAAACGCTTGAAACCTTAGATATTGAACAAATGGATAGAGAA ACGCTTGATAAATTAGCCTATGTCTTAACATTAAACACTGAGAGGGAAGGTATTCAAGAAG CCTTAGAACATGAATTTGCTGATGGTAGCTTTAGCCAGAAGCAAGTTGACGAATTGGTTCAA TTCCGCAAAGCAAATAGTTCCATTTTTGGAAAAGGATGGCATAATTTTTCTGTCAAACTGAT GATGGAGTTAATTCCAGAATTGTATGAGACGTCAGAAGAGCAAATGACTATCCTGACACGA [5 CTTGGAAAACAAAAACGACTTCGTCTTCAAATAAAACAAAATATTTCAAATAAAACAAAAT ATATAGATGAGAAACTATTAACTGAAGAAATCTATAATCCTGTTGTTGCTAAGTCTGTTCGC CAGGCTATAAAAATCGTAAATGCGGCGATTAAAGAATACGGAGACTTTGACAATATTGTCA TCGAAATGGCTCGTGAAACAAATGAAGATGATGAAAAGAAAGCTATTCAAAAGATTCAAAA AGCCAACAAAGATGAAAAAGATGCAGCAATGCTTAAGGCTGCTAACCAATATAATGGAAA !0 GGCTGAATTACCACATAGTGTTTTCCACGGTCATAAGCAATTAGCGACTAAAATCCGCCTTT GGCATCAGCAAGGAGAACGTTGCCTTTATACTGGTAAGACAATCTCAATCCATGATTTGATA AATAATCCTAATCAGTTTGAAGTAGATCATATTTTACCTCTTTCTATCACATTCGATGATAGC CTTGCAAATAAGGTTTTGGTTTATGCAACTGCTAACCAAGAAAAAGGACAACGAACACCTT ATCAGGCTTTAGATAGTATGGATGATGCGTGGTCTTTCCGTGAATTAAAAGCTTTTGTACGT !5 GAGTCAAAAACACTTTCAAACAAGAAAAAAGAATACCTCCTTACAGAAGAAGATATTTCAA AGTTTGATGTTCGAAAGAAATTTATTGAACGAAATCTTGTAGATACAAGATACGCTTCAAGA GTTGTCCTCAATGCCCTTCAAGAACACTTTAGAGCTCACAAGATTGATACAAAAGTTTCCGT GGTTCGTGGCCAATTTACATCTCAATTGAGACGCCATTGGGGAATTGAGAAGACTCGTGATA CTTATCATCACCATGCTGTCGATGCATTGATTATTGCCGCCTCAAGTCAGTTGAATTTGTGGA ;0 AAAAACAAAAGAATACCCTTGTAAGTTATTCAGAAGAACAACTCCTTGATATTGAAACAGG TGAACTTATTAGTGATGATGAGTACAAGGAATCTGTGTTCAAAGCCCCTTATCAACATTTTG TTGATACATTGAAGAGTAAAGAATTTGAAGACAGTATCTTATTCTCATATCAAGTGGATTCT AAGTTTAATCGTAAAATATCAGATGCCACTATTTATGCGACAAGACAGGCTAAAGTGGGAA AAGATAAGAAGGATGAAACTTATGTCTTAGGGAAAATCAAAGATATCTATACTCAGGATGG ;5 TTATGATGCCTTTATGAAGATTTATAAGAAGGATAAGTCAAAATTCCTCATGTATCGTCACG ACCCACAAACCTTTGAGAAAGTTATCGAGCCAATTTTAGAGAACTATCCTAATAAGCAAAT GAATGAAAAAGGAAAAGAGGTACCATGTAATCCTTTCCTAAAATATAAAGAAGAACATGGC TATATTCGTAAATATAGTAAAAAAGGCAATGGTCCTGAAATCAAGAGTCTTAAATACTATG ATAGTAAGCTTTTAGGTAATCCTATTGATATTACTCCAGAGAATAGTAAAAATAAAGTTGTC W0 TTACAGTCATTAAAACCTTGGAGAACAGATGTCTATTTCAATAAGGCTACTGGAAAATACGA AATCCTTGGATTAAAATATGCTGATCTACAATTTGAGAAAGGGACAGGAACATATAAGATT TCCCAGGAAAAATACAATGACATTAAGAAAAAAGAGGGTGTAGATTCTGATTCAGAATTCA AGTTTACACTTTATAAAAATGATTTGTTACTCGTTAAAGATACAGAAACAAAAGAACAACA GCTTTTCCGTTTTCTTTCTCGAACTTTACCTAAACAAAAGCATTATGTTGAATTAAAACCTTA 45 TGATAAACAGAAATTTGAAGGAGGTGAGGCGTTAATTAAAGTGTTGGGTAACGTTGCTAAT GGTGGTCAATGCATAAAAGGACTAGCAAAATCAAATATTTCTATTTATAAAGTAAGAACAG ATGTCCTAGGAAATCAGCATATCATCAAAAATGAGGGTGATAAGCCTAAGCTAGATTTTTA A (SEQ ID NO:462) 50 SEQ ID NO:463: ATGACTTGGAGAGTTGTACATGTCAGTCAAAGTGAGAAGATGCGCTTAAAGCTTGATAACTT ATTAGTGCAAAAAATGGGACAAGAGTTTACGGTGCCACTAAGTGATATTTCGATAATCGTTG CAGAAGGTGGGGATACAGTTGTTACCCTTCGTCTATTAAGTGCCTTAAGTAAATATAATATT GCCTTGGTCGTTTGTGATAACGAACATTTACCAACAGGAATTTATCACTCACAAAATGGGCA 55 CTTTAGAGCGTACAAGCGCTTGAAAGAACAGCTGGATTGGTCTCAGAAACAAAAGGACAAG GCATGGCAGATTGTAACTTATTATAAAATCAATAACCAAGAGGATGTTCTAGCCATGTTTGA AAAAAGTCTGGACAACATTAGATTACTTTCAGACTATAAAGAGCAGATAGAACCTGGTGAT AGAACGAATAGAGAGGGACATGCTGCCAAGGTCTACTTTAATGAGCTCTTTGGTAAACAAT

TTGTCAGAGTAACTCAGCAAGAAGCTGATGTCATCAATGCTGGTTTAAACTATGGCTATGCT

155 5 ATCATGAGGGCTCAGATGGCTAGAATAGTGGCGGGTTATGGTTTAAATGGCCTATTAGGAA TCTTCCATAAAAATGAATACAATCAGTTTAATTTGGTTGACGATTTGATGGAGCCATTTAGA CAGATTGTAGATGTTTGGGTATATGATAATCTACGAGATCAGGAATTCCTTAAGTATGAGTA TAGGTTGGGATTGACAGATTTACTCAATGCTAAAATCAAATATGGCAAAGAGACTTGCTCA GTGACAGTTGCTATGGACAAATATGTCAAAGGCTTTATCAAATATATTTCGGAAAAAGATA [0 GTAGTAAATTTCACTGCCCAGTGGTATCAAGTTTAGAGTGGAGAAAATAA (SEQ ID NO:463) SEQ ID NO:464: ATGAGGTATGAAGCATTGAGATTATTATGTTTTTTTGATTTACCAATGGAATCCAAGGATGA AAAAAGAATATATCGTAATTTTCGTAAAGAATTAATTTCAAATGGGTTTGAAATGTTACAAT [5 TTTCGGTCTACTATCGCACTTGTCCTAATAGAAGCTTTGCAAATAAATTTTATAAGAAGTTA AAGATTAGCAATCTTCCTGCTGGGAATGTGAGACTTTTGGCAGTTACTGAAAAACAATTTTC AGAGATGACATTAATTATAGGTGGTAAAACTAAGCAAGAAGAAATCGTCAGTGATAATAAG TTGGTGGTTATATGA (SEQ ID NO:464) !0 SEQ ID NO:465: ATGAAATATTTTGTACAACATCCTTACAAAGAACGTATTGAATTAAATATTGGTGCAATCAC ACAAATTGTTGGTCAGAATAAAGAACTCAAATATTATATTTGGCAAATTTTGAGCTGGTATT TTGGCGGAAAAAAATACTCAAGTGAGGACTTAAGTATTTTTGATTATGAGGAACCTACTATA CTTGATGAGTCTGGAGAAATAGTGAAGCGAAGTAGCTATCACTATATCGACATTTCAAGTTT !5 TAAGGATTTACTGGAGCAGATGGAATACAAGAAAGGAACACTTGCTCAGGGTTACCTTAGT AAAATTCTCAATCAGGTTGATATTGTAGGCCATTTGGAGAAAATTAATGAACAAGTAGAGC TTATAGAAGGAGCAATGAATCAGCATATAAACTTAAACTGTGGTCAGGTGGAGTACCATTT GGAGAATCACCCTCTAACACTAGACCAATTACTTTCAAAAAATTTTAGTCCCTTTTTTGCTAT CGAGAATAAGAATTTATCTTTTGAATGGGTTTCAAATACTGATAAACTTTCTCTCTTTCTAGA ;0 AATGTTAGACCGCCTTCTGTCACAAACAACAGAGAAGTATCTCATTGTGCTAAAAAATATTG ATGGCTTTATCTCAGAAGAATCTTATACTATTTTTTATAGGCAAATCTGTCATCTGGTCAAGA AGTATCCAAATCTAACCTTTATTTTGTTTCCTAGTGACCAAGGCTATTTAAAAATTGATGAA GAAAATAGTAGGTTCGTCAATATTTTATCTGACCAGGTGGAGCATTTGTATGATGTTGAGTT TATGTATGAAAGAGTAATGAAATATTATCCAAGTAATGATTTTCCGACGAGAGAAGGTTTTA ;5 GGATGTCTTTAGAAACTGTGACACCTTATTTATTGACAAAAATGCTGAGACAACCTAGTCTC TCACTTGTTGATTCAGTAATATTGAATATCCTAAATCAGTTGTTTCATTTTAGTTACCGTATA AGATATTCTCAGACACCTGATAAGGAACTATTACATAAATTTTTAGAAAGTAAGGATTGA (SEQ ID NO:465) 40 SEQ ID NO:473: ATGAGTGACTTAGTTTTAGGACTTGATATCGGTATAGGTTCTGTTGGTGTAGGTATCCTTAAC AAAGTGACAGGAGAAATTATCCATAAAAACTCACGCATCTTCCCAGCAGCTCAAGCAGAAA ATAACCTAGTACGTAGAACGAATCGTCAAGGAAGACGCTTGACACGACGTAAAAAACATCG TATAGTTCGTTTAAATCGTCTATTTGAGGAAAGTGGATTAATCACCGATTTTACGAAGATTT 45 CAATTAATCTTAACCCATATCAATTACGAGTTAAGGGCTTGACCGATGAATTGTCTAATGAA GAACTGTTTATCGCTCTTAAAAATATGGTGAAACACCGTGGGATTAGTTACCTCGATGATGC TAGTGATGACGGAAATTCATCAGTAGGAGACTATGCACAAATTGTTAAGGAAAATAGTAAA CAATTAGAAACTAAGACACCGGGACAGATACAGTTGGAACGCTACCAAACATATGGTCAAT TACGTGGTGATTTTACTGTTGAGAAAGATGGCAAAAAACATCGCTTGATTAATGTCTTTCCA 50 ACATCAGCTTATCGTTCAGAAGCCTTAAGGATACTGCAAACTCAACAAGAATTTAATTCACA GATTACAGATGAATTTATTAATCGTTATCTCGAAATTTTAACTGGAAAACGGAAATATTATC ATGGACCCGGAAATGAAAAGTCACGGACTGATTATGGTCGTTACAGAACGAATGGAGAAAC TTTAGACAATATTTTTGGAATTCTAATTGGGAAATGTACATTTTATCCAGACGAGTTTAGAG CAGCAAAAGCTTCCTACACGGCTCAAGAATTCAATTTGCTAAATGATTTGAACAATCTAACA 55 GTTCCTACTGAAACCAAAAAGTTGAGCAAAGAACAGAAGAATCAAATCATTAATTATGTCA AAAATGAAAAGGTAATGGGGCCAGCGAAACTTTTTAAATATATCGCTAAATTACTTTCTTGT GATGTTGCAGATATCAAGGGACACCGTATCGACAAATCAGGTAAGGCTGAGATTCATACTT

TCGAAGCCTATCGAAAAATGAAAACGCTTGAAACCTTAGATATTGAGCAAATGGATAGAGA

156 5 AACGCTTGATAAATTAGCCTATGTCTTAACATTAAACACTGAGAGGGAAGGTATTCAAGAA GCTTTAGAACATGAATTTGCTGATGGTAGCTTTAGCCAGAAGCAAGTTGACGAATTGGTTCA ATTCCGCAAAGCAAATAGTTCCATTTTTGGAAAAGGATGGCATAATTTTTCTGTCAAACTGA TGATGGAGTTAATTCCAGAATTGTATGAGACGTCAGAAGAGCAAATGACTATCCTGACACG ACTTGGAAAACAAAAAACAACTTCGTCTTCAAATAAAACAAAATATATAGATGAGAAACTA 0 TTAACTGAAGAAATCTATAATCCTGTTGTTGCTAAGTCTGTTCGCCAGGCTATAAAAATCGT AAATGCGGCGATTAAAGAATACGGAGACTTTGACAATATTGTCATCGAAATGGCTCGTGAA ACAAATGAAGATGATGAAAAGAAAGCTATTCAAAAGATTCAAAAAGCCAACAAAGATGAA AAAGATGCAGCAATGCTTAAGGCTGCTAACCAATATAATGGAAAGGCTGAATTACCACATA GTGTTTTCCACGGTCATAAGCAATTAGCGACTAAAATCCGCCTTTGGCATCAGCAAGGAGAA [5 CGTTGCCTTTATACTGGTAAGACAATCTCAATCCATGATTTGATAAATAATCCTAATCAGTTT GAAGTAGATCATATTTTACCTCTTTCTATCACATTCGATGATAGCCTTGCAAATAAGGTTTTG GTTTATGCAACTGCTAACCAAGAAAAAGGACAACGAACACCTTATCAGGCTTTAGATAGTA TGGATGATGCGTGGTCTTTCCGTGAATTAAAAGCTTTTGTACGTGAGTCAAAAACACTTTCA AACAAGAAAAAAGAATACCTCCTTACAGAAGAAGATATTTCAAAGTTTGATGTTCGAAAGA !0 AATTTATTGAACGAAATCTTGTAGATACAAGATACGCTTCAAGAGTTGTCCTCAATGCCCTT CAAGAACACTTTAGAGCTCACAAGATTGATACAAAAGTTTCCGTGGTTCGTGGCCAATTTAC ATCTCAATTGAGACGCCATTGGGGAATTGAGAAGACTCGTGATACTTATCATCACCATGCTG TCGATGCATTGATTATTGCCGCCTCAAGTCAGTTGAATTTGTGGAAAAAACAAAAGAATACC CTTGTAAGTTATTCAGAAGAACAACTCCTTGATATTGAAACAGGTGAACTTATTAGTGATGA !5 TGAGTACAAGGAATCTGTGTTCAAAGCCCCTTATCAACATTTTGTTGATACATTGAAGAGTA AAGAATTTGAAGACAGTATCTTATTCTCATATCAAGTGGATTCTAAGTTTAATCGTAAAATA TCAGATGCCACTATTTATGCGACAAGACAGGCTAAAGTGGGAAAAGATAAGAAGGATGAA ACTTATGTCTTAGGGAAAATCAAAGATATCTATACTCAGGATGGTTATGATGCCTTTATGAA GATTTATAAGAAGGATAAGTCAAAATTCCTCATGTATCGTCACGACCCACAAACCTTTGAGA ;0 AAGTTATCGAGCCAATTTTAGAGAACTATCCTAATAAGGAAATGAATGAAAAAGGGAAAGA AGTACCATGTAATCCTTTCCTAAAATATAAAGAAGAACATGGCTATATTCGTAAATATAGTA AAAAAGGCAATGGTCCTGAAATCAAGAGTCTTAAATACTATGATAGTAAGCTTTTAGGTAA TCCTATTGATATTACTCCAGAGAATAGTAAAAATAAAGTTGTCTTACAGTCATTAAAACCTT GGAGAACAGATGTCTATTTCAATAAAAATACTGGTAAATATGAAATTTTAGGACTGAAATA ;5 TGCTGATTTACAATTTGAAAAGAAGACAGGAACATATAAGATTTCCCAGGAAAAATACAAT GGCATTATGAAAGAAGAGGGTGTAGATTCTGATTCAGAATTCAAGTTTACACTTTATAAAAA TGATTTGTTACTCGTTAAAGATACAGAAACAAAAGAACAACAGCTTTTCCGTTTTCTTTCTC GAACTATGCCTAATGTGAAATATTATGTAGAGTTAAAGCCTTATTCAAAAGATAAATTTGAG AAGAATGAGTCACTTATTGAAATTTTAGGTTCTGCAGATAAGTCAGGACGATGTATAAAAG W- GGCTAGGAAAATCAAATATTTCTATTTATAAGGTAAGAACAGATGTCCTAGGAAATCAGCA TATCATCAAAAATGAGGGTGATAAGCCTAAGCTAGATTTTTAATATTAATTGTTAAAAAAGT GTTGCAATTATAGTTATCATATGCTATAATAATCGTGTAAGGGACGCCTTACACAGTTACTT AAATCTTGCAGAAGCTACAAAGATAAGGCTTCATGCCGAAATCAACACCCTGTCATTTTATG GCAGGGTGTTTTCGTTATTTAAAGAGGAGAAGAAATGACTTGGAGAGTTGTACATGTCAGTC 45 AAAGTGAGAAGATGCGCTTAAAGCTTGATAACTTATTAGTGCAAAAGATGGGACAAGAGTT TACGGTGCCACTAAGTGATATTTCGATAATCGTTGCAGAAGGTGGGGATACAGTTGTTACCC TTCGTCTATTAAGTGCCTTAAGTAAATATAATATTGCCTTGGTCGTTTGTGATAACGAACATT TACCAACAGGAATTTATCACTCACAAAATGGGCACTTTAGAGCGTACAAGCGCTTGAAAGA ACAGCTGGATTGGTCTCAGAAACAAAAGGAAAAGGCATGGCAGATTGTAACTTATTATAAA 50 ATCAATAACCAAGAGGATGTCCTAGCCATGTTTGAAAAAAGTCTGGACAACATTAGATTAC TTTCAGACTATAAAGAGCAGATAGAACCTGGTGATAGAACGAATAGAGAGGGACATGCTGC CAAGGTCTACTTTAATGAGCTCTTTGGTAAACAATTTGTCAGAGTAACTCAGCAAGAAGCTG ATGTCATCAATGCTGGTTTAAACTATGGCTATGCTATCATGAGGGCTCAGATGGCTAGAATA GTGGCGGGTTATGGTTTAAATGGCCTATTAGGAATCTTCCATAAAAATGAATACAATCAGTT 55 TAATTTGGTTGACGATTTGATGGAGCCATTTAGACAGATTGTAGATGTTTGGGTATATGATA ATCTACGAGATCAGGAATTCCTTAAGTATGAGTATAGGTTGGGATTGACAGATTTACTCAAT GCTAAAATCAAATATGGCAAAGAGACTTGCTCAGTGACAGTTGCTATGGACAAATATGTCA AAGGCTTTATCAAATATATTTCGGAAAAAGATAGTAGTAAATTTCACTGCCCAGTGGTATCA AGTTTAGAGTGGAGAAAATAAGATGAGGTATGAAGCATTGAGATTATTATGTTTTTTTGATT 60 TACCAATGGAATCCAAGGATGAAAAAAGAATATATCGTAATTTTCGTAAAGAATTAATTTC 157 5 AAATGGGTTTGAAATGTTACAATTTTCGGTCTACTATCGCACTTGTCCTAATAGAAGCTTTGC AAATAAATTTTATAAGAAGTTAAAGATGAGCAATCTTCCTGCTGGGAATGTGAGACTTTTGG CAGTTACTGAAAAACAATTTTCAGAGATGACATTAATTATAGGTGGTAAAACTAAGCAAGA AGAAATCGTCAGTGATAATAAGTTGGTGATCATATGAAATTTTTTGTACAACATCCTTACAA AGAACGTATTGAATTAAATATTGGTGCAATCACACAAATTGTTGGTCAGAATAATGAACTCA [0 AATATTATACTTGGCAGATTTTGAGCTGGTATTTTGGTGGAAAAAAATACTCAAGTGAGGAC TTAAGTATTTTTGATTATGAGGAGCCTACCATACTTGATGAGGCCAGAGAAATAGTGAAACG AAGTAGCTATCACTATATCGACATTTCAAGTTTTAAGGATTTACTGGAGCAGATGGAATACA AGAAAGGAACACTTGCTCAGGGTTACCTTCGTAAAATTGTCAATCAAGTTGATATTGTAGGC CATTTGGAGAAAATTAATGAACAAGTAGAGCTTATTGAAGAAGCTATGAATCGGCATATAA [5 ACTTAAACTGTGGACAGGTAGAATACCATTTGGAGAATCTCCCTCTAACACTAGACCAACTA CTCACAAAAAATTTTAGCCCATTTTTTGCCATTGAGAACAAGAATCTATCTTTTGAATGGGTT TCTAATATTGATAAACTATCCCTCTTTTTAGAAATGTTAGACCATCTTCTTTCACAAACAACA GAGAAGTATCTCATTGTGCTAAAAAATATTGATGGCTTTATCTCAGAAGAATCTTATACTAT TTTTTATAGGCAAATCTGTCATCTGGTCAAGAAGTATCCAAATCTAACCTTTATTTTGTTTCC !0 TAGTGACCAAGGCTATTTAAAAATTGATGAAGAAAATAGTAGGTTCGTCAATATTTTATCTG ACCAGGTGGAACATTTGTATGATGTTGAGTTTATGTATGAAAGGGTAATGAAATATTATCCA AGTAATGATTTTCCGACGAGAGAAGGTTTTAGGATGTCTTTAGAAACTGTGACACCTTATTT ATTGACAAAAATGCTGAGACAACCTAGTCTCTCACTTGTTGATTCAGTAATATTGAATATCC TAAATCAGCTGTTTCATTTTAGTTACCGTATAAGATGTTCTCAGACACCTGATAAGGAACTA !5 TTACAGAAATTTTTAGAAAGTAAGGATTGA (SEQ ID NO:473) SEQ ID NO:474: ATGAGTGACTTAGTTTTAGGACTTGATATCGGTATAGGTTCTGTTGGTGTAGGTATCCTTAAC AAAGTGACAGGAGAAATTATCCATAAAAACTCACGCATCTTCCCAGCAGCTCAAGCAGAAA ;0 ATAACCTAGTACGTAGAACGAATCGTCAAGGAAGACGCTTGACACGACGTAAAAAACATCG TATAGTTCGTTTAAATCGTCTATTTGAGGAAAGTGGATTAATCACCGATTTTACGAAGATTT CAATTAATCTTAACCCATATCAATTACGAGTTAAGGGCTTGACCGATGAATTGTCTAATGAA GAACTGTTTATCGCTCTTAAAAATATGGTGAAACACCGTGGGATTAGTTACCTCGATGATGC TAGTGATGACGGAAATTCATCAGTAGGAGACTATGCACAAATTGTTAAGGAAAATAGTAAA ;5 CAATTAGAAACTAAGACACCGGGACAGATACAGTTGGAACGCTACCAAACATATGGTCAAT TACGTGGTGATTTTACTGTTGAGAAAGATGGCAAAAAACATCGCTTGATTAATGTCTTTCCA ACATCAGCTTATCGTTCAGAAGCCTTAAGGATACTGCAAACTCAACAAGAATTTAATTCACA GATTACAGATGAATTTATTAATCGTTATCTCGAAATTTTAACTGGAAAACGGAAATATTATC ATGGACCCGGAAATGAAAAGTCACGGACTGATTATGGTCGTTACAGAACGAATGGAGAAAC 40 TTTAGACAATATTTTTGGAATTCTAATTGGGAAATGTACATTTTATCCAGACGAGTTTAGAG CAGCAAAAGCTTCCTACACGGCTCAAGAATTCAATTTGCTAAATGATTTGAACAATCTAACA GTTCCTACTGAAACCAAAAAGTTGAGCAAAGAACAGAAGAATCAAATCATTAATTATGTCA AAAATGAAAAGGTAATGGGGCCAGCGAAACTTTTTAAATATATCGCTAAATTACTTTCTTGT GATGTTGCAGATATCAAGGGACACCGTATCGACAAATCAGGTAAGGCTGAGATTCATACTT 45 TCGAAGCCTATCGAAAAATGAAAACGCTTGAAACCTTAGATATTGAGCAAATGGATAGAGA AACGCTTGATAAATTAGCCTATGTCTTAACATTAAACACTGAGAGGGAAGGTATTCAAGAA GCTTTAGAACATGAATTTGCTGATGGTAGCTTTAGCCAGAAGCAAGTTGACGAATTGGTTCA ATTCCGCAAAGCAAATAGTTCCATTTTTGGAAAAGGATGGCATAATTTTTCTGTCAAACTGA TGATGGAGTTAATTCCAGAATTGTATGAGACGTCAGAAGAGCAAATGACTATCCTGACACG 50 ACTTGGAAAACAAAAAACAACTTCGTCTTCAAATAAAACAAAATATATAGATGAGAAACTA TTAACTGAAGAAATCTATAATCCTGTTGTTGCTAAGTCTGTTCGCCAGGCTATAAAAATCGT AAATGCGGCGATTAAAGAATACGGAGACTTTGACAATATTGTCATCGAAATGGCTCGTGAA ACAAATGAAGATGATGAAAAGAAAGCTATTCAAAAGATTCAAAAAGCCAACAAAGATGAA AAAGATGCAGCAATGCTTAAGGCTGCTAACCAATATAATGGAAAGGCTGAATTACCACATA 55 GTGTTTTCCACGGTCATAAGCAATTAGCGACTAAAATCCGCCTTTGGCATCAGCAAGGAGAA CGTTGCCTTTATACTGGTAAGACAATCTCAATCCATGATTTGATAAATAATCCTAATCAGTTT GAAGTAGATCATATTTTACCTCTTTCTATCACATTCGATGATAGCCTTGCAAATAAGGTTTTG GTTTATGCAACTGCTAACCAAGAAAAAGGACAACGAACACCTTATCAGGCTTTAGATAGTA

TGGATGATGCGTGGTCTTTCCGTGAATTAAAAGCTTTTGTACGTGAGTCAAAAACACTTTCA

158 5 AACAAGAAAAAAGAATACCTCCTTACAGAAGAAGATATTTCAAAGTTTGATGTTCGAAAGA AATTTATTGAACGAAATCTTGTAGATACAAGATACGCTTCAAGAGTTGTCCTCAATGCCCTT CAAGAACACTTTAGAGCTCACAAGATTGATACAAAAGTTTCCGTGGTTCGTGGCCAATTTAC ATCTCAATTGAGACGCCATTGGGGAATTGAGAAGACTCGTGATACTTATCATCACCATGCTG TCGATGCATTGATTATTGCCGCCTCAAGTCAGTTGAATTTGTGGAAAAAACAAAAGAATACC [0 CTTGTAAGTTATTCAGAAGAACAACTCCTTGATATTGAAACAGGTGAACTTATTAGTGATGA TGAGTACAAGGAATCTGTGTTCAAAGCCCCTTATCAACATTTTGTTGATACATTGAAGAGTA AAGAATTTGAAGACAGTATCTTATTCTCATATCAAGTGGATTCTAAGTTTAATCGTAAAATA TCAGATGCCACTATTTATGCGACAAGACAGGCTAAAGTGGGAAAAGATAAGAAGGATGAA ACTTATGTCTTAGGGAAAATCAAAGATATCTATACTCAGGATGGTTATGATGCCTTTATGAA [5 GATTTATAAGAAGGATAAGTCAAAATTCCTCATGTATCGTCACGACCCACAAACCTTTGAGA AAGTTATCGAGCCAATTTTAGAGAACTATCCTAATAAGGAAATGAATGAAAAAGGGAAAGA AGTACCATGTAATCCTTTCCTAAAATATAAAGAAGAACATGGCTATATTCGTAAATATAGTA AAAAAGGCAATGGTCCTGAAATCAAGAGTCTTAAATACTATGATAGTAAGCTTTTAGGTAA TCCTATTGATATTACTCCAGAGAATAGTAAAAATAAAGTTGTCTTACAGTCATTAAAACCTT !0 GGAGAACAGATGTCTATTTCAATAAAAATACTGGTAAATATGAAATTTTAGGACTGAAATA TGCTGATTTACAATTTGAAAAGAAGACAGGAACATATAAGATTTCCCAGGAAAAATACAAT GGCATTATGAAAGAAGAGGGTGTAGATTCTGATTCAGAATTCAAGTTTACACTTTATAAAAA TGATTTGTTACTCGTTAAAGATACAGAAACAAAAGAACAACAGCTTTTCCGTTTTCTTTCTC GAACTATGCCTAATGTGAAATATTATGTAGAGTTAAAGCCTTATTCAAAAGATAAATTTGAG !5 AAGAATGAGTCACTTATTGAAATTTTAGGTTCTGCAGATAAGTCAGGACGATGTATAAAAG GGCTAGGAAAATCAAATATTTCTATTTATAAGGTAAGAACAGATGTCCTAGGAAATCAGCA TATCATCAAAAATGAGGGTGATAAGCCTAAGCTAGATTTTTAA (SEQ ID NO:474) SEQ ID NO:475: ;0 ATGACTTGGAGAGTTGTACATGTCAGTCAAAGTGAGAAGATGCGCTTAAAGCTTGATAACTT ATTAGTGCAAAAGATGGGACAAGAGTTTACGGTGCCACTAAGTGATATTTCGATAATCGTTG CAGAAGGTGGGGATACAGTTGTTACCCTTCGTCTATTAAGTGCCTTAAGTAAATATAATATT GCCTTGGTCGTTTGTGATAACGAACATTTACCAACAGGAATTTATCACTCACAAAATGGGCA CTTTAGAGCGTACAAGCGCTTGAAAGAACAGCTGGATTGGTCTCAGAAACAAAAGGAAAAG ;5 GCATGGCAGATTGTAACTTATTATAAAATCAATAACCAAGAGGATGTCCTAGCCATGTTTGA AAAAAGTCTGGACAACATTAGATTACTTTCAGACTATAAAGAGCAGATAGAACCTGGTGAT AGAACGAATAGAGAGGGACATGCTGCCAAGGTCTACTTTAATGAGCTCTTTGGTAAACAAT TTGTCAGAGTAACTCAGCAAGAAGCTGATGTCATCAATGCTGGTTTAAACTATGGCTATGCT ATCATGAGGGCTCAGATGGCTAGAATAGTGGCGGGTTATGGTTTAAATGGCCTATTAGGAA 40 TCTTCCATAAAAATGAATACAATCAGTTTAATTTGGTTGACGATTTGATGGAGCCATTTAGA CAGATTGTAGATGTTTGGGTATATGATAATCTACGAGATCAGGAATTCCTTAAGTATGAGTA TAGGTTGGGATTGACAGATTTACTCAATGCTAAAATCAAATATGGCAAAGAGACTTGCTCA GTGACAGTTGCTATGGACAAATATGTCAAAGGCTTTATCAAATATATTTCGGAAAAAGATA GTAGTAAATTTCACTGCCCAGTGGTATCAAGTTTAGAGTGGAGAAAATAA (SEQ ID NO:475) 45 SEQ ID NO:476: ATGAGGTATGAAGCATTGAGATTATTATGTTTTTTTGATTTACCAATGGAATCCAAGGATGA AAAAAGAATATATCGTAATTTTCGTAAAGAATTAATTTCAAATGGGTTTGAAATGTTACAAT TTTCGGTCTACTATCGCACTTGTCCTAATAGAAGCTTTGCAAATAAATTTTATAAGAAGTTA 50 AAGATGAGCAATCTTCCTGCTGGGAATGTGAGACTTTTGGCAGTTACTGAAAAACAATTTTC AGAGATGACATTAATTATAGGTGGTAAAACTAAGCAAGAAGAAATCGTCAGTGATAATAAG TTGGTGATCATATGA (SEQ ID NO:476) 55 SEQ ID NO:477: ATGAAATTTTTTGTACAACATCCTTACAAAGAACGTATTGAATTAAATATTGGTGCAATCAC ACAAATTGTTGGTCAGAATAATGAACTCAAATATTATACTTGGCAGATTTTGAGCTGGTATT

TTGGTGGAAAAAAATACTCAAGTGAGGACTTAAGTATTTTTGATTATGAGGAGCCTACCATA

159 5 CTTGATGAGGCCAGAGAAATAGTGAAACGAAGTAGCTATCACTATATCGACATTTCAAGTTT TAAGGATTTACTGGAGCAGATGGAATACAAGAAAGGAACACTTGCTCAGGGTTACCTTCGT AAAATTGTCAATCAAGTTGATATTGTAGGCCATTTGGAGAAAATTAATGAACAAGTAGAGC TTATTGAAGAAGCTATGAATCGGCATATAAACTTAAACTGTGGACAGGTAGAATACCATTTG GAGAATCTCCCTCTAACACTAGACCAACTACTCACAAAAAATTTTAGCCCATTTTTTGCCAT [0 TGAGAACAAGAATCTATCTTTTGAATGGGTTTCTAATATTGATAAACTATCCCTCTTTTTAGA AATGTTAGACCATCTTCTTTCACAAACAACAGAGAAGTATCTCATTGTGCTAAAAAATATTG ATGGCTTTATCTCAGAAGAATCTTATACTATTTTTTATAGGCAAATCTGTCATCTGGTCAAGA AGTATCCAAATCTAACCTTTATTTTGTTTCCTAGTGACCAAGGCTATTTAAAAATTGATGAA GAAAATAGTAGGTTCGTCAATATTTTATCTGACCAGGTGGAACATTTGTATGATGTTGAGTT [5 TATGTATGAAAGGGTAATGAAATATTATCCAAGTAATGATTTTCCGACGAGAGAAGGTTTTA GGATGTCTTTAGAAACTGTGACACCTTATTTATTGACAAAAATGCTGAGACAACCTAGTCTC TCACTTGTTGATTCAGTAATATTGAATATCCTAAATCAGCTGTTTCATTTTAGTTACCGTATA AGATGTTCTCAGACACCTGATAAGGAACTATTACAGAAATTTTTAGAAAGTAAGGATTGA (SEQ ID NO:477) !0 with repeat sequences: SEQ ID NO:1 to SEQ ID NO:10 Functional Combination #2: 5 cas sequences: SEQ ID NO:466 to SEQ ID NO:472, and SEQ ID NO:478 to SEQ ID NO:487 (all of which are S. thermophilus sequences), as shown below: SEQ ID NO:466: ATGAGCGATTTATATAGTCAAAGGTCCAATTATTACCTGTCCTTATCTGAACAAAGAATTAT ;0 CATTAAAAATGATAATAAAGAGATTGTCAAAGAAGTGTCCATTTCACTCGTTGATAATGTAT TACTTTTTGGTAATGCACAACTGACCACCCAACTCATCAAAGCCTTGTCAAAGAACAAGGTG AATGTTTACTATTTCTCAAATGTTGGTCAATTTATTTCTAGTATTGAAACCCACAGGCAGGAC GAATTCCAAAAGCAAGAGTTGCAAGCAAAGGCTTATTTTGAAGAGGATTTCCGTTTAGAGG TTGCGAGGAGTATTGCTACGACCAAGGTGAGGCACCCAATTGCCTTACTTAGAGAGTTTGAT ;5 ACGGATGGTCTACTAGATACCTCAGATTATTCTAGGTTTGAAGATAGTGTCAATGATATTCA GAAAGCTTATTCCATTACAGAAATTATGGGTTACGAAGGTCGCCTTGCGAAATCCTATTTTT ACTATCTGAATTTACTCGTTCCTAATGACTTTCATTTTAATGGTAGGAGTAGACGGCCTGGG GAGGATTGTTTTAACAGTGCCCTCAATTTTGGCTATAGTATCTTATATTCTTGCTTAATGGGC TGATTAAGAAAAACGGGCTAAGCTTGGGATTTGGGGTAATTCACAAGCATCATCAGCATCA 40 TGCGACCTTGGCCAGTGATTTAATGGAAGAATGGAGACCTATCATCGTCGATAATACGCTTA TGGAGTTGGTACGAAATGGTAAACTTCTTTTAAGTCATTTTGAAAATAAGGATCAAGACTTC ATACTCACCCATGAAGGCAGAGAAATCTTTGCACGGGCTTTACGTTCAAGAATATTAGAAGT CCATCAGTATATTGAGTTAGATAAAAAACGCTATTCTTTTCTTTATACAGCAGATAGGCAAA TCAAGAGTTTGATTAGGGCTTTTAGAGAACTTGACCCTAGTCTCTATGAGACAAGTTACACA 45 GGAGGGCATTAATGGGACTTTACTTTAACCTCAGCGAAGAAGAGCGTGAGTTTGCCAAACA AAAAAACCATGTTTTGTCTGATTATTTATGATATTCGAAGTAACAAACGTAGACTTAAACTC TCGAAATTACTTGAGGGTTATGGCGTGAGGGTGCAAAAATCCTGTTTCGAAGTCGACCTGTC AAGAAATGATTATCAGTCTCTCCTTAAGGATATCGAGGGCTTCTCCAAGGCTGATGAAGAA GACAGCATAATAGTGTATGTGCCAACCAAAGAAGAGGTGACTAGTTTTAGCCCCTACCATA 50 GTGCTGAAAAATTAGATGACATTCTCTTCCCCTAAGCCTTTATAGACCTTTAATCATATGGTA CACTATAGATAGTGTTTCCAGAGGCTCTTAAGGAAATCAAAGATAGAGAGACACTTCAAAG ATTTTGTAGATATATGGAAGCATTAGTAGCCTATTTCAAGTTTTATGGAGGTAAAGATTAAT GACATTCGCTAAGATTAAATTTTCAGCTCAAATTCGTTTAGAGACAGGCCTCCATATTGGTG GAAGCGATGCTTTTGCAGCCATTGGTGCAATCGATTCGCCTGTTATTAAAGATCCTATTACC 55 AACCTACCGATCATTCCTGGTTCAAGTCTCAAAGGAAAAATGAGAACGCTTCTTGCCAAGGT TTATAATGAAAAGGTAGCTGAGAAACCAAGCGATGACAGTGATATTCTTAGCCGTTTATTTG GGAATAGTAAAGATAAACGATTCAAAATGGGACGCTTGATTTTTCGTGATGCCTTCTTGTCA

AACGCTGATGAGCTAGACTCTCTTGGGGTAAGAAGTTATACAGAAGTAAAATTTGAAAATA

160 5 CAATTGACCGTATCACTGCCGAAGCTAATCCAAGACAAATTGAACGTGCTATTCGTACCAGT ACTTTTGATTTCGAGTTGATTTATGAAATTACAGATGAGAATGAAAATCAAGTCGAAGAAG ATTCCAAAGTGATTCGAGATGGTTTAAAACTGCTTGAACTTGATTATCTTGGTGGTTCTGGA TCTCGAGGTTACGGTAAGGTTGCTTTTGAAAACCTCAAAGCTACTACCGTATTTGGTAATTA TGATGTTAAAACATTAAATGAACTTTTAACTGCGGAGGTCTAATATGACCTATAAACTGTAT [0 ATTATGACCTTTCAGAATGCTCATTTTGGTTCGGGCACTCTTGATAGCTCAAAATTAACATTC TCAGCAGACCGTATCTTCTCAGCACTAGTGCTAGAATCCCTAAAAATGGGAAAACTCGATGC ATTTCTTGCGGAAGCTAACCAAGACAAGTTCACGCTCACAGATGCCTTTCCATTTCAATTTG GTCCCTTTTTGCCGAAACCTATTGGTTATCCCAAACATGACCAAATAGATCAATCAGTTGAT GTCAAAGAGGTTCGCCGTCAAGCAAAATTGTCTAAGAAACTGCAATTTCTTGCTCTAGAAAA [5 TGTTGACGATTATATCAATGGAGAGTTATTTGAAAATGAAGAGCATGCAGTCATCGATACTG TGACAAAAAATCAACCACATAAGGACGGCAATCTTTATCAGGTAGCTACAACCAGATTTTC AAATGATACGTCGCTTTACGTCATCGCAAACGAATCTGATTTGCTTAATGAGTTGATGTCTA GTCTTCAGTATTCAGGTCTTGGTGGAAAGCGTTCAAGTGGTTTTGGTCGTTTTGAGTTAGATA TTCAAAATATCCCACTAGAATTGTCAGATAGACTGACTAAGAATCATTCAGATAAAGTGATG !0 AGTCTTACGACAGCACTTCCTGTAGATGCTGACCTTGAAGAAGCAATGGAAGATGGACATT ACTTATTAACTAAATCAAGTGGTTTTGCATTTAGTCATGCCACCAATGAGAATTATCGTAAG CAGGATCTTTACAAATTTGCTTCTGGTTCAACTTTTAGTAAAACATTTGAAGGTCAGATTGTT GATGTGAGACCACTTGATTTCCCTCATGCTGTTTTAAATTATGCTAAACCACTCTTCTTTAAA TTGGAGGTATAAAAATGAAAAATGACTATAGAACATTTAAATTAAGCCTCCTGACACTTGCT !5 CCAATTCATATTGGTAATGGAGAGAAGTATACCTCTAGAGAATTTATCTATGAAAATAAAA AGTTTTACTTTCCTGACATGGGGAAATTCTATAATAAAATGGTGGAGAAGAGGCTTGCTGAA AAGTTTGAAGCATTTCTAATTCAAACTCGTCCAAATGCACGTAATAATCGTCTTATTTCCTTC TTAAATGATAACCGAATTGCAGAGCGTTCTTTTGGAGGTTATAGTATCTCTGAAACAGGTTT AGAATCGGACAAAAATCCTGATTCAACCGGAGCTATTAACGAAGTTAATAAATTTATTCGA ;0 GATGCTTTTGGAAATCCCTACATTCCTGGTAGCTCACTAAAAGGTGCTATTCGTACCATTTTA ATGAATACTACCCCTAAGTGGAATAATGAAAATGCTGTAAATGACTTTGGAAGATTTCCGA AAGAGAATAAGAACCTTATCCCTTGGGGACCAAAAAAGGGAAAAGAATACGATGATTTGTT TAACGCAATTCGTGTGAGTGATAGTAAGCCTTTTGATAATAAGAGTCTTATCTTAGTGCAGA AATGGGATTATTCAGCGAAAACAAATAAAGCTAAACCACTTCCCTTGTATAGAGAATCAAT ;5 CTCTCCATTAACAAAAATTGAATTTGAGATTACAACAACCACTGATGAAGCTGGAAGATTG ATTGAAGAATTAGGTAAGAGAGCACAAGCGTTTTATAAAGACTATAAGGCATTTTTCCTATC TGAATTTCCTGATGATAAGATTCAAGCCAATCTACAATACCCAATTTATTTAGGTGCGGGGA GCGGTGCTTGGACAAAGACTCTATTTAAGCAAGCTGATGGTATTTTACAAAGACGATACAGT CGAATGAAAACTAAAATGGTTAAAAAAGGAGTTCTTAAGCTCACAAAAGCACCTCTTAAAA W- CAGTTAAGATTCCATCTGGTAATCATTCATTAGTCAAGAACCACGAGTCCTTTTATGAAATG GGAAAAGCTAATTTCATGATTAAGGAGATTGATAAATGA (SEQ ID NO:466) SEQ ID NO:467: ATGAGCGATTTATATAGTCAAAGGTCCAATTATTACCTGTCCTTATCTGAACAAAGAATTAT 45 CATTAAAAATGATAATAAAGAGATTGTCAAAGAAGTGTCCATTTCACTCGTTGATAATGTAT TACTTTTTGGTAATGCACAACTGACCACCCAACTCATCAAAGCCTTGTCAAAGAACAAGGTG AATGTTTACTATTTCTCAAATGTTGGTCAATTTATTTCTAGTATTGAAACCCACAGGCAGGAC GAATTCCAAAAGCAAGAGTTGCAAGCAAAGGCTTATTTTGAAGAGGATTTCCGTTTAGAGG TTGCGAGGAGTATTGCTACGACCAAGGTGAGGCACCCAATTGCCTTACTTAGAGAGTTTGAT 50 ACGGATGGTCTACTAGATACCTCAGATTATTCTAGGTTTGAAGATAGTGTCAATGATATTCA GAAAGCTTATTCCATTACAGAAATTATGGGTTACGAAGGTCGCCTTGCGAAATCCTATTTTT ACTATCTGAATTTACTCGTTCCTAATGACTTTCATTTTAATGGTAGGAGTAGACGGCCTGGG GAGGATTGTTTTAACAGTGCCCTCAATTTTGGCTATAGTATCTTATATTCTTGCTTAATGGGC TGA (SEQ ID NO:467) 55 SEQ ID NO:468: TTGCTTAATGGGCTGATTAAGAAAAACGGGCTAAGCTTGGGATTTGGGGTAATTCACAAGC ATCATCAGCATCATGCGACCTTGGCCAGTGATTTAATGGAAGAATGGAGACCTATCATCGTC

GATAATACGCTTATGGAGTTGGTACGAAATGGTAAACTTCTTTTAAGTCATTTTGAAAATAA

161 5 GGATCAAGACTTCATACTCACCCATGAAGGCAGAGAAATCTTTGCACGGGCTTTACGTTCAA GAATATTAGAAGTCCATCAGTATATTGAGTTAGATAAAAAACGCTATTCTTTTCTTTATACA GCAGATAGGCAAATCAAGAGTTTGATTAGGGCTTTTAGAGAACTTGACCCTAGTCTCTATGA GACAAGTTACACAGGAGGGCATTAA (SEQ ID NO:468) to SEQ ID NO:469: ATGTTTTGTCTGATTATTTATGATATTCGAAGTAACAAACGTAGACTTAAACTCTCGAAATT ACTTGAGGGTTATGGCGTGAGGGTGCAAAAATCCTGTTTCGAAGTCGACCTGTCAAGAAAT GATTATCAGTCTCTCCTTAAGGATATCGAGGGCTTCTCCAAGGCTGATGAAGAAGACAGCAT AATAGTGTATGTGCCAACCAAAGAAGAGGTGACTAGTTTTAGCCCCTACCATAGTGCTGAA [5 AAATTAGATGACATTCTCTTCCCCTAA (SEQ ID NO:469) SEQ ID NO:470: ATGACATTCGCTAAGATTAAATTTTCAGCTCAAATTCGTTTAGAGACAGGCCTCCATATTGG TGGAAGCGATGCTTTTGCAGCCATTGGTGCAATCGATTCGCCTGTTATTAAAGATCCTATTA !0 CCAACCTACCGATCATTCCTGGTTCAAGTCTCAAAGGAAAAATGAGAACGCTTCTTGCCAAG GTTTATAATGAAAAGGTAGCTGAGAAACCAAGCGATGACAGTGATATTCTTAGCCGTTTATT TGGGAATAGTAAAGATAAACGATTCAAAATGGGACGCTTGATTTTTCGTGATGCCTTCTTGT CAAACGCTGATGAGCTAGACTCTCTTGGGGTAAGAAGTTATACAGAAGTAAAATTTGAAAA TACAATTGACCGTATCACTGCCGAAGCTAATCCAAGACAAATTGAACGTGCTATTCGTACCA !5 GTACTTTTGATTTCGAGTTGATTTATGAAATTACAGATGAGAATGAAAATCAAGTCGAAGAA GATTCCAAAGTGATTCGAGATGGTTTAAAACTGCTTGAACTTGATTATCTTGGTGGTTCTGG ATCTCGAGGTTACGGTAAGGTTGCTTTTGAAAACCTCAAAGCTACTACCGTATTTGGTAATT ATGATGTTAAAACATTAAATGAACTTTTAACTGCGGAGGTCTAA (SEQ ID NO:470) ;0 SEQ ID NO:471: ATGACCTATAAACTGTATATTATGACCTTTCAGAATGCTCATTTTGGTTCGGGCACTCTTGAT AGCTCAAAATTAACATTCTCAGCAGACCGTATCTTCTCAGCACTAGTGCTAGAATCCCTAAA AATGGGAAAACTCGATGCATTTCTTGCGGAAGCTAACCAAGACAAGTTCACGCTCACAGAT GCCTTTCCATTTCAATTTGGTCCCTTTTTGCCGAAACCTATTGGTTATCCCAAACATGACCAA ;5 ATAGATCAATCAGTTGATGTCAAAGAGGTTCGCCGTCAAGCAAAATTGTCTAAGAAACTGC AATTTCTTGCTCTAGAAAATGTTGACGATTATATCAATGGAGAGTTATTTGAAAATGAAGAG CATGCAGTCATCGATACTGTGACAAAAAATCAACCACATAAGGACGGCAATCTTTATCAGG TAGCTACAACCAGATTTTCAAATGATACGTCGCTTTACGTCATCGCAAACGAATCTGATTTG CTTAATGAGTTGATGTCTAGTCTTCAGTATTCAGGTCTTGGTGGAAAGCGTTCAAGTGGTTTT 40 GGTCGTTTTGAGTTAGATATTCAAAATATCCCACTAGAATTGTCAGATAGACTGACTAAGAA TCATTCAGATAAAGTGATGAGTCTTACGACAGCACTTCCTGTAGATGCTGACCTTGAAGAAG CAATGGAAGATGGACATTACTTATTAACTAAATCAAGTGGTTTTGCATTTAGTCATGCCACC AATGAGAATTATCGTAAGCAGGATCTTTACAAATTTGCTTCTGGTTCAACTTTTAGTAAAAC ATTTGAAGGTCAGATTGTTGATGTGAGACCACTTGATTTCCCTCATGCTGTTTTAAATTATGC 45 TAAACCACTCTTCTTTAAATTGGAGGTATAA (SEQ ID NO:471) SEQ ID NO:472: ATGAAAAATGACTATAGAACATTTAAATTAAGCCTCCTGACACTTGCTCCAATTCATATTGG TAATGGAGAGAAGTATACCTCTAGAGAATTTATCTATGAAAATAAAAAGTTTTACTTTCCTG 50 ACATGGGGAAATTCTATAATAAAATGGTGGAGAAGAGGCTTGCTGAAAAGTTTGAAGCATT TCTAATTCAAACTCGTCCAAATGCACGTAATAATCGTCTTATTTCCTTCTTAAATGATAACCG AATTGCAGAGCGTTCTTTTGGAGGTTATAGTATCTCTGAAACAGGTTTAGAATCGGACAAAA ATCCTGATTCAACCGGAGCTATTAACGAAGTTAATAAATTTATTCGAGATGCTTTTGGAAAT CCCTACATTCCTGGTAGCTCACTAAAAGGTGCTATTCGTACCATTTTAATGAATACTACCCCT 55 AAGTGGAATAATGAAAATGCTGTAAATGACTTTGGAAGATTTCCGAAAGAGAATAAGAACC TTATCCCTTGGGGACCAAAAAAGGGAAAAGAATACGATGATTTGTTTAACGCAATTCGTGT GAGTGATAGTAAGCCTTTTGATAATAAGAGTCTTATCTTAGTGCAGAAATGGGATTATTCAG

CGAAAACAAATAAAGCTAAACCACTTCCCTTGTATAGAGAATCAATCTCTCCATTAACAAA

162 5 AATTGAATTTGAGATTACAACAACCACTGATGAAGCTGGAAGATTGATTGAAGAATTAGGT AAGAGAGCACAAGCGTTTTATAAAGACTATAAGGCATTTTTCCTATCTGAATTTCCTGATGA TAAGATTCAAGCCAATCTACAATACCCAATTTATTTAGGTGCGGGGAGCGGTGCTTGGACAA AGACTCTATTTAAGCAAGCTGATGGTATTTTACAAAGACGATACAGTCGAATGAAAACTAA AATGGTTAAAAAAGGAGTTCTTAAGCTCACAAAAGCACCTCTTAAAACAGTTAAGATTCCA [0 TCTGGTAATCATTCATTAGTCAAGAACCACGAGTCCTTTTATGAAATGGGAAAAGCTAATTT CATGATTAAGGAGATTGATAAATGA (SEQ ID NO:472) SEQ ID NO:478: ATGAGCGATTTATATAGTCAAAGGTCCAATTATTACCTGTCCTTATCTGAACAAAGAATTAT [5 CATTAAAAATGATAATAAAGAGATTGTCAAAGAAGTGTCCATTTCACTCGTTGATAATGTAT TACTTTTTGGTAATGCACAACTGACCACCCAACTCATCAAAGCCTTGTCAAAGAACAAGGTG AATGTTTACTATTTCTCAAATGTTGGTCAATTTATTTCTAGTATTGAAACCCACAGGCAGGAC GAATTCCAAAAGCAAGAGTTGCAAGCAAAGGCTTATTTTGAAGAGGATTTCCGTTTAGAGG TTGCGAGGAGTATTGCTACGACCAAGGTGAGGCACCCAATTGCCTTACTTAGAGAGTTTGAT !0 ACGGATGGTCTACTAGATACCTCAGATTATTCTAGGTTTGAAGATAGTGTCAATGATATTCA GAAAGCTTATTCCATTACAGAAATTATGGGTTACGAAGGTCGCCTTGCGAAATCCTATTTTT ACTATCTGAATTTACTCGTTCCTAATGACTTTCATTTTAATGGTAGGAGTAGACGGCCTGGG GAGGATTGTTTTAACAGTGCCCTCAATTTTGGCTATAGTATCTTATATTCTTGCTTAATGGGC TGATTAAGAAAAACGGGCTAAGCTTGGGATTTGGGGTAATTCACAAGCATCATCAGCATCA !5 TGCGACCTTGGCCAGTGATTTAATGGAAGAATGGAGACCTATCATCGTCGATAATACGCTTA TGGAGTTGGTACGAAATGGTAAACTTCTTTTAAGTCATTTTGAAAATAAGGATCAAGACTTC ATACTCACCCATGAAGGCAGAGAAATCTTTGCACGGGCTTTACGTTCAAGAATATTAGAAGT CCATCAGTATATTGAGTTAGATAAAAAACGCTATTCTTTTCTTTATACAGCAGATAGGCAAA TCAAGAGTTTGATTAGGGCTTTTAGAGAACTTGACCCTAGTCTCTATGAGACAAGTTACACA ;0 GGAGGGCATTAATGGGACTTTACTTTAACCTCAGCGAAGAAGAGCGTGAGTTTGCCAAACA AAAAACCATGTTTTGTCTGATTATTTATGATATTCGAAGTAACAAACGTAGACTTAAACTCT CGAAATTACTTGAGGGTTATGGCGTGAGGGTGCAAAAATCCTGTTTCGAAGTCAACCTGTCA AGAAATGATTATCAGTCTCTCCTTAAGGATATCGAGGGCTTCTACAAGGCTGATGAAGAAG ACAGCATAATAGTGTATGTGACAACCAAAGAAGAGGTGACTAGTTTTAGCCCCTACCATAG ;5 TGCTGAAAAATTAGATGACATTCTCTTCTTCTAAGCCTTTATAGACCTTTAATCATATGGTAC ACTATAGATAGTGTTTCCAGTAGGTCCTACATCTTGTGCCTCTAGCAACTGCCTAGAGCACA AGATATGGGGATATAAACCTAATTACCTCGAGAGGGGACGGAAACGCTTTCTAGCTCGCTA TAATTACCCATTCCTAGAAAGATATAAACCTAATTACCTCGAGAGGGGACGGAAACTTTGA ATAGTCTTTGAATCGCATTTGAACCATATAGATATAAACCTAATTACCTCGAGAGGGGACGG 40 AAACAGGTTTTTTGCCATAGATTTTCCAAGACCTTCCCAACTGATATAAACCTAATTACCTC GAGAGGGGACGGAAACGCTTTCTAGCTCGCTATAATTACCCATTCCTAGAAAGATATAAAC CTAATTACCTCGAGAGGGGACTTTTTTGAAAATTTTGAAAACAGTATTGATACCGCTTCCAG AAAGTGTTAGACTAAAAGCACATTAAGGGCGCCCCAATGAGTTGAAAAGTACTTTCAGCTT TTGGGGTTTTTTCATACAAAGATGAAGGAGTCGAATGAAAAAATTAGTATTTACTTTTAAAA 45 GGATCGACCATCCTGCACAAGATTTGGCTGTTAAATTTCATGGCTTCTTGATGGAGCAGTTG GATAGTGACTATGTTGATTATCTGCATCAGCAGCAAACAAATCCCTATGCGACCAAGGTAAT CCAAGGGAAAGAAAACACGCAGTGGGTTGTACATCTGCTCACAGACGACATCGAGGATAAG GTTTTTATGACCTTATTACAGATTAAAGAGGTGTCCTTAAACGATCTGCCTAAACTCAGTGT CGAAAAAGTTGAGATTCAGGAGTTGGGGGCAGATAAACTGTTAGAGATTTTCAATAGTGAG 50 GAAAATCAAACCTATTTTTCAATTATTTTTGAGACTCCAACAGGTTTTAAATCTCAAGGTTCC TACGTCATCTTCCCGTCTATGCGTTTGATTTTTCAAAGTTTGATGCAAAAGTATGGAAGGTTG GTTGAAAATCAACCTGAAATTGAAGAGGATACCTTAGATTACCTATCTGAACACAGCACTAT CACGAATTATCGCTTGGAGACGAGTTATTTCAGGGTGCACAGGCAACGAATTCCTGCCTTTA GAGGAAAGTTAACCTTTAAAGTACAAGGCGCCCAAACTCTAAAAGCTTATGTCAAAATGCT 55 TCTAACATTCGGTGAATATTCAGGTCTTGGCATGAAAACGAGTCTCGGTATGGGAGGGATA AAGCTTGAAGAAAGAAAAGATTGATTTATTTTACGGAGCTCTTTTGCATGATATCGGTAAGG TCATTCAAAGGGCGACAGGAGAACGAAAAAAACACGCCTTGGTAGGCGCGGATTGGTTTGA TGAGATTGCTGATAATCAAGTTATTTCCGATCAAATTAGATATCACATGGCTAACTACCAGA

GTGATAAACTTGGAAATGACCATCTTGCTTACATAACTTATATCGCTGATAACATTGCCTCT

163 5 GGTGTCGACAGAAGACAGTCAAATGAGGAGAGTGACGAGGATACATCAGCTAAGATTTGG GATACCTATACAAACCAGGCTGATATTTTTAACGTTTTTGGGGCACAAACGGATAAACGCTA CTTTAAACCGACGGTTCTAAACTTGAAATCTAAACCTAACTTTGCGTCGGCAACATATGAAC CTTTCTCAAAAGGTGATTATGCGGCAATTGCGACTCGTATCAAAAATGAATTGGCAGAATTT GAGTTTAATCAAGTACAAATTGACTCTTTGTTAAATCTGTTCGAAGCAACCCTCTCTTTTGTG 0 CCTTCTTCGACTAATACTAAAGAAATCGCTGATATTTCACTTGCTGATCATAGTCGTCTGACA GCAGCTTTTGCTCTAGCCATCTATGATTACTTGGAAGACAAAGGTCGTCATAACTATAAGGA GGACTTGTTTACTAAAGCATCAGCCTTTTATGAGGAAGAAGCTTTTCTCCTAGCTAGCTTTG ACTTATCAGGGATTCAAGACTTTATCTATAATATTAATATTGCGACGAATGGTGCTGCTAAA CAATTGAAGGCTAGATCTTTATATCTTGACTTTATGAGCGAGTATATAGCAGACAGTTTACT [5 TGATAAACTAGGCCTCAATCGGGCTAATATGCTCTATGTCGGTGGGGGACATGCTTACTTTG TCCTAGCCAATACTGAAAAAACGGTAGAAACACTCGTTCAATTTGAAAAAGATTTCAATCA ATTTTTATTGGCAAATTTCCAAACCAGATTATATGTTGCCTTTGGTTGGGGAAGCTTTGCGGC TAAGGATATCATGAGCGAACTGAACTCACCTGAAAGCTATAGACAGGTCTATCAAAAGGCT AGTCGCATGATTTCTGAGAAAAAAATCTCAAGGTATGATTATCAAACCCTTATGTTGTTGAA !0 CAGGGGCGGTAAATCTTCTGAAAGAGAGTGCGAGATTTGTCATTCCGTTGAGAATTTAGTTG CTTATCATGACCAAAAAGTGTGTGACATTTGTCGAGGCTTGTATCAATTTTCTAAAGAGATT GCCCATGACCATTTCATTATCACTGAAAATGAAGGGCTTCCTATTGGTCCGAACGCATGTCT TAAGGGTGTTGCATTTGAAAAGCTGAGCCAAGAAGCTTTTTCCCGTGTCTATGTCAAAAATG ACTATAAGGCTGGTACAGTTAAGGCAACCCATGTTTTTGTTGGAGATTACCAGTATGATGAA !5 ATATACAATTATGCTGCCTTATCTAAAAACGAAAATGGGTTAGGTATTAAACGTTTAGCTGT TGTACGTCTTGACGTGGATGATTTGGGAGCAGCCTTTATGGCTGGCTTCTCCCAACAAGGAA ATGGGCAATATAGTACTCTATCACGCTCAGCCACTTTCTCTCGAAGCATGAGTCTTTTCTTCA AGGTTTATATTAACCAGTTTGCTAGTGATAAGAAGCTCTCTATCATCTATGCCGGTGGGGAT GATGTTTTTGCTATTGGCTCTTGGCAAGATATTATTGCCTTTACTGTTGAACTTCGTGAGAAC ;0 TTCATTAAATGGACAAATGGAAAACTAACACTATCAGCTGGTATCGGTCTGTTTGCTGATAA GACCCCTATTAGCTTAATGGCACATCAAACAGGGGAGCTAGAAGAAACAGCTAAAGGCAAT GAGAAAGATAGTATTTCACTCTTTAGTTCCGACTATACCTTTAAATTTGATCGGTTTATCACT AATGTTTACGACGATAAGTTAGAGCAGATTCGCTATTTCTTTAATCACCAAGATGAACGAGG CAAGAATTTCATTTATAAATTGATTGAATTGCTTCGAAATTATGATCGTATGAATATGGCAC ;5 GTTTAGCTTATTATTTAACACGACTTGAAGAATTGACGCGTGAAACAGACAGGGATAAATTT AAAACATTTAAAAATTTATTCTATTCTTGGTACACAAATAAGGATGATAAGGATAGAAAAG AAGCAGAGTTAGCCTTGCTTCTCTATATCTATGAGATTAGAAAGGATTAGGATATGACAATC TTGACTGATGAGAATTACGTTGATATTGCAGAAAAAGCAATTCTAAAACTAGAAAGAAATA CTAGGAACAGAAAGAATCCTGATGCCTTCTTTCTTACAACAAGTAAGCTCAGAAACTTGCTG W- AGCTTAACTAGTACACTTTTTGATGAGAGTAAGGTCAAAGAATATGATGCTCTCCTTGATCG TATTGCTTATTTAAGAGTACAATTTGTCTACCAAGCAGGTAGAGAGATTGCAGTAAAAGATC TGATAGAAAAGGCTCAAATTCTTGAGGCTCTTAAGGAAATCAAAGATAGAGAGACACTTCA AAGATTTTGTAGATATATGGAAGCATTAGTAGCCTATTTCAAGTTTTATGGAGGTAAAGATT AATGACATTCGCTAAGATTAAATTTTCAGCTCAAATTCGTTTAGAGACAGGCCTCCATATTG 45 GTGGAAGCGATGCTTTTGCAGCCATTGGTGCAATCGATTCGCCTGTTATTAAAGATCCTATT ACCAACCTACCGATCATTCCTGGTTCAAGTCTCAAAGGAAAAATGAGAACGCTTCTTGCCAA GGTTTATAATGAAAAGGTAGCTGAGAAACCAAGCGATGACAGTGATATTCTTAGCCGTTTAT TTGGGAATAGTAAAGATAAACGATTCAAAATGGGACGCTTGATTTTTCGTGATGCCTTCTTG TCAAACGCTGATGAGCTAGACTCTCTTGGGGTAAGAAGTTATACAGAAGTAAAATTTGAAA 50 ATACAATTGACCGTATCACTGCCGAAGCTAATCCAAGACAAATTGAACGTGCTATTCGTACC AGTACTTTTGATTTCGAGTTGATTTATGAAATTACAGATGAGAATGAAAATCAAGTCGAAGA AGATTTCAAAGTGATTCGAGATGGTTTAAAACTGCTTGAACTTGATTATCTTGGTGGTTCTG GATCTCGAGGTTACGGTAAGGTTGCTTTTGAAAAACTCAAAGCTACTACCGTATTTGGTAAT TATGATGTTAAAACATTAAATGAACTTTTAACTGCGGAGGTCTAATATGACCTATAAACTGT 55 ATATTATGACCTTTCAGAATGCTCATTTTGGTTCGGGCACTCTTGATAGCTCAAAATTAACAT TCTCAGCAGACCGTATCTTCTCAGCACTAGTGCTAGAATCCCTAAAAATGGGAAAACTCGAT GCATTTCTTGCGGAAGCTAACCAAGACAAGTTCACGCTCACAGATGCCTTTCCATTTCAATT TGGTCCCTTTTTGCCGAAACCGATTGGTTATCCCAAACATGACCAAATAGATCAATCAGTTG ATGTCAAAGAGGTTCGCCGTCAAGCAAAATTGTCTAAGAAACTGCAATTTCTTGCTCTAGAA 60 AATGTTGACGATTATCTCAATGGAGAGTTATTTGAAAATGAAGAGCATGCAGTCATCGATAC 164 5 TGTGACAAAAAATCAACCACATAAGGACGGCAATCTTTATCAGGTAGCTACAACCAGATTT TCAAATGATACGTCGCTTTACGTCATCGCAAACGAATCTGATTTGCTTAATGAGTTGATGTC TAGTCTTCAGTATTCAGGTCTTGGTGGAAAGCGTTCAAGTGGTTTTGGTCGTTTTGAGTTAGA TATTCAAAATATCCCACTAGAATTGTCAGATAGACTGACTAAGAATCATTCAGATAAAGTGA TGAGTCTTACGACAGCACTTCCTGTAGATGCTGACCTTGAAGAAGCAATGGAAGATGGACA [0 TTACTTATTAACTAAATCAAGTGGTTTTGCATTTAGTCATGCTACCAATGAGAATTATCGTAA GCAGGATCTTTACAAATTTGCTTCTGGTTCAACTTTTAGTAAAACATTTGAAGGTCAGATTGT TGATGTGAGACCACTTGATTTCCCTCATGCTGTTTTAAATTATGCTAAACCACTCTTCTTTAA ATTGGAGGTATAAAAATGAAAAATGACTATAGAACATTTAAATTAAGCCTCCTGACACTTG CTCCAATTCATATTGGTAATGGAGAGAAGTATACCTCTAGAGAATTTATCTATGAAAATAAG [5 AAGTTTTACTTTCCTGACATGGGGAAATTCTATAATAAAATGGTGGAGAAGAGGCTTGCTGA AAAGTTTGAAGCATTTCTAATTCAAACTCGTCCAAATGCACGTAATAATCGTCTTATTTCCTT CTTAAATGATAACCGAATTGCAGAGCGTTCTTTTGGAGGTTATAGTATCTCTGAAACAGGTT TAGAATCGGACAAAAATCCTGATTCAGCCGGAGCTATTAACGAAGTTAATAAATTTATTCGA GATGCTTTTGGAAATCCCTACATTCCTGGTAGCTCACTAAAAGGTGCTATTCGTACCATTTTA !0 ATGAATACTACCCCTAAGTGGAATAATGAAAATGCTGTAAATGACTTTGGAAGATTTCCGA AAGAGAATAAGAACCTTATCCCTTGGGGACCAAAAAAGGGAAAAGAATACGATGATTTGTT TAACGCAATTCGTGTGAGTGATAGTAAGCCTTTTGATAATAAGAGTCTTATCTTAGTGCAGA AATGGGATTATTCAGCGAAAACAAATAAAGCTAAACCACTTCCCTTGTATAGAGAATCAAT CTCTCCATTAACAAAAATTGAATTTGAGATTACAACAACCACTGATGAAGCTGGAAGATTG !5 ATTGAAGAATTAGGTAAGAGAGCACAAGCGTTTTATAAAGACTATAAGGCATTTTTCCTATC TGAATTTCCTGATGATAAGATTCAAGCCAATCTACAATACCCAATTTATTTAGGTGCGGGGA GCGGTGCTTGGACAAAGACTCTATTTAAGCAAGCTGATGGTATTTTACAAAGACGATACAGT CGAATGAAAACTAAAATGGTTAAAAAAGGAGTTCTTAAGCTCACAAAAGCACCTCTTAAAA CAGTTAAGATTCCATCTGGTAATCATTCATTAGTCAAGAACCACGAGTCCTTTTATGAAATG ;0 GGAAAAGCTAATTTCATGATTAAGGAGATTGATAAATGA (SEQ ID NO:478) SEQ ID NO:479: ATGAGCGATTTATATAGTCAAAGGTCCAATTATTACCTGTCCTTATCTGAACAAAGAATTAT CATTAAAAATGATAATAAAGAGATTGTCAAAGAAGTGTCCATTTCACTCGTTGATAATGTAT ;5 TACTTTTTGGTAATGCACAACTGACCACCCAACTCATCAAAGCCTTGTCAAAGAACAAGGTG AATGTTTACTATTTCTCAAATGTTGGTCAATTTATTTCTAGTATTGAAACCCACAGGCAGGAC GAATTCCAAAAGCAAGAGTTGCAAGCAAAGGCTTATTTTGAAGAGGATTTCCGTTTAGAGG TTGCGAGGAGTATTGCTACGACCAAGGTGAGGCACCCAATTGCCTTACTTAGAGAGTTTGAT ACGGATGGTCTACTAGATACCTCAGATTATTCTAGGTTTGAAGATAGTGTCAATGATATTCA 40 GAAAGCTTATTCCATTACAGAAATTATGGGTTACGAAGGTCGCCTTGCGAAATCCTATTTTT ACTATCTGAATTTACTCGTTCCTAATGACTTTCATTTTAATGGTAGGAGTAGACGGCCTGGG GAGGATTGTTTTAACAGTGCCCTCAATTTTGGCTATAGTATCTTATATTCTTGCTTAATGGGC TGA (SEQ ID NO:479) 45 SEQ ID NO:480: TTGCTTAATGGGCTGATTAAGAAAAACGGGCTAAGCTTGGGATTTGGGGTAATTCACAAGC ATCATCAGCATCATGCGACCTTGGCCAGTGATTTAATGGAAGAATGGAGACCTATCATCGTC GATAATACGCTTATGGAGTTGGTACGAAATGGTAAACTTCTTTTAAGTCATTTTGAAAATAA GGATCAAGACTTCATACTCACCCATGAAGGCAGAGAAATCTTTGCACGGGCTTTACGTTCAA 50 GAATATTAGAAGTCCATCAGTATATTGAGTTAGATAAAAAACGCTATTCTTTTCTTTATACA GCAGATAGGCAAATCAAGAGTTTGATTAGGGCTTTTAGAGAACTTGACCCTAGTCTCTATGA GACAAGTTACACAGGAGGGCATTAA (SEQ ID NO:480) SEQ ID NO:481: 55 ATGGGACTTTACTTTAACCTCAGCGAAGAAGAGCGTGAGTTTGCCAAACAAAAAACCATGT TTTGTCTGATTATTTATGATATTCGAAGTAACAAACGTAGACTTAAACTCTCGAAATTACTTG AGGGTTATGGCGTGAGGGTGCAAAAATCCTGTTTCGAAGTCAACCTGTCAAGAAATGATTA

TCAGTCTCTCCTTAAGGATATCGAGGGCTTCTACAAGGCTGATGAAGAAGACAGCATAATA

165 5 GTGTATGTGACAACCAAAGAAGAGGTGACTAGTTTTAGCCCCTACCATAGTGCTGAAAAAT TAGATGACATTCTCTTCTTCTAA (SEQ ID NO:481) SEQ ID NO:482: ATGAAAAAATTAGTATTTACTTTTAAAAGGATCGACCATCCTGCACAAGATTTGGCTGTTAA [0 ATTTCATGGCTTCTTGATGGAGCAGTTGGATAGTGACTATGTTGATTATCTGCATCAGCAGC AAACAAATCCCTATGCGACCAAGGTAATCCAAGGGAAAGAAAACACGCAGTGGGTTGTACA TCTGCTCACAGACGACATCGAGGATAAGGTTTTTATGACCTTATTACAGATTAAAGAGGTGT CCTTAAACGATCTGCCTAAACTCAGTGTCGAAAAAGTTGAGATTCAGGAGTTGGGGGCAGA TAAACTGTTAGAGATTTTCAATAGTGAGGAAAATCAAACCTATTTTTCAATTATTTTTGAGA [5 CTCCAACAGGTTTTAAATCTCAAGGTTCCTACGTCATCTTCCCGTCTATGCGTTTGATTTTTC AAAGTTTGATGCAAAAGTATGGAAGGTTGGTTGAAAATCAACCTGAAATTGAAGAGGATAC CTTAGATTACCTATCTGAACACAGCACTATCACGAATTATCGCTTGGAGACGAGTTATTTCA GGGTGCACAGGCAACGAATTCCTGCCTTTAGAGGAAAGTTAACCTTTAAAGTACAAGGCGC CCAAACTCTAAAAGCTTATGTCAAAATGCTTCTAACATTCGGTGAATATTCAGGTCTTGGCA !0 TGAAAACGAGTCTCGGTATGGGAGGGATAAAGCTTGAAGAAAGAAAAGATTGA (SEQ ID NO:482) SEQ ID NO:483: TTGAAGAAAGAAAAGATTGATTTATTTTACGGAGCTCTTTTGCATGATATCGGTAAGGTCAT !5 TCAAAGGGCGACAGGAGAACGAAAAAAACACGCCTTGGTAGGCGCGGATTGGTTTGATGA GATTGCTGATAATCAAGTTATTTCCGATCAAATTAGATATCACATGGCTAACTACCAGAGTG ATAAACTTGGAAATGACCATCTTGCTTACATAACTTATATCGCTGATAACATTGCCTCTGGT GTCGACAGAAGACAGTCAAATGAGGAGAGTGACGAGGATACATCAGCTAAGATTTGGGAT ACCTATACAAACCAGGCTGATATTTTTAACGTTTTTGGGGCACAAACGGATAAACGCTACTT ;0 TAAACCGACGGTTCTAAACTTGAAATCTAAACCTAACTTTGCGTCGGCAACATATGAACCTT TCTCAAAAGGTGATTATGCGGCAATTGCGACTCGTATCAAAAATGAATTGGCAGAATTTGA GTTTAATCAAGTACAAATTGACTCTTTGTTAAATCTGTTCGAAGCAACCCTCTCTTTTGTGCC TTCTTCGACTAATACTAAAGAAATCGCTGATATTTCACTTGCTGATCATAGTCGTCTGACAG CAGCTTTTGCTCTAGCCATCTATGATTACTTGGAAGACAAAGGTCGTCATAACTATAAGGAG ;5 GACTTGTTTACTAAAGCATCAGCCTTTTATGAGGAAGAAGCTTTTCTCCTAGCTAGCTTTGAC TTATCAGGGATTCAAGACTTTATCTATAATATTAATATTGCGACGAATGGTGCTGCTAAACA ATTGAAGGCTAGATCTTTATATCTTGACTTTATGAGCGAGTATATAGCAGACAGTTTACTTG ATAAACTAGGCCTCAATCGGGCTAATATGCTCTATGTCGGTGGGGGACATGCTTACTTTGTC CTAGCCAATACTGAAAAAACGGTAGAAACACTCGTTCAATTTGAAAAAGATTTCAATCAAT 40 TTTTATTGGCAAATTTCCAAACCAGATTATATGTTGCCTTTGGTTGGGGAAGCTTTGCGGCTA AGGATATCATGAGCGAACTGAACTCACCTGAAAGCTATAGACAGGTCTATCAAAAGGCTAG TCGCATGATTTCTGAGAAAAAAATCTCAAGGTATGATTATCAAACCCTTATGTTGTTGAACA GGGGCGGTAAATCTTCTGAAAGAGAGTGCGAGATTTGTCATTCCGTTGAGAATTTAGTTGCT TATCATGACCAAAAAGTGTGTGACATTTGTCGAGGCTTGTATCAATTTTCTAAAGAGATTGC 45 CCATGACCATTTCATTATCACTGAAAATGAAGGGCTTCCTATTGGTCCGAACGCATGTCTTA AGGGTGTTGCATTTGAAAAGCTGAGCCAAGAAGCTTTTTCCCGTGTCTATGTCAAAAATGAC TATAAGGCTGGTACAGTTAAGGCAACCCATGTTTTTGTTGGAGATTACCAGTATGATGAAAT ATACAATTATGCTGCCTTATCTAAAAACGAAAATGGGTTAGGTATTAAACGTTTAGCTGTTG TACGTCTTGACGTGGATGATTTGGGAGCAGCCTTTATGGCTGGCTTCTCCCAACAAGGAAAT 50 GGGCAATATAGTACTCTATCACGCTCAGCCACTTTCTCTCGAAGCATGAGTCTTTTCTTCAAG GTTTATATTAACCAGTTTGCTAGTGATAAGAAGCTCTCTATCATCTATGCCGGTGGGGATGA TGTTTTTGCTATTGGCTCTTGGCAAGATATTATTGCCTTTACTGTTGAACTTCGTGAGAACTT CATTAAATGGACAAATGGAAAACTAACACTATCAGCTGGTATCGGTCTGTTTGCTGATAAGA CCCCTATTAGCTTAATGGCACATCAAACAGGGGAGCTAGAAGAAACAGCTAAAGGCAATGA 55 GAAAGATAGTATTTCACTCTTTAGTTCCGACTATACCTTTAAATTTGATCGGTTTATCACTAA TGTTTACGACGATAAGTTAGAGCAGATTCGCTATTTCTTTAATCACCAAGATGAACGAGGCA AGAATTTCATTTATAAATTGATTGAATTGCTTCGAAATTATGATCGTATGAATATGGCACGT

TTAGCTTATTATTTAACACGACTTGAAGAATTGACGCGTGAAACAGACAGGGATAAATTTAA

166 5 AACATTTAAAAATTTATTCTATTCTTGGTACACAAATAAGGATGATAAGGATAGAAAAGAA GCAGAGTTAGCCTTGCTTCTCTATATCTATGAGATTAGAAAGGATTAG (SEQ ID NO:483) SEQ ID NO:484: ATGACAATCTTGACTGATGAGAATTACGTTGATATTGCAGAAAAAGCAATTCTAAAACTAG [0 AAAGAAATACTAGGAACAGAAAGAATCCTGATGCCTTCTTTCTTACAACAAGTAAGCTCAG AAACTTGCTGAGCTTAACTAGTACACTTTTTGATGAGAGTAAGGTCAAAGAATATGATGCTC TCCTTGATCGTATTGCTTATTTAAGAGTACAATTTGTCTACCAAGCAGGTAGAGAGATTGCA GTAAAAGATCTGATAGAAAAGGCTCAAATTCTTGAGGCTCTTAAGGAAATCAAAGATAGAG AGACACTTCAAAGATTTTGTAGATATATGGAAGCATTAGTAGCCTATTTCAAGTTTTATGGA [5 GGTAAAGATTAA (SEQ ID NO:484) SEQ ID NO:485: ATGACATTCGCTAAGATTAAATTTTCAGCTCAAATTCGTTTAGAGACAGGCCTCCATATTGG TGGAAGCGATGCTTTTGCAGCCATTGGTGCAATCGATTCGCCTGTTATTAAAGATCCTATTA !0 CCAACCTACCGATCATTCCTGGTTCAAGTCTCAAAGGAAAAATGAGAACGCTTCTTGCCAAG GTTTATAATGAAAAGGTAGCTGAGAAACCAAGCGATGACAGTGATATTCTTAGCCGTTTATT TGGGAATAGTAAAGATAAACGATTCAAAATGGGACGCTTGATTTTTCGTGATGCCTTCTTGT CAAACGCTGATGAGCTAGACTCTCTTGGGGTAAGAAGTTATACAGAAGTAAAATTTGAAAA TACAATTGACCGTATCACTGCCGAAGCTAATCCAAGACAAATTGAACGTGCTATTCGTACCA !5 GTACTTTTGATTTCGAGTTGATTTATGAAATTACAGATGAGAATGAAAATCAAGTCGAAGAA GATTTCAAAGTGATTCGAGATGGTTTAAAACTGCTTGAACTTGATTATCTTGGTGGTTCTGG ATCTCGAGGTTACGGTAAGGTTGCTTTTGAAAAACTCAAAGCTACTACCGTATTTGGTAATT ATGATGTTAAAACATTAAATGAACTTTTAACTGCGGAGGTCTAA (SEQ ID NO:485) ;0 SEQ ID NO:486: ATGACCTATAAACTGTATATTATGACCTTTCAGAATGCTCATTTTGGTTCGGGCACTCTTGAT AGCTCAAAATTAACATTCTCAGCAGACCGTATCTTCTCAGCACTAGTGCTAGAATCCCTAAA AATGGGAAAACTCGATGCATTTCTTGCGGAAGCTAACCAAGACAAGTTCACGCTCACAGAT GCCTTTCCATTTCAATTTGGTCCCTTTTTGCCGAAACCGATTGGTTATCCCAAACATGACCAA ;5 ATAGATCAATCAGTTGATGTCAAAGAGGTTCGCCGTCAAGCAAAATTGTCTAAGAAACTGC AATTTCTTGCTCTAGAAAATGTTGACGATTATCTCAATGGAGAGTTATTTGAAAATGAAGAG CATGCAGTCATCGATACTGTGACAAAAAATCAACCACATAAGGACGGCAATCTTTATCAGG TAGCTACAACCAGATTTTCAAATGATACGTCGCTTTACGTCATCGCAAACGAATCTGATTTG CTTAATGAGTTGATGTCTAGTCTTCAGTATTCAGGTCTTGGTGGAAAGCGTTCAAGTGGTTTT 40 GGTCGTTTTGAGTTAGATATTCAAAATATCCCACTAGAATTGTCAGATAGACTGACTAAGAA TCATTCAGATAAAGTGATGAGTCTTACGACAGCACTTCCTGTAGATGCTGACCTTGAAGAAG CAATGGAAGATGGACATTACTTATTAACTAAATCAAGTGGTTTTGCATTTAGTCATGCTACC AATGAGAATTATCGTAAGCAGGATCTTTACAAATTTGCTTCTGGTTCAACTTTTAGTAAAAC ATTTGAAGGTCAGATTGTTGATGTGAGACCACTTGATTTCCCTCATGCTGTTTTAAATTATGC 45 TAAACCACTCTTCTTTAAATTGGAGGTATAA (SEQ ID NO:486) SEQ ID NO:487 ATGAAAAATGACTATAGAACATTTAAATTAAGCCTCCTGACACTTGCTCCAATTCATATTGG TAATGGAGAGAAGTATACCTCTAGAGAATTTATCTATGAAAATAAGAAGTTTTACTTTCCTG 50 ACATGGGGAAATTCTATAATAAAATGGTGGAGAAGAGGCTTGCTGAAAAGTTTGAAGCATT TCTAATTCAAACTCGTCCAAATGCACGTAATAATCGTCTTATTTCCTTCTTAAATGATAACCG AATTGCAGAGCGTTCTTTTGGAGGTTATAGTATCTCTGAAACAGGTTTAGAATCGGACAAAA ATCCTGATTCAGCCGGAGCTATTAACGAAGTTAATAAATTTATTCGAGATGCTTTTGGAAAT CCCTACATTCCTGGTAGCTCACTAAAAGGTGCTATTCGTACCATTTTAATGAATACTACCCCT 55 AAGTGGAATAATGAAAATGCTGTAAATGACTTTGGAAGATTTCCGAAAGAGAATAAGAACC TTATCCCTTGGGGACCAAAAAAGGGAAAAGAATACGATGATTTGTTTAACGCAATTCGTGT GAGTGATAGTAAGCCTTTTGATAATAAGAGTCTTATCTTAGTGCAGAAATGGGATTATTCAG

CGAAAACAAATAAAGCTAAACCACTTCCCTTGTATAGAGAATCAATCTCTCCATTAACAAA

167 5 AATTGAATTTGAGATTACAACAACCACTGATGAAGCTGGAAGATTGATTGAAGAATTAGGT AAGAGAGCACAAGCGTTTTATAAAGACTATAAGGCATTTTTCCTATCTGAATTTCCTGATGA TAAGATTCAAGCCAATCTACAATACCCAATTTATTTAGGTGCGGGGAGCGGTGCTTGGACAA AGACTCTATTTAAGCAAGCTGATGGTATTTTACAAAGACGATACAGTCGAATGAAAACTAA AATGGTTAAAAAAGGAGTTCTTAAGCTCACAAAAGCACCTCTTAAAACAGTTAAGATTCCA [0 TCTGGTAATCATTCATTAGTCAAGAACCACGAGTCCTTTTATGAAATGGGAAAAGCTAATTT CATGATTAAGGAGATTGATAAATGA (SEQ ID NO:487) with repeat sequences: SEQ ID NO: 11 and/or SEQ ID NO: 12 [5 Functional Combination #3: cas sequences: SEQ ID NO:488 to SEQ ID NO:508, and SEQ ID NO:517 to SEQ ID NO:521, as shown below. SEQ ID NOS:488-497 are from S. agalactiae, while SEQ ID NOS:498-503 are from S. mutans, and SEQ ID NOS:504-508, 517-521 are from S. pyogenes. SEQ ID NO:488: !0 ATGAATAAGCCATATTCAATAGGCCTTGACATCGGTACTAATTCCGTCGGATGGAGCATTAT TACAGATGATTATAAAGTACCTGCTAAGAAGATGAGAGTTTTAGGGAACACTGATAAAGAA TATATTAAGAAGAATCTCATAGGTGCTCTGCTTTTTGATGGCGGGAATACTGCTGCAGATAG ACGCTTGAAGCGAACTGCTCGTCGTCGTTATACACGTCGTAGAAATCGTATTCTATATTTAC AAGAAATTTTTGCAGAGGAAATGAGTAAAGTTGATGATAGTTTCTTTCATCGATTAGAGGAT !5 TCTTTTCTAGTTGAGGAAGATAAGAGAGGGAGCAAGTATCCTATCTTTGCAACATTGCAGGA AGAGAAAGATTATCATGAAAAATTTTCGACAATCTATCATTTGAGAAAAGAATTAGCTGAC AAGAAAGAAAAAGCAGACCTTCGTCTTATTTATATTGCTCTAGCTCATATCATTAAATTTAG AGGGCATTTCCTAATTGAGGATGATAGCTTTGATGTCAGGAATACAGACATTTCAAAACAAT ATCAAGATTTTTTAGAAATCTTTAATACAACTTTTGAAAATAATGATTTGTTATCTCAAAACG ;0 TTGACGTAGAGGCAATACTAACAGATAAGATTAGCAAGTCTGCGAAGAAAGATCGTATTTT AGCGCAGTATCCTAACCAAAAATCTACTGGCATTTTTGCAGAATTTTTGAAATTGATTGTCG GAAATCAAGCTGACTTCAAGAAATATTTCAATTTGGAGGATAAAACGCCGCTTCAATTCGCT AAGGATAGCTACGATGAAGATTTAGAAAATCTTCTTGGACAGATTGGTGATGAATTTGCAG ACTTATTCTCAGCAGCGAAAAAGTTATATGATAGTGTCCTTTTGTCTGGCATTCTTACAGTAA ;5 TCGACCTCAGTACCAAGGCGCCACTTTCAGCTTCTATGATTCAGCGTTATGATGAACATAGA GAGGACTTGAAACAGTTAAAACAATTCGTAAAAGCTTCATTGCCGGAAAAATATCAAGAAA TATTTGCTGATTCATCAAAAGATGGCTACGCTGGTTATATTGAAGGTAAAACTAATCAAGAA GCTTTTTATAAATACCTGTCAAAATTGTTGACCAAGCAAGAAGATAGCGAGAATTTTCTTGA AAAAATCAAGAATGAAGATTTCTTGAGAAAACAAAGGACCTTTGATAATGGCTCAATTCCA 40 CACCAAGTCCATTTGACAGAGCTGAAAGCTATTATCCGCCGTCAATCAGAATACTATCCCTT CTTGAAAGAGAATCAAGATAGGATTGAAAAAATCCTTACCTTTAGAATTCCTTATTATATCG GGCCACTAGCACGTGAGAAGAGTGATTTTGCATGGATGACTCGCAAAACAGATGACAGTAT TCGACCTTGGAATTTTGAAGACTTGGTTGATAAAGAAAAATCTGCGGAAGCTTTTATCCATC GTATGACCAACAATGATTTTTATCTTCCTGAAGAAAAAGTTTTACCAAAGCATAGTCTTATT 45 TATGAAAAATTTACGGTCTATAATGAGTTGACTAAGGTTAGATATAAAAATGAGCAAGGTG AGACTTATTTTTTTGATAGCAATATTAAACAAGAAATCTTTGATGGAGTATTCAAGGAACAT CGTAAGGTATCCAAGAAGAAGTTGCTAGATTTTCTGGCTAAAGAATATGAGGAGTTTAGGA TAGTAGATGTTATTGGTCTAGATAAAGAAAATAAAGCTTTCAACGCCTCATTGGGAACTTAC CACGATCTCGAAAAAATACTAGACAAAGATTTTCTAGATAATCCAGATAATGAGTCTATTCT 50 GGAAGATATCGTCCAAACTCTAACATTATTTGAAGACAGAGAAATGATTAAGAAGCGTCTT GAAAACTATAAAGATCTTTTTACAGAGTCACAACTAAAAAAACTCTATCGTCGTCACTATAC TGGCTGGGGACGATTGTCTGCTAAGTTAATCAATGGTATTCGAGATAAAGAGAGTCAAAAA ACAATCTTGGACTATCTTATTGATGATGGTAGATCTAATCGCAACTTTATGCAGTTGATAAA TGATGATGGTCTATCTTTCAAATCAATTATCAGTAAGGCACAGGCTGGTAGTCATTCAGATA 55 ATCTAAAAGAAGTTGTAGGTGAGCTTGCAGGTAGCCCTGCTATTAAAAAGGGAATTCTACA AAGTTTGAAAATTGTTGATGAGCTTGTTAAAGTCATGGGATACGAACCTGAACAAATTGTGG

TTGAGATGGCGCGTGAGAATCAAACAACAAATCAAGGTCGTCGTAACTCTCGACAACGCTA

168 5 TAAACTTCTTGATGATGGCGTTAAGAATCTAGCTAGTGACTTGAATGGCAATATTTTGAAAG AATATCCTACGGATAATCAAGCGTTGCAAAATGAAAGACTTTTCCTTTACTACTTACAAAAC GGAAGAGATATGTATACAGGGGAAGCTCTAGATATTGACAATTTAAGTCAATATGATATTG ACCACATTATTCCTCAAGCTTTCATAAAAGATGATTCTATTGATAATCGTGTTTTGGTATCAT CTGCTAAAAATCGTGGAAAGTCAGATGATGTTCCTAGCCTTGAAATTGTAAAAGATTGTAAA 0 GTTTTCTGGAAAAAATTACTTGATGCTAAGTTAATGAGTCAGCGTAAGTATGATAATTTGAC TAAGGCAGAGCGCGGAGGCCTAACTTCCGATGATAAGGCAAGATTTATCCAACGTCAGTTG GTTGAGACACGACAAATTACCAAGCATGTTGCCCGTATCTTGGATGAACGCTTTAATAATGA GCTTGATAGTAAAGGTAGAAGGATCCGCAAAGTTAAAATTGTAACCTTGAAGTCAAATTTG GTTTCAAATTTCCGAAAAGAATTTGGATTCTATAAAATTCGTGAAGTTAACAATTATCACCA [5 TGCACATGATGCCTATCTTAATGCAGTAGTTGCTAAAGCTATTCTAACCAAATATCCTCAGT TAGAGCCAGAATTTGTCTACGGCGACTATCCAAAATATAATAGTTACAAAACGCGTAAATC CGCTACAGAAAAGCTATTTTTCTATTCAAATATTATGAACTTCTTTAAAACTAAGGTAACTTT AGCGGATGGAACCGTTGTTGTAAAAGATGATATTGAAGTTAATAATGATACGGGTGAAATT GTTTGGGATAAAAAGAAACACTTTGCGACAGTTAGAAAAGTCTTGTCATACCCTCAGAACA !0 ATATCGTGAAGAAGACAGAGATTCAGACAGGTGGTTTCTCTAAGGAATCAATCTTGGCGCA TGGTAACTCAGATAAGTTGATTCCAAGAAAAACGAAGGATATTTATTTAGATCCTAAGAAA TATGGAGGTTTTGATAGTCCGATAGTAGCTTACTCTGTTTTAGTTGTAGCTGATATCAAAAA GGGTAAAGCACAAAAACTAAAAACAGTTACGGAACTTTTAGGAATTACCATCATGGAGAGG TCCAGATTTGAGAAAAATCCATCAGCTTTCCTTGAATCAAAAGGCTATTTAAATATTAGGGC !5 TGATAAACTAATTATTTTGCCCAAGTATAGTCTGTTCGAATTAGAAAATGGGCGTCGTCGAT TACTTGCTAGTGCTGGTGAATTACAAAAAGGTAATGAGCTAGCCTTACCAACACAATTTATG AAGTTCTTATACCTTGCAAGTCGTTATAATGAGTCAAAAGGTAAACCAGAGGAGATTGAGA AGAAACAAGAATTTGTAAATCAACATGTCTCTTATTTTGATGACATCCTTCAATTAATTAAT GATTTTTCAAAACGAGTTATTCTAGCAGATGCTAATTTAGAGAAAATCAATAAGCTTTACCA ;0 AGATAATAAGGAAAATATATCAGTAGATGAACTTGCTAATAATATTATCAATCTATTTACTT TTACCAGTCTAGGAGCTCCAGCAGCTTTTAAATTTTTTGATAAAATAGTTGATAGAAAACGC TATACATCAACTAAAGAAGTACTTAATTCTACCCTAATTCATCAATCTATTACTGGACTTTAT GAAACACGTATTGATTTGGGTAAGTTAGGAGAAGATTGATATGGCAGGTTGGCGAACCGTT GTTGTAAATACACATTCTAAGCTCTCTTATAAAAATAATCATCTGATTTTTAAAGATTCTTAT ;5 CAGACGGAAATGATTCATCTATCAGAGATTGACATTCTAATCATGGAAACAACAGATATCG TTTTGTCGACCATGCTGATTAAACGTTTGGTTGATGAAAATATTTTAGTTATATTTTGTGACG ATAAACGCTTGCCAACAGCTATGTTAATGCCGTACTATGCCAGACATGATTCGAGTTTACAA TTATCTAGGCAGATGTCATGGATTGAAGATGTCAAAGCAGATGTTTGGACATCAATTATTGC ACAAAAAATTTTGAATCAGTCTTTTTATCTCGGTGAGTGTTCTTTCTTTGAAAAATCCCAGTC W0 TATTATGAATCTCTACCATGACTTAGAACCTTTTGATCCTTCTAATCGTGAGGGGCATGCTGC TAGGATTTATTTCAATACACTTTTTGGAAATGATTTTTCAAGAGAGCAGGATAATCCAATAA ATGCTGGTTTAGACTACGGATATTCATTGCTTTTGAGTATGTTTGCGCGTGAAGTTGTTAAGT GTGGTTGCATGACACAATTTGGCTTGAAGCATGCTAATCAATTTAATCAGTTCAACCTAGCA AGCGATATTATGGAACCATTTCGCCCAATCGTTGATAGGATTATTTATGAAAATAGGCAGAG 45 TGATTTTGTCAAAATGAAAAGAGAACTCTTTTCTATGTTTTCAGAGACATACAGCTACAATG GTAAAGAAATGTATCTCTCAAATATTGTCAGCGACTATACCAAAAAAGTTATTAAGTCGCTA AATAGTGATGGGAATGGAATTCCGGAGTTTAGGATATGAGTTATCGGTATATGCGAATGATT TTAATGTTTGATATGCCTACTGAAACAGCAGAAGAACGGAAGGCGTATCGTAAGTTTAGAA AGTTTCTCTTGAGCGAAGGCTTTATCATGCATCAGTTTTCTGTTTATAGTAAATTATTACTCA 50 ATAATACAGCTAATAATGCTATGATAGGTCGGCTTAAAGTGAATAATCCTAAAAAGGGTAA TATCACACTCTTAACAGTTACGGAAAAACAATTTGCGAGAATGGTTTACCTCCATGGAGAAC GCAACACAAGTGTTGCCAACTCTGATAGTCGCTTGGTTTTCCTAGGAGATTCTTATGATCAA GATTAATTTTCCAATTTTAGATGAACCATTAGTGTTAAGTAATGCTACGATTTTAACGATAG AAGATGTTTCAGTTTATTCTTCATTGGTGAAACATTTTTATCAATATGACGTAGATGAACATT 55 TGAAATTATTTGATGATAAGCAGAAAAGTCTGAAGGCAACAGAGTTAATGCTGGTTACAGA TATCTTAGGATACGATGTCAACTCAGCACCTATTCTAAAGTTGATACATGGTGACTTAGAAA ATCAATTCAACGAAAAGCCAGAAGTGAAATCAATGGTAGAAAAATTAGCAGCTACTATTAC AGAACTTATCGCATTTGAGTGTCTAGAGAATGAGCTTGATTTAGAATACGATGAAATTAAGA TTTTAGAACTCATTAAGGCACTGGGAGTCAAAATTGAGACACAGAGCGACACTATCTTTGA 60 AAAATGTTTTGAAATTATACAAGTTTACCATTATTTAACGAAAAAGAATCTCTTGGTTTTTGT 169 5 TAATAGCGGAGCTTATCTTACCAAAGATGAAGTTATAAAATTATGTGAATACATCAATTTAA TGCAAAAGTCAGTACTCTTTCTAGAACCTAGAAGACTCTATGATTTACCGCAATATGTTATT GATAAGGATTATTTCTTGATAGGCGAAAATATGGTATAA (SEQ ID NO:488) SEQ ID NO:489: [0 ATGAATAAGCCATATTCAATAGGCCTTGACATCGGTACTAATTCCGTCGGATGGAGCATTAT TACAGATGATTATAAAGTACCTGCTAAGAAGATGAGAGTTTTAGGGAACACTGATAAAGAA TATATTAAGAAGAATCTCATAGGTGCTCTGCTTTTTGATGGCGGGAATACTGCTGCAGATAG ACGCTTGAAGCGAACTGCTCGTCGTCGTTATACACGTCGTAGAAATCGTATTCTATATTTAC AAGAAATTTTTGCAGAGGAAATGAGTAAAGTTGATGATAGTTTCTTTCATCGATTAGAGGAT [5 TCTTTTCTAGTTGAGGAAGATAAGAGAGGGAGCAAGTATCCTATCTTTGCAACATTGCAGGA AGAGAAAGATTATCATGAAAAATTTTCGACAATCTATCATTTGAGAAAAGAATTAGCTGAC AAGAAAGAAAAAGCAGACCTTCGTCTTATTTATATTGCTCTAGCTCATATCATTAAATTTAG AGGGCATTTCCTAATTGAGGATGATAGCTTTGATGTCAGGAATACAGACATTTCAAAACAAT ATCAAGATTTTTTAGAAATCTTTAATACAACTTTTGAAAATAATGATTTGTTATCTCAAAACG !0 TTGACGTAGAGGCAATACTAACAGATAAGATTAGCAAGTCTGCGAAGAAAGATCGTATTTT AGCGCAGTATCCTAACCAAAAATCTACTGGCATTTTTGCAGAATTTTTGAAATTGATTGTCG GAAATCAAGCTGACTTCAAGAAATATTTCAATTTGGAGGATAAAACGCCGCTTCAATTCGCT AAGGATAGCTACGATGAAGATTTAGAAAATCTTCTTGGACAGATTGGTGATGAATTTGCAG ACTTATTCTCAGCAGCGAAAAAGTTATATGATAGTGTCCTTTTGTCTGGCATTCTTACAGTAA !5 TCGACCTCAGTACCAAGGCGCCACTTTCAGCTTCTATGATTCAGCGTTATGATGAACATAGA GAGGACTTGAAACAGTTAAAACAATTCGTAAAAGCTTCATTGCCGGAAAAATATCAAGAAA TATTTGCTGATTCATCAAAAGATGGCTACGCTGGTTATATTGAAGGTAAAACTAATCAAGAA GCTTTTTATAAATACCTGTCAAAATTGTTGACCAAGCAAGAAGATAGCGAGAATTTTCTTGA AAAAATCAAGAATGAAGATTTCTTGAGAAAACAAAGGACCTTTGATAATGGCTCAATTCCA ;0 CACCAAGTCCATTTGACAGAGCTGAAAGCTATTATCCGCCGTCAATCAGAATACTATCCCTT CTTGAAAGAGAATCAAGATAGGATTGAAAAAATCCTTACCTTTAGAATTCCTTATTATATCG GGCCACTAGCACGTGAGAAGAGTGATTTTGCATGGATGACTCGCAAAACAGATGACAGTAT TCGACCTTGGAATTTTGAAGACTTGGTTGATAAAGAAAAATCTGCGGAAGCTTTTATCCATC GTATGACCAACAATGATTTTTATCTTCCTGAAGAAAAAGTTTTACCAAAGCATAGTCTTATT ;5 TATGAAAAATTTACGGTCTATAATGAGTTGACTAAGGTTAGATATAAAAATGAGCAAGGTG AGACTTATTTTTTTGATAGCAATATTAAACAAGAAATCTTTGATGGAGTATTCAAGGAACAT CGTAAGGTATCCAAGAAGAAGTTGCTAGATTTTCTGGCTAAAGAATATGAGGAGTTTAGGA TAGTAGATGTTATTGGTCTAGATAAAGAAAATAAAGCTTTCAACGCCTCATTGGGAACTTAC CACGATCTCGAAAAAATACTAGACAAAGATTTTCTAGATAATCCAGATAATGAGTCTATTCT 40 GGAAGATATCGTCCAAACTCTAACATTATTTGAAGACAGAGAAATGATTAAGAAGCGTCTT GAAAACTATAAAGATCTTTTTACAGAGTCACAACTAAAAAAACTCTATCGTCGTCACTATAC TGGCTGGGGACGATTGTCTGCTAAGTTAATCAATGGTATTCGAGATAAAGAGAGTCAAAAA ACAATCTTGGACTATCTTATTGATGATGGTAGATCTAATCGCAACTTTATGCAGTTGATAAA TGATGATGGTCTATCTTTCAAATCAATTATCAGTAAGGCACAGGCTGGTAGTCATTCAGATA 45 ATCTAAAAGAAGTTGTAGGTGAGCTTGCAGGTAGCCCTGCTATTAAAAAGGGAATTCTACA AAGTTTGAAAATTGTTGATGAGCTTGTTAAAGTCATGGGATACGAACCTGAACAAATTGTGG TTGAGATGGCGCGTGAGAATCAAACAACAAATCAAGGTCGTCGTAACTCTCGACAACGCTA TAAACTTCTTGATGATGGCGTTAAGAATCTAGCTAGTGACTTGAATGGCAATATTTTGAAAG AATATCCTACGGATAATCAAGCGTTGCAAAATGAAAGACTTTTCCTTTACTACTTACAAAAC 50 GGAAGAGATATGTATACAGGGGAAGCTCTAGATATTGACAATTTAAGTCAATATGATATTG ACCACATTATTCCTCAAGCTTTCATAAAAGATGATTCTATTGATAATCGTGTTTTGGTATCAT CTGCTAAAAATCGTGGAAAGTCAGATGATGTTCCTAGCCTTGAAATTGTAAAAGATTGTAAA GTTTTCTGGAAAAAATTACTTGATGCTAAGTTAATGAGTCAGCGTAAGTATGATAATTTGAC TAAGGCAGAGCGCGGAGGCCTAACTTCCGATGATAAGGCAAGATTTATCCAACGTCAGTTG 55 GTTGAGACACGACAAATTACCAAGCATGTTGCCCGTATCTTGGATGAACGCTTTAATAATGA GCTTGATAGTAAAGGTAGAAGGATCCGCAAAGTTAAAATTGTAACCTTGAAGTCAAATTTG GTTTCAAATTTCCGAAAAGAATTTGGATTCTATAAAATTCGTGAAGTTAACAATTATCACCA TGCACATGATGCCTATCTTAATGCAGTAGTTGCTAAAGCTATTCTAACCAAATATCCTCAGT

TAGAGCCAGAATTTGTCTACGGCGACTATCCAAAATATAATAGTTACAAAACGCGTAAATC

170 5 CGCTACAGAAAAGCTATTTTTCTATTCAAATATTATGAACTTCTTTAAAACTAAGGTAACTTT AGCGGATGGAACCGTTGTTGTAAAAGATGATATTGAAGTTAATAATGATACGGGTGAAATT GTTTGGGATAAAAAGAAACACTTTGCGACAGTTAGAAAAGTCTTGTCATACCCTCAGAACA ATATCGTGAAGAAGACAGAGATTCAGACAGGTGGTTTCTCTAAGGAATCAATCTTGGCGCA TGGTAACTCAGATAAGTTGATTCCAAGAAAAACGAAGGATATTTATTTAGATCCTAAGAAA [0 TATGGAGGTTTTGATAGTCCGATAGTAGCTTACTCTGTTTTAGTTGTAGCTGATATCAAAAA GGGTAAAGCACAAAAACTAAAAACAGTTACGGAACTTTTAGGAATTACCATCATGGAGAGG TCCAGATTTGAGAAAAATCCATCAGCTTTCCTTGAATCAAAAGGCTATTTAAATATTAGGGC TGATAAACTAATTATTTTGCCCAAGTATAGTCTGTTCGAATTAGAAAATGGGCGTCGTCGAT TACTTGCTAGTGCTGGTGAATTACAAAAAGGTAATGAGCTAGCCTTACCAACACAATTTATG [5 AAGTTCTTATACCTTGCAAGTCGTTATAATGAGTCAAAAGGTAAACCAGAGGAGATTGAGA AGAAACAAGAATTTGTAAATCAACATGTCTCTTATTTTGATGACATCCTTCAATTAATTAAT GATTTTTCAAAACGAGTTATTCTAGCAGATGCTAATTTAGAGAAAATCAATAAGCTTTACCA AGATAATAAGGAAAATATATCAGTAGATGAACTTGCTAATAATATTATCAATCTATTTACTT TTACCAGTCTAGGAGCTCCAGCAGCTTTTAAATTTTTTGATAAAATAGTTGATAGAAAACGC !0 TATACATCAACTAAAGAAGTACTTAATTCTACCCTAATTCATCAATCTATTACTGGACTTTAT GAAACACGTATTGATTTGGGTAAGTTAGGAGAAGATTGA (SEQ ID NO:489) SEQ ID NO:490: ATGGCAGGTTGGCGAACCGTTGTTGTAAATACACATTCTAAGCTCTCTTATAAAAATAATCA !5 TCTGATTTTTAAAGATTCTTATCAGACGGAAATGATTCATCTATCAGAGATTGACATTCTAAT CATGGAAACAACAGATATCGTTTTGTCGACCATGCTGATTAAACGTTTGGTTGATGAAAATA TTTTAGTTATATTTTGTGACGATAAACGCTTGCCAACAGCTATGTTAATGCCGTACTATGCCA GACATGATTCGAGTTTACAATTATCTAGGCAGATGTCATGGATTGAAGATGTCAAAGCAGAT GTTTGGACATCAATTATTGCACAAAAAATTTTGAATCAGTCTTTTTATCTCGGTGAGTGTTCT ;0 TTCTTTGAAAAATCCCAGTCTATTATGAATCTCTACCATGACTTAGAACCTTTTGATCCTTCT AATCGTGAGGGGCATGCTGCTAGGATTTATTTCAATACACTTTTTGGAAATGATTTTTCAAG AGAGCAGGATAATCCAATAAATGCTGGTTTAGACTACGGATATTCATTGCTTTTGAGTATGT TTGCGCGTGAAGTTGTTAAGTGTGGTTGCATGACACAATTTGGCTTGAAGCATGCTAATCAA TTTAATCAGTTCAACCTAGCAAGCGATATTATGGAACCATTTCGCCCAATCGTTGATAGGAT ;5 TATTTATGAAAATAGGCAGAGTGATTTTGTCAAAATGAAAAGAGAACTCTTTTCTATGTTTT CAGAGACATACAGCTACAATGGTAAAGAAATGTATCTCTCAAATATTGTCAGCGACTATAC CAAAAAAGTTATTAAGTCGCTAAATAGTGATGGGAATGGAATTCCGGAGTTTAGGATATGA (SEQ ID NO:490) 40 SEQ ID NO:491: ATGCGAATGATTTTAATGTTTGATATGCCTACTGAAACAGCAGAAGAACGGAAGGCGTATC GTAAGTTTAGAAAGTTTCTCTTGAGCGAAGGCTTTATCATGCATCAGTTTTCTGTTTATAGTA AATTATTACTCAATAATACAGCTAATAATGCTATGATAGGTCGGCTTAAAGTGAATAATCCT AAAAAGGGTAATATCACACTCTTAACAGTTACGGAAAAACAATTTGCGAGAATGGTTTACC 45 TCCATGGAGAACGCAACACAAGTGTTGCCAACTCTGATAGTCGCTTGGTTTTCCTAGGAGAT TCTTATGATCAAGATTAA (SEQ ID NO:491) SEQ ID NO:492: ATGATCAAGATTAATTTTCCAATTTTAGATGAACCATTAGTGTTAAGTAATGCTACGATTTTA 50 ACGATAGAAGATGTTTCAGTTTATTCTTCATTGGTGAAACATTTTTATCAATATGACGTAGAT GAACATTTGAAATTATTTGATGATAAGCAGAAAAGTCTGAAGGCAACAGAGTTAATGCTGG TTACAGATATCTTAGGATACGATGTCAACTCAGCACCTATTCTAAAGTTGATACATGGTGAC TTAGAAAATCAATTCAACGAAAAGCCAGAAGTGAAATCAATGGTAGAAAAATTAGCAGCTA CTATTACAGAACTTATCGCATTTGAGTGTCTAGAGAATGAGCTTGATTTAGAATACGATGAA 55 ATTAAGATTTTAGAACTCATTAAGGCACTGGGAGTCAAAATTGAGACACAGAGCGACACTA TCTTTGAAAAATGTTTTGAAATTATACAAGTTTACCATTATTTAACGAAAAAGAATCTCTTG

GTTTTTGTTAATAGCGGAGCTTATCTTACCAAAGATGAAGTTATAAAATTATGTGAATACAT

171 5 CAATTTAATGCAAAAGTCAGTACTCTTTCTAGAACCTAGAAGACTCTATGATTTACCGCAAT ATGTTATTGATAAGGATTATTTCTTGATAGGCGAAAATATGGTATAA (SEQ ID NO:492) SEQ ID NO:493: ATGAATAAGCCATATTCAATAGGCCTTGACATCGGTACTAATTCCGTCGGATGGAGCATTAT [0 TACAGATGATTATAAAGTACCTGCTAAGAAGATGAGAGTTTTAGGGAACACTGATAAAGAA TATATTAAGAAGAATCTCATAGGTGCTCTGCTTTTTGATGGCGGGAATACTGCTGCAGATAG ACGCTTGAAGCGAACTGCTCGTCGTCGTTATACACGTCGTAGAAATCGTATTCTATATTTAC AAGAAATTTTTGCAGAGGAAATGAGTAAAGTTGATGATAGTTTCTTTCATCGATTAGAGGAT TCTTTTCTAGTTGAGGAAGATAAGAGAGGTAGCAAGTATCCTATCTTTGCAACAATGCAGGA [5 GGAGAAATATTATCATGAAAAATTTCCGACAATCTATCATTTGAGAAAAGAATTGGCTGAC AAGAAAGAAAAAGCAGACCTTCGTCTTGTTTATCTGGCTCTAGCTCATATCATTAAATTCAG AGGGCATTTCCTAATTGAGGATGATAGATTTGATGTGAGGAATACCGATATTCAAAAACAA TATCAAGCCTTTTTAGAAATTTTTGATACTACCTTTGAAAATAATCATTTGTTATCTCAAAAT GTAGATGTAGAAGCAATTCTAACAGATAAGATTAGCAAGTCTGCGAAGAAGGATCGCATCT !0 TAGCGCAGTATCCTAACCAAAAATCTACTGGTATTTTTGCAGAATTTTTGAAATTGATTGTC GGAAATCAAGCTGACTTCAAGAAACATTTCAATTTGGAGGATAAAACACCGCTTCAATTCG CTAAGGATAGCTACGATGAAGATTTAGAAAATCTTCTTGGACAGATTGGTGATGAATTTGCA GACTTATTCTCAGTAGCGAAAAAGCTATATGATAGTGTTCTTTTATCTGGCATTCTTACAGTA ACTGATCTCAGTACCAAGGCGCCACTTTCTGCCTCTATGATTCAGCGTTATGATGAACATCA !5 TGAGGACTTAAAGCATCTAAAACAATTCGTAAAAGCTTCATTACCTGAAAATTATCGGGAA GTATTTGCTGATTCATCAAAAGATGGCTACGCTGGCTATATTGAAGGCAAAACTAATCAAGA AGCTTTTTATAAATATCTGTTAAAATTGTTGACCAAACAAGAAGGTAGCGAGTATTTTCTTG AGAAAATTAAGAATGAAGATTTTTTGAGAAAACAGAGAACCTTTGATAATGGCTCAATCCC GCATCAAGTCCATTTGACAGAATTGAGGGCTATTATTCGACGTCAATCAGAATACTATCCAT ;0 TCTTGAAAGAGAATCAAGATAGGATTGAAAAAATCCTTACCTTTAGAATTCCTTATTATGTC GGGCCACTAGCACGTGAGAAGAGTGATTTTGCATGGATGACTCGCAAAACAGATGACAGTA TTCGACCTTGGAATTTTGAAGACTTGGTTGATAAAGAAAAATCTGCGGAAGCTTTTATCCAT CGCATGACCAACAATGACCTCTATCTTCCAGAAGAAAAAGTTTTACCAAAGCATAGTCTTAT TTATGAAAAATTTACTGTTTACAATGAATTAACGAAGGTTAGATTTTTGGCAGAAGGCTTTA ;5 AAGATTTTCAATTTTTAAATAGGAAGCAAAAAGAAACTATCTTTAACAGCTTGTTTAAGGAA AAACGTAAAGTAACTGAAAAGGATATTATTAGTTTTTTGAATAAAGTTGATGGATATGAAG GAATTGCAATCAAAGGAATTGAGAAACAGTTTAACGCTAGCCTTTCAACCTATCATGATCTT AAAAAAATACTTGGCAAGGATTTCCTTGATAATACAGATAACGAGCTTATTTTGGAAGATAT CGTCCAAACTCTAACCTTATTTGAAGATAGAGAAATGATTAAGAAGTGTCTTGACATCTATA 40 AAGATTTTTTTACAGAGTCACAGCTTAAAAAGCTCTATCGCCGTCACTATACTGGCTGGGGA CGATTGTCTGCTAAGCTAATAAATGGCATCCGAAATAAAGAGAATCAAAAAACAATCTTGG ACTATCTTATTGATGATGGAAGTGCAAACCGAAACTTCATGCAGTTGATAAATGATGATGAT CTATCATTTAAACCAATTATTGACAAGGCACGAACTGGTAGTCATTCGGATAATCTGAAAGA AGTTGTAGGTGAACTTGCTGGTAGCCCTGCTATTAAAAAAGGGATTCTACAAAGTTTGAAAA 45 TAGTTGATGAGCTGGTTAAAGTCATGGGCTATGAACCTGAACAAATCGTGGTTGAAATGGC ACGTGAGAACCAAACGACAGCAAAAGGATTAAGTCGTTCACGACAACGCTTGACAACCTTG AGAGAATCTCTTGCTAATTTGAAGAGTAATATTTTGGAAGAGAAAAAGCCTAAGTATGTGA AAGATCAAGTTGAAAATCATCATTTATCTGATGACCGTCTTTTCCTTTACTACTTACAAAACG GAAGAGATATGTATACAAAAAAGGCTCTGGATATTGATAATTTAAGTCAATATGATATTGA 50 CCACATTATTCCTCAAGCTTTCATAAAAGATGATTCTATTGATAATCGTGTTTTGGTATCATC TGCTAAAAATCGTGGAAAATCAGATGATGTTCCTAGCATTGAAATTGTAAAAGCTCGCAAA ATGTTCTGGAAAAATTTACTGGATGCTAAGTTAATGAGTCAGCGTAAGTATGATAATTTGAC TAAGGCAGAGCGCGGAGGCCTAACTTCCGATGATAAGGCAAGATTTATCCAACGTCAGTTG GTTGAGACTCGACAAATTACCAAGCATGTAGCTCGTATCTTGGATGAACGCTTCAATAATGA 55 AGTTGATAATGGTAAAAAGATTTGCAAGGTTAAAATTGTAACCTTGAAGTCAAATTTGGTTT CAAATTTCCGAAAAGAATTTGGATTCTATAAAATTCGTGAAGTTAATGATTATCACCATGCA CACGATGCTTATCTTAATGCAGTAGTTGCCAAAGCTATTCTAACCAAATATCCACAGTTAGA GCCAGAGTTTGTCTACGGAATGTATAGACAGAAAAAACTTTCGAAAATCGTTCATGAGGAT

AAGGAAGAAAAATATAGTGAAGCAACCAGGAAAATGTTTTTCTACTCCAACTTGATGAATA

172 5 TGTTCAAAAGAGTTGTGAGGTTAGCAGATGGTTCTATTGTTGTAAGACCAGTAATAGAAACT GGTAGATATATGAGAAAAACTGCATGGGATAAAAAGAAACACTTTGCGACAGTTAGAAAA GTCTTGTCATACCCTCAGAACAATATCGTGAAGAAGACAGAGATTCAGACAGGTGGTTTCTC TAAGGAATCAATCTTGGCGCATGGTAACTCAGATAAGTTGATTCCAAGAAAAACGAAGGAT ATTTATTTAGATCCTAAGAAATATGGAGGTTTTGATAGTCCGATAGTAGCTTACTCTGTTTTA 0 GTTGTAGCTGATATCAAAAAAGGTAAAGCACAAAAACTAAAAACAGTTACGGAACTTTTAG GAATTACCATCATGGAGAGGTCCAGATTTGAGAAAAATCCATCAGCTTTCCTTGAATCAAAA GGTTATTTAAATATTAGGGACGATAAATTAATGATTTTACCGAAGTATAGTCTGTTCGAATT AGAAAATGGGCGTCGTCGATTACTTGCTAGTGCTGGTGAATTACAAAAAGGTAACGAGCTA GCCTTACCAACACAATTTATGAAGTTCTTATACCTTGCAAGTCGTTATAATGAGTCAAAAGG [5 TAAACCAGAGGAGATTGAGAAGAAACAAGAATTTGTAAATCAACATGTCTCTTATTTTGAT GACATCCTTCAATTAATTAATGATTTTTCAAAACGAGTTATTCTAGCAGATGCTAATTTAGA GAAAATCAATAAGCTTTACCAGGATAATAAGGAAAATATACCAGTAGATGAACTTGCTAAT AATATTATCAATCTATTTACTTTTACCAGTCTAGGAGCTCCAGCAGCTTTTAAATTTTTTGAT AAAATAGTTGATAGAAAACGCTATACATCAACTAAAGAAGTACTTAATTCTACTCTAATCCA !0 TCAATCTATTACTGGACTTTATGAAACACGTATTGATTTGGGTAAATTAGGAGAAGATTGAT ATGGCAGGTTGGCGAACTGTTGTTGTAAATACACATTCTAAGCTCTCTTATAAAAATAATCA TCTGATTTTTAAAGATTCTTATCAGACGGAAATGATTCATCTTTCAGAGATTGATATTCTAAT CATGGAAACGACAGATATTGTTTTGTCGACTATGCTGATTAAACGTTTGGTTGATGAAAATA TTTTAGTCATATTTTGTGATGATAAACGCTTGCCAACAGCTATGTTAATGCCGTACTATGCTA !5 GACATGATTCGAGTTTACAATTATCTAGGCAGATGTCATGGATTGAGGATGTCAAAGCGGAT GTTTGGACATCAATTATTGCACAAAAAATTTTGAATCAGTCCTTTTATCTCGGTGAGTGTTCT TTCTTTGAAAAATCCCAGTCTATTATGAATCTCTATCATGATTTAGAATCTTTTGACCCTTCC AATCGTGAAGGTCATGCAGCTAGGATTTATTTCAATACACTTTTTGGAAATGATTTTTCAAG AGAGCAGGATAATCCAATAAATGCTGGTTTAGACTATGGATATTCTCTGATTTTGAGTATGT ;0 TTGCGCGTGAAGTTGTTAAGTGTGGTTGCATGACACAATTTGGCTTAAAGCATGCTAATCAA TTTAATCAGTTCAACCTAGCAAGCGATATTATGGAACCATTTCGCCCAATCGTTGATAGGAT TATTTATGAAAATAGGCAGAGTGATTTTGTCAAAATGAAAAGAGAACTCTTTTCTATGTTTT CAGAGACATACAGCTACAACGGTAAAGAAATGTATCTTTCAAATATTGTCAGCGATTACAC CAAAAAAGTTATTAAGTCGCTAAATAGTGATGGGAATGGAATTCCGGAGTTTAGGATATGA ;5 GTTATCGGTATATGAGAATGATTTTAATGTTTGATATGCCTACTGAAACAGTAGAAGAACGT AAGGCGTATCGTAAGTTTAGAAAGTTTCTGTTGAGCGAAGGTTTTATTATGCATCAGTTCTC TGTTTATAGTAAATTATTGCTCAATAATACAGCTAATAATGCCATGATAGGTCGGCTTAAAG TGAATAATCCTAAGAAAGGGAGTATAACTCTTTTGACAGTTACCGAGAAGCAGTTTGCAAG GATGGTTTATCTACATGGTGAACATAATATGAGTGTTGCCAACTCTGATAGTCGCTTGGTTTT W- CCTAGGAGATTCTTATGATCAAGATTAATTTTCCAATTTTAGATGAACCATTAGTGTTAAGT AATGCTACGATTTTAACGATAGAAGATGTTTCAGTTTATTCTTCATTGGTGAAACATTTTTAT CAATATGACGTAGATGAACATTTGAAATTATTTGATGATAAGCAGAAAAGTCTGAAGGCAA CGGAGTTAATGTTAGTTACAGATATCTTAGGATACGATGTCAACTCAGCACCTATTCTAAAG TTGATACATGGTGACTTAGAAAATCAATTCAACGAAAAGCCAGAAGTGAAATCAATGGTAG 45 AAAAATTAGCAGCTACTATTACAGAACTTATCGCATTTGAGTGTCTAGAGAATGAGCTTGAT TTAGAATACGATGAAATTACGATTTTAGAACTCATTAAGGCACTGGGAGTCAAAATTGAGA CACAGAGCGACACTATCTTTGAAAAATGTTTTGAAATTATACAAGTTTACCATTATTTAACG AAAAAGAATCTCTTAGTTTTTGTTAATAGCGGAGCTTATCTTACCAAAGATGAAGTTATAAA ATTATGTGAATACATCAATTTAATGCAAAAGTCAGTACTCTTTCTAGAACCTAGAAGACTCT 50 ATGATTTACCGCAATATGTTATTGATAAGGATTATTTCTTGATAGGCGAAAATATGGTATAA (SEQ ID NO:493) SEQ ID NO:494: ATGAATAAGCCATATTCAATAGGCCTTGACATCGGTACTAATTCCGTCGGATGGAGCATTAT 55 TACAGATGATTATAAAGTACCTGCTAAGAAGATGAGAGTTTTAGGGAACACTGATAAAGAA TATATTAAGAAGAATCTCATAGGTGCTCTGCTTTTTGATGGCGGGAATACTGCTGCAGATAG ACGCTTGAAGCGAACTGCTCGTCGTCGTTATACACGTCGTAGAAATCGTATTCTATATTTAC AAGAAATTTTTGCAGAGGAAATGAGTAAAGTTGATGATAGTTTCTTTCATCGATTAGAGGAT

TCTTTTCTAGTTGAGGAAGATAAGAGAGGTAGCAAGTATCCTATCTTTGCAACAATGCAGGA

173 5 GGAGAAATATTATCATGAAAAATTTCCGACAATCTATCATTTGAGAAAAGAATTGGCTGAC AAGAAAGAAAAAGCAGACCTTCGTCTTGTTTATCTGGCTCTAGCTCATATCATTAAATTCAG AGGGCATTTCCTAATTGAGGATGATAGATTTGATGTGAGGAATACCGATATTCAAAAACAA TATCAAGCCTTTTTAGAAATTTTTGATACTACCTTTGAAAATAATCATTTGTTATCTCAAAAT GTAGATGTAGAAGCAATTCTAACAGATAAGATTAGCAAGTCTGCGAAGAAGGATCGCATCT 0 TAGCGCAGTATCCTAACCAAAAATCTACTGGTATTTTTGCAGAATTTTTGAAATTGATTGTC GGAAATCAAGCTGACTTCAAGAAACATTTCAATTTGGAGGATAAAACACCGCTTCAATTCG CTAAGGATAGCTACGATGAAGATTTAGAAAATCTTCTTGGACAGATTGGTGATGAATTTGCA GACTTATTCTCAGTAGCGAAAAAGCTATATGATAGTGTTCTTTTATCTGGCATTCTTACAGTA ACTGATCTCAGTACCAAGGCGCCACTTTCTGCCTCTATGATTCAGCGTTATGATGAACATCA [5 TGAGGACTTAAAGCATCTAAAACAATTCGTAAAAGCTTCATTACCTGAAAATTATCGGGAA GTATTTGCTGATTCATCAAAAGATGGCTACGCTGGCTATATTGAAGGCAAAACTAATCAAGA AGCTTTTTATAAATATCTGTTAAAATTGTTGACCAAACAAGAAGGTAGCGAGTATTTTCTTG AGAAAATTAAGAATGAAGATTTTTTGAGAAAACAGAGAACCTTTGATAATGGCTCAATCCC GCATCAAGTCCATTTGACAGAATTGAGGGCTATTATTCGACGTCAATCAGAATACTATCCAT !0 TCTTGAAAGAGAATCAAGATAGGATTGAAAAAATCCTTACCTTTAGAATTCCTTATTATGTC GGGCCACTAGCACGTGAGAAGAGTGATTTTGCATGGATGACTCGCAAAACAGATGACAGTA TTCGACCTTGGAATTTTGAAGACTTGGTTGATAAAGAAAAATCTGCGGAAGCTTTTATCCAT CGCATGACCAACAATGACCTCTATCTTCCAGAAGAAAAAGTTTTACCAAAGCATAGTCTTAT TTATGAAAAATTTACTGTTTACAATGAATTAACGAAGGTTAGATTTTTGGCAGAAGGCTTTA !5 AAGATTTTCAATTTTTAAATAGGAAGCAAAAAGAAACTATCTTTAACAGCTTGTTTAAGGAA AAACGTAAAGTAACTGAAAAGGATATTATTAGTTTTTTGAATAAAGTTGATGGATATGAAG GAATTGCAATCAAAGGAATTGAGAAACAGTTTAACGCTAGCCTTTCAACCTATCATGATCTT AAAAAAATACTTGGCAAGGATTTCCTTGATAATACAGATAACGAGCTTATTTTGGAAGATAT CGTCCAAACTCTAACCTTATTTGAAGATAGAGAAATGATTAAGAAGTGTCTTGACATCTATA ;0 AAGATTTTTTTACAGAGTCACAGCTTAAAAAGCTCTATCGCCGTCACTATACTGGCTGGGGA CGATTGTCTGCTAAGCTAATAAATGGCATCCGAAATAAAGAGAATCAAAAAACAATCTTGG ACTATCTTATTGATGATGGAAGTGCAAACCGAAACTTCATGCAGTTGATAAATGATGATGAT CTATCATTTAAACCAATTATTGACAAGGCACGAACTGGTAGTCATTCGGATAATCTGAAAGA AGTTGTAGGTGAACTTGCTGGTAGCCCTGCTATTAAAAAAGGGATTCTACAAAGTTTGAAAA ;5 TAGTTGATGAGCTGGTTAAAGTCATGGGCTATGAACCTGAACAAATCGTGGTTGAAATGGC ACGTGAGAACCAAACGACAGCAAAAGGATTAAGTCGTTCACGACAACGCTTGACAACCTTG AGAGAATCTCTTGCTAATTTGAAGAGTAATATTTTGGAAGAGAAAAAGCCTAAGTATGTGA AAGATCAAGTTGAAAATCATCATTTATCTGATGACCGTCTTTTCCTTTACTACTTACAAAACG GAAGAGATATGTATACAAAAAAGGCTCTGGATATTGATAATTTAAGTCAATATGATATTGA W- CCACATTATTCCTCAAGCTTTCATAAAAGATGATTCTATTGATAATCGTGTTTTGGTATCATC TGCTAAAAATCGTGGAAAATCAGATGATGTTCCTAGCATTGAAATTGTAAAAGCTCGCAAA ATGTTCTGGAAAAATTTACTGGATGCTAAGTTAATGAGTCAGCGTAAGTATGATAATTTGAC TAAGGCAGAGCGCGGAGGCCTAACTTCCGATGATAAGGCAAGATTTATCCAACGTCAGTTG GTTGAGACTCGACAAATTACCAAGCATGTAGCTCGTATCTTGGATGAACGCTTCAATAATGA 45 AGTTGATAATGGTAAAAAGATTTGCAAGGTTAAAATTGTAACCTTGAAGTCAAATTTGGTTT CAAATTTCCGAAAAGAATTTGGATTCTATAAAATTCGTGAAGTTAATGATTATCACCATGCA CACGATGCTTATCTTAATGCAGTAGTTGCCAAAGCTATTCTAACCAAATATCCACAGTTAGA GCCAGAGTTTGTCTACGGAATGTATAGACAGAAAAAACTTTCGAAAATCGTTCATGAGGAT AAGGAAGAAAAATATAGTGAAGCAACCAGGAAAATGTTTTTCTACTCCAACTTGATGAATA 50 TGTTCAAAAGAGTTGTGAGGTTAGCAGATGGTTCTATTGTTGTAAGACCAGTAATAGAAACT GGTAGATATATGAGAAAAACTGCATGGGATAAAAAGAAACACTTTGCGACAGTTAGAAAA GTCTTGTCATACCCTCAGAACAATATCGTGAAGAAGACAGAGATTCAGACAGGTGGTTTCTC TAAGGAATCAATCTTGGCGCATGGTAACTCAGATAAGTTGATTCCAAGAAAAACGAAGGAT ATTTATTTAGATCCTAAGAAATATGGAGGTTTTGATAGTCCGATAGTAGCTTACTCTGTTTTA 55 GTTGTAGCTGATATCAAAAAAGGTAAAGCACAAAAACTAAAAACAGTTACGGAACTTTTAG GAATTACCATCATGGAGAGGTCCAGATTTGAGAAAAATCCATCAGCTTTCCTTGAATCAAAA GGTTATTTAAATATTAGGGACGATAAATTAATGATTTTACCGAAGTATAGTCTGTTCGAATT AGAAAATGGGCGTCGTCGATTACTTGCTAGTGCTGGTGAATTACAAAAAGGTAACGAGCTA GCCTTACCAACACAATTTATGAAGTTCTTATACCTTGCAAGTCGTTATAATGAGTCAAAAGG 60 TAAACCAGAGGAGATTGAGAAGAAACAAGAATTTGTAAATCAACATGTCTCTTATTTTGAT 174 5 GACATCCTTCAATTAATTAATGATTTTTCAAAACGAGTTATTCTAGCAGATGCTAATTTAGA GAAAATCAATAAGCTTTACCAGGATAATAAGGAAAATATACCAGTAGATGAACTTGCTAAT AATATTATCAATCTATTTACTTTTACCAGTCTAGGAGCTCCAGCAGCTTTTAAATTTTTTGAT AAAATAGTTGATAGAAAACGCTATACATCAACTAAAGAAGTACTTAATTCTACTCTAATCCA TCAATCTATTACTGGACTTTATGAAACACGTATTGATTTGGGTAAATTAGGAGAAGATTGA t0 (SEQ ID NO:494) SEQ ID NO:495: ATGGCAGGTTGGCGAACTGTTGTTGTAAATACACATTCTAAGCTCTCTTATAAAAATAATCA TCTGATTTTTAAAGATTCTTATCAGACGGAAATGATTCATCTTTCAGAGATTGATATTCTAAT [5 CATGGAAACGACAGATATTGTTTTGTCGACTATGCTGATTAAACGTTTGGTTGATGAAAATA TTTTAGTCATATTTTGTGATGATAAACGCTTGCCAACAGCTATGTTAATGCCGTACTATGCTA GACATGATTCGAGTTTACAATTATCTAGGCAGATGTCATGGATTGAGGATGTCAAAGCGGAT GTTTGGACATCAATTATTGCACAAAAAATTTTGAATCAGTCCTTTTATCTCGGTGAGTGTTCT TTCTTTGAAAAATCCCAGTCTATTATGAATCTCTATCATGATTTAGAATCTTTTGACCCTTCC !0 AATCGTGAAGGTCATGCAGCTAGGATTTATTTCAATACACTTTTTGGAAATGATTTTTCAAG AGAGCAGGATAATCCAATAAATGCTGGTTTAGACTATGGATATTCTCTGATTTTGAGTATGT TTGCGCGTGAAGTTGTTAAGTGTGGTTGCATGACACAATTTGGCTTAAAGCATGCTAATCAA TTTAATCAGTTCAACCTAGCAAGCGATATTATGGAACCATTTCGCCCAATCGTTGATAGGAT TATTTATGAAAATAGGCAGAGTGATTTTGTCAAAATGAAAAGAGAACTCTTTTCTATGTTTT !5 CAGAGACATACAGCTACAACGGTAAAGAAATGTATCTTTCAAATATTGTCAGCGATTACAC CAAAAAAGTTATTAAGTCGCTAAATAGTGATGGGAATGGAATTCCGGAGTTTAGGATATGA (SEQ ID NO:495) SEQ ID NO:496: ;0 ATGAGTTATCGGTATATGAGAATGATTTTAATGTTTGATATGCCTACTGAAACAGTAGAAGA ACGTAAGGCGTATCGTAAGTTTAGAAAGTTTCTGTTGAGCGAAGGTTTTATTATGCATCAGT TCTCTGTTTATAGTAAATTATTGCTCAATAATACAGCTAATAATGCCATGATAGGTCGGCTT AAAGTGAATAATCCTAAGAAAGGGAGTATAACTCTTTTGACAGTTACCGAGAAGCAGTTTG CAAGGATGGTTTATCTACATGGTGAACATAATATGAGTGTTGCCAACTCTGATAGTCGCTTG ;5 GTTTTCCTAGGAGATTCTTATGATCAAGATTAA (SEQ ID NO:496) SEQ ID NO:497: ATGATCAAGATTAATTTTCCAATTTTAGATGAACCATTAGTGTTAAGTAATGCTACGATTTTA ACGATAGAAGATGTTTCAGTTTATTCTTCATTGGTGAAACATTTTTATCAATATGACGTAGAT 40 GAACATTTGAAATTATTTGATGATAAGCAGAAAAGTCTGAAGGCAACGGAGTTAATGTTAG TTACAGATATCTTAGGATACGATGTCAACTCAGCACCTATTCTAAAGTTGATACATGGTGAC TTAGAAAATCAATTCAACGAAAAGCCAGAAGTGAAATCAATGGTAGAAAAATTAGCAGCTA CTATTACAGAACTTATCGCATTTGAGTGTCTAGAGAATGAGCTTGATTTAGAATACGATGAA ATTACGATTTTAGAACTCATTAAGGCACTGGGAGTCAAAATTGAGACACAGAGCGACACTA 45 TCTTTGAAAAATGTTTTGAAATTATACAAGTTTACCATTATTTAACGAAAAAGAATCTCTTA GTTTTTGTTAATAGCGGAGCTTATCTTACCAAAGATGAAGTTATAAAATTATGTGAATACAT CAATTTAATGCAAAAGTCAGTACTCTTTCTAGAACCTAGAAGACTCTATGATTTACCGCAAT ATGTTATTGATAAGGATTATTTCTTGATAGGCGAAAATATGGTATAA (SEQ ID NO:497) 50 SEQ ID NO:498: ATGAAAAAACCTTACTCTATTGGACTTGATATTGGAACCAATTCTGTTGGTTGGGCTGTTGT GACAGATGACTACAAAGTTCCTGCTAAGAAGATGAAGGTTCTGGGAAATACAGATAAAAGT CATATCGAGAAAAATTTGCTTGGCGCTTTATTATTTGATAGCGGGAATACTGCAGAAGACAG ACGGTTAAAGAGAACTGCTCGCCGTCGTTACACACGTCGCAGAAATCGTATTTTATATTTGC 55 AAGAGATTTTTTCAGAAGAAATGGGCAAGGTAGATGATAGTTTCTTTCATCGTTTAGAGGAT TCTTTTCTTGTTACTGAGGATAAACGAGGAGAGCGCCATCCCATTTTTGGGAATCTTGAAGA AGAAGTTAAGTATCATGAAAATTTTCCAACCATTTATCATTTGCGGCAATATCTTGCGGATA

ATCCAGAAAAAGTTGATTTGCGTTTAGTTTATTTGGCTTTGGCACATATAATTAAGTTTAGA

175 5 GGTCATTTTTTAATTGAAGGAAAGTTTGATACACGCAATAATGATGTACAAAGACTGTTTCA AGAATTTTTAGCAGTCTATGATAATACTTTTGAGAATAGTTCGCTTCAGGAGCAAAATGTTC AAGTTGAAGAAATTCTGACTGATAAAATCAGTAAATCTGCTAAGAAAGATAGAGTTTTGAA ACTTTTTCCTAATGAAAAGTCTAATGGCCGCTTTGCAGAATTTCTAAAACTAATTGTTGGTA ATCAAGCTGATTTTAAAAAGCATTTTGAATTAGAAGAGAAAGCACCATTGCAATTTTCTAAA 0 GATACTTATGAAGAAGAGTTAGAAGTACTATTAGCTCAAATTGGAGATAATTACGCAGAGC TCTTTTTATCAGCAAAGAAACTGTATGATAGTATCCTTTTATCAGGGATTTTAACAGTTACTG ATGTTGGTACCAAAGCGCCTTTATCTGCTTCGATGATTCAGCGATATAATGAACATCAGATG GATTTAGCTCAGCTTAAACAATTCATTCGTCAGAAATTATCAGATAAATATAACGAAGTTTT TTCTGATGTTTCAAAAGACGGCTATGCGGGTTATATTGATGGGAAAACAAATCAAGAAGCTT [5 TTTATAAATACCTTAAAGGTCTATTAAATAAGATTGAGGGAAGTGGCTATTTCCTTGATAAA ATTGAGCGTGAAGATTTTCTAAGAAAGCAACGTACCTTTGACAATGGCTCTATTCCACATCA GATTCATCTTCAAGAAATGCGTGCTATCATTCGTAGACAGGCTGAATTTTATCCGTTTTTAGC AGACAATCAAGATAGGATTGAGAAATTATTGACTTTCCGTATTCCCTACTATGTTGGTCCAT TAGCGCGCGGAAAAAGTGATTTTGCTTGGTTAAGTCGGAAATCGGCTGATAAAATTACACC !0 ATGGAATTTTGATGAAATCGTTGATAAAGAATCCTCTGCAGAAGCTTTTATCAATCGTATGA CAAATTATGATTTGTACTTGCCAAATCAAAAAGTTCTTCCTAAACATAGTTTATTATACGAA AAATTTACTGTTTACAATGAATTAACAAAGGTTAAATATAAAACAGAGCAAGGAAAAACAG CATTTTTTGATGCCAATATGAAGCAAGAAATCTTTGATGGCGTATTTAAGGTTTATCGAAAA GTAACTAAAGATAAATTAATGGATTTCCTTGAAAAAGAATTTGATGAATTTCGTATTGTTGA !5 TTTAACAGGTCTGGATAAAGAAAATAAAGTATTTAACGCTTCTTATGGAACTTATCATGATT TGTGTAAAATTTTAGATAAAGATTTTCTCGATAATTCAAAGAATGAAAAGATTTTAGAAGAT ATTGTGTTGACCTTAACGTTATTTGAAGATAGAGAAATGATTAGAAAACGTCTAGAAAATTA CAGTGATTTATTGACCAAAGAACAAGTGAAAAAGCTGGAAAGACGTCATTATACTGGTTGG GGAAGATTATCAGCTGAGTTAATTCATGGTATTCGCAATAAAGAAAGCAGAAAAACAATTC ;0 TTGATTATCTCATTGATGATGGCAATAGCAATCGGAACTTTATGCAACTGATTAACGATGAT GCTCTTTCTTTCAAAGAAGAGATTGCTAAGGCACAAGTTATTGGAGAAACAGACAATCTAA ATCAAGTTGTTAGTGATATTGCTGGCAGCCCTGCTATTAAAAAAGGAATTTTACAAAGCTTG AAGATTGTTGATGAGCTTGTCAAAATTATGGGACATCAACCTGAAAATATCGTCGTGGAGAT GGCGCGTGAAAACCAGTTTACCAATCAGGGACGACGAAATTCACAGCAACGTTTGAAAGGT ;5 TTGACAGATTCTATTAAAGAATTTGGAAGTCAAATTCTTAAAGAACATCCGGTTGAGAATTC ACAGTTACAAAATGATAGATTGTTTCTATATTATTTACAAAACGGCAGAGATATGTATACTG GAGAAGAATTGGATATTGATTATCTAAGCCAGTATGATATAGACCATATTATCCCGCAAGCT TTTATAAAGGATAATTCTATTGATAATAGAGTATTGACTAGCTCAAAGGAAAATCGTGGAA AATCGGATGATGTACCAAGTAAAGATGTTGTTCGTAAAATGAAATCCTATTGGAGTAAGCT W0 ACTTTCGGCAAAGCTTATTACACAACGTAAATTTGATAATTTGACAAAAGCTGAACGAGGTG GATTGACCGACGATGATAAAGCTGGATTCATCAAGCGTCAATTAGTAGAAACACGACAAAT TACCAAACATGTAGCACGTATTCTGGACGAACGATTTAATACAGAAACAGATGAAAACAAC AAGAAAATTCGTCAAGTAAAAATTGTGACCTTGAAATCAAATCTTGTTTCCAATTTCCGTAA AGAGTTTGAACTCTACAAAGTGCGTGAAATTAATGACTATCATCATGCACATGATGCCTATC 45 TCAATGCTGTAATTGGAAAGGCTTTACTAGGTGTTTACCCACAATTGGAACCTGAATTTGTT TATGGTGATTATCCTCATTTTCATGGACATAAAGAAAATAAAGCAACTGCTAAGAAATTTTT CTATTCAAATATTATGAACTTCTTTAAAAAAGATGATGTCCGTACTGATAAAAATGGTGAAA TTATCTGGAAAAAAGATGAGCATATTTCTAATATTAAAAAAGTGCTTTCTTATCCACAAGTT AATATTGTTAAGAAAGTAGAGGAGCAAACGGGAGGATTTTCTAAAGAATCTATCTTGCCGA 50 AAGGTAATTCTGACAAGCTTATTCCTCGAAAAACGAAGAAATTTTATTGGGATACCAAGAA ATATGGAGGATTTGATAGCCCGATTGTTGCTTATTCTATTTTAGTTATTGCTGATATTGAAAA AGGTAAATCTAAAAAATTGAAAACAGTCAAAGCCTTAGTTGGTGTCACTATTATGGAAAAG ATGACTTTTGAAAGGGATCCAGTTGCTTTTCTTGAGCGAAAAGGCTATCGAAATGTTCAAGA AGAAAATATTATAAAGTTACCAAAATATAGTTTATTTAAACTAGAAAACGGACGAAAAAGG 55 CTATTGGCAAGTGCTAGGGAACTTCAAAAGGGAAATGAAATCGTTTTGCCAAATCATTTAG GAACCTTGCTTTATCACGCTAAAAATATTCATAAAGTTGATGAACCAAAGCATTTGGACTAT GTTGATAAACATAAAGATGAATTTAAGGAGTTGCTAGATGTTGTGTCAAACTTTTCTAAAAA ATATACTTTAGCAGAAGGAAATTTAGAAAAAATCAAAGAATTATATGCACAAAATAATGGT GAAGATCTTAAAGAATTAGCAAGTTCATTTATCAACTTATTAACATTTACTGCTATAGGAGC 60 ACCGGCTACTTTTAAATTCTTTGATAAAAATATTGATCGAAAACGATATACTTCAACTACTG 176 5 AAATTCTCAACGCTACCCTCATCCACCAATCCATCACCGGTCTTTATGAAACGCGGATTGAT CTCAATAAGTTAGGAGGAGACTAATGGGCTGGCGGACAGTGGTTGTTAATACGCATTCCAA GTTGTCTTATAAGAACAACCACTTGATTTTTAAAGATGCTTATCAGACAGAGATGATTCATC TGTCTGAGATTGACATCTTATTACTTGAGACAACAGATATTGTTTTGTCAACTATGCTAATCA AACGCTTGGTTGATGAGAATATTTTGGTCATTTTTTGTGATGACAAACGTCTGCCAACAGCC [0 ATGCTCATGCCTTACTATGCGCGTCACGATTCCAGCTTGCAGCTGAGTCATCAGATTTCTTGG ACAGAAGAAGTGAAATGCGATGTCTGGACAACAATCATCGCTCAAAAGATTTTGAATCAGT CATGTTATTTGGGAGAATGTTTTTATTTTGAAAAATCTCAGTCAATTATGGATTTATATCATG ACTTAGAGCCTTTTGACCCTAGTAATCGAGAAGGACATTCTGCGCGGATTTATTTCAATACC TTATTTGGAAATGTTTTTTCCAGAGAACAAGATAATGATATTAATGCAGGTCTTGACTATGG [5 TTATACGCTGCTGTTAAGTATGTTTGCGCGTGAAGTGGTTGTATCTGGCTGTATGACACAATT TGGTCTCAAGCATGCCAACCAATTCAATCAGTTTAACTTTGCCAGTGATATTATGGAGCCTT TTCGTCCAATTGTTGACCGTATTGTTTATGAAAATCGAAATAACTCTTTTATTAAAATAAAAC GTGAGCTATTCAGCATGTTTTCAGACACCTATCTTTATAATAATAAGGAGATGTATTTGACA AATATTGTCAGCGATTATACCAAAAAGGTAATCAAGGCGCTGAATAATGATGGGAAAGGAG !0 TTCCTGAGTTTAGGATATGAGTTACCGATATATGCGAATGATTTTAATGTTTGATATGCCAA CAGATACTGCTGAGGAACGCAAAGCTTATCGTAAATTTCGGAAATTTTTACTGAGCGAAGGT TTCATCATGCATCAGTTTTCAGTATACAGCAAGCTGCTTTTGAATAACTCTGCCAATACAGC CATGATTGCCCGCTTGAAGGAGAATAATCCAAAGAAGGGCAATATCACCTTGTTGACCGTG ACTGAAAAGCAGTTTGCCCGTATGATTTACCTGAATGGTGAGCGTGATACTAGCATTGCTAA !5 TTCGGATTCACGACTGGTCTTTCTAGGGGAGGCTTTTCCTGATGAAACTTAATTTTCCTATAT TGGATGAACCAATAACTCTTGAAAAATCTACGATTTTGGTATTAGAAGATGTGCAAGTTTTT GCTCAAATGGTGAGAAATCTTTATCAATATGATGAAGATAGTGAACTTAAATTTTTTAATAG AAAATTTAAGAGTCTGAAACCATCTGAGTTAATGCTTGTGACAGATATTTTAGGTTATGATG TCAATGCCCCGTCCTTGCTGAAGTTGGTTCACGCTGATTTAGAAAATCAGTTTAATGAAAAA ;0 CCAGAGGTTAAGTCTATGGTTGAAAAACTGGCAAATACCATTACGGAATTAATTGCTTATGA ATGTTTAGAAAATGAATTGGACTTAGAATATGATGAGATTACTATTTTAGAGTTAATCAAAG CTTTAGGCGTCAAAATTGAAACACAAAGTGATACCATTTTTGAAAAAATGTTTGAAGTCCTT CAAGTTTATAAGTATCTAAATAAAAAGAAGCTTCTCGTTTTTATCAATACTTTATCCTATTTT AAAAGAGAAGAAATCGCGCAAATTCTAGAATATATTCACTTATCCGATATGGTTGTTTTATT ;5 TCTTGAACCCCGTAAAATTGATGGTTTTGCTCAATATATTTTAGATGAAGATTATTTCTTGAT AACAGAAAGCAACAACTAAATACGAATAATAAGATAGTTTCTAAATCAGGGGCTGTCTTTT ATTATGGATTGACAAATGCGTATAATGCGTATAAAATAAAAAGAGAAATGTTATTTGCCATT AACAGGGAAAGAATTAGCTAAATTAGCGATAAACAATGGATGGGAAGAAGTTCGGGTGAG AGGAAGTCATCATCATTTCAAGAAAGATGGAGTATCTTATATTGTGACGATTCCTATTCATG W0 GAAATAAAGTGCTTAAAATTGGTCTTGAAAAGAAACTCTTAAGGGATTTAAATTTATTATGA TAGAGGAGGAAGTCGTCATGTTAAAATCATATCCTGTAATTTTTCATAAGGAAGAGGAAGG GTATTGGGTTGAATTTCCTGAATTTGGCGGTGGTACGCAAGGGGAAGATTTGGAAGAAGCC ATGAAGAACGCTCGTCAGATGTTAGAAAGTGTGTTGGCATCTTATCTTGATGAAGGGTTGGT TCTACCCATTTCAAGCGATATTCAGAAAATATCTGTTGAAGATGGTTTTGCGACCATGATTC 45 AAGCTGATCCTAGTCCTTATCTCAAAAATAACAAAGCTATTCGGAAAAATGTTACCGTGCCT GAGTGGTTGATACGATTAGCAGACCGTGACCGAGTAAATTATTCTGAAGTATTAACAAAGG CTTTGGAAAAGAAACTACAATTATAA (SEQ ID NO:498) SEQ ID NO:499: 50 ATGAAAAAACCTTACTCTATTGGACTTGATATTGGAACCAATTCTGTTGGTTGGGCTGTTGT GACAGATGACTACAAAGTTCCTGCTAAGAAGATGAAGGTTCTGGGAAATACAGATAAAAGT CATATCGAGAAAAATTTGCTTGGCGCTTTATTATTTGATAGCGGGAATACTGCAGAAGACAG ACGGTTAAAGAGAACTGCTCGCCGTCGTTACACACGTCGCAGAAATCGTATTTTATATTTGC AAGAGATTTTTTCAGAAGAAATGGGCAAGGTAGATGATAGTTTCTTTCATCGTTTAGAGGAT 55 TCTTTTCTTGTTACTGAGGATAAACGAGGAGAGCGCCATCCCATTTTTGGGAATCTTGAAGA AGAAGTTAAGTATCATGAAAATTTTCCAACCATTTATCATTTGCGGCAATATCTTGCGGATA ATCCAGAAAAAGTTGATTTGCGTTTAGTTTATTTGGCTTTGGCACATATAATTAAGTTTAGA GGTCATTTTTTAATTGAAGGAAAGTTTGATACACGCAATAATGATGTACAAAGACTGTTTCA

AGAATTTTTAGCAGTCTATGATAATACTTTTGAGAATAGTTCGCTTCAGGAGCAAAATGTTC

177 5 AAGTTGAAGAAATTCTGACTGATAAAATCAGTAAATCTGCTAAGAAAGATAGAGTTTTGAA ACTTTTTCCTAATGAAAAGTCTAATGGCCGCTTTGCAGAATTTCTAAAACTAATTGTTGGTA ATCAAGCTGATTTTAAAAAGCATTTTGAATTAGAAGAGAAAGCACCATTGCAATTTTCTAAA GATACTTATGAAGAAGAGTTAGAAGTACTATTAGCTCAAATTGGAGATAATTACGCAGAGC TCTTTTTATCAGCAAAGAAACTGTATGATAGTATCCTTTTATCAGGGATTTTAACAGTTACTG 0 ATGTTGGTACCAAAGCGCCTTTATCTGCTTCGATGATTCAGCGATATAATGAACATCAGATG GATTTAGCTCAGCTTAAACAATTCATTCGTCAGAAATTATCAGATAAATATAACGAAGTTTT TTCTGATGTTTCAAAAGACGGCTATGCGGGTTATATTGATGGGAAAACAAATCAAGAAGCTT TTTATAAATACCTTAAAGGTCTATTAAATAAGATTGAGGGAAGTGGCTATTTCCTTGATAAA ATTGAGCGTGAAGATTTTCTAAGAAAGCAACGTACCTTTGACAATGGCTCTATTCCACATCA [5 GATTCATCTTCAAGAAATGCGTGCTATCATTCGTAGACAGGCTGAATTTTATCCGTTTTTAGC AGACAATCAAGATAGGATTGAGAAATTATTGACTTTCCGTATTCCCTACTATGTTGGTCCAT TAGCGCGCGGAAAAAGTGATTTTGCTTGGTTAAGTCGGAAATCGGCTGATAAAATTACACC ATGGAATTTTGATGAAATCGTTGATAAAGAATCCTCTGCAGAAGCTTTTATCAATCGTATGA CAAATTATGATTTGTACTTGCCAAATCAAAAAGTTCTTCCTAAACATAGTTTATTATACGAA !0 AAATTTACTGTTTACAATGAATTAACAAAGGTTAAATATAAAACAGAGCAAGGAAAAACAG CATTTTTTGATGCCAATATGAAGCAAGAAATCTTTGATGGCGTATTTAAGGTTTATCGAAAA GTAACTAAAGATAAATTAATGGATTTCCTTGAAAAAGAATTTGATGAATTTCGTATTGTTGA TTTAACAGGTCTGGATAAAGAAAATAAAGTATTTAACGCTTCTTATGGAACTTATCATGATT TGTGTAAAATTTTAGATAAAGATTTTCTCGATAATTCAAAGAATGAAAAGATTTTAGAAGAT !5 ATTGTGTTGACCTTAACGTTATTTGAAGATAGAGAAATGATTAGAAAACGTCTAGAAAATTA CAGTGATTTATTGACCAAAGAACAAGTGAAAAAGCTGGAAAGACGTCATTATACTGGTTGG GGAAGATTATCAGCTGAGTTAATTCATGGTATTCGCAATAAAGAAAGCAGAAAAACAATTC TTGATTATCTCATTGATGATGGCAATAGCAATCGGAACTTTATGCAACTGATTAACGATGAT GCTCTTTCTTTCAAAGAAGAGATTGCTAAGGCACAAGTTATTGGAGAAACAGACAATCTAA ;0 ATCAAGTTGTTAGTGATATTGCTGGCAGCCCTGCTATTAAAAAAGGAATTTTACAAAGCTTG AAGATTGTTGATGAGCTTGTCAAAATTATGGGACATCAACCTGAAAATATCGTCGTGGAGAT GGCGCGTGAAAACCAGTTTACCAATCAGGGACGACGAAATTCACAGCAACGTTTGAAAGGT TTGACAGATTCTATTAAAGAATTTGGAAGTCAAATTCTTAAAGAACATCCGGTTGAGAATTC ACAGTTACAAAATGATAGATTGTTTCTATATTATTTACAAAACGGCAGAGATATGTATACTG ;5 GAGAAGAATTGGATATTGATTATCTAAGCCAGTATGATATAGACCATATTATCCCGCAAGCT TTTATAAAGGATAATTCTATTGATAATAGAGTATTGACTAGCTCAAAGGAAAATCGTGGAA AATCGGATGATGTACCAAGTAAAGATGTTGTTCGTAAAATGAAATCCTATTGGAGTAAGCT ACTTTCGGCAAAGCTTATTACACAACGTAAATTTGATAATTTGACAAAAGCTGAACGAGGTG GATTGACCGACGATGATAAAGCTGGATTCATCAAGCGTCAATTAGTAGAAACACGACAAAT W- TACCAAACATGTAGCACGTATTCTGGACGAACGATTTAATACAGAAACAGATGAAAACAAC AAGAAAATTCGTCAAGTAAAAATTGTGACCTTGAAATCAAATCTTGTTTCCAATTTCCGTAA AGAGTTTGAACTCTACAAAGTGCGTGAAATTAATGACTATCATCATGCACATGATGCCTATC TCAATGCTGTAATTGGAAAGGCTTTACTAGGTGTTTACCCACAATTGGAACCTGAATTTGTT TATGGTGATTATCCTCATTTTCATGGACATAAAGAAAATAAAGCAACTGCTAAGAAATTTTT 45 CTATTCAAATATTATGAACTTCTTTAAAAAAGATGATGTCCGTACTGATAAAAATGGTGAAA TTATCTGGAAAAAAGATGAGCATATTTCTAATATTAAAAAAGTGCTTTCTTATCCACAAGTT AATATTGTTAAGAAAGTAGAGGAGCAAACGGGAGGATTTTCTAAAGAATCTATCTTGCCGA AAGGTAATTCTGACAAGCTTATTCCTCGAAAAACGAAGAAATTTTATTGGGATACCAAGAA ATATGGAGGATTTGATAGCCCGATTGTTGCTTATTCTATTTTAGTTATTGCTGATATTGAAAA 50 AGGTAAATCTAAAAAATTGAAAACAGTCAAAGCCTTAGTTGGTGTCACTATTATGGAAAAG ATGACTTTTGAAAGGGATCCAGTTGCTTTTCTTGAGCGAAAAGGCTATCGAAATGTTCAAGA AGAAAATATTATAAAGTTACCAAAATATAGTTTATTTAAACTAGAAAACGGACGAAAAAGG CTATTGGCAAGTGCTAGGGAACTTCAAAAGGGAAATGAAATCGTTTTGCCAAATCATTTAG GAACCTTGCTTTATCACGCTAAAAATATTCATAAAGTTGATGAACCAAAGCATTTGGACTAT 55 GTTGATAAACATAAAGATGAATTTAAGGAGTTGCTAGATGTTGTGTCAAACTTTTCTAAAAA ATATACTTTAGCAGAAGGAAATTTAGAAAAAATCAAAGAATTATATGCACAAAATAATGGT GAAGATCTTAAAGAATTAGCAAGTTCATTTATCAACTTATTAACATTTACTGCTATAGGAGC ACCGGCTACTTTTAAATTCTTTGATAAAAATATTGATCGAAAACGATATACTTCAACTACTG AAATTCTCAACGCTACCCTCATCCACCAATCCATCACCGGTCTTTATGAAACGCGGATTGAT 60 CTCAATAAGTTAGGAGGAGACTAA (SEQ ID NO:499) 178 5 SEQ ID NO:500: ATGGGCTGGCGGACAGTGGTTGTTAATACGCATTCCAAGTTGTCTTATAAGAACAACCACTT GATTTTTAAAGATGCTTATCAGACAGAGATGATTCATCTGTCTGAGATTGACATCTTATTACT TGAGACAACAGATATTGTTTTGTCAACTATGCTAATCAAACGCTTGGTTGATGAGAATATTT [0 TGGTCATTTTTTGTGATGACAAACGTCTGCCAACAGCCATGCTCATGCCTTACTATGCGCGTC ACGATTCCAGCTTGCAGCTGAGTCATCAGATTTCTTGGACAGAAGAAGTGAAATGCGATGTC TGGACAACAATCATCGCTCAAAAGATTTTGAATCAGTCATGTTATTTGGGAGAATGTTTTTA TTTTGAAAAATCTCAGTCAATTATGGATTTATATCATGACTTAGAGCCTTTTGACCCTAGTAA TCGAGAAGGACATTCTGCGCGGATTTATTTCAATACCTTATTTGGAAATGTTTTTTCCAGAG [5 AACAAGATAATGATATTAATGCAGGTCTTGACTATGGTTATACGCTGCTGTTAAGTATGTTT GCGCGTGAAGTGGTTGTATCTGGCTGTATGACACAATTTGGTCTCAAGCATGCCAACCAATT CAATCAGTTTAACTTTGCCAGTGATATTATGGAGCCTTTTCGTCCAATTGTTGACCGTATTGT TTATGAAAATCGAAATAACTCTTTTATTAAAATAAAACGTGAGCTATTCAGCATGTTTTCAG ACACCTATCTTTATAATAATAAGGAGATGTATTTGACAAATATTGTCAGCGATTATACCAAA !0 AAGGTAATCAAGGCGCTGAATAATGATGGGAAAGGAGTTCCTGAGTTTAGGATATGA (SEQ ID NO:500) SEQ ID NO:501: ATGCGAATGATTTTAATGTTTGATATGCCAACAGATACTGCTGAGGAACGCAAAGCTTATCG !5 TAAATTTCGGAAATTTTTACTGAGCGAAGGTTTCATCATGCATCAGTTTTCAGTATACAGCA AGCTGCTTTTGAATAACTCTGCCAATACAGCCATGATTGCCCGCTTGAAGGAGAATAATCCA AAGAAGGGCAATATCACCTTGTTGACCGTGACTGAAAAGCAGTTTGCCCGTATGATTTACCT GAATGGTGAGCGTGATACTAGCATTGCTAATTCGGATTCACGACTGGTCTTTCTAGGGGAGG CTTTTCCTGATGAAACTTAA (SEQ ID NO:501) ;0 SEQ ID NO:502: ATGGTGAGAAATCTTTATCAATATGATGAAGATAGTGAACTTAAATTTTTTAATAGAAAATT TAAGAGTCTGAAACCATCTGAGTTAATGCTTGTGACAGATATTTTAGGTTATGATGTCAATG CCCCGTCCTTGCTGAAGTTGGTTCACGCTGATTTAGAAAATCAGTTTAATGAAAAACCAGAG ;5 GTTAAGTCTATGGTTGAAAAACTGGCAAATACCATTACGGAATTAATTGCTTATGAATGTTT AGAAAATGAATTGGACTTAGAATATGATGAGATTACTATTTTAGAGTTAATCAAAGCTTTAG GCGTCAAAATTGAAACACAAAGTGATACCATTTTTGAAAAAATGTTTGAAGTCCTTCAAGTT TATAAGTATCTAAATAAAAAGAAGCTTCTCGTTTTTATCAATACTTTATCCTATTTTAAAAGA GAAGAAATCGCGCAAATTCTAGAATATATTCACTTATCCGATATGGTTGTTTTATTTCTTGAA 40 CCCCGTAAAATTGATGGTTTTGCTCAATATATTTTAGATGAAGATTATTTCTTGATAACAGA AAGCAACAACTAA (SEQ ID NO:502) SEQ ID NO:503: ATGTTAAAATCATATCCTGTAATTTTTCATAAGGAAGAGGAAGGGTATTGGGTTGAATTTCC 45 TGAATTTGGCGGTGGTACGCAAGGGGAAGATTTGGAAGAAGCCATGAAGAACGCTCGTCAG ATGTTAGAAAGTGTGTTGGCATCTTATCTTGATGAAGGGTTGGTTCTACCCATTTCAAGCGA TATTCAGAAAATATCTGTTGAAGATGGTTTTGCGACCATGATTCAAGCTGATCCTAGTCCTT ATCTCAAAAATAACAAAGCTATTCGGAAAAATGTTACCGTGCCTGAGTGGTTGATACGATTA GCAGACCGTGACCGAGTAAATTATTCTGAAGTATTAACAAAGGCTTTGGAAAAGAAACTAC 50 AATTATAA (SEQ ID NO:503) SEQ ID NO:504: ATGGATAAGAAATACTCAATAGGCTTAGATATCGGCACAAATAGCGTCGGATGGGCGGTGA TCACTGATGAATATAAGGTTCCGTCTAAAAAGTTCAAGGTTCTGGGAAATACAGACCGCCA 55 CAGTATCAAAAAAAATCTTATAGGGGCTCTTTTATTTGACAGTGGAGAGACAGCGGAAGCG ACTCGTCTCAAACGGACAGCTCGTAGAAGGTATACACGTCGGAAGAATCGTATTTGTTATCT

ACAGGAGATTTTTTCAAATGAGATGGCGAAAGTAGATGATAGTTTCTTTCATCGACTTGAAG

179 5 AGTCTTTTTTGGTGGAAGAAGACAAGAAGCATGAACGTCATCCTATTTTTGGAAATATAGTA GATGAAGTTGCTTATCATGAGAAATATCCAACTATCTATCATCTGCGAAAAAAATTGGTAGA TTCTACTGATAAAGCGGATTTGCGCTTAATCTATTTGGCCTTAGCGCATATGATTAAGTTTCG TGGTCATTTTTTGATTGAGGGAGATTTAAATCCTGATAATAGTGATGTGGACAAACTATTTA TCCAGTTGGTACAAACCTACAATCAATTATTTGAAGAAAACCCTATTAACGCAAGTGGAGTA 0 GATGCTAAAGCGATTCTTTCTGCACGATTGAGTAAATCAAGACGATTAGAAAATCTCATTGC TCAGCTCCCCGGTGAGAAGAAAAATGGCTTATTTGGGAATCTCATTGCTTTGTCATTGGGTT TGACCCCTAATTTTAAATCAAATTTTGATTTGGCAGAAGATGCTAAATTACAGCTTTCAAAA GATACTTACGATGATGATTTAGATAATTTATTGGCGCAAATTGGAGATCAATATGCTGATTT GTTTTTGGCAGCTAAGAATTTATCAGATGCTATTTTACTTTCAGATATCCTAAGAGTAAATAC [5 TGAAATAACTAAGGCTCCCCTATCAGCTTCAATGATTAAACGCTACGATGAACATCATCAAG ACTTGACTCTTTTAAAAGCTTTAGTTCGACAACAACTTCCAGAAAAGTATAAAGAAATCTTT TTTGATCAATCAAAAAACGGATATGCAGGTTATATTGATGGGGGAGCTAGCCAAGAAGAAT TTTATAAATTTATCAAACCAATTTTAGAAAAAATGGATGGTACTGAGGAATTATTGGTGAAA CTAAATCGTGAAGATTTGCTGCGCAAGCAACGGACCTTTGACAACGGCTCTATTCCCCATCA !0 AATTCACTTGGGTGAGCTGCATGCTATTTTGAGAAGACAAGAAGACTTTTATCCATTTTTAA AAGACAATCGTGAGAAGATTGAAAAAATCTTGACTTTTCGAATTCCTTATTATGTTGGTCCA TTGGCGCGTGGCAATAGTCGTTTTGCATGGATGACTCGGAAGTCTGAAGAAACAATTACCCC ATGGAATTTTGAAGAAGTTGTCGATAAAGGTGCTTCAGCTCAATCATTTATTGAACGCATGA CAAACTTTGATAAAAATCTTCCAAATGAAAAAGTACTACCAAAACATAGTTTGCTTTATGAG !5 TATTTTACGGTTTATAACGAATTGACAAAGGTCAAATATGTTACTGAAGGAATGCGAAAACC AGCATTTCTTTCAGGTGAACAGAAGAAAGCCATTGTTGATTTACTCTTCAAAACAAATCGAA AAGTAACCGTTAAGCAATTAAAAGAAGATTATTTCAAAAAAATAGAATGTTTTGATAGTGTT GAAATTTCAGGAGTTGAAGATAGATTTAATGCTTCATTAGGTACCTACCATGATTTGCTAAA AATTATTAAAGATAAAGATTTTTTGGATAATGAAGAAAATGAAGATATCTTAGAGGATATT ;0 GTTTTAACATTGACCTTATTTGAAGATAGGGAGATGATTGAGGAAAGACTTAAAACATATGC TCACCTCTTTGATGATAAGGTGATGAAACAGCTTAAACGTCGCCGTTATACTGGTTGGGGAC GTTTGTCTCGAAAATTGATTAATGGTATTAGGGATAAGCAATCTGGCAAAACAATATTAGAT TTTTTGAAATCAGATGGTTTTGCCAATCGCAATTTTATGCAGCTGATCCATGATGATAGTTTG ACATTTAAAGAAGACATTCAAAAAGCACAAGTGTCTGGACAAGGCGATAGTTTACATGAAC ;5 ATATTGCAAATTTAGCTGGTAGCCCTGCTATTAAAAAAGGTATTTTACAGACTGTAAAAGTT GTTGATGAATTGGTCAAAGTAATGGGGCGGCATAAGCCAGAAAATATCGTTATTGAAATGG CACGTGAAAATCAGACAACTCAAAAGGGCCAGAAAAATTCGCGAGAGCGTATGAAACGAA TCGAAGAAGGTATCAAAGAATTAGGAAGTCAGATTCTTAAAGAGCATCCTGTTGAAAATAC TCAATTGCAAAATGAAAAGCTCTATCTCTATTATCTCCAAAATGGAAGAGACATGTATGTGG W- ACCAAGAATTAGATATTAATCGTTTAAGTGATTATGATGTCGATCACATTGTTCCACAAAGT TTCCTTAAAGACGATTCAATAGACAATAAGGTCTTAACGCGTTCTGATAAAAATCGTGGTAA ATCGGATAACGTTCCAAGTGAAGAAGTAGTCAAAAAGATGAAAAACTATTGGAGACAACTT CTAAACGCCAAGTTAATCACTCAACGTAAGTTTGATAATTTAACGAAAGCTGAACGTGGAG GTTTGAGTGAACTTGATAAAGCTGGTTTTATCAAACGCCAATTGGTTGAAACTCGCCAAATC 45 ACTAAGCATGTGGCACAAATTTTGGATAGTCGCATGAATACTAAATACGATGAAAATGATA AACTTATTCGAGAGGTTAAAGTGATTACCTTAAAATCTAAATTAGTTTCTGACTTCCGAAAA GATTTCCAATTCTATAAAGTACGTGAGATTAACAATTACCATCATGCCCATGATGCGTATCT AAATGCCGTCGTTGGAACTGCTTTGATTAAGAAATATCCAAAACTTGAATCGGAGTTTGTCT ATGGTGATTATAAAGTTTATGATGTTCGTAAAATGATTGCTAAGTCTGAGCAAGAAATAGGC 50 AAAGCAACCGCAAAATATTTCTTTTACTCTAATATCATGAACTTCTTCAAAACAGAAATTAC ACTTGCAAATGGAGAGATTCGCAAACGCCCTCTAATCGAAACTAATGGGGAAACTGGAGAA ATTGTCTGGGATAAAGGGCGAGATTTTGCCACAGTGCGCAAAGTATTGTCCATGCCCCAAGT CAATATTGTCAAGAAAACAGAAGTACAGACAGGCGGATTCTCCAAGGAGTCAATTTTACCA AAAAGAAATTCGGACAAGCTTATTGCTCGTAAAAAAGACTGGGATCCAAAAAAATATGGTG 55 GTTTTGATAGTCCAACGGTAGCTTATTCAGTCCTAGTGGTTGCTAAGGTGGAAAAAGGGAAA TCGAAGAAGTTAAAATCCGTTAAAGAGTTACTAGGGATCACAATTATGGAAAGAAGTTCCT TTGAAAAAAATCCGATTGACTTTTTAGAAGCTAAAGGATATAAGGAAGTTAAAAAAGACTT AATCATTAAACTACCTAAATATAGTCTTTTTGAGTTAGAAAACGGTCGTAAACGGATGCTGG CTAGTGCCGGAGAATTACAAAAAGGAAATGAGCTGGCTCTGCCAAGCAAATATGTGAATTT 60 TTTATATTTAGCTAGTCATTATGAAAAGTTGAAGGGTAGTCCAGAAGATAACGAACAAAAA 180 5 CAATTGTTTGTGGAGCAGCATAAGCATTATTTAGATGAGATTATTGAGCAAATCAGTGAATT TTCTAAGCGTGTTATTTTAGCAGATGCCAATTTAGATAAAGTTCTTAGTGCATATAACAAAC ATAGAGACAAACCAATACGTGAACAAGCAGAAAATATTATTCATTTATTTACGTTGACGAA TCTTGGAGCTCCCGCTGCTTTTAAATATTTTGATACAACAATTGATCGTAAACGATATACGTC TACAAAAGAAGTTTTAGATGCCACTCTTATCCATCAATCCATCACTGGTCTTTATGAAACAC 0 GCATTGATTTGAGTCAGCTAGGAGGTGACTGATGGCTGGTTGGCGTACTGTTGTGGTAAATA CCCACTCGAAATTATCCTATAAGAATAATCATCTGATTTTTAAGGATGCCTATAAAACGGAG CTGATCCATTTATCAGAAATTGATATTTTGTTATTAGAAACGACCGATATTGTCTTGTCCACT ATGCTGGTAAAACGGCTAGTGGATGAGAATGTCCTTGTCATATTCTGTGATGATAAACGATT ACCAACAGCTATGCTGATGCCTTTTTATGGTCGTCATGATTCGAGTTTACAGCTTGGGAAAC [5 AAATGTCCTGGTCAGAAACAGTCAAATCGCAGGTTTGGACGACGATTATTGCTCAAAAGAT TTTGAATCAATCTTGCTATCTAGGAGCATGCTCCTATTTTGAAAAATCCCAATCTATTATGGA TTTATATCATGGTTTGGAAAATTTTGATCCGAGTAATCGAGAAGGGCATGCAGCGAGAATTT ATTTTAATACACTTTTTGGGAACGATTTCTCAAGAGATTTGGAGCATCCAATCAATGCAGGT CTGGATTATGGTTATACTTTATTATTGAGTATGTTTGCGCGTGAAGTGGTTGTGTCTGGATGT !0 ATGACTCAGTTTGGGCTTAAACACGCTAATCAGTTTAATCAGTTCAATTTTGCTAGCGATATT ATGGAACCATTTAGGCCTTTAGTGGATAAGATTGTTTATGAAAATCGAAATCAGCCTTTTCC CAAAATAAAGAGAGAGTTATTTACTTTGTTTTCAGATACATTTTCATATAATGGTAAAGAGA TGTATCTCACGAATATTATTAGCGATTATACTAAAAAAGTTGTCAAAGCTCTGAATAATGAA GGGAAAGGAGTTCCTGAATTTAGGATATGAGTTATAGATATATGAGAATGATACTTATGTTT !5 GATATGCCGACGGACACCGCTGAGGAACGAAAAGCCTATCGAAAATTTCGGAAATTTTTAC TTAGTGAAGGGTTTATCATGCATCAATTTTCTATTTATAGTAAGTTGCTGTTGAATAATACAG CTAACAATGCCATGATTGGTCGGCTGAGGGAGCATAATCCTAATAAAGGAAATATTACATT ACTAACGGTCACGGAAAAACAGTTTGCACGAATGATTTATTTACATGGTGAAAGAAATAAT TGTATTGCAAACTCCGATGAAAGACTTGTATTTCTTGGGGAGGCTTTTGATGAATCTTAATTT ;0 TTCCTTACTAGATGAACCGATTCCATTAAGAGGCGGTACAATTCTTGTGCTCGAAGATGTCT GTGTATTTTCAAAAATAGTGCAATATTGTTACCAATATGAGGAAGATTCTGAACTTAAATTT TTTGATCACAAGATGAAAACAATCAAAGAATCAGAAATCATGCTTGTAACAGATATTTTAG GATTTGATGTTAACTCCTCAACCATTTTAAAATTGATTCATGCAGATTTAGAATCTCAATTTA ATGAGAAACCCGAAGTGAAATCGATGATTGACAAATTGGTTGCTACGATTACAGAACTGAT ;5 TGTCTTTGAATGCTTAGAAAATGAATTAGATTTAGAGTATGATGAAATCACAATCCTGGAAT TGATTAAGTCCTTAGGAGTAAAAGTAGAAACGCAAAGTGATACTATTTTTGAAAAATGTCTA GAGATACTTCAAATTTTCAAATATCTCACTAAGAAAAAGTTGCTTATTTTTGTCAATAGCGG AGCTTTTCTAACAAAGGATGAAGTGGCTAGTTTACAAGAGTATATATCATTGACAAATTTAA CAGTTCTCTTTTTAGAACCACGTGAACTATATGATTTTCCGCAGTATATTTTAGATGAAGATT W- ATTTCTTAATAACTAAAAATATGGTATAA (SEQ ID NO:504) SEQ ID NO:505: ATGGATAAGAAATACTCAATAGGCTTAGATATCGGCACAAATAGCGTCGGATGGGCGGTGA TCACTGATGAATATAAGGTTCCGTCTAAAAAGTTCAAGGTTCTGGGAAATACAGACCGCCA 45 CAGTATCAAAAAAAATCTTATAGGGGCTCTTTTATTTGACAGTGGAGAGACAGCGGAAGCG ACTCGTCTCAAACGGACAGCTCGTAGAAGGTATACACGTCGGAAGAATCGTATTTGTTATCT ACAGGAGATTTTTTCAAATGAGATGGCGAAAGTAGATGATAGTTTCTTTCATCGACTTGAAG AGTCTTTTTTGGTGGAAGAAGACAAGAAGCATGAACGTCATCCTATTTTTGGAAATATAGTA GATGAAGTTGCTTATCATGAGAAATATCCAACTATCTATCATCTGCGAAAAAAATTGGTAGA 50 TTCTACTGATAAAGCGGATTTGCGCTTAATCTATTTGGCCTTAGCGCATATGATTAAGTTTCG TGGTCATTTTTTGATTGAGGGAGATTTAAATCCTGATAATAGTGATGTGGACAAACTATTTA TCCAGTTGGTACAAACCTACAATCAATTATTTGAAGAAAACCCTATTAACGCAAGTGGAGTA GATGCTAAAGCGATTCTTTCTGCACGATTGAGTAAATCAAGACGATTAGAAAATCTCATTGC TCAGCTCCCCGGTGAGAAGAAAAATGGCTTATTTGGGAATCTCATTGCTTTGTCATTGGGTT 55 TGACCCCTAATTTTAAATCAAATTTTGATTTGGCAGAAGATGCTAAATTACAGCTTTCAAAA GATACTTACGATGATGATTTAGATAATTTATTGGCGCAAATTGGAGATCAATATGCTGATTT GTTTTTGGCAGCTAAGAATTTATCAGATGCTATTTTACTTTCAGATATCCTAAGAGTAAATAC TGAAATAACTAAGGCTCCCCTATCAGCTTCAATGATTAAACGCTACGATGAACATCATCAAG

ACTTGACTCTTTTAAAAGCTTTAGTTCGACAACAACTTCCAGAAAAGTATAAAGAAATCTTT

181 5 TTTGATCAATCAAAAAACGGATATGCAGGTTATATTGATGGGGGAGCTAGCCAAGAAGAAT TTTATAAATTTATCAAACCAATTTTAGAAAAAATGGATGGTACTGAGGAATTATTGGTGAAA CTAAATCGTGAAGATTTGCTGCGCAAGCAACGGACCTTTGACAACGGCTCTATTCCCCATCA AATTCACTTGGGTGAGCTGCATGCTATTTTGAGAAGACAAGAAGACTTTTATCCATTTTTAA AAGACAATCGTGAGAAGATTGAAAAAATCTTGACTTTTCGAATTCCTTATTATGTTGGTCCA 0 TTGGCGCGTGGCAATAGTCGTTTTGCATGGATGACTCGGAAGTCTGAAGAAACAATTACCCC ATGGAATTTTGAAGAAGTTGTCGATAAAGGTGCTTCAGCTCAATCATTTATTGAACGCATGA CAAACTTTGATAAAAATCTTCCAAATGAAAAAGTACTACCAAAACATAGTTTGCTTTATGAG TATTTTACGGTTTATAACGAATTGACAAAGGTCAAATATGTTACTGAAGGAATGCGAAAACC AGCATTTCTTTCAGGTGAACAGAAGAAAGCCATTGTTGATTTACTCTTCAAAACAAATCGAA [5 AAGTAACCGTTAAGCAATTAAAAGAAGATTATTTCAAAAAAATAGAATGTTTTGATAGTGTT GAAATTTCAGGAGTTGAAGATAGATTTAATGCTTCATTAGGTACCTACCATGATTTGCTAAA AATTATTAAAGATAAAGATTTTTTGGATAATGAAGAAAATGAAGATATCTTAGAGGATATT GTTTTAACATTGACCTTATTTGAAGATAGGGAGATGATTGAGGAAAGACTTAAAACATATGC TCACCTCTTTGATGATAAGGTGATGAAACAGCTTAAACGTCGCCGTTATACTGGTTGGGGAC !0 GTTTGTCTCGAAAATTGATTAATGGTATTAGGGATAAGCAATCTGGCAAAACAATATTAGAT TTTTTGAAATCAGATGGTTTTGCCAATCGCAATTTTATGCAGCTGATCCATGATGATAGTTTG ACATTTAAAGAAGACATTCAAAAAGCACAAGTGTCTGGACAAGGCGATAGTTTACATGAAC ATATTGCAAATTTAGCTGGTAGCCCTGCTATTAAAAAAGGTATTTTACAGACTGTAAAAGTT GTTGATGAATTGGTCAAAGTAATGGGGCGGCATAAGCCAGAAAATATCGTTATTGAAATGG !5 CACGTGAAAATCAGACAACTCAAAAGGGCCAGAAAAATTCGCGAGAGCGTATGAAACGAA TCGAAGAAGGTATCAAAGAATTAGGAAGTCAGATTCTTAAAGAGCATCCTGTTGAAAATAC TCAATTGCAAAATGAAAAGCTCTATCTCTATTATCTCCAAAATGGAAGAGACATGTATGTGG ACCAAGAATTAGATATTAATCGTTTAAGTGATTATGATGTCGATCACATTGTTCCACAAAGT TTCCTTAAAGACGATTCAATAGACAATAAGGTCTTAACGCGTTCTGATAAAAATCGTGGTAA ;0 ATCGGATAACGTTCCAAGTGAAGAAGTAGTCAAAAAGATGAAAAACTATTGGAGACAACTT CTAAACGCCAAGTTAATCACTCAACGTAAGTTTGATAATTTAACGAAAGCTGAACGTGGAG GTTTGAGTGAACTTGATAAAGCTGGTTTTATCAAACGCCAATTGGTTGAAACTCGCCAAATC ACTAAGCATGTGGCACAAATTTTGGATAGTCGCATGAATACTAAATACGATGAAAATGATA AACTTATTCGAGAGGTTAAAGTGATTACCTTAAAATCTAAATTAGTTTCTGACTTCCGAAAA ;5 GATTTCCAATTCTATAAAGTACGTGAGATTAACAATTACCATCATGCCCATGATGCGTATCT AAATGCCGTCGTTGGAACTGCTTTGATTAAGAAATATCCAAAACTTGAATCGGAGTTTGTCT ATGGTGATTATAAAGTTTATGATGTTCGTAAAATGATTGCTAAGTCTGAGCAAGAAATAGGC AAAGCAACCGCAAAATATTTCTTTTACTCTAATATCATGAACTTCTTCAAAACAGAAATTAC ACTTGCAAATGGAGAGATTCGCAAACGCCCTCTAATCGAAACTAATGGGGAAACTGGAGAA W- ATTGTCTGGGATAAAGGGCGAGATTTTGCCACAGTGCGCAAAGTATTGTCCATGCCCCAAGT CAATATTGTCAAGAAAACAGAAGTACAGACAGGCGGATTCTCCAAGGAGTCAATTTTACCA AAAAGAAATTCGGACAAGCTTATTGCTCGTAAAAAAGACTGGGATCCAAAAAAATATGGTG GTTTTGATAGTCCAACGGTAGCTTATTCAGTCCTAGTGGTTGCTAAGGTGGAAAAAGGGAAA TCGAAGAAGTTAAAATCCGTTAAAGAGTTACTAGGGATCACAATTATGGAAAGAAGTTCCT 45 TTGAAAAAAATCCGATTGACTTTTTAGAAGCTAAAGGATATAAGGAAGTTAAAAAAGACTT AATCATTAAACTACCTAAATATAGTCTTTTTGAGTTAGAAAACGGTCGTAAACGGATGCTGG CTAGTGCCGGAGAATTACAAAAAGGAAATGAGCTGGCTCTGCCAAGCAAATATGTGAATTT TTTATATTTAGCTAGTCATTATGAAAAGTTGAAGGGTAGTCCAGAAGATAACGAACAAAAA CAATTGTTTGTGGAGCAGCATAAGCATTATTTAGATGAGATTATTGAGCAAATCAGTGAATT 50 TTCTAAGCGTGTTATTTTAGCAGATGCCAATTTAGATAAAGTTCTTAGTGCATATAACAAAC ATAGAGACAAACCAATACGTGAACAAGCAGAAAATATTATTCATTTATTTACGTTGACGAA TCTTGGAGCTCCCGCTGCTTTTAAATATTTTGATACAACAATTGATCGTAAACGATATACGTC TACAAAAGAAGTTTTAGATGCCACTCTTATCCATCAATCCATCACTGGTCTTTATGAAACAC GCATTGATTTGAGTCAGCTAGGAGGTGACTGA (SEQ ID NO:505) 55 SEQ ID NO:506: ATGGCTGGTTGGCGTACTGTTGTGGTAAATACCCACTCGAAATTATCCTATAAGAATAATCA

TCTGATTTTTAAGGATGCCTATAAAACGGAGCTGATCCATTTATCAGAAATTGATATTTTGTT

182 5 ATTAGAAACGACCGATATTGTCTTGTCCACTATGCTGGTAAAACGGCTAGTGGATGAGAATG TCCTTGTCATATTCTGTGATGATAAACGATTACCAACAGCTATGCTGATGCCTTTTTATGGTC GTCATGATTCGAGTTTACAGCTTGGGAAACAAATGTCCTGGTCAGAAACAGTCAAATCGCA GGTTTGGACGACGATTATTGCTCAAAAGATTTTGAATCAATCTTGCTATCTAGGAGCATGCT CCTATTTTGAAAAATCCCAATCTATTATGGATTTATATCATGGTTTGGAAAATTTTGATCCGA [0 GTAATCGAGAAGGGCATGCAGCGAGAATTTATTTTAATACACTTTTTGGGAACGATTTCTCA AGAGATTTGGAGCATCCAATCAATGCAGGTCTGGATTATGGTTATACTTTATTATTGAGTAT GTTTGCGCGTGAAGTGGTTGTGTCTGGATGTATGACTCAGTTTGGGCTTAAACACGCTAATC AGTTTAATCAGTTCAATTTTGCTAGCGATATTATGGAACCATTTAGGCCTTTAGTGGATAAG ATTGTTTATGAAAATCGAAATCAGCCTTTTCCCAAAATAAAGAGAGAGTTATTTACTTTGTT [5 TTCAGATACATTTTCATATAATGGTAAAGAGATGTATCTCACGAATATTATTAGCGATTATA CTAAAAAAGTTGTCAAAGCTCTGAATAATGAAGGGAAAGGAGTTCCTGAATTTAGGATATG A (SEQ ID NO:506) SEQ ID NO:507: !0 ATGAGTTATAGATATATGAGAATGATACTTATGTTTGATATGCCGACGGACACCGCTGAGGA ACGAAAAGCCTATCGAAAATTTCGGAAATTTTTACTTAGTGAAGGGTTTATCATGCATCAAT TTTCTATTTATAGTAAGTTGCTGTTGAATAATACAGCTAACAATGCCATGATTGGTCGGCTG AGGGAGCATAATCCTAATAAAGGAAATATTACATTACTAACGGTCACGGAAAAACAGTTTG CACGAATGATTTATTTACATGGTGAAAGAAATAATTGTATTGCAAACTCCGATGAAAGACTT !5 GTATTTCTTGGGGAGGCTTTTGATGAATCTTAA (SEQ ID NO:507) SEQ ID NO:508: ATGAATCTTAATTTTTCCTTACTAGATGAACCGATTCCATTAAGAGGCGGTACAATTCTTGTG CTCGAAGATGTCTGTGTATTTTCAAAAATAGTGCAATATTGTTACCAATATGAGGAAGATTC ;0 TGAACTTAAATTTTTTGATCACAAGATGAAAACAATCAAAGAATCAGAAATCATGCTTGTAA CAGATATTTTAGGATTTGATGTTAACTCCTCAACCATTTTAAAATTGATTCATGCAGATTTAG AATCTCAATTTAATGAGAAACCCGAAGTGAAATCGATGATTGACAAATTGGTTGCTACGATT ACAGAACTGATTGTCTTTGAATGCTTAGAAAATGAATTAGATTTAGAGTATGATGAAATCAC AATCCTGGAATTGATTAAGTCCTTAGGAGTAAAAGTAGAAACGCAAAGTGATACTATTTTTG ;5 AAAAATGTCTAGAGATACTTCAAATTTTCAAATATCTCACTAAGAAAAAGTTGCTTATTTTT GTCAATAGCGGAGCTTTTCTAACAAAGGATGAAGTGGCTAGTTTACAAGAGTATATATCATT GACAAATTTAACAGTTCTCTTTTTAGAACCACGTGAACTATATGATTTTCCGCAGTATATTTT AGATGAAGATTATTTCTTAATAACTAAAAATATGGTATAA (SEQ ID NO:508) 40 SEQ ID NO:517: ATGGATAAGAAATACTCAATAGGCTTAGATATCGGCACAAATAGCGTCGGATGGGCGGTGA TCACTGATGATTATAAGGTTCCGTCTAAAAAGCTCAAGGGTCTGGGAAATACAGACCGCCA CGGTATCAAAAAAAATCTTATAGGGGCTCTTTTATTTGACAGTGGAGAGACAGCGGAAGCG ACTCGTCTCAAACGGACAGCTCGTAGAAGGTATACACGTCGGAAGAATCGTATTTGTTATCT 45 ACAGGAGATTTTTTCAAATGAGATGGCGAAAGTAGATGATAGTTTCTTTCATCGACTTGAAG AGTCTTTTTTGGTGGAAGAAGACAAGAAGCATGAACGTCATCCTATTTTTGGAAATATAGTA GATGAAGTTGCTTATCATGAGAAATATCCAACTATCTATCATCTGCGAAAAAAATTGGCAGA TTCTACTGATAAAGTGGATTTGCGCTTAATCTATTTGGCCTTAGCGCATATGATTAAGTTTCG TGGTCATTTTTTGATTGAGGGAGATTTAAATCCTGATAATAGTGATGTGGACAAACTATTTA 50 TCCAGTTGGTACAAACCTACAATCAATTATTTGAAGAAAACCCTATTAACGCAAGTAGAGTA GATGCTAAAGCGATTCTTTCTGCACGATTGAGTAAATCAAGACGATTAGAAAATCTCATTGC TCAGCTCCCCGGTGAGAAGAAAAATGGATTGTTTGGGAATCTCATTGCTTTGTCATTGGGAT TGACCCCTAATTTTAAATCAAATTTTGATTTGGCAGAAGATGCTAAATTACAGCTTTCAAAA GATACTTACGATGATGATTTAGATAATTTATTGGCGCAAATTGGAGATCAATATGCTGATTT 55 GTTTTTGGCAGCTAAGAATTTATCAGATGCTACTTTACTTTCAGATATCCTAAGAGTAAATA GTGAAATAACTAAGGCTCCCCTATCAGCTTCAATGATTAAGCGCTACGATGAACATCATCAA GACTTGACTCTTTTAAAAGCTTTAGTTCGACAACAACTTCCAGAAAAGTATAAAGAAATCTT

TTTTGATCAATCAAAAAACGGATATGCAGGTTATATTGATGGGGGAGCTAGCCAAGAAGAA

183 5 TTTTATAAATTTATCAAACCAATTTTAGAAAAAATGGATGGTACTGAGGAATTATTGGCGAA ACTAAATCGTGAAGATTTGCTGCGCAAGCAACGGACCTTTGACAACGGCTCTATTCCCTATC AAATTCACTTGGGTGAGCTGCATGCTATTTTGAGAAGACAAGAAGACTTTTATCCATTTTTA AAAGACAATCGTGAGAAGATTGAAAAAATCTTGACTTTTCGAATTCCTTATTATGTTGGTCC ATTGGCGCGTGGCAATAGTCGTTTTGCATGGATGACTCGGAAGTCTGAAGAAACAATTACCC 0 CATGGAATTTTGAAGAAGTTGTCGATAAAGGTGCTTCAGCTCAATCATTTATTGAACGCATG ACAAACTTTGATAAAAATCTTCCAAATGAAAAAGTACTACCAAAACATAGTTTGCTTTATGA GTATTTTACGGTTTATAACGAATTGACAAAAGTCAAATATGTTACTGAGGGAATGCGAAAA CCAGCATTTCTTTCAGGTGAACAGAAGAAAGCCATTGTTGATTTACTCTTCAAAACAAATCG AAAAGTAACCGTTAAGCAATTAAAAGAAGATTATTTCAAAAAAATAGAATGTTTTGATAGT [5 GTTGAAATTTCAGGAGTTGAAGATAGATTTAATGCTTCATTAGGTACCTACCATGATTTGCT AAAAATTATTAAAGATAAAGATTTTTTGGATAATGAAGAAAACGAAGATATCTTAGAGGAT ATTGTTTTAACATTGACCTTATTTGAAGATAGGGAGATGATTGAGGAAAGACTTAAAACATA TGCTCACCTCTTTGATGATAAGGTGATGAAACAGCTTAAACGTCGCCGTTATACTGGTTGGG GACGTTTGTCTCGAAAATTGATTAATGGTATTAGGGATAAGCAATCTGGCAAAACAATATTA !0 GATTTTTTGAAATCAGATGGTTTTGCCAATCGCAATTTTATGCAGCTGATCCATGATGATAGT TTGACATTTAAAGAAGACATTCAAAAAGCACAAGTGTCTGGACAAGGCGATAGTTTACATG AACATATTGCAAATTTAGCTGGTAGCCCTGCTATTAAAAAAGGTATTTTACAGACTGTAAAA GTTGTTGATGAATTGGTCAAAGTAATGGGGCGGCATAAGCCAGAAAATATCGTTATTGAAA TGGCACGTGAAAATCAGACAACTCAAAAGGGCCAGAAAAATTCGCGTGAGCGTATGAAAC !5 GTATTGAAGAAGGAATAAAAGAACTAGGAAGTGATATTCTAAAGGAGTATCCTGTTGAAAA CACTCAATTACAAAATGAAAAGCTCTATCTCTATTATCTCCAAAATGGAAGAGACATGTATG TGGACCAAGAATTAGATATTAATCGTTTAAGTGATTATGATGTCGATCACATTGTTCCACAA AGTTTCCTTAAAGACGATTCAATAGACAATAAGGTCTTAACGCGTTCTGATAAAAATCGTGG TAAATCGGATAACGTTCCAAGTGAAGAAGTAGTCAAAAAGATGAAAAACTATTGGAGACAA ;0 CTTCTAAACGCCAAGTTAATCACTCAACGTAAGTTTGATAATTTAACAAAAGCTGAACGTGG AGGTTTGAGTGAACTTGATAAAGTTGGTTTTATCAAACGCCAATTGGTTGAAACTCGCCAAA TCACTAAGCATGTGGCACAAATTTTGGATAGTCGCATGAATACTAAATACGATGAAAATGA TAAACTTATTCGAGAGGTTAGAGTGATTACCTTAAAATCTAAATTAGTTTCTGACTTCCGAA AAGATTTCCAATTCTATAAAGTACGTGAGATTAACAATTACCATCATGCCCATGATGCGTAT ;5 CTTAATGCCGTCGTTGGAACTGCTTTGATTAAGAAATATCCAAAACTTGAATCGGAGTTTGT CTATGGTGATTATAAAGTTTATGATGTTCGTAAAATGATTGCTAAGTCTGAGCAGGAAATAG GCAAAGCAACCGCAAAATATTTCTTTTACTCTAATATCATGAACTTCTTCAAAACAGAAATT ACACTTGCAAATGGAGAGATTCGCAAACGCCCTCTAATCGAAACTAATGGGGAAACTGGAG AAATTGTCTGGGATAAAGGGCGAGATTTTGCCACAGTGCGCAAAGTATTGTCCATGCCCCA W- AGTCAATATTGTCAAGAAAACAGAAGTACAGACAGGCGGATTCTCCAAGGAGTCAATTTTA CCAAAAAGAAATTCGGACAAGCTTATTGCTCGTAAAAAAGACTGGGATCCAAAAAAATATG GTGGTTTTGATAGTCCAACGGTAGCTTATTCAGTCCTAGTGGTTGCTAAGGTGGAAAAAGGG AAATCGAAGAAGTTAAAATCCGTTAAAGAGTTACTAGGGATCACAATAATGGAAAGAAGCT CTTTTGAAAAAGATCCGATTGACTTTTTAGAAGCTAAAGGATATAAGGAAGTTAGAAAAGA 45 CTTAATCATTAAACTACCTAAATATAGTCTTTTTGAGTTAGAAAACGGTCGTAAACGGATGC TGGCTAGTGCCGGAGAATTGCAAAAAGGAAATGAGCTAGCTCTGCCAAGCAAATATGTGAA TTTTTTATATTTAGCTAGTCATTATGAAAAGTTGAAGGGTAGTCCAGAAGATAACGAACAAA AACAATTGTTTGTGGAGCAGCATAAGCATTATTTAGATGAGATTATTGAGCAAATCAGTGAA TTTTCTAAGCGTGTTATTTTAGCAGATGCCAATTTAGATAAAGTTCTTAGTGCATATAACAA 50 ACATAGAGACAAACCAATACGTGAACAAGCAGAAAATATTATTCATTTATTTACGTTGACG AATCTTGGAGCTCCCGCTGCTTTTAAATATTTTGATACAACAATTGATCGTAAACGATATAC GTCTACAAAAGAAGTTTTAGATGCCACTCTTATCCATCAATCCATCACTGGTCTTTATGAAA CACGCATTGATTTGAGTCAGCTAGGAGGTGACTGATGGCTGGTTGGCGTACTGTTGTGGTAA ATACCCACTCGAAATTATCCTATAAGAATAATCATCTGATTTTTAAGGATGCCTATAAAACG 55 GAGCTGATCCATTTATCAGAAATTGATATTTTGTTATTAGAAACGACCGATATTGTCTTGTCC ACTATGCTGGTAAAACGGCTAGTGGATGAGAATGTCCTTGTCATATTCTGTGATGATAAACG ATTACCAACAGCTATGCTGATGCCTTTTTATGGTCGTCATGATTCGAGTTTACAGCTTGGGA AACAAATGTCCTGGTCAGAAACAGTCAAATCGCAGGTTTGGACGACGATTATTGCTCAAAA GATTTTGAATCAATCTTGCTATCTAGGAGCATGCTCCTATTTTGAAAAATCCCAATCTATTAT 60 GGATTTATATCATGGTTTGGAAAATTTTGATCCGAGTAATCGAGAAGGGCATGCAGCGAGA 184 5 ATTTATTTTAATACACTTTTTGGGAACGATTTCTCAAGAGATTTGGAGCATCCAATCAATGC AGGTCTGGATTATGGTTATACTTTATTATTGAGTATGTTTGCGCGTGAAGTGGTTGTGTCTGG ATGTATGACTCAATTTGGACTCAAACACGCCAATCAGTTTAATCAGTTCAATTTTGCTAGCG ATATTATGGAACCATTTAGGCCTTTGGTGGATAAGATTGTTTATGAAAATCGAAATCAGCCT TTTCCCAAAATAAAGAGAGAGTTATTTACTTTGTTTTCAGATACATTTTCATATAATGGTAAA [0 GAGATGTATCTCACGAATATTATTAGCGATTATACTAAAAAAGTTGTCAAAGCTCTGAATAA TGAAGGGAAAGGAGTTCCTGAATTTAGGATATGAGTTATAGATATATGAGAATGATACTTA TGTTTGATATGCCGACGGACACTGCTGAGGAACGAAAAGCTTATCGAAAATTTCGGAAATTT TTACTTAGTGAAGGGTTTATCATGCATCAATTTTCTATTTATAGTAAGTTACTGTTGAATAAT ACAGCTAACAACGCCATGATTGGTCGGCTGAGGGAGCATAATCCTCATAAAGGAAATATTA [5 CATTACTAACAGTCACAGAAAAACAGTTTGCACGAATGATTTATTTACATGGTGAAAGAAA TAATTGTATTGCAAACTCCGATGAGAGACTTGTATTTCTTGGGGAGGCTTTTGATGAATCTT AATTTTCCCTTATTAGATGAACCGATTCCATTAAGAGGCGGTACAATTCTTGTGCTCGAAGA TGTCTGTGTATTTTCAAAAATAGTGCAATATTGTTACAAATATGAGGAAGATTCTGAACTTA AATTTTTTGATCACAAGATGAAAACCATCAAAGAATCAGAAATCATGCTTGTAACAGATATT !0 TTAGGATTTGATGTTAACTCCTCAACCATTTTAAAATTGATTCATGCAGATTTAGAATCTCAA TTTAATGAGAAACCCGAAGTGAAATCGATGATTGACAAATTGGTTGCTACGATTACAGAAC TGATTGTCTTTGAATGCTTAGAAAATGAATTAGATTTAGAGTATGATGAAATCACAATCCTG GAATTGATTAAGTCCTTAGGAGTAAAAGTAGAAACGCAAAGTGATACTATTTTTGAAAAAT GTCTAGAGATACTTCAAATTTTCAAATATCTCACTAAGAAAAAGTTGCTTATTTTTGTCAATA !5 GCGGAGCTTTTCTAACAAAGGATGAAGTGGCTAGTTTACAAGAGTATATATCATTGACAAAT TTAACAGTTCTCTTTTTAGAACCACGTGAACTATATGATTTTCCGCAGTATATTTTAGATGAA GATTATTTCTTAATAACTAAAAATATGGTATAA (SEQ ID NO:517) SEQ ID NO:518: ;0 ATGGATAAGAAATACTCAATAGGCTTAGATATCGGCACAAATAGCGTCGGATGGGCGGTGA TCACTGATGATTATAAGGTTCCGTCTAAAAAGCTCAAGGGTCTGGGAAATACAGACCGCCA CGGTATCAAAAAAAATCTTATAGGGGCTCTTTTATTTGACAGTGGAGAGACAGCGGAAGCG ACTCGTCTCAAACGGACAGCTCGTAGAAGGTATACACGTCGGAAGAATCGTATTTGTTATCT ACAGGAGATTTTTTCAAATGAGATGGCGAAAGTAGATGATAGTTTCTTTCATCGACTTGAAG ;5 AGTCTTTTTTGGTGGAAGAAGACAAGAAGCATGAACGTCATCCTATTTTTGGAAATATAGTA GATGAAGTTGCTTATCATGAGAAATATCCAACTATCTATCATCTGCGAAAAAAATTGGCAGA TTCTACTGATAAAGTGGATTTGCGCTTAATCTATTTGGCCTTAGCGCATATGATTAAGTTTCG TGGTCATTTTTTGATTGAGGGAGATTTAAATCCTGATAATAGTGATGTGGACAAACTATTTA TCCAGTTGGTACAAACCTACAATCAATTATTTGAAGAAAACCCTATTAACGCAAGTAGAGTA 40 GATGCTAAAGCGATTCTTTCTGCACGATTGAGTAAATCAAGACGATTAGAAAATCTCATTGC TCAGCTCCCCGGTGAGAAGAAAAATGGATTGTTTGGGAATCTCATTGCTTTGTCATTGGGAT TGACCCCTAATTTTAAATCAAATTTTGATTTGGCAGAAGATGCTAAATTACAGCTTTCAAAA GATACTTACGATGATGATTTAGATAATTTATTGGCGCAAATTGGAGATCAATATGCTGATTT GTTTTTGGCAGCTAAGAATTTATCAGATGCTACTTTACTTTCAGATATCCTAAGAGTAAATA 45 GTGAAATAACTAAGGCTCCCCTATCAGCTTCAATGATTAAGCGCTACGATGAACATCATCAA GACTTGACTCTTTTAAAAGCTTTAGTTCGACAACAACTTCCAGAAAAGTATAAAGAAATCTT TTTTGATCAATCAAAAAACGGATATGCAGGTTATATTGATGGGGGAGCTAGCCAAGAAGAA TTTTATAAATTTATCAAACCAATTTTAGAAAAAATGGATGGTACTGAGGAATTATTGGCGAA ACTAAATCGTGAAGATTTGCTGCGCAAGCAACGGACCTTTGACAACGGCTCTATTCCCTATC 50 AAATTCACTTGGGTGAGCTGCATGCTATTTTGAGAAGACAAGAAGACTTTTATCCATTTTTA AAAGACAATCGTGAGAAGATTGAAAAAATCTTGACTTTTCGAATTCCTTATTATGTTGGTCC ATTGGCGCGTGGCAATAGTCGTTTTGCATGGATGACTCGGAAGTCTGAAGAAACAATTACCC CATGGAATTTTGAAGAAGTTGTCGATAAAGGTGCTTCAGCTCAATCATTTATTGAACGCATG ACAAACTTTGATAAAAATCTTCCAAATGAAAAAGTACTACCAAAACATAGTTTGCTTTATGA 55 GTATTTTACGGTTTATAACGAATTGACAAAAGTCAAATATGTTACTGAGGGAATGCGAAAA CCAGCATTTCTTTCAGGTGAACAGAAGAAAGCCATTGTTGATTTACTCTTCAAAACAAATCG AAAAGTAACCGTTAAGCAATTAAAAGAAGATTATTTCAAAAAAATAGAATGTTTTGATAGT GTTGAAATTTCAGGAGTTGAAGATAGATTTAATGCTTCATTAGGTACCTACCATGATTTGCT

AAAAATTATTAAAGATAAAGATTTTTTGGATAATGAAGAAAACGAAGATATCTTAGAGGAT

185 5 ATTGTTTTAACATTGACCTTATTTGAAGATAGGGAGATGATTGAGGAAAGACTTAAAACATA TGCTCACCTCTTTGATGATAAGGTGATGAAACAGCTTAAACGTCGCCGTTATACTGGTTGGG GACGTTTGTCTCGAAAATTGATTAATGGTATTAGGGATAAGCAATCTGGCAAAACAATATTA GATTTTTTGAAATCAGATGGTTTTGCCAATCGCAATTTTATGCAGCTGATCCATGATGATAGT TTGACATTTAAAGAAGACATTCAAAAAGCACAAGTGTCTGGACAAGGCGATAGTTTACATG 0 AACATATTGCAAATTTAGCTGGTAGCCCTGCTATTAAAAAAGGTATTTTACAGACTGTAAAA GTTGTTGATGAATTGGTCAAAGTAATGGGGCGGCATAAGCCAGAAAATATCGTTATTGAAA TGGCACGTGAAAATCAGACAACTCAAAAGGGCCAGAAAAATTCGCGTGAGCGTATGAAAC GTATTGAAGAAGGAATAAAAGAACTAGGAAGTGATATTCTAAAGGAGTATCCTGTTGAAAA CACTCAATTACAAAATGAAAAGCTCTATCTCTATTATCTCCAAAATGGAAGAGACATGTATG [5 TGGACCAAGAATTAGATATTAATCGTTTAAGTGATTATGATGTCGATCACATTGTTCCACAA AGTTTCCTTAAAGACGATTCAATAGACAATAAGGTCTTAACGCGTTCTGATAAAAATCGTGG TAAATCGGATAACGTTCCAAGTGAAGAAGTAGTCAAAAAGATGAAAAACTATTGGAGACAA CTTCTAAACGCCAAGTTAATCACTCAACGTAAGTTTGATAATTTAACAAAAGCTGAACGTGG AGGTTTGAGTGAACTTGATAAAGTTGGTTTTATCAAACGCCAATTGGTTGAAACTCGCCAAA !0 TCACTAAGCATGTGGCACAAATTTTGGATAGTCGCATGAATACTAAATACGATGAAAATGA TAAACTTATTCGAGAGGTTAGAGTGATTACCTTAAAATCTAAATTAGTTTCTGACTTCCGAA AAGATTTCCAATTCTATAAAGTACGTGAGATTAACAATTACCATCATGCCCATGATGCGTAT CTTAATGCCGTCGTTGGAACTGCTTTGATTAAGAAATATCCAAAACTTGAATCGGAGTTTGT CTATGGTGATTATAAAGTTTATGATGTTCGTAAAATGATTGCTAAGTCTGAGCAGGAAATAG !5 GCAAAGCAACCGCAAAATATTTCTTTTACTCTAATATCATGAACTTCTTCAAAACAGAAATT ACACTTGCAAATGGAGAGATTCGCAAACGCCCTCTAATCGAAACTAATGGGGAAACTGGAG AAATTGTCTGGGATAAAGGGCGAGATTTTGCCACAGTGCGCAAAGTATTGTCCATGCCCCA AGTCAATATTGTCAAGAAAACAGAAGTACAGACAGGCGGATTCTCCAAGGAGTCAATTTTA CCAAAAAGAAATTCGGACAAGCTTATTGCTCGTAAAAAAGACTGGGATCCAAAAAAATATG ;0 GTGGTTTTGATAGTCCAACGGTAGCTTATTCAGTCCTAGTGGTTGCTAAGGTGGAAAAAGGG AAATCGAAGAAGTTAAAATCCGTTAAAGAGTTACTAGGGATCACAATAATGGAAAGAAGCT CTTTTGAAAAAGATCCGATTGACTTTTTAGAAGCTAAAGGATATAAGGAAGTTAGAAAAGA CTTAATCATTAAACTACCTAAATATAGTCTTTTTGAGTTAGAAAACGGTCGTAAACGGATGC TGGCTAGTGCCGGAGAATTGCAAAAAGGAAATGAGCTAGCTCTGCCAAGCAAATATGTGAA ;5 TTTTTTATATTTAGCTAGTCATTATGAAAAGTTGAAGGGTAGTCCAGAAGATAACGAACAAA AACAATTGTTTGTGGAGCAGCATAAGCATTATTTAGATGAGATTATTGAGCAAATCAGTGAA TTTTCTAAGCGTGTTATTTTAGCAGATGCCAATTTAGATAAAGTTCTTAGTGCATATAACAA ACATAGAGACAAACCAATACGTGAACAAGCAGAAAATATTATTCATTTATTTACGTTGACG AATCTTGGAGCTCCCGCTGCTTTTAAATATTTTGATACAACAATTGATCGTAAACGATATAC W- GTCTACAAAAGAAGTTTTAGATGCCACTCTTATCCATCAATCCATCACTGGTCTTTATGAAA CACGCATTGATTTGAGTCAGCTAGGAGGTGACTGA (SEQ ID NO:518) SEQ ID NO:519: ATGGCTGGTTGGCGTACTGTTGTGGTAAATACCCACTCGAAATTATCCTATAAGAATAATCA 45 TCTGATTTTTAAGGATGCCTATAAAACGGAGCTGATCCATTTATCAGAAATTGATATTTTGTT ATTAGAAACGACCGATATTGTCTTGTCCACTATGCTGGTAAAACGGCTAGTGGATGAGAATG TCCTTGTCATATTCTGTGATGATAAACGATTACCAACAGCTATGCTGATGCCTTTTTATGGTC GTCATGATTCGAGTTTACAGCTTGGGAAACAAATGTCCTGGTCAGAAACAGTCAAATCGCA GGTTTGGACGACGATTATTGCTCAAAAGATTTTGAATCAATCTTGCTATCTAGGAGCATGCT 50 CCTATTTTGAAAAATCCCAATCTATTATGGATTTATATCATGGTTTGGAAAATTTTGATCCGA GTAATCGAGAAGGGCATGCAGCGAGAATTTATTTTAATACACTTTTTGGGAACGATTTCTCA AGAGATTTGGAGCATCCAATCAATGCAGGTCTGGATTATGGTTATACTTTATTATTGAGTAT GTTTGCGCGTGAAGTGGTTGTGTCTGGATGTATGACTCAATTTGGACTCAAACACGCCAATC AGTTTAATCAGTTCAATTTTGCTAGCGATATTATGGAACCATTTAGGCCTTTGGTGGATAAG 55 ATTGTTTATGAAAATCGAAATCAGCCTTTTCCCAAAATAAAGAGAGAGTTATTTACTTTGTT TTCAGATACATTTTCATATAATGGTAAAGAGATGTATCTCACGAATATTATTAGCGATTATA CTAAAAAAGTTGTCAAAGCTCTGAATAATGAAGGGAAAGGAGTTCCTGAATTTAGGATATG A (SEQ ID NO:519) 186 5 SEQ ID NO:520: ATGAGAATGATACTTATGTTTGATATGCCGACGGACACTGCTGAGGAACGAAAAGCTTATC GAAAATTTCGGAAATTTTTACTTAGTGAAGGGTTTATCATGCATCAATTTTCTATTTATAGTA AGTTACTGTTGAATAATACAGCTAACAACGCCATGATTGGTCGGCTGAGGGAGCATAATCCT CATAAAGGAAATATTACATTACTAACAGTCACAGAAAAACAGTTTGCACGAATGATTTATTT [0 ACATGGTGAAAGAAATAATTGTATTGCAAACTCCGATGAGAGACTTGTATTTCTTGGGGAG GCTTTTGATGAATCTTAA (SEQ ID NO:520) SEQ ID NO:521: ATGAATCTTAATTTTCCCTTATTAGATGAACCGATTCCATTAAGAGGCGGTACAATTCTTGTG [5 CTCGAAGATGTCTGTGTATTTTCAAAAATAGTGCAATATTGTTACAAATATGAGGAAGATTC TGAACTTAAATTTTTTGATCACAAGATGAAAACCATCAAAGAATCAGAAATCATGCTTGTAA CAGATATTTTAGGATTTGATGTTAACTCCTCAACCATTTTAAAATTGATTCATGCAGATTTAG AATCTCAATTTAATGAGAAACCCGAAGTGAAATCGATGATTGACAAATTGGTTGCTACGATT ACAGAACTGATTGTCTTTGAATGCTTAGAAAATGAATTAGATTTAGAGTATGATGAAATCAC !0 AATCCTGGAATTGATTAAGTCCTTAGGAGTAAAAGTAGAAACGCAAAGTGATACTATTTTTG AAAAATGTCTAGAGATACTTCAAATTTTCAAATATCTCACTAAGAAAAAGTTGCTTATTTTT GTCAATAGCGGAGCTTTTCTAACAAAGGATGAAGTGGCTAGTTTACAAGAGTATATATCATT GACAAATTTAACAGTTCTCTTTTTAGAACCACGTGAACTATATGATTTTCCGCAGTATATTTT AGATGAAGATTATTTCTTAATAACTAAAAATATGGTATAA (SEQ ID NO:521) with repeat sequences: SEQ ID NO:13 to SEQ ID NO:19 ;0 Functional Combination #4: cas sequences: SEQ ID NO:509 to SEQ ID NO:516 (all of which are from S. pyogenes), as shown below: SEQ ID NO:509: ATGAGAATGATTTTAGCACACTATGACTGTAAAAAAGATAAAAAGCAATCTTTAGATGAGC ;5 ATTTATGGCATGTGGCCTGTTCTAGTCGACAGGAAGCATCTATAATTGGTCAAGGAGATGTG CTTTTTTTAATTGGTCTTTACCACGACCTGGGCAAAGCTGATCGAACCTTTCAAGATAAATTA TTAAATAATCCAAATCGGCATGTTGATCACTCTTATGCAGGGGCAAAATACTTATGTTCTAT TATTGGGCCTCATCTAAAAAACCGAGGGGTTGATAAAAATGAGAGAATGACATTCAACGAA ATGGTGGGGTATGTCATCTCTGCTCATCATGGGATGTATGATTTATGCTACTATTTTGACGAT 40 GCTGAATATTATGGCTTTAATAAGTTTAAAAATCGTATCAATAGAGACTTAGATGGTTATCA CTATCATGAAGATATTAAAGGGTACGCTCTAAAATTAGAAAAAAAATTATGTGATTATGGCT ACAAAGATTTAAGGGAGCTTATTGATAAAGCTTTTGATAATTACCAACAAGCCATGTCTTCC TTAAACTGGCAAGATAAGAGTGAGTGGGATTATTATCAGTCTTGTATGGTGAGACTTTACTT GTCACTCTTAAAAAACGCTGATATTTTGGACACAGTAAATGCCTATGGCCTTAAGATAAGTC 45 CTATGGATAAAACAGAGCGATCCTTTCTAAAACACTCCTATTTAGCGGCCATTGAACAAAAA TATGCTAGCTTTGGACAGCCAAACAATCAGTTGAACACTATTCGGACAGAAATCGCTGAGC GTGTTAAAGAAAGAGGTAAACGAGATTCCAAGGGGATTTATCGCTTAGATTTACCGACAGG AGCTGGCAAGACTAATCTTAGTATGCGTTATGCGTTTCACCAATTAGTTCATCACGACAAAT CAAGGTTTTTTTACATAACTCCCTTTCTTTCGGTTCTTGAGCAAAATGCTTCCGAAATTAGAA 50 AAGTTACAGGTGACCTTGGCGTTCTAGAACACCATTCCAATGTGGTGAAACAGGCTAATGA AGATGATGATGATAAGGACAGTTTATTGTCAGCTTATCTTAGTGATAGCTGGGACAGTCAAG TAGTCTTGACTTCTATGGTTCAATTTTTCCAAACACTTTTCAAAACAAAATCAGCTAATCTGA GACGTTTTTCAAGTTTGATTAATAGTGTTGTGATTCTAGATGAAGTTCAATCCCTGCCTATTG AAGTCACCACTTTGTTTAATTTAACGATGAATTTTTTAAATAAAGTTATGGATACAACCATC 55 GTTCTTTGCACAGCGACACAACCTGCTTATGATTCTTCAGAGATTGACCATCGTATCTGTTAT GGAGGGAACTTGGGAGAATTAGCTGAAATAGTTGAGTTAACGATTGAAGAAAAACAGATTT

TTTCAAGGACAGAGCTTAGAAAATTTGATGATAGTGATCAGAAAGTTCACTTGACTGATGTT

187 5 ATTAACCTTATTCTAGGTGAGGAAAACTCAGTTCTTGCTATTTTTAATACGAAAAAAACGGT TCATAACTGCTATACTATGCTAAAAGACATGACTGATAGACCGGTCTATCAGCTTTCGACAA ATATGTGTGCGCAGCATAGACTTGACTTGATTGCTAAGATCAAAACGGAGTTACAAAATAA TATCCCTATTATTTGTATTAGCACGCAATTAATTGAAGCAGGTGTAGATGTTGATTTTCATCG CGTCATTCGTTCCTACTCAGGGATTGATTCTATTGTTCAGGCTGCTGGACGGTGTAACCGAG 0 AAGGCAAACGAGATAAAGGGCAAGTCACTCTTGTCAATCTGACCAATGAAGAGGAAAATAT TTCTAGGCTGACAGAAATAAAAACTAAAAAAGAAGCCACAGAATCTATTCTTCATAAGATT GGGTCTCCAATTGATATCTCAACTTTAAACCGTGACTTTTTTGAGTATTATTATGCCAATAAT CAGGGACTGATGGATTATCCTTTGGAAGACAACCTATCAATCTACGACTATTTAAGCCTTAA TATTTATCAGACGGCAAATAAAAAGTTCAAAGGTAAGTTAAAACAAGCTTTTAAAACAGCA [5 GGAGCCAAAATGAACCTCATCAATAATGATATGATAGGAATTCTCGTACCTTATGGCGAAG CTGAGAAAAAATTGGCTTATTTAGAAGAATTAGGTGTGTCACATTTTTTATCAGCAAAAGAT TATCAAACGATAAAATCATTACTAAAAGAGTTACAACCTTTTACGGTTAATGTCCGCGAGAA CGATCCTCTCTTTGAGACAACAAAATCTTATCTAAATGGTCAGATTCTGGTTTTGACGTCGG AGTATTATGACACGGAAAGAGGAGTTAAATACGATTCAGCTAGCTTTTACTTCTAACTCAAA !0 ACGAAAGAAGATTAACAAAAGGTTGTTAGAGGACCTTGTTAACCTGCCAATCATCATTAGT AATTATTATCAATTTAGACTATTTAATAAAATTAGATTACAAAAAAACAGAAGGAGGAAAG TAGCTTGTACAGATCTAGAGACTTCTACGTGAGAGTAAGTGGTCAGCGAGCTCTTTTTACAA ATCCAGCCACAAAAGGGGGATCGGAACGCTCATCCTATTCGGTTCCGACTAGACAGGCACT GAATGGTATCGTTGATGCCATCTATTATAAGCCGACCTTTACTAATATCGTCACAGAGGTTA !5 AGGTTATTAACCAGATTCAAACCGAATTACAGGGTGTCAGGGCTCTGTTACATGATTATAGT GCAGATTTAAGTTATGTATCCTATTTGAGTGATGTTGTTTATCTGATCAAGTTTCATTTTGTTT GGAATGAAGATAGAAAAGATTTGAACTCAGATAGACTTCCAGCTAAACATGAAGCCATTAT GGAGCGTTCTATTCGTAAAGGGGGACGTCGAGATGTGTTTTTGGGTACAAGAGAATGTTTAG GGCTTGTAGATGATATCAGCCAAGAAGAGTATGAGACTACTGTGTCGTATTATAATGGTGTC ;0 AATATCGACTTGGGAATCATGTTCCATTCCTTTGCCTATCCGAAGGACAAAAAGACACCATT AAAATCATACTTTACAAAGACTGTGATGAAAAATGGAGTCATTACGTTTAAAGCACAGTCT GAATGCGATATTGTTAACACGCTTTCTAGTTATGCTTTTAAAGCACCAGAGGAGATAAAATC GGTTAACGATGAATGCATGGAGTATGATGCCATGGAGAAAGGAGAAAACTGATGGATTTTT TTACTTCTCTCTTGAAGACTTATGAAAAAGCAGAGCTAGCAGACTTGGTTGATCATCAAAAA ;5 AGAAATAATGAGCCGGTTTTACTGCCGATTTATCATACGAGTTTAAAGTCAAATGGTAAAAA TATCATTTCAGTGAAACTTGACAAAGATGGCCAGTTTCACAAGGCAGAATTTATGGCAGATA AGCAAATGATTATTTTTCCTGTAACGGCTGATTCTGTTGCTAGGTCAGGTAGTCATCCTGCAC CGCATCCCCTAGTCGATAAATTTGCTTATTATAGTGCTGAAATGGGGCAGATTCAGTATGAT TCTTTTCATAAGCAACTGAATAACTGGATTGATTATTGTGAGGAGGGTGATGTCAAGAAATT W- TTTAACCTTTGTTCAGCAGTTCATTTTGAAGCCAGAATTTCTAACATTGATTCTTGATTCTTT AATTGGTCCTGATTATCAACATAATCAATTAAAAGTCACATTTTGTGATGCCACTGGAAAAG AAAAATTAATTGATTTATCAGCTTGCTTTTTAGAATTTTCAATTGATCAGTTCCAGGGCTTTA AAAATGAATCGGTTTCGACATTTAAAGCCTTACACCAATCCTATATTTCTTTTGTTGAAGCCA ATCGTGAAAATCTCGGTATTTGTAATATTAGTGGACGAGAGGAACAGCTTACCGATAAGCA 45 TAGAGGTTTGATGGGGAATGCTAAAATCATCTCTGTTAGTAATAAAAGAGAAGCTTATAAA GGACGTTTTAGAGAACGCGAAGACGTTTTTAGTGTTGGCTATGAAACTTCCGAAAAGATTCA TTTAATGCTCAAGTACCTTTTAGAAAATAAAAATACCAGTACTTGGTTAGGGTCTTCTCAAT ATTTAATCAACTGGTTCAGCGATGATTTAACAAATGATAGTCGGTTGGATATTGTATCACCA ATCTTTGATGATGGACTTGAAGAAGATGATGATGACGATACGCCTCCTGTTATAACATTAGC 50 AACTGAAGACAATAAAAGAATTGGTAAATCATTCATCAAGGGACAAAAATTATTTGCTAAT GATGCCACTTACTACGTTGCTATTTTGAATAAAACCAGCAATGGGCGGATTGCTTTAAAATA TTTTCGTCAGCTTCAAGCGTCCCAATTACTCACCAATCTTAACAAGTGGCAGGAAACATACA GTTGGGAGTCGCGATCTAAGTTTGGGAAAAGTCGCTTAAGAACCCCTACTTTTCATGACATC CTTAATGTGTCCTACGGGGTTGATAGGGATCGCTTCCTTGAATTAGATAATGATAACTTCAA 55 AAGTGATCAAATTCAAAAGTTAGTGGCAAGTTTGATTGATGGTAAACCGATGCCACAGTCC ATTGTCAAAAAGTTAGGTAACAATGTTAAAGAACGACATCGTTACCGTAAGCACTGGTATC AAGTTGAGCAGGTCTGCTTAGCAATTTTACACAAACAAAATGGGGAGGAATTTTCACCGAT GCTAGATCATACCAATCAAAATCGTTCCTATCTTTTTGGACGATTATTAGCAATTTTTGAATT AATCGAGACCTTGCGTTATGGCTTGGATGGAAACAATAACGACCGTATTACCAATGCTGAA 60 CGTTATTGGACAGCCTATACTGGACAACCAACAAAATTGATGATGTTATTGGAAAATAAAA 188 5 TTAAGCCTTACGAAGAACCATTGAAATTAAATCGTCGTGGCAGTTGGATGAAATTAGAAAA AGAAAAAGAAGAGATTTTAGAACTGTTAAATCCTCTGTTAGAAACAGAAACAATGGAAAAA CCCTTAGATTACCGCTTTATTTTTGGGTATTATGCTGAGAAAAACTATTACTATACAAAACA AAACACGGAAGTAACAGAAAGTGAGGAGTAAAAAGATGTTGGAACACAAAATTGATTTTAT GGTAACTCTTGAAGTGAAAGAAGCAAATGCAAATGGTGATCCCTTAAATGGAAACATGCCT 0 CGTACAGATGCCAAAGGATATGGTGTGATGAGTGATGTCTCCATTAAACGTAAGATTCGTA ATCGTTTGCAAGATATGGGGAAGTCTATTTTTGTGCAAGCTAATGAGCGTATTGAAGATGAT TTTCGTTCACTGGAAAAACGCTTTTCGCAACATTTTACAGCTAAGACACCTGACAAAGAAAT TGAAGAAAAAGCAAATGCATTATGGTTTGATGTTCGTGCTTTTGGACAAGTTTTTACTTATCT GAAAAAATCAATTGGGGTGCGTGGACCAGTTTCCATCAGTATGGCTAAGTCCTTGGAGCCA [5 ATTGTCATTTCCAGCCTTCAAATTACGCGTAGTACCAATGGTATGGAAGCTAAGAATAATAG TGGCCGCTCTTCTGATACGATGGGGACAAAACATTTTGTAGATTATGGTGTGTATGTACTTA AAGGTTCTATCAATGCTTATTTTGCTGAAAAGACTGGTTTTTCTCAGGAAGATGCTGAGGCT ATTAAAGAAGTTTTGGTTAGCTTGTTTGAAAATGATGCGTCGTCTGCACGTCCGGAAGGCTC TATGCGAGTTTGTGAAGTCTTTTGGTTTACGCATTCAAGCAAATTGGGAAATGTTTCAAGTG !0 CGCGTGTCTTTGACTTGTTAGAGTATCATCAATCAATAGAAGAAAAAAGCACTTATGACGCT TATCAGATTCATCTAAATCAAGAAAAATTGGCTAAATATGAAGCGAAAGGGTTAACGCTTG AAATCCTAGAAGGACTCTAGTATGGTCTATGCCGAAGATGATTATTTAATGCTGTCAGGTAT TCAGCATTTCCAATTTTGTAAACGTCAATGGGCGTTGATCCATATTGAGCAACAATGGCTTG ATAATGAAGCGACAGCGCATGGACAGGTTTTACATACTAAAGCAGATAACCCTTACATTAA !5 AGAAAAACGAAAAGAGCTTTTGGTCTCACGTGCTATGCCCATTTCTTCTGCAGAACTTGGAC TTTCAGGAATTATGGATGTTGTGGAATTTTATAAAGATGATCAAGGTGTGTCTTTGAGGGGA AAACGTGGGAAATGGTTACCAAAAGTTGTGGAATACAAGCGCGGAAAACCTAAAAAAGAT ACCAGAGATATTGTCCAGTTGGTGGCTCAGACCATGTGTTTAGAAGAAACGCTAGACTGCG ACATTAACGAAGGTTGTCTTTATTACCATAGTGTCAATCAAAGAGTGATTGTTCCTATGACA ;0 TCAGCTTTGCGTCAAGAAGTGAAGGAATTAGCCGCAGAGATGCATGAGGTTTATCAGAGTC AAATGCTACCTAAAGCAGCTTATTTTAAAAACTGTCAGCTTTGTTCTTTAGTCGATATTTGTA AGCCCAGGTTGAGTAAAAAAACAAGGAGTGTGTCGCGTTACATCAATGAGGCTATGACCAG TGAGGAGATGGACCTATGAAGAAGTTGCTAAATACCTTGTATTTGACGCAAGAAGATTTTTA TGTCACTAAAGAGGGCGATAACATTGTTATCAAGCAAGAAGGTAAGGTTCTCAAACGGTTT ;5 CCGTTTCGGATTATTGACGGTATTGTCTGTTTTTCTTATTTGGGTGTGTCGTCTGCTTTGGTGA AGTTATGTACGGAGAATCAGATTAATTTATCGTTTCATACACCACAAGGGCGTTTTTGTGGT CGCTATATTGGTTCAACCAATGGGAATGTGTTGTTGCGTAGAGAACATTATCGTTTATCTGA TCGTGAGGAATCTTTGGAATACGCAAAGCGGTTTATTTTGGCTAAAATTTCCAACTCAAGGA AATACTTGCTACGCTTTAAACGAGATCATCGTCAACAGATTGATACCAAGCTTTTTGAGGCT W0 GTTAATGACGAATTGATATGGGCTTTAGAGATGGTTCAGGCAGCAGATAATAAAGACTCTTT AAGAGGGATTGAAGGCCAAGCTGCTAATCAGTATTTTCGCATATTTAATGACCTGGTGTTGA CGGACAAAAAAACGTTTTACTTCCAAGGTCGGAGTAAACGACCACCCTTAGATTGTGTTAAT GCCCTCTTGTCTTTTGGTTACAGTTTACTGACCTTTGAATGTCAATCTGCCTTGGAAGCTGTC GGATTAGACAGTTACGTTGGTTTCTTTCACACGGATCGTCCTGGGCGTGCTAGTTTAGCGCTT 45 GATTTAGTTGAAGAGTTCCGCTCATATATTGTAGATCGTTTTGTCTTTTCATTAATTAATAAA GGACAACTTCAGAAAAAACACTTTGAGGTTAAAGAAAATGGTAGTATTTTATTGACGGAAA ATGGCAGAGCTATTTTTATTGATTTGTGGCAGAAGCGTAAGCATACTGAGGTAGAACATCCT TTTACAAAAGAGAAAGTAAAACTTATGTTATTACCCTATGTACAAGCGCAGCTTTTAGCTAA GGCTATACGAGGAGATTTAGAAAGCTATCCACCTTTTATGGTTTAGGAGATGTTATATGATG 50 GTTTTAGTCACTTATGATGTAAATACGGAAACACCTGCTGGTAGAAAAAGATTGCGTCATGT TGCCAAACTCTGTGTGGACTATGGGCAACGTGTTCAAAATTCTGTTTTTGAATGTTCTGTGAC ACCCGCAGAATTTGTGGATATAAAGCACCGCTTAACACAAATCATTGATGAGAAAACTGAT AGTATTCGCTTTTATTTATTGGGGAAAAATTGGCAGAGGCGTGTGGAAACACTTGGTCGCTC AGACAGCTATGACCCAGATAAAGGTGTCTTATTATTGTAA (SEQ ID NO:509) 55 SEQ ID NO:510: ATGAGAATGATTTTAGCACACTATGACTGTAAAAAAGATAAAAAGCAATCTTTAGATGAGC ATTTATGGCATGTGGCCTGTTCTAGTCGACAGGAAGCATCTATAATTGGTCAAGGAGATGTG

CTTTTTTTAATTGGTCTTTACCACGACCTGGGCAAAGCTGATCGAACCTTTCAAGATAAATTA

189 5 TTAAATAATCCAAATCGGCATGTTGATCACTCTTATGCAGGGGCAAAATACTTATGTTCTAT TATTGGGCCTCATCTAAAAAACCGAGGGGTTGATAAAAATGAGAGAATGACATTCAACGAA ATGGTGGGGTATGTCATCTCTGCTCATCATGGGATGTATGATTTATGCTACTATTTTGACGAT GCTGAATATTATGGCTTTAATAAGTTTAAAAATCGTATCAATAGAGACTTAGATGGTTATCA CTATCATGAAGATATTAAAGGGTACGCTCTAAAATTAGAAAAAAAATTATGTGATTATGGCT 0 ACAAAGATTTAAGGGAGCTTATTGATAAAGCTTTTGATAATTACCAACAAGCCATGTCTTCC TTAAACTGGCAAGATAAGAGTGAGTGGGATTATTATCAGTCTTGTATGGTGAGACTTTACTT GTCACTCTTAAAAAACGCTGATATTTTGGACACAGTAAATGCCTATGGCCTTAAGATAAGTC CTATGGATAAAACAGAGCGATCCTTTCTAAAACACTCCTATTTAGCGGCCATTGAACAAAAA TATGCTAGCTTTGGACAGCCAAACAATCAGTTGAACACTATTCGGACAGAAATCGCTGAGC [5 GTGTTAAAGAAAGAGGTAAACGAGATTCCAAGGGGATTTATCGCTTAGATTTACCGACAGG AGCTGGCAAGACTAATCTTAGTATGCGTTATGCGTTTCACCAATTAGTTCATCACGACAAAT CAAGGTTTTTTTACATAACTCCCTTTCTTTCGGTTCTTGAGCAAAATGCTTCCGAAATTAGAA AAGTTACAGGTGACCTTGGCGTTCTAGAACACCATTCCAATGTGGTGAAACAGGCTAATGA AGATGATGATGATAAGGACAGTTTATTGTCAGCTTATCTTAGTGATAGCTGGGACAGTCAAG !0 TAGTCTTGACTTCTATGGTTCAATTTTTCCAAACACTTTTCAAAACAAAATCAGCTAATCTGA GACGTTTTTCAAGTTTGATTAATAGTGTTGTGATTCTAGATGAAGTTCAATCCCTGCCTATTG AAGTCACCACTTTGTTTAATTTAACGATGAATTTTTTAAATAAAGTTATGGATACAACCATC GTTCTTTGCACAGCGACACAACCTGCTTATGATTCTTCAGAGATTGACCATCGTATCTGTTAT GGAGGGAACTTGGGAGAATTAGCTGAAATAGTTGAGTTAACGATTGAAGAAAAACAGATTT !5 TTTCAAGGACAGAGCTTAGAAAATTTGATGATAGTGATCAGAAAGTTCACTTGACTGATGTT ATTAACCTTATTCTAGGTGAGGAAAACTCAGTTCTTGCTATTTTTAATACGAAAAAAACGGT TCATAACTGCTATACTATGCTAAAAGACATGACTGATAGACCGGTCTATCAGCTTTCGACAA ATATGTGTGCGCAGCATAGACTTGACTTGATTGCTAAGATCAAAACGGAGTTACAAAATAA TATCCCTATTATTTGTATTAGCACGCAATTAATTGAAGCAGGTGTAGATGTTGATTTTCATCG ;0 CGTCATTCGTTCCTACTCAGGGATTGATTCTATTGTTCAGGCTGCTGGACGGTGTAACCGAG AAGGCAAACGAGATAAAGGGCAAGTCACTCTTGTCAATCTGACCAATGAAGAGGAAAATAT TTCTAGGCTGACAGAAATAAAAACTAAAAAAGAAGCCACAGAATCTATTCTTCATAAGATT GGGTCTCCAATTGATATCTCAACTTTAAACCGTGACTTTTTTGAGTATTATTATGCCAATAAT CAGGGACTGATGGATTATCCTTTGGAAGACAACCTATCAATCTACGACTATTTAAGCCTTAA ;5 TATTTATCAGACGGCAAATAAAAAGTTCAAAGGTAAGTTAAAACAAGCTTTTAAAACAGCA GGAGCCAAAATGAACCTCATCAATAATGATATGATAGGAATTCTCGTACCTTATGGCGAAG CTGAGAAAAAATTGGCTTATTTAGAAGAATTAGGTGTGTCACATTTTTTATCAGCAAAAGAT TATCAAACGATAAAATCATTACTAAAAGAGTTACAACCTTTTACGGTTAATGTCCGCGAGAA CGATCCTCTCTTTGAGACAACAAAATCTTATCTAAATGGTCAGATTCTGGTTTTGACGTCGG -0 AGTATTATGACACGGAAAGAGGAGTTAAATACGATTCAGCTAGCTTTTACTTCTAA (SEQ ID NO:510) SEQ ID NO:511 TTGTACAGATCTAGAGACTTCTACGTGAGAGTAAGTGGTCAGCGAGCTCTTTTTACAAATCC 45 AGCCACAAAAGGGGGATCGGAACGCTCATCCTATTCGGTTCCGACTAGACAGGCACTGAAT GGTATCGTTGATGCCATCTATTATAAGCCGACCTTTACTAATATCGTCACAGAGGTTAAGGT TATTAACCAGATTCAAACCGAATTACAGGGTGTCAGGGCTCTGTTACATGATTATAGTGCAG ATTTAAGTTATGTATCCTATTTGAGTGATGTTGTTTATCTGATCAAGTTTCATTTTGTTTGGA ATGAAGATAGAAAAGATTTGAACTCAGATAGACTTCCAGCTAAACATGAAGCCATTATGGA 50 GCGTTCTATTCGTAAAGGGGGACGTCGAGATGTGTTTTTGGGTACAAGAGAATGTTTAGGGC TTGTAGATGATATCAGCCAAGAAGAGTATGAGACTACTGTGTCGTATTATAATGGTGTCAAT ATCGACTTGGGAATCATGTTCCATTCCTTTGCCTATCCGAAGGACAAAAAGACACCATTAAA ATCATACTTTACAAAGACTGTGATGAAAAATGGAGTCATTACGTTTAAAGCACAGTCTGAAT GCGATATTGTTAACACGCTTTCTAGTTATGCTTTTAAAGCACCAGAGGAGATAAAATCGGTT 55 AACGATGAATGCATGGAGTATGATGCCATGGAGAAAGGAGAAAACTGA (SEQ ID NO:511) SEQ ID NO:512: ATGGATTTTTTTACTTCTCTCTTGAAGACTTATGAAAAAGCAGAGCTAGCAGACTTGGTTGA

TCATCAAAAAAGAAATAATGAGCCGGTTTTACTGCCGATTTATCATACGAGTTTAAAGTCAA

190 5 ATGGTAAAAATATCATTTCAGTGAAACTTGACAAAGATGGCCAGTTTCACAAGGCAGAATT TATGGCAGATAAGCAAATGATTATTTTTCCTGTAACGGCTGATTCTGTTGCTAGGTCAGGTA GTCATCCTGCACCGCATCCCCTAGTCGATAAATTTGCTTATTATAGTGCTGAAATGGGGCAG ATTCAGTATGATTCTTTTCATAAGCAACTGAATAACTGGATTGATTATTGTGAGGAGGGTGA TGTCAAGAAATTTTTAACCTTTGTTCAGCAGTTCATTTTGAAGCCAGAATTTCTAACATTGAT [0 TCTTGATTCTTTAATTGGTCCTGATTATCAACATAATCAATTAAAAGTCACATTTTGTGATGC CACTGGAAAAGAAAAATTAATTGATTTATCAGCTTGCTTTTTAGAATTTTCAATTGATCAGTT CCAGGGCTTTAAAAATGAATCGGTTTCGACATTTAAAGCCTTACACCAATCCTATATTTCTTT TGTTGAAGCCAATCGTGAAAATCTCGGTATTTGTAATATTAGTGGACGAGAGGAACAGCTTA CCGATAAGCATAGAGGTTTGATGGGGAATGCTAAAATCATCTCTGTTAGTAATAAAAGAGA [5 AGCTTATAAAGGACGTTTTAGAGAACGCGAAGACGTTTTTAGTGTTGGCTATGAAACTTCCG AAAAGATTCATTTAATGCTCAAGTACCTTTTAGAAAATAAAAATACCAGTACTTGGTTAGGG TCTTCTCAATATTTAATCAACTGGTTCAGCGATGATTTAACAAATGATAGTCGGTTGGATATT GTATCACCAATCTTTGATGATGGACTTGAAGAAGATGATGATGACGATACGCCTCCTGTTAT AACATTAGCAACTGAAGACAATAAAAGAATTGGTAAATCATTCATCAAGGGACAAAAATTA !0 TTTGCTAATGATGCCACTTACTACGTTGCTATTTTGAATAAAACCAGCAATGGGCGGATTGC TTTAAAATATTTTCGTCAGCTTCAAGCGTCCCAATTACTCACCAATCTTAACAAGTGGCAGG AAACATACAGTTGGGAGTCGCGATCTAAGTTTGGGAAAAGTCGCTTAAGAACCCCTACTTTT CATGACATCCTTAATGTGTCCTACGGGGTTGATAGGGATCGCTTCCTTGAATTAGATAATGA TAACTTCAAAAGTGATCAAATTCAAAAGTTAGTGGCAAGTTTGATTGATGGTAAACCGATGC !5 CACAGTCCATTGTCAAAAAGTTAGGTAACAATGTTAAAGAACGACATCGTTACCGTAAGCA CTGGTATCAAGTTGAGCAGGTCTGCTTAGCAATTTTACACAAACAAAATGGGGAGGAATTTT CACCGATGCTAGATCATACCAATCAAAATCGTTCCTATCTTTTTGGACGATTATTAGCAATTT TTGAATTAATCGAGACCTTGCGTTATGGCTTGGATGGAAACAATAACGACCGTATTACCAAT GCTGAACGTTATTGGACAGCCTATACTGGACAACCAACAAAATTGATGATGTTATTGGAAA ;0 ATAAAATTAAGCCTTACGAAGAACCATTGAAATTAAATCGTCGTGGCAGTTGGATGAAATT AGAAAAAGAAAAAGAAGAGATTTTAGAACTGTTAAATCCTCTGTTAGAAACAGAAACAATG GAAAAACCCTTAGATTACCGCTTTATTTTTGGGTATTATGCTGAGAAAAACTATTACTATAC AAAACAAAACACGGAAGTAACAGAAAGTGAGGAGTAA (SEQ ID NO:512) ;5 SEQ ID NO:513: ATGTTGGAACACAAAATTGATTTTATGGTAACTCTTGAAGTGAAAGAAGCAAATGCAAATG GTGATCCCTTAAATGGAAACATGCCTCGTACAGATGCCAAAGGATATGGTGTGATGAGTGA TGTCTCCATTAAACGTAAGATTCGTAATCGTTTGCAAGATATGGGGAAGTCTATTTTTGTGC AAGCTAATGAGCGTATTGAAGATGATTTTCGTTCACTGGAAAAACGCTTTTCGCAACATTTT 40 ACAGCTAAGACACCTGACAAAGAAATTGAAGAAAAAGCAAATGCATTATGGTTTGATGTTC GTGCTTTTGGACAAGTTTTTACTTATCTGAAAAAATCAATTGGGGTGCGTGGACCAGTTTCC ATCAGTATGGCTAAGTCCTTGGAGCCAATTGTCATTTCCAGCCTTCAAATTACGCGTAGTAC CAATGGTATGGAAGCTAAGAATAATAGTGGCCGCTCTTCTGATACGATGGGGACAAAACAT TTTGTAGATTATGGTGTGTATGTACTTAAAGGTTCTATCAATGCTTATTTTGCTGAAAAGACT 45 GGTTTTTCTCAGGAAGATGCTGAGGCTATTAAAGAAGTTTTGGTTAGCTTGTTTGAAAATGA TGCGTCGTCTGCACGTCCGGAAGGCTCTATGCGAGTTTGTGAAGTCTTTTGGTTTACGCATTC AAGCAAATTGGGAAATGTTTCAAGTGCGCGTGTCTTTGACTTGTTAGAGTATCATCAATCAA TAGAAGAAAAAAGCACTTATGACGCTTATCAGATTCATCTAAATCAAGAAAAATTGGCTAA ATATGAAGCGAAAGGGTTAACGCTTGAAATCCTAGAAGGACTCTAG (SEQ ID NO:513) 50 SEQ ID NO:514: ATGGTCTATGCCGAAGATGATTATTTAATGCTGTCAGGTATTCAGCATTTCCAATTTTGTAAA CGTCAATGGGCGTTGATCCATATTGAGCAACAATGGCTTGATAATGAAGCGACAGCGCATG GACAGGTTTTACATACTAAAGCAGATAACCCTTACATTAAAGAAAAACGAAAAGAGCTTTT 55 GGTCTCACGTGCTATGCCCATTTCTTCTGCAGAACTTGGACTTTCAGGAATTATGGATGTTGT GGAATTTTATAAAGATGATCAAGGTGTGTCTTTGAGGGGAAAACGTGGGAAATGGTTACCA AAAGTTGTGGAATACAAGCGCGGAAAACCTAAAAAAGATACCAGAGATATTGTCCAGTTGG TGGCTCAGACCATGTGTTTAGAAGAAACGCTAGACTGCGACATTAACGAAGGTTGTCTTTAT

TACCATAGTGTCAATCAAAGAGTGATTGTTCCTATGACATCAGCTTTGCGTCAAGAAGTGAA

191 5 GGAATTAGCCGCAGAGATGCATGAGGTTTATCAGAGTCAAATGCTACCTAAAGCAGCTTAT TTTAAAAACTGTCAGCTTTGTTCTTTAGTCGATATTTGTAAGCCCAGGTTGAGTAAAAAAAC AAGGAGTGTGTCGCGTTACATCAATGAGGCTATGACCAGTGAGGAGATGGACCTATGA (SEQ ID NO:514) -0 SEQ ID NO:515: ATGAAGAAGTTGCTAAATACCTTGTATTTGACGCAAGAAGATTTTTATGTCACTAAAGAGGG CGATAACATTGTTATCAAGCAAGAAGGTAAGGTTCTCAAACGGTTTCCGTTTCGGATTATTG ACGGTATTGTCTGTTTTTCTTATTTGGGTGTGTCGTCTGCTTTGGTGAAGTTATGTACGGAGA [5 ATCAGATTAATTTATCGTTTCATACACCACAAGGGCGTTTTTGTGGTCGCTATATTGGTTCAA CCAATGGGAATGTGTTGTTGCGTAGAGAACATTATCGTTTATCTGATCGTGAGGAATCTTTG GAATACGCAAAGCGGTTTATTTTGGCTAAAATTTCCAACTCAAGGAAATACTTGCTACGCTT TAAACGAGATCATCGTCAACAGATTGATACCAAGCTTTTTGAGGCTGTTAATGACGAATTGA TATGGGCTTTAGAGATGGTTCAGGCAGCAGATAATAAAGACTCTTTAAGAGGGATTGAAGG !0 CCAAGCTGCTAATCAGTATTTTCGCATATTTAATGACCTGGTGTTGACGGACAAAAAAACGT TTTACTTCCAAGGTCGGAGTAAACGACCACCCTTAGATTGTGTTAATGCCCTCTTGTCTTTTG GTTACAGTTTACTGACCTTTGAATGTCAATCTGCCTTGGAAGCTGTCGGATTAGACAGTTAC GTTGGTTTCTTTCACACGGATCGTCCTGGGCGTGCTAGTTTAGCGCTTGATTTAGTTGAAGAG TTCCGCTCATATATTGTAGATCGTTTTGTCTTTTCATTAATTAATAAAGGACAACTTCAGAAA !5 AAACACTTTGAGGTTAAAGAAAATGGTAGTATTTTATTGACGGAAAATGGCAGAGCTATTTT TATTGATTTGTGGCAGAAGCGTAAGCATACTGAGGTAGAACATCCTTTTACAAAAGAGAAA GTAAAACTTATGTTATTACCCTATGTACAAGCGCAGCTTTTAGCTAAGGCTATACGAGGAGA TTTAGAAAGCTATCCACCTTTTATGGTTTAG (SEQ ID NO:515) ;0 SEQ ID NO:516: ATGATGGTTTTAGTCACTTATGATGTAAATACGGAAACACCTGCTGGTAGAAAAAGATTGCG TCATGTTGCCAAACTCTGTGTGGACTATGGGCAACGTGTTCAAAATTCTGTTTTTGAATGTTC TGTGACACCCGCAGAATTTGTGGATATAAAGCACCGCTTAACACAAATCATTGATGAGAAA ACTGATAGTATTCGCTTTTATTTATTGGGGAAAAATTGGCAGAGGCGTGTGGAAACACTTGG ;5 TCGCTCAGACAGCTATGACCCAGATAAAGGTGTCTTATTATTGTAA (SEQ ID NO:516) with repeat sequences: SEQ ID NO:20 and SEQ ID NO:22 All patents and publications mentioned in the specification are indicative of the levels of those 40 skilled in the art to which the invention pertains. All patents and publications are herein incorporated by reference to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference. Those of skill in the art readily appreciate that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those inherent therein. The 45 compositions and methods described herein are representative of preferred embodiments, are exemplary, and are not intended as limitations on the scope of the invention. It is readily apparent to one skilled in the art that varying substitutions and modifications may be made to the invention disclosed herein without departing from the scope and spirit of the invention. The invention illustratively described herein suitably may be practiced in the absence of any 50 element or elements, limitation or limitations which is not specifically disclosed herein. The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention that in the use of such terms and expressions of excluding any equivalents of the features 192 5 shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments and optional features, modification and variation of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention. [0 The invention has been described broadly and generically herein. Each of the narrower species and subgeneric groupings falling within the generic disclosure also form part of the invention. This includes the generic description of the invention with a proviso or negative limitation removing any subject matter from the genus, regardless of whether or not the excised material is specifically recited herein. [5 Where the terms "comprise", "comprises", "comprised" or "comprising" are used in this specification, they are to be interpreted as specifying the presence of the stated features, integers, steps or components referred to, but not to preclude the presence or addition of one or more other feature, integer, step, component or group thereof. Further, any prior art reference or statement provided in the specification is not to be taken as an !0 admission that such art constitutes, or is to be understood as constituting, part of the common general knowledge in Australia.

Claims (24)

1. A method for generating a mixed bacterial starter culture comprising at least two different bacteriophage resistant variant strains, comprising the steps of: 5 (a) exposing a parent bacterial strain comprising at least a portion of a CRISPR locus to at least one bacteriophage to produce a mixture of bacteria comprising at least one bacteriophage resistant variant strain comprising a modified CRISPR locus comprising at least one additional spacer in said modified CRISPR locus; (b) exposing a parent bacterial strain comprising at least a portion of a CRISPR 10 locus, different to the parent bacterial strain of step (a), to a different at least one bacteriophage to that of step (a) to produce a mixture of bacteria comprising at least another bacteriophage resistant variant strain comprising a modified CRISPR locus comprising at least one additional spacer in said modified CRISPR locus; (c) selecting said bacteriophage resistant variant strains from said mixtures of 15 bacteria; (d) selecting said bacteriophage resistant variant strains comprising an additional spacer in said modified CRISPR locus from said bacteriophage resistant strains selected in step (c); and (e) isolating said bacteriophage resistant variant strains, wherein said strains 20 comprise an additional spacer in said modified CRISPR locus.

2. The method of Claim 1, wherein the method comprises the steps of: (a) exposing a parent bacterial strain comprising at least a portion of a CRISPR locus to a mixture of two or more bacteriophages to produce a mixture of bacteria comprising 25 at least one bacteriophage resistant variant strain comprising a modified CRISPR locus comprising at least one additional spacer in said modified CRISPR locus; (b) exposing a parent bacterial strain comprising at least a portion of a CRISPR locus, different to the parent bacterial strain of step (a), to a different mixture of two or more bacteriophages to that of step (a) to produce a mixture of bacteria comprising at least another 30 bacteriophage resistant variant strain comprising a modified CRISPR locus comprising at least one additional spacer in said modified CRISPR locus; (c) selecting said bacteriophage resistant variant strains from said mixtures of bacteria; (d) selecting said bacteriophage resistant variant strains comprising an additional 35 spacer in said modified CRISPR locus from said bacteriophage resistant strains selected in step (c); and 194 (e) isolating said bacteriophage resistant variant strains, wherein said strains comprise an additional spacer in said modified CRISPR locus.

3. The method of Claim 1 or Claim 2, wherein said parent bacterial strain is 5 simultaneously exposed to two or more bacteriophages.

4. The method of Claim 1 or Claim 2, wherein said parent bacterial strain is sequentially exposed to two or more bacteriophages. 10

5. The method of Claim 1 or Claim 2, wherein said parent bacterial strain is infected by the bacteriophage.

6. The method of Claim 5, wherein said at least one bacteriophage is selected from the group of virus families consisting of: Corticoviridae, Cystoviridae, Inoviridae, 15 Leviviridae, Microviridae, Myoviridae, Podoviridae, Siphoviridae, and Tectiviridae.

7. The method of Claim 5, wherein said at least one bacteriophage is a mutated bacteriophage obtained through selective pressure using a bacteriophage resistant bacterium. 20

8. The method of Claim 1 or Claim 2, wherein the 5' end and/or the 3' end of said CRISPR locus of the parent bacterial strain is compared with said modified CRISPR locus of said bacteriophage resistant variant strain.

9. The method of Claim 1 or Claim 2, wherein the 5' and/or the 3' end of the 25 first CRISPR spacer of said CRISPR locus of said parent bacterial strain is compared with said modified CRISPR locus of said bacteriophage resistant variant strain.

10. The method of any one of Claims 1 to 9, wherein said additional spacer in said modified CRISPR locus forms part of a repeat-spacer unit. 30

11. The method of Claim 10, wherein said repeat-spacer unit comprises at least one nucleotide sequence that has at least about 95% identity to a nucleotide sequence in the genome of at least one bacteriophage. 35

12. The method of any one of Claims 1 to 11, wherein said parent bacterial strain is suitable for use as a starter cultures, a probiotic culture, and/or a dietary supplement culture. 195

13. The method of Claim 12, wherein said parent bacterial strain is selected from Escherichia, Shigella, Salmonella, Erwinia, Yersinia, Bacillus, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Agrobacterium, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, 5 Borrelia, Francisella, Brucella, Campylobacter, Klebsiella, Frankia, Bartonella, Rickettsia, Shewanella, Serratia, Enterobacter, Proteus, Providencia, Brochothrix, Bifidobacterium, Brevibacterium, Propionibacterium, Lactococcus, Lactobacillus, Pediococcus, Leuconostoc, and Oenococcus. 10

14. The method of Claim 1 or Claim 2, wherein two or more difference spacers each integrate into two or more different CRISPR loci.

15. The method of Claim 1 or Claim 2, wherein two or more different spacers integrate into one CRISPR locus. 15

16. A starter culture obtained by the method of any one of the preceding Claims.

17. The starter culture according to Claim 16 in the form of a dried starter culture, a dehydrated starter culture, a frozen starter culture, or a concentrated starter culture. 20

18. The starter culture according to Claim 17 in which the dried starter culture is wettable, spray dried, freeze-dried or lyophilized.

19. The starter culture according to Claim 17 in the form of a frozen pellet or a 25 freeze-dried powder.

20. The starter culture according to Claim 17 in the form of a concentrate.

21. A fermentation method comprising adding the starter culture of any one of 30 Claims 16 to 20 to a fermentation medium under conditions such that fermentation of the components of said fermentation medium occur.

22. The method of Claim 21, wherein said fermentation medium is a food product. 35

23. The method of Claim 22, wherein said food product is a dairy product. 196

24. The method of Claim 23, wherein said dairy product is milk.